ribavirin has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 2332 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.09) | 18.7374 |
| 1990's | 135 (5.79) | 18.2507 |
| 2000's | 1005 (43.10) | 29.6817 |
| 2010's | 1075 (46.10) | 24.3611 |
| 2020's | 115 (4.93) | 2.80 |
| Authors | Studies |
|---|---|
| Hosmane, RS; Korba, BE; Zhang, N; Zhang, P | 1 |
| Bartels, DJ; Brennan, DL; Chu, HM; Hanzelka, BL; Kwong, AD; Lin, C; Müh, U; Rao, BG; Swenson, L; Tigges, AM; Wei, Y; Zhou, Y | 1 |
| Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G | 1 |
| Boguszewska-Chachulska, AM; Bretner, M; Krawczyk, M; Najda-Bernatowicz, A; Stankiewicz-Drogoń, A | 1 |
| Agrawal, B; Kumar, R; Liang, C; Shakya, N; Tyrrell, DL; Vedi, S | 1 |
| Ban, S; Ikeda, M; Kato, N; Matsuno, K; Miyachi, H; Ohashi, M; Ueda, Y | 1 |
| Abe, H; Andrei, G; Balzarini, J; Haraguchi, K; Hotta, K; Kaneda, R; Kato, N; Kitagawa, Y; Miyaike, T; Mori, K; Shimada, H; Shuto, S; Snoeck, R; Tanaka, H; Ueda, Y | 1 |
| Ahn, HJ; Akter, S; Cho, WJ; Choi, TG; Ha, J; Jang, M; Jin, Y; K R, J; Kang, I; Khadka, DB; Kim, HY; Kim, JH; Kim, M; Kim, SS; Lim, S; Oh, BC; Windisch, MP; Yang, S; Zhao, C | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kim, M; Lee, HW; Li, X; Yang, S | 1 |
| Brzuska, G; Ferry, A; Gallier, F; Gonzalez, S; Krol, E; Lubin-Germain, N; Ouarti, A; Solarte, C; Uziel, J | 1 |
| Kim, CY; Morelli, J; Willner, IR | 1 |
| Kryczka, W | 1 |
| Farley, J; Farley, TA; Fischer, B; Haydon, E; Rehm, J; Vasdev, S | 1 |
| Caldwell, SH; Dalkin, AC; Ellis, DS; Harris, DM; Hespenheide, EE; Kirk, SE | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW | 1 |
| Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G | 1 |
| Chan, HSY; Cheng, VCC; Chew, NFS; Fung, KSC; Hon, KL; Leung, AWS; Leung, KH; Lo, KHY; Ng, KHL; Situ, J; Sridhar, S; Tsang, OTY; Tse, CWS; Wong, SCY; Wu, S; Yip, CCY; Yuen, KY | 1 |
| Baré, PC; Cairo, FM; Cocco, PA; Massenzio, NE; Picchio, GR; Villamil, FG | 1 |
| Christensen, PB; Søholm, J; Øvrehus, A | 1 |
| Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S | 1 |
| Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J | 1 |
| Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH | 1 |
| Kao, JH; Liu, CH; Liu, CJ | 1 |
| Ahn, SB; An, J; Jun, DW; Ko, MJ; Lee, J; Park, DA; Yim, SY; Yoo, JJ | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Öksüz, Z; Serin, MS; Sezgin, O; Temel, GÖ; Üçbilek, E; Yaraş, S | 1 |
| Ansari, MA; Barnes, E; Harrer, CE; Klenerman, P; Marchi, E; Ramamurthy, N | 1 |
| Azzari, C; Bartolini, E; Indolfi, G; Moriondo, M; Resti, M; Ricci, S; Rubino, C; Stinco, M; Trapani, S; Veronese, P | 1 |
| Ebell, M; Elshafie, S; Trivedi-Kapoor, R | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Aimaiti, A; Cao, Y; Ye, D; Zhou, L; Zhu, Z | 1 |
| Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Belyavtsev, AN; Dedova, AV; Kuprianov, VV; Nikolaeva, LI; Samokhvalov, EI; Sapronov, GV; Shastina, NS; Shevchenko, NG; Stuchinskaya, MD | 1 |
| Joshita, S; Okumura, T; Ota, M; Sugiura, A; Umemura, T | 1 |
| Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE | 1 |
| Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D | 1 |
| Bergersen, BM; Dalgard, O; Finbråten, AK; Hagen, K; Lagging, M; Leiva, RA; Mikkelsen, Y; Roberts, RS; Rosseland, CM; Sandvei, PK; Simonsen, Ø; Singh, R; Young, L | 1 |
| Biliotti, E; Calvani, R; Capuani, G; Giampaoli, O; Miccheli, A; Sciubba, F; Spagnoli, M; Taliani, G; Tomassini, A | 1 |
| Fernandes, F; Pereira, G; Perez, R; Piedade, J; Victor, L; Villela-Nogueira, CA | 1 |
| Balbi, E; Cardoso, SW; Carius, L; Grinsztejn, B; Halpern, M; Pacheco, L; Perazzo, H; Pinto, L; Roma, J; Veloso, VG | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Chang, CC; Chang, YS; Chen, JH; Chen, SC; Chou, SM; Hsu, HC; Kuo, TT; Lin, TM; Shen, YC; Yeh, HJ | 1 |
| Fu, X; Guo, M; He, YQ; Li, CY; Qiao, M; Ren, XD | 1 |
| Cordie, A; Esmat, G; Kamel, AM; Sabry, N | 1 |
| Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J | 1 |
| Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK | 1 |
| Clément, AC; Cooper, CL; Crawley, AM; Doyle, MA; Fadzeyeva, E; Fullerton, MD; Hanson, AA; Jacobs, RL; Jeraj, N; Kim, KH; Locatelli, CA; Lorenzen-Schmidt, I; Morrow, NM; Mulvihill, EE; Nguyen, MA; Nunes, JR; O'Dwyer, C; Pulente, SM; Seymour, R; Travis, N; Trzaskalski, NA; van der Veen, JN; Vulesevic, B | 1 |
| Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS | 1 |
| Poddar, U; Umesh Reddy, DV | 1 |
| Amendola Pires, M; Barbosa, ENP; Brandão Mello, CE; Campos, LB; de Almeida, NAA; de Barros, JJF; de Paula, VS; de Santana, CG; Horta, MAP | 1 |
| Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ | 1 |
| Berak, H; Brzdęk, M; Citko, J; Dybowska, D; Flisiak, R; Garlicki, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Lorenc, B; Mazur, W; Parfieniuk-Kowerda, A; Piekarska, A; Tomasiewicz, K; Tronina, O; Zarębska-Michaluk, D | 1 |
| Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H | 1 |
| Nagaraju, SP; Nair N, S; Pai, G; Prabhu, AR; Rajwar, E; Rao, IR; Reddy, NP; Suvarna, D; Venkatesh, BT | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E | 1 |
| Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N | 1 |
| Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME | 1 |
| Al-Qahtani, SD; Alalawy, AI; Alatawi, K; El-Mehasseb, IM; El-Shafai, NM; Farrag, MA; Nada, AI | 1 |
| Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L | 1 |
| Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ | 1 |
| Ahmad, B; Ahmad, J; Ahmad, L; Bashir, K; Chen, TW; Hameed, H; Haq, I; Haq, M; Hussain, K; M Aljowaie, R; Malik, G; Maryam, A; Mohsen Abougazia, E; Ullah, A | 1 |
| Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M | 1 |
| Daryani, N; Imam, U; Mumtaz, F; Parkash, A | 1 |
| Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA | 1 |
| Chaiyabutr, C; Charoenpipatsin, N; Chularojanamontri, L; Nimanong, S; Silpa-Archa, N; Wongpraparut, C | 1 |
| Berenguer, J; Carrero, A; Crespo, M; de Los Santos, I; Gómez, J; González-García, J; Guardiola, JM; Jiménez-Sousa, MÁ; Martínez, I; Resino, S; Vázquez-Morón, S; Vigón, L; Von Wichmann, MA; Yélamos, MB | 1 |
| Bortnikova, VV; Deryabin, PG; Fateeva, TV; Krepkova, LV; Mizina, PG | 1 |
| Grasso, AG; Loiacono, S; Maestro, A; Maximova, N; Sonzogni, A; Zanon, D | 1 |
| Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
| Anderson, M; Banda, CC; Bhebhe, L; Blackard, JT; Choga, WT; Essex, M; Gaseitsiwe, S; Mbangiwa, T; Melamu, P; Moyo, S; Musonda, RM; Phinius, BB; Shaver, ZM; Souda, S; Zumbika, E | 1 |
| Amin, J; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Read, P; Shaw, D | 1 |
| Carvalho, L; Daniels, E; Eveson, L; Foxton, M; Nelson, M; Pillai, S; Sellers, P; Whyte, R | 1 |
| Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S | 1 |
| Cui, LY; Liu, LD; Nan, YM; Zhao, W | 1 |
| Aguilar, H; Asatryan, A; Bondin, M; Cacoub, P; Carvalho, A; Castro, RE; Charafeddine, M; Cohen, DE; Dieterich, D; Felizarta, F; Hu, YB; Khan, N; Marinho, RT; Poordad, F; Siddique, A | 1 |
| Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M | 1 |
| Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S | 1 |
| David, J; Delahooke, T; Dustan, S; Iliffe, M; Kurmoo, F; Lai, FY; May, S; Patel, A; Stephenson, I; Tang, JW; Wiselka, M | 1 |
| Ahmadi Vasmehjani, A; Baharlou, R; Hajikhezri, Z; Kiani, SJ; Sadeghi, K | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Cheng, X; Du, LY; Liao, J; Ma, YJ; Tang, H; Xie, WW; Yan, LB | 1 |
| Bair, MJ; Chen, CJ; Chen, CY; Chen, JJ; Cheng, JS; Cheng, PN; Chien, RN; Chiu, YC; Chu, CH; Chuang, WL; Dai, CY; Hsu, WF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Kuo, HT; Lai, HC; Lee, PL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Lo, GH; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Tung, SY; Wang, CC; Wang, JH; Yan, SL; Yang, CC; Yu, ML | 1 |
| Ben-Ari, Z; Bruck, R; Cohen-Ezra, O; Deutsch, L; Gozlan, Y; Houri, I; Issachar, A; Katchman, H; Menachem, Y; Mor, O; Shibolet, O; Shlomai, A; Veitsman, E; Zelber-Sagi, S | 1 |
| El-Sayed, HM; Elmasry, MS; Hassan, WS; Shalaby, A; Zidan, DW | 1 |
| Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P | 1 |
| Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M | 1 |
| Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A | 1 |
| Khalil, H; Kim, NG; Kullar, R; Saab, S | 1 |
| Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR | 1 |
| Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
| Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N | 1 |
| Barbera, F; Conaldi, PG; Curcio, G; Gallo, A; Pietrosi, G; Russelli, G; Tuzzolino, F; Vizzini, G; Volpes, R | 1 |
| Bruchfeld, A | 1 |
| Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J | 1 |
| Jalota, A; Lerma, EV; Lindner, BK; Thomas, B | 1 |
| Applegate, TL; Barash, D; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Martinello, M; Matthews, GV; Uprichard, SL; Walsh, K; Yardeni, D | 1 |
| Abdurakhmanov, DT; Burnevich, EZ; Filatova, AL; Karpov, VV; Milovanova, SY; Moiseev, SV; Nikulkina, EN; Rozina, TP; Severov, MV; Tanashuk, EL | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S | 1 |
| Liu, CJ; Shih, YF | 1 |
| Geller, J; Jakovleva, J; Kurtenkov, O; Sergejev, B | 1 |
| Du, P; Li, X; Ma, Z; Sun, Y | 1 |
| An, Y; Jia, L; Li, X; Liu, Q; Luo, G; Ouyang, J; Song, R; Zhang, B; Zhang, R | 1 |
| Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T | 1 |
| Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S; Weiland, O | 1 |
| Bellón, JM; Berenguer, J; Carrero, A; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; Hernández-Quero, J; Hontañón, V; Jiménez-Sousa, MA; Martínez, E; Navarro, J; Pérez-Latorre, L; Quereda, C; Resino, S; Santos, I; Sanz, J; Téllez, MJ; von Wichmann, MA | 1 |
| Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
| Masuda, T; Miyasaka, A; Okamoto, H; Suzuki, A; Takikawa, Y; Yoshida, Y | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Abd El-Maksoud, MDE; Ahmed, AE; Ahmed, OM; El-Garem, H; Gamal, A; Sakr, AA | 1 |
| Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH | 1 |
| Doretto, P; Ermacora, A; Fumagalli, S; Gattei, V; Mauro, E; Mazzaro, C; Toffolutti, F; Tonizzo, M | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Farooq, MO; Malik, K; Mengal, FUA; Salim, A | 1 |
| Choi, IS; Kim, KM; Shim, SG | 1 |
| Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T | 1 |
| Braillon, A | 1 |
| Gattei, V; Mazzaro, C; Pozzato, G | 1 |
| Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iliescu, L; Istratescu, D; Manuc, M; Pop, CS; Preda, CM; Tieranu, C; Voiosu, T | 1 |
| Calabrese, DR | 1 |
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Zarębska-Michaluk, D | 1 |
| Ahmad, I; Hamza, A; Uneeb, M | 1 |
| Ahmed, M; Bashir, A; Farooq, MS; Iftikhar, U; Kamran, SH; Saeed, H; Saleem, N; Saleem, Z | 1 |
| Khedhiri, M; Triki, H | 1 |
| Briones, C; de Ávila, AI; Domingo, E; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Lobo-Vega, R; Martínez-González, B; Moreno, E; Perales, C; Quer, J; Soria, ME; Vázquez-Sirvent, L | 1 |
| Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U | 1 |
| Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N | 1 |
| Bai, L; Chen, L; Du, L; He, M; Kang, S; Li, C; Ma, F; Tang, H | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Flisiak, R; Groth, M; Grubczak, K; Grzeszczuk, A; Hryniewicz, A; Kretowska-Grunwald, A; Moniuszko, M | 1 |
| Falade-Nwulia, O; Fried, MW; Nelson, DR; Segal, JB; Suarez-Cuervo, C; Sulkowski, MS | 1 |
| Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B | 1 |
| Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D | 1 |
| Wang, Y; Yan, Z | 1 |
| Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R | 1 |
| Chowdhury, R; Tsen, A | 1 |
| Cheng, K; Chevaliez, S; Cloherty, G; Cohen, DE; Dawson, GJ; Feld, JJ; Hackett, J; Herman, C; Maasoumy, B; Pawlotsky, JM; Rockstroh, JK; Sarrazin, C; Wedemeyer, H | 1 |
| Fialho, R; Harrison, N; Pereira, M; Rusted, J; Whale, R | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Angarano, G; Bruno, G; Milella, M; Saracino, A | 1 |
| Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M | 1 |
| Almawi, WY; Ghazoueni, E; Loueslati, BY; Mouelhi, L; Rabia, NA; Sghaier, I | 1 |
| Callard, RE; Klein, NJ; Lewis, J; Majekodunmi, AO; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Abd-Elsalam, S; Ahmed, OA; Hassan A Fouad, M; Hawash, N; Kaisar, HH; Rizk, F; Samir, H; Shabana, SST | 1 |
| Aghemo, A; Boccaccio, V; Bruno, S; Cabibbo, G; Calvaruso, V; Colombo, M; Craxì, A; Crosignani, A; Di Marco, V; Giacomelli, L; Iavarone, M; Maisonneuve, P; Roffi, L; Rossi, S | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; Degasperi, E | 1 |
| Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A | 1 |
| Haba, S; Kobayashi, Y; Matsuda, S; Miyagishima, T; Morikawa, K; Nakano, S; Oda, H; Sakamoto, N; Sarashina, K; Sogabe, S; Takahashi, K; Takahashi, T; Terashita, K; Yamamura, T; Yoshikawa, A | 1 |
| Asante-Appiah, E; Barr, E; Gane, E; Haber, B; Hwang, P; Luketic, V; Nahass, R; Robertson, M; Wahl, J | 1 |
| Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E | 1 |
| Chen, LC; Xie, Q | 1 |
| Ida, Y; Iguchi, M; Kato, J; Kawashima, A; Kitano, M; Maekita, T; Moribata, K; Nakao, T; Nasu, T; Shimizu, R; Shingaki, N; Tamai, H | 1 |
| Angiola, A; Caruso, A; Casari, S; Castelli, F; Festa, E; Gargiulo, F; Lanza, P; Nasta, P; Odolini, S; Rodella, A; Urbinati, L; Vavassori, A; Viganò, M; Zaltron, S | 1 |
| Applegate, TL; Backmund, M; Bruggmann, P; Cloherty, G; Conway, B; Cunningham, EB; Cunningham, P; Dalgard, O; Dore, GJ; Foster, GR; Grebely, J; Hajarizadeh, B; Lamoury, FMJ; Marks, P; Martinez, D; Robaeys, G; Soker, A; Swan, T | 1 |
| Alves, K; Burroughs, M; Chayama, K; Kato, K; Kumada, H; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Zhang, X | 1 |
| Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E | 1 |
| Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Metreveli, D; Ruadze, E; Sharvadze, L; Tsertsvadze, T | 1 |
| Andriulli, A; Guarino, M; Morisco, F | 1 |
| Alavian, SM; Rezaee-Zavareh, MS | 1 |
| Akutagawa, M; Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H; Yamanaka, M | 1 |
| Amin, J; Applegate, TL; Backmund, M; Bourgeois, S; Bruggmann, P; Bruneau, J; Conway, B; Cunningham, EB; Dalgard, O; Dore, GJ; Dunlop, A; Foster, GR; Grebely, J; Hajarizadeh, B; Hellard, M; Marks, PS; Midgard, H; Quiene, S; Robaeys, G; Shaw, D; Swan, T; Thurnheer, MC; Weltman, M | 1 |
| Elsharkawy, AM; Schmidt-Martin, D | 1 |
| Amin, J; Backmund, M; Bourgeois, S; Bruggmann, P; Bruneau, J; Conway, B; Cunningham, EB; Dalgard, O; Dore, GJ; Dunlop, A; Foster, GR; Grebely, J; Hajarizadeh, B; Hellard, M; Marks, PS; Midgard, H; Quiene, S; Robaeys, G; Thurnheer, MC; Weltman, M | 1 |
| Dillon, JF; Radley, A; Tait, J | 1 |
| GeurtsvanKessel, CH; Hullegie, SJ; Ramakers, C; Rijnders, BJA; van der Eijk, AA | 1 |
| Chen, PJ; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Kao, JH; Liu, CJ; Liu, TW; Su, TH; Wang, SC; Yeh, ML; Yu, ML | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S | 1 |
| Altice, FL; Barnard, T; Filippovych, S; Mazhnaya, A; Meteliuk, A; Zelenev, A | 1 |
| Cheema, HA; Hashmi, MA | 1 |
| Bella, R; Bertino, G; Borzì, AM; Drago, F; Gagliano, C; Madeddu, R; Malaguarnera, G; Malaguarnera, M; Pennisi, M | 1 |
| Casari, S; Castelli, F; Cattaneo, C; Chirico, C; Festa, E; Grecchi, C; Izzo, I; Odolini, S; Spinetti, A; Zaltron, S; Zanotti, P | 1 |
| Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D | 1 |
| Ahmad, I; Asad, MJ; Aziz, H; Irfan, J; Mehmood, A; Ovais, M; Raza, A; Zaman, N | 1 |
| Rostkowska, K; Simon, K; Szymanek-Pasternak, A | 1 |
| Caletti, G; Calvanese, C; Fiorenza, S; Fusaroli, P; Lisotti, A; Mandreoli, M | 1 |
| Comstock, E; Kottilil, S; Kumar, NS; Mathur, P; McSweegan, E; Mercer, N | 1 |
| Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Manns, MP; Port, K; Schlevogt, B; Solbach, P; Wedemeyer, H | 1 |
| Feroz, F; Sajid, M; Talat, H; Wahid, Z | 1 |
| Buccino, RV; Del Prete, V; Facciorusso, A; Muscatiello, N; Nacchiero, MC; Turco, A | 1 |
| Abd-Elsalam, S; Ahmad, YK; Badawi, R; Elfert, A; Sharaf-Eldin, M; Soliman, S | 1 |
| Duan, J; Liu, D; Ma, J; Wang, Y | 1 |
| Berendt-Obołończyk, M; Bianek-Bodzak, A; Lakomy, A; Lewczuk, A; Michalska, Z; Moszkowska, G; Obołończyk, Ł; Radowska, D; Siekierska-Hellmann, M; Sworczak, K; Wiśniewski, P | 1 |
| Liu, TW; Tsai, PC; Yu, ML | 1 |
| Bjøro, B; Dalgard, O; Midgard, H; Rustøen, T; Småstuen, MC; Verbaan, H | 1 |
| Liao, X; Lu, D; Sun, L; Zhou, W; Zhuang, L | 1 |
| Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA | 1 |
| Andreone, P; Di Donato, R; Furlini, G; Galli, C; Galli, S; Grandini, E; Guarneri, V; Loggi, E; Margotti, M; Re, MC; Vitale, G; Vukotic, R | 1 |
| Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M | 1 |
| Arora, A; Gupta, V; Kumar, A; Sharma, P | 1 |
| David, YJ; Riaz, M; Tahir, A | 1 |
| Abou-Samra, AB; Butt, AA; Shaikh, OS; Yan, P | 1 |
| Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Carlton-Smith, C; Chung, RT; Holmes, JA; Kim, AY; Lauer, GM; Lidofsky, A; Naggie, S | 1 |
| Aaltonen, V; Al-Juhaish, M; Alavesa, M; Pirilä, L; Vesti, E | 1 |
| Agarwal, K; Carey, I; Lampejo, T | 1 |
| Albillos, A; García González, M; Gea Rodríguez, F; Rodríguez de Santiago, E; Tavío Hernández, E; Téllez Villajos, L; Velázquez Kennedy, K | 1 |
| Apornpong, T; Avihingsanon, A; Burger, DM; Chaiyahong, P; Chittmittraprap, S; Colbers, A; Cuprasitrut, T; de Kanter, CTMM; Khemnark, S; Smolders, EJ; Tangkijvanich, P; Thammajaruk, N | 1 |
| Garcia-Broncano, P; Genebat, M; Harrington, S; Hua, S; Leal, M; Lichterfeld, M; Marchetti, G; Negron, J; Resino, S; Ruiz-Mateos, E; Tse, S; Vigano, S; Yu, XG; Zhengyu, O | 1 |
| Bräu, N; Dieterich, DT; Gorman, JM; Marcus, SM; Prieto, S; Stivala, A; Weiss, JJ | 1 |
| Morikawa, K; Ogawa, K; Sakamoto, N; Suda, G | 1 |
| El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A | 1 |
| Bao, Y; Grunow, N; Hudgens, S; Mehta, D; Pinsky, B; Saab, S | 1 |
| Elfert, AA | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z | 1 |
| Scott, LJ | 1 |
| Asthana, M; Chakrabarti, S; Chatterjee, K; Chattopadhya, NR; Choudhuri, T; Das, P; Kumar, A; Mohanty, S; Rajasubramaniam, S; Sahu, SK; Singh, SP | 1 |
| Amundsen, EJ; Dalgard, O; Kløvstad, H; Løvlie, AL; Meijerink, H; White, R; Wisløff, T | 1 |
| Ali, M; Aziz, H; Raza, A; Shinwari, ZK; Zia, A; Zia, M | 1 |
| Afdhal, N; Babusis, D; Curry, MP; Kirby, B; Mathias, A; McHutchison, JG; Murakami, E; Park, Y; Ray, AS; Wang, T | 1 |
| Fan, R; Hou, J; Liang, X; Sun, J | 1 |
| Collado, A; de Los Santos, I; Macías, J; Mancebo, M; Merino, D; Morano-Amado, LE; Palacios, R; Pérez, AB; Pérez-Pérez, M; Pineda, JA; Ríos, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Andreoni, M; Antinori, A; Bigoni, S; Boffa, N; Borghi, V; Bovis, F; Bruno, R; Cacopardo, B; Cattelan, A; Chirianni, A; D'Arminio Monforte, A; Di Biagio, A; Di Perri, G; Giacometti, A; Gori, A; Gubertini, G; Hasson, H; Mastroianni, C; Milazzo, L; Montagnani, F; Nicolini, LA; Niero, F; Parruti, G; Pasquazzi, C; Puoti, M; Saracino, A; Segala, D; Sollima, S; Spinetti, A; Taliani, G; Taramasso, L; Teti, E; Vullo, V | 1 |
| Andrade, LEC; Boylan, K; Calise, SJ; Cavazzana, I; Ceribelli, A; Chan, EKL; de la Torre, IG; Fritzler, MJ; Hasegawa, T; Hiepe, F; Isailovic, N; Kohl, K; Satoh, M; Selmi, C; Shoenfeld, Y; Tincani, A; Zheng, B | 1 |
| Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P | 1 |
| Abbott, JC; Boesecke, C; Jagjit Singh, GK; Kaye, S; McClure, MO; Nelson, M; Rockstroh, J | 1 |
| Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T | 1 |
| Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R | 1 |
| Ansari, MA; Barnes, E; Bowden, R; Hudson, E; Klenerman, P; Marchi, E; Mclean, A; Pedergnana, V; Ramamurthy, N; Spencer, CCA | 1 |
| Bukh, J; Galli, A; Gerstoft, J; Gottwein, JM; Mens, H | 1 |
| Kaplan, DE | 1 |
| Aziz, MT; Qazi, MH; Qureshi, S | 1 |
| Benson, AA; Lederman, N; Safadi, R; Wolf, D | 1 |
| Biernat, W; Czarny, J; Lange, M; Lewandowski, K; Niedoszytko, M; Nowicki, R; Wasąg, B; Ługowska-Umer, H | 1 |
| Applegate, TL; Bhagani, S; Cooke, G; Dore, GJ; Gane, E; Grebely, J; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Orkin, C; Pagani, N; Petoumenos, K; Tu, E | 1 |
| Adragão, T; Birne, R; Bruges, M; Carvalho, L; Chagas, C; Jorge, C; Lebre, L; Machado, D; Matias, P; Nascimento, C; Querido, S; Weigert, A | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| Basile, M; Cicchetti, A; Drago, C; Favaretti, C; Kheiraoui, F; Rolli, FR; Ruggeri, M | 1 |
| Feng, Y; Huang, P; Liu, M; Wu, J; Xia, X; Yao, Y; Yu, R; Yue, M; Zang, F; Zhuo, L | 1 |
| Bhushan, A; Chinnaswamy, S | 1 |
| Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M | 1 |
| Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM | 1 |
| Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR | 1 |
| Sadler, MD | 1 |
| Christensen, S; Sarrazin, C; Schulze Zur Wiesch, J; Vermehren, J; von Felden, J | 1 |
| Ali, A; Idrees, M; Naz, Z; Rafique, S; Saleem, K; Usman, S; Wahid, B | 1 |
| Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G | 1 |
| Kim, SM; Song, IH | 1 |
| Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R | 1 |
| Apostu, D; Campian, RS; Ciobanu, L; Ilea, A; Lucaciu, O; Mester, A | 1 |
| Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T | 1 |
| Clark, PJ; Clement, M; Dubois, L; Himmel, T; Kottilil, S; Lucas, JE; Lusk, S; Moseley, MA; Naggie, S; Osinusi, A; Patel, K; Thompson, WJ | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N | 1 |
| Hsu, CS; Wu, CC | 1 |
| Aurora, R; Kanda, T; Kato, N; Meyer, K; Moriyama, M; Ray, R; Ray, RB; Sasaki, R; Yokosuka, O | 1 |
| Jacobson, IM | 1 |
| Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G | 1 |
| Ahmed, AE; Bahy, D; El-Dahshan, D; Hanora, A; Wahid, A | 1 |
| Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M | 1 |
| Lee, TY; Yang, SS | 1 |
| Almeida, J; Arrelaro, R; Cintra, M; Corrêa, B; Cunha-Silva, M; Lopes, T; Lorena, S; Mazo, D; Rabello, M; Sevá-Pereira, T; Torino, AB; Vaz, N | 1 |
| Ashfaq, UA; Khalid, H; Masoud, MS | 1 |
| Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB | 1 |
| Al Khalloufi, K; Flocco, G; Kapila, N; Zervos, XB | 1 |
| Zeuzem, S | 4 |
| Hsiang, JC; Kumar, R; Tan, J; Thurairajah, PH | 1 |
| Buzzetti, E; Davidson, BR; Gurusamy, KS; Kalafateli, M; Thorburn, D; Tsochatzis, E | 2 |
| Gross, R; Guyatt, G; Lev-Ran, S; Saad, A; Yekutieli, D | 1 |
| Chang, KC; Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, FY; Lu, SN; Wang, JH; Yen, YH | 1 |
| Kimura, K | 1 |
| Asahina, Y; Doi, A; Hikita, H; Kai, Y; Kato, T; Kodama, T; Murayama, A; Nakabori, T; Nitta, S; Saito, Y; Sakamori, R; Suemizu, H; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R | 1 |
| Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I | 1 |
| Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R | 1 |
| Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H | 1 |
| Inoue, A; Komiyama, T; Matsumura, H; Mizunuma, T; Otori, K; Tanaka, Y; Yokomori, H | 1 |
| Brainard, DM; Gao, Z; Huang, R; Jiang, D; Li, W; Massetto, B; Mo, H; Rao, H; Stamm, LM; Wei, L; Xie, Q | 1 |
| Pol, S | 7 |
| Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q | 1 |
| Chen, M; Hu, P; Liu, K; Pan, Z; Peng, M; Qiu, K; Ren, H; Shen, Y; Xue, W | 1 |
| Cunningham, HE; Grgic, T; Lachiewicz, AM; Shea, TC | 1 |
| Abravanel, F; Alric, L; Bellière, J; Del Bello, A; Izopet, J; Kamar, N; Lavayssiere, L; Lhomme, S | 1 |
| Abou-Samra, AB; Aslam, S; Butt, AA; Shaikh, OS; Yan, P | 1 |
| Maasoumy, B; Manns, MP; Sandmann, L | 1 |
| Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X | 1 |
| Ahmed, GK; Darwish, AM; Hassaan, SH; Hassany, SM; Khalifa, H; Moustafa, EF; Ramadan, HKA | 1 |
| Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V | 1 |
| Frosi, A; Frosi, G; Meloni, MF | 1 |
| Kanda, T; Kaneko, T; Komoriya, T; Kuroda, K; Matsumoto, N; Matsuoka, S; Moriyama, M; Nakajima, N; Nirei, K; Ogawa, M; Shibata, T; Takayama, T; Tamura, A; Yamamoto, T; Yamazaki, M | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Wu, SH | 1 |
| Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ | 1 |
| Amin, J; Artenie, AA; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dore, GJ; Erratt, A; Feld, JJ; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Quiene, S; Read, P; Stedman, C | 1 |
| Wahid, B | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A | 1 |
| Feng, Y; Huang, P; Liu, M; Wu, J; Wu, X; Xia, X; Yang, S; Yu, R; Zang, F; Zhuo, L | 1 |
| Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM | 1 |
| Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP | 1 |
| Davis, GL; Klintmalm, GB; McKenna, GJ; O'Leary, JG | 1 |
| Ho, CK; Manos, MM; Murphy, RC; Shvachko, VA | 1 |
| de los Santos-Gil, I; Gea, I; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merchante, N; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F; Torres-Cornejo, A | 1 |
| Anthony, D; Asaad, R; Debernardo, R; Funderburg, NT; Harding, CV; Hardy, GA; Jiang, W; Lederman, MM; Mudd, J; Pilch-Cooper, HA; Rabin, RL; Rodriguez, B; Schacker, T; Sieg, S | 1 |
| Cohn, J; Piot, P; Swan, T; von Schoen-Angerer, T | 1 |
| Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ | 1 |
| Banfi, G; Battista Fogazzi, G; Cresseri, D; Fabrizi, F; Francesca Donato, M; Martin, P; Messa, P | 1 |
| Hopwood, M | 1 |
| Ding, CB; Hu, ZY; Jiang, JD; Peng, ZG; Qin, W; Song, DQ; Tong, JW; Zhang, JP; Zhao, LX; Zhao, Y | 1 |
| Barnes, E; Bucci, C; Christian, A; Collier, J; Flemming, VM; Halliday, J; Harrison, A; Irving, W; Klenerman, P; Manganis, C; von Delft, A | 1 |
| Congeni, JP; Kirkpatrick, RB | 1 |
| Fukuhara, T; Furusyo, N; Ikegami, T; Kato, M; Kotoh, K; Maehara, Y; Motomura, T; Shimoda, S; Shirabe, K; Soejima, Y; Yoshizumi, T | 1 |
| Castelnovo, D; Fisher, M; Gilleece, Y; Keller, M; Mistry, H; Tibble, J; Webster, DP; Wojcikiewicz, T | 1 |
| Berg, T; Buggisch, P; Cornberg, M; Deterding, K; Diepolder, H; Feyerabend, S; Galle, PR; Großhennig, A; Grüner, N; Hinrichsen, H; Jung, MC; Koch, A; Lüth, S; Malek, N; Manns, MP; Potthoff, A; Rogalska-Taranta, M; Schlaphoff, V; Spengler, U; Wedemeyer, H; Wiegand, J | 1 |
| Addis, MF; Babudieri, S; Cossu-Rocca, P; Dore, MP; Madeddu, G; Massarelli, G; Mura, MS; Nieddu, P; Pagnozzi, D; Soddu, A; Tanca, A; Uzzau, S | 1 |
| Ariumi, Y; Hiramoto, A; Hiraoka, O; Ikeda, M; Kato, N; Mori, K; Wataya, Y | 1 |
| Abdel-Rahman, M; El-Akel, W; El-Beshlawy, M; El-Raziky, M; Esmat, G; Saad, Y; Said, M; Zayed, N | 1 |
| Bassiony, H; El Raziky, M; El-Ghor, AM; El-Kamary, SS; Esmat, G; Mohamed, MM; Shaker, O | 1 |
| Alessio, L; Coppola, N; Messina, V; Pasquale, G; Pisaturo, M; Sagnelli, C; Sagnelli, E; Stanzione, M; Starace, M | 1 |
| Barbato, A; Cimino, E; Coppola, A; Di Minno, MN; Granata, F; Liccardo, S; Rossi, D; Ruosi, C | 1 |
| Bonnet, F; Hessamfar, M; Michaux, C; Morlat, P; Randrianasolo, D; Vandenhende, MA | 1 |
| Aqel, BA; Charlton, MR; Henry, TM; Keaveny, AP; Koning, L; Murphy, JL; Pungpapong, S; Rosser, BG; Ryland, KL; Satyanarayana, R; Vargas, HE; Yataco, ML | 1 |
| Baumert, TF; Felmlee, DJ; Xiao, F | 1 |
| Cheung, RC; Wong, RJ | 1 |
| Branch, AD; Chung, RT; Glesby, MJ; Hollabaugh, K; Kang, M; Wyatt, CM | 1 |
| Du, YJ; Li, X; Lu, RH; Wu, H; Xu, Y; Yu, JY; Zhang, L; Zou, HB | 1 |
| Alshuth, U; Böker, K; Heyne, R; Hüppe, D; John, C; Lutz, T; Mauss, S; Moog, G; Niederau, C; Witthöft, T | 1 |
| Abdelbary, MS; El-Akel, W; El-Kholy, B; El-Raziky, M; Esmat, G; Khairy, M; Khatab, H; Mabrouk, M | 1 |
| Mendes-Correa, MC; Núñez, M | 1 |
| Bory, F; Cañete, N; Carrión, JA; Castaño, JR; Castellví, P; Cirera, I; Coll, S; Galeras, JA; García-Retortillo, M; Giménez, MD; Gonzalez-Colominas, E; Márquez, C; Martin-Escudero, V; Martín-Santos, R; Navinés, R; Salas, E; Solà, R | 1 |
| Balart, L; Box, T; Brunda, M; Buggisch, P; Cooper, C; Ferenci, P; Hooper, G; Labriola-Tompkins, E; Larrey, D; Lawitz, E; Le Pogam, S; Lim, CY; Marcellin, P; Nájera, I; Navarro, MT; Shulman, NS; Terrault, NA; Thomas, D; Weltman, M; Yetzer, ES; Yoshida, E; Zhang, Y | 1 |
| Bergin, C; Farrell, G; Gardiner, CM; Keane, C; O'Shea, D; Peck-Radosavljevic, M; Reiberger, T | 1 |
| Koretz, RL | 1 |
| Baumert, TF; Doffoël, M; Fofana, I; Gut, JP; Habersetzer, F; Moenne-Loccoz, R; Murray, JM; Schvoerer, E; Stoll-Keller, F; Velay, A; Zeisel, MB | 1 |
| Barreiro, P; Camacho, A; Caruz, A; Di Lello, FA; Herrero, R; Macías, J; Merino, D; Neukam, K; Pineda, JA; Real, LM; Rivero, A; Rivero-Juárez, A; Soriano, V | 1 |
| Boland, GJ; Burger, DM; de Kanter, CT; Drenth, JP; Koek, GH; Siersema, PD; van Erpecum, KJ; van Loon, AM; van Soest, H; van Vlerken, LG | 1 |
| Bondí, ML; Cavallaro, G; Craparo, EF; Licciardi, M; Teresi, G | 1 |
| Bikharam, D; Musarat, K; Samiullah, S | 1 |
| Gordovskaia, NB; Ignatova, TM; Korotchaeva, IuV; Kozlovskaia, LV; Milovanova, SIu | 1 |
| Conway, B; Grebely, J; Hilsden, RJ; Lee, SS; Macphail, G | 1 |
| Backmund, M; Gansefort, D; Gerken, G; Gölz, J; Reimer, J; Scherbaum, N; Schmidt, CS; Schulte, B; Verthein, U | 1 |
| Amin, B; Jariwala, S; Patel, P; Rampur, L; Rosenstreich, DL | 1 |
| Aichelburg, MC; Breitenecker, F; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Scheiner, B; Trauner, M | 1 |
| Allen, AM; Kim, WR; Larson, J; Loftus, EV | 1 |
| Aziz, H; Gill, ML; Gill, U | 1 |
| Del Rio Martin, J; Fiel, MI; Satapathy, SK; Schiano, TD; Vanatta, JM | 1 |
| Berg, T; Fischer, J; Nuraldeen, R; Strnad, P; Trautwein, C | 1 |
| Aston, CE; Bader, T; Dunnam, M; Fazili, J; Frost, B; Gonterman, A; Hughes, LD; Madhoun, M | 1 |
| Camacho, A; Caruz, A; Gutierrez-Valencia, A; Lopez-Cortes, LF; Martinez-Dueñas, L; Rivero, A; Rivero-Juarez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A | 1 |
| Euliano, R; Juneja, M; Lewis, JH; Satoskar, R | 1 |
| Baumgarten, A; Boesecke, C; Ingiliz, P; Krämer, B; Mauss, S; Nattermann, J; Nischalke, HD; Rockstroh, JK; Spengler, U; Stellbrink, HJ; Voigt, E | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Peytavin, G; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Lo, GH | 1 |
| Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X | 1 |
| Arena, R; Azzaroli, F; Ballardini, G; Buonfiglioli, F; Calvanese, C; Cecinato, P; Colecchia, A; D'Errico, A; Del Gaudio, M; Lisotti, A; Mazzella, G; Pinna, AD; Quarneti, C; Tamè, M | 1 |
| Dusheiko, GM; Rosenberg, WM; Tanwar, S; Trembling, PM | 1 |
| Bichoupan, K; Branch, A; Brinkley, S; Dieterich, D; Martel-Laferrière, V; Perumalswami, P; Posner, S; Schiano, T; Stivala, A; Sulkowski, M | 1 |
| Hsu, YC; Wu, CY | 1 |
| Hashizume, H; Horiguchi, N; Kakizaki, S; Mori, M; Sato, K; Yamazaki, Y; Yanagisawa, M | 1 |
| Andrade, RJ; García-Samaniego, J | 1 |
| Serfaty, L | 3 |
| Chiari, E; Cocca, G; Moioli, MC; Morreale, M; Orso, M; Panzeri, C; Puoti, M; Rossotti, R; Travi, G | 1 |
| Caudle, KE; Gong, L; Johnson, SG; Klein, TE; Lee, MT; Muir, AJ; Nelson, DR; Williams, MS | 1 |
| Karatapanis, S; Lisgos, P; Ntetskas, G; Papakonstantinou, L; Papastergiou, V; Prodromidou, K; Skorda, L; Stampori, M | 1 |
| Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A | 1 |
| Khokhar, N; Niazi, TK; Qureshi, MO | 1 |
| Bansal, M; Bichoupan, K; Branch, AD; Crismale, JF; Dieterich, DT; Liu, LU; Martel-Laferrière, V; Odin, JA; Pappas, A; Perumalswami, PV; Schiano, TD; Schonfeld, E; Wyatt, C | 1 |
| Altamura, S; Crowe, J; Muckenthaler, M; Ryan, JD | 1 |
| Ho, HJ; Hsiao, NW; Hsu, YC; Huang, YT; Kao, YH; Lin, JT; Liu, YY; Wu, CY; Wu, MS | 1 |
| Morgan, TR; O'Brien, TR; Pfeiffer, RM; Wang, AS | 1 |
| Caruz, A; Cifuentes, C; Macías, J; Mira, JA; Neukam, K; Pineda, JA; Real, LM; Rivero, A; Rivero-Juarez, A; Soriano, V | 1 |
| Bride, BE; Nackerud, LG; Sims, OT; Whalen, CC | 1 |
| Botros, J; Clark, G; Dhaliwal, S; Li, CS; Minoletti, MM; Rossaro, L; Torruellas, C | 1 |
| Chiba, T; Fujimoto, Y; Haga, H; Ito, T; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
| Kottilil, S; Lee, YJ; Murphy, A; Shivasabesan, G; Siebenlist, U; Suffredini, AF; Vazquez, E; Wang, H; Young, HA; Zhang, X | 1 |
| Andonov, A; Lu, Y; Wong, DK | 1 |
| Akuta, N; Arase, Y; Fukushima, T; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Liu, CJ | 1 |
| Backus, LI; Belperio, PS; Cheung, R; Mole, LA; Shahoumian, TA | 1 |
| Abadir, N; Cooper, C; Elkashab, M; Enns, R; Farley, J; Greenbloom, S; Hilzenrat, N; Neuman, M; Shafran, S; Williams, K | 1 |
| El Zanaty, T; Mohamed Seif, S; Mostafa, A; Omran, MH; Saad, A; Youssef, SS | 1 |
| Bhagani, S; Rockstroh, JK | 1 |
| Barluenga, E; Clotet, B; Jou, A; López, JJ; Muga, R; Ojanguren, I; Planas, R; Sanmartín, R; Sanvisens, A; Tor, J; Tural, C; Videla, S | 1 |
| Bányai, T; De Bartolomeo, G; Gervain, J; Habersetzer, F; Mangia, A; Mulkay, JP; Ouzan, D; Parruti, G; Passariello, N; Remy, AJ; Rizzetto, M; Rodriguez-Torres, M; Schmitz, M; Shiffman, ML; Tatsch, F; Tice, AD | 1 |
| Berg, RK; Buzon, MJ; Ferrando-Martinez, S; Leal, M; Lichterfeld, M; Ruiz-Mateos, E; Shaw, A; Sun, H; Yu, XG | 1 |
| Akimitsu, N; Salam, KA | 1 |
| Anthony, DD; Blanton, RE; Judge, CJ; Meng, Q; Phat, S; Rani, MR; Rodriguez, B; Sugalski, JM | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Toon, CD; Tsochatzis, E; Xirouchakis, E | 1 |
| Cozen, ML; Hartigan-O'Connor, DJ; Lanier, LL; Lin, D; Manos, MM; McCune, JM; Ryan, JC; Segal, MR; Shvachko, VA; Terrault, NA | 1 |
| Aires, R; Ancuta, I; Arohnson, A; Cheinquer, H; Delic, D; Ferenci, P; Gschwantler, M; Larrey, D; Ouzan, D; Schmitz, M; Tallarico, L; Tatsch, F | 1 |
| Ferguson, MC | 1 |
| Agnesod, D; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Mohamed Abdi, A; Simiele, M | 1 |
| Gadano, AC; Marciano, S | 1 |
| Corouge, M; Pol, S; Vallet-Pichard, A | 1 |
| El Kassas, M; El Raziky, M; Esmat, G; Gamil, M; Hassany, M | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Guedj, J; Kern, S; Levi, M; Li, B; Naoumov, NV; Perelson, AS; Yu, J | 1 |
| Brass, CA; Bräu, N; Galler, GW; Lawitz, EJ; Lee, WM; Long, J; McHutchison, JG; Melia, MT; Muir, AJ; Noviello, S; Nyberg, LM; Pedicone, LD; Poordad, F; Schiff, E; Shiffman, ML; Sulkowski, MS | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Dekio, F; Malik, S; Wen, JW | 1 |
| Callanan, M; Fugier, E; Hoang, XS; Jouvin-Marche, E; Leroy, V; Macek Jílková, Z; Marche, H; Marche, PN; Marlu, A; Sturm, N; Thelu, MA; Van Campenhout, N; Zarski, JP | 1 |
| Angarano, G; Babudieri, S; Di Perri, G; Fabris, P; Fasano, M; Marino, N; Pizzigallo, E; Sagnelli, E; Santantonio, T; Toti, M; Tundo, P | 1 |
| Ahmed, AI; Aziz, IA; Bahnasy, KA; Fathelbab, IF; Hafez, TA; Kamal, SM; Kassim, SK; Mahmoud, S; Mansour, HM | 1 |
| Ali, RJ; Bonanzinga, S; Bowden, DS; Cheng, WS; Crawford, DH; Desmond, PV; Dore, GJ; Holmes, JA; Matthews, GV; McCaughan, GW; Roberts, SK; Sievert, W; Sundararajan, V; Thompson, AJ; Visvanathan, K; Weltman, MD | 1 |
| Kang, W; Lu, Y; Sun, Y; Tong, HI | 1 |
| Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Guillaudeau, A; Jacques, J; Legros, R; Loustaud-Ratti, V; Sautereau, D; Vong, C | 1 |
| Koh, C; Liang, TJ | 1 |
| Furusyo, N; Hayashi, J; Hiramine, S; Ikezaki, H; Kainuma, M; Mitsumoto, F; Murata, M; Ogawa, E; Shimizu, M; Takayama, K; Toyoda, K | 1 |
| Campo, DS; Dimitrova, Z; Forbi, JC; Khudyakov, Y; Lau, DT; Skums, P; Teo, CG; Vaughan, G | 1 |
| Abdel-Hady, M; Bansal, S; Barnes, E; Brown, M; Davies, P; Davison, SM; Kelly, DA; Mieli-Vergani, G; Mulla, S; Tizzard, SA | 1 |
| Badenhoop, K; Berg, T; Boecher, WO; Buggisch, P; Dikopoulos, N; Encke, J; Goeser, T; Grammatikos, G; Klinker, H; Lange, C; Penna-Martinez, M; Sarrazin, C; Schulte-Frohlinde, E; Schwendy, S; Susser, S; Teuber, G; Thimme, R; Zeuzem, S | 1 |
| Carrion, AF; Gutierrez, J; Martin, P | 1 |
| Buhl, MR; Christensen, PB; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Martner, A; Mørch, K; Nilsson, S; Norkrans, G; Nyström, K; Pedersen, C; Rembeck, K; Waldenström, J; Westin, J | 2 |
| De Biasi, C; Dukan, P; Javelle, E; Lightburne, E; Morand, JJ | 1 |
| Ali, M; Idrees, M; Rehman, IU | 1 |
| Buljan, D; Gelo, J; Sakoman, LN; Sindik, I; Vrbanac, DB | 1 |
| Fabien, S; Filomena, C; Gautier, G; Khaldoun, G; Laurissa, O; Lynda, A; Nadira, D; Olivier, M; Vivian, V; Yvon, C | 1 |
| Aldámiz, T; Benito, JM; Berenguer, J; Fernández-Rodríguez, A; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; López, JC; Miralles, P; Rallón, N; Resino, S; Restrepo, C; Soriano, V | 1 |
| Angarano, G; Bruno, R; Capetti, A; Caputo, A; Cariti, G; Carosi, G; Galli, M; Gulminetti, R; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Raise, E; Ravasio, V; Verucchi, G | 1 |
| Chuang, WL; Dai, CY; Yu, ML | 3 |
| Fasano, M; Sagnelli, E; Santantonio, TA | 1 |
| Gutierrez, JA; Wyles, DL | 1 |
| Andreone, P; Beumont-Mauviel, M; Bronowicki, JP; Brown, A; De La Rosa, G; Forns, X; Gane, E; Horban, A; Kalmeijer, R; Lawitz, E; Lenz, O; Ouwerkerk-Mahadevan, S; Peeters, M; Scott, J; Sinha, R; Zeuzem, S | 1 |
| Ampuero, J; Reddy, KR; Romero-Gómez, M | 2 |
| Hoshino, T; Kakizaki, S; Koitabashi, E; Kudo, T; Naganuma, A; Okamoto, H; Ryusaki, K; Sakamoto, N; Takagi, H; Uehara, S | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Bechstein, WO; Farnik, H; Ferreiros, N; Galle, PR; Geisslinger, G; Herrmann, E; Kronenberger, B; Labocha, S; Sarrazin, C; Welker, MW; Zeuzem, S; Zimmermann, T | 1 |
| Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N | 1 |
| Allen, R; Bau, S; Busuttil, RW; Durazo, F; El-Kabany, M; Goldstein, L; Han, S; Manne, V; Reynolds, JA; Saab, S | 1 |
| Ahlenstiel, G; Chepa-Lotrea, X; Feld, JJ; Liang, TJ; Noureddin, M; Rehermann, B; Rotman, Y; Serti, E; Stoltzfus, J; Werner, JM | 1 |
| Nair, S; Waters, B | 1 |
| Fridell, JA; Ghabril, M; Joseph Tector, A; Kwo, PY; Lacerda, MA; Vianna, R | 1 |
| Abdo, AA; Al-Ahdal, MN; Al-Ashgar, HI; Al-Qahtani, AA; Alhamlan, FS; ElHefnawi, M; Khalaf, NZ; Sanai, FM; Zaid, A | 1 |
| Asselah, T; Berg, T; Böcher, WO; Datsenko, Y; Dieterich, D; Ferenci, P; Guyader, D; Larrey, D; Maieron, A; Mauss, S; Ozan, M; Ratziu, V; Schuchmann, M; Steinmann, G; Stern, JO | 1 |
| Boix, L; Bruix, J; Coto-Llerena, M; Forns, X; Friesland, M; Gastaminza, P; López-Oliva, JM; Mingorance, L; Pérez-del-Pulgar, S | 1 |
| Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J | 1 |
| Goto, S; Hayashi, N; Izumi, N; Kato, M; Ki, R; Komada, Y; Kumada, H; Okanoue, T; Seto, C; Tsubouchi, H; Yatsuhashi, H | 1 |
| Antoine, SL; Mathes, T; Pieper, D | 1 |
| Fukuhara, T; Harimoto, N; Ikegami, T; Konishi, H; Maehara, Y; Matsumoto, Y; Motomura, T; Shirabe, K; Soejima, Y; Yoshizumi, T | 1 |
| Mondelli, MU | 1 |
| Aghemo, A; Castaldi, D; Colombo, M; D'Ambrosio, R; Degasperi, E; Galmozzi, E; Grassi, E; Rumi, MG; Soffredini, R | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Abdelrahman, T; Hughes, J; Main, J; McLauchlan, J; Thomson, E; Thursz, M | 1 |
| Akuta, N; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Brown, RS; Burton, JR; Dodge, JL; Everson, GT; Levitsky, J; O'Leary, JG; Saxena, V; Stravitz, RT; Terrault, NA; Trotter, JF; Verna, EC | 1 |
| Cooper, CL; Klein, MB | 1 |
| Berg, T; Buggisch, P; Buslau, A; Hinrichsen, H; Maasoumy, B; Sarrazin, C; Schiefke, I; Wedemeyer, H; Wiegand, J | 1 |
| Ballester, R; Bernaards, C; Bertasso, A; Dwyer, C; Gane, EJ; Hammond, J; Kindrick, A; Marcellin, P; Morcos, PN; Nájera, I; Pockros, PJ; Shikhman, A; Shulman, NS; Smith, P; Stancic, S; Tong, X; Yetzer, ES; Zeuzem, S; Zhou, J | 1 |
| Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O | 1 |
| An, J; Deng, H; Feng, Y; Ji, F; Li, Z; Xiao, S; Zhang, Y | 1 |
| Andrade, LE; Chan, EK; Ferraz, ML; Keppeke, GD; Satoh, M | 1 |
| Chen, CL; Chiu, KW; Hu, TH; Kabiling, C; Lin, CC; Lin, YH; Liu, YW; Wang, CC | 1 |
| Chan, J | 1 |
| Ohmichi, T; Oka, N; Yasuda, R; Yoshioka, A; Yuki, N | 1 |
| Bell, MC; Curto, TM; Dienstag, JL; Snow, KK; Stoddard, AM; Wright, EC | 1 |
| Ahmad, N; Ali, L; Hashmi, AH; Khan, KM; Mansoor, A; Riaz, S; Shakoori, AR; Siddiqi, S | 1 |
| Rice, CM; Saeed, M | 1 |
| Abdel-Hamid, M; Albert, ML; Bonnard, P; Casrouge, A; Duffy, D; El-Daly, M; Fontanet, A; Hézode, C; Izopet, J; Laird, ME; LeFouler, L; Mallet, V; Mamdouh, R; Mohamed, MK; Mohsen, A; Pawlotsky, JM; Pol, S; Rafik, M; Renard, P; Rosa, I; Soulier, A | 1 |
| Brown, RS; Dove, LM; Fox, AN; Lukose, T; Mentore, K; Olsen, SK; Shetty, K; Terry, N; Verna, EC | 1 |
| Holmes, JA; Matthews, GV; Thompson, AJ | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Corouge, M; Pol, S | 1 |
| Camacho, A; Gordon, A; López-Cortés, LF; Pineda, JA; Rivero, A; Rivero-Juarez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A; Viciana, P | 1 |
| Gatanaga, H; Igari, T; Ishikane, M; Kikuchi, Y; Masaki, N; Nozaki, Y; Oka, S; Tsukada, K; Watanabe, K; Yanase, M | 1 |
| Cabré Serres, M; Gorgas Torner, MQ; Parra Uribe, I; Pontes García, C; Rudi Sola, N; Vergara Gómez, M | 1 |
| Blunn, A; Chitturi, S; Farrell, G; Kaye, G; Rodrigo, K; Rodriguez-Morales, I; Shadbolt, B; Teoh, N; To, C; Wu, JY | 1 |
| Burki, T | 1 |
| Colić-Cvrlje, V; Kanizaj, TF; Mrzljak, A; Ostojić, R | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Itoh, A; Katano, Y; Kumada, T; Kuzuya, T; Nakano, I; Toyoda, H; Yoshioka, K | 1 |
| El-Saadany, ZA; Foad, NB; Gouda, HM; Salama, RM | 1 |
| Chung, RT; Feeney, ER | 1 |
| Abraham, P; Alagammai, PL; Basu, G; Goel, A; Mahajan, R; Ramachandran, J; Sivakumar, J; Tamilarasi, V | 1 |
| Sakamoto, N | 1 |
| Carrier, P; Chambaraud, T; Debette-Gratien, M; Essig, M; Jacques, J; Loustaud-Ratti, V; Rousseau, A; Sautereau, D; Vong, C | 1 |
| Arends, JE; Baumgarten, A; Boesecke, C; Hoepelman, AI; Ingiliz, P; Rockstroh, JK; Schwarze-Zander, C; Stellbrink, HJ; Strassburg, CP; van Assen, S; Wasmuth, JC | 1 |
| Bruno, R; Capetti, A; Cariti, G; Galli, M; Iannacone, C; Nasta, P; Palmieri, G; Puoti, M; Raise, E; Ravasio, V | 1 |
| Izumi, N | 1 |
| Bichoupan, K; Branch, AD; Crismale, J; Dieterich, DT; Gardenier, D; Khaitova, V; Linderman, M; Liu, L; Martel-Laferriere, V; Moskowitz, AJ; Ng, M; Odin, JA; Pappas, A; Perumalswami, PV; Sachs, D; Schiano, TD; Schonfeld, EA; Stivala, A | 1 |
| Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P | 1 |
| Avasthi, A; Chawla, YK; Grover, S; Mahajan, S | 1 |
| Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E | 1 |
| Diament, J; Fan, M; Fleckenstein, JF; Handorf, CR; Handorf, E; Li, K; Marion, TN; Pfeffer, LM; Pfeffer, SR; Yang, CH | 1 |
| Arenas, JI; Bárcena, R; Buti, M; Calleja, JL; Crespo, J; de la Revilla, J; Delgado, M; Fernández-Rodríguez, CM; Forns, X; Gea, F; Larrubia, JR; Navarro, JM; Pascasio, JM; Pérez-Álvarez, R; Planas, R; Romero-Gómez, M; Ruiz-Antorán, B; Solá, R; Sousa, JM | 1 |
| Blanco, JL; Gatell, JM; González-Cordón, A; Laguno, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Monteiro, P; Pérez, I; Rojas, JF; Torres, B | 1 |
| Melchjorsen, J; Ruiz-Sanchis, P; Smith, AA; Tolstrup, M; Wohl, BM; Zelikin, AN; Zuwala, K | 1 |
| Berak, H; Bukowska-Ośko, I; Caraballo Cortés, K; Demkow, U; Fic, M; Horban, A; Laskus, T; Pawełczyk, A; Perlejewski, K; Płoski, R; Radkowski, M | 1 |
| Alavian, SM; Bokharaei-Salim, F; Keyvani, H; Mehrnoush, L; Monavari, SH; Sadeghi, F; Salehi-Vaziri, M | 1 |
| Andreone, P; Conti, F; Vitale, G | 1 |
| Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F | 1 |
| Falconer, K; Malone, DF; Sandberg, JK; Weiland, O | 1 |
| Bruzzi, P; Girardi, E; Ippolito, G; Lanini, S; Mammone, A; Puro, V | 1 |
| Price, JC; Terrault, NA | 1 |
| Bernard, PH; Bernardeschi, C; Duclos-Vallée, JC; Dupin, N; Gressier, L; Hezode, C; Mallet, V; Milpied, B; Ortonne, N; Pol, S; Samuel, D; Valeyrie-Allanore, L; Wallet-Faber, N | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Aishima, S; Harimoto, N; Ikegami, T; Ito, S; Kawanaka, H; Maehara, Y; Ninomiya, M; Shirabe, K; Soejima, Y; Uchiyama, H; Wang, H; Yoshizumi, T | 1 |
| Barreca, GS; Basso, M; Costa, C; De Maria, V; Di Salvo, S; Focà, A; Franzetti, MM; Giancotti, F; Lamberti, AG; Liberto, MC; Marascio, N; Matera, G; Parisi, SG; Pisani, V; Postorino, MC; Strazzulla, A; Torti, C; Zicca, E | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Briz, V; Carrero, A; Diez, C; García-Álvarez, M; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez, S | 1 |
| Amadasi, S; Castelli, F; Cerini, C; Giralda, M; Nasta, P; Odolini, S | 1 |
| Ashkenazi, YJ; Cotler, SJ; D'Amato, M; Dahari, H; Gafanovich, I; Goldin, E; Lurie, Y; Pohl, RT; Shteingart, S; Tichler, T; Weiss, G | 1 |
| Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA | 1 |
| Kwong, AD; Tong, X | 1 |
| Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D | 1 |
| Foster, GR | 2 |
| Abdel-Mohsen, M; Danesh, A; Deng, X; Günthard, HF; Jacobs, ES; Ledergerber, B; Liegler, T; Norris, PJ; Pillai, SK; Rauch, A; Wong, JK | 1 |
| Abate, ML; Caviglia, GP; Ciancio, A; Olivero, A; Pellicano, R; Rizzetto, M; Rosso, C; Smedile, A; Strona, S; Touscoz, GA | 1 |
| Andriulli, A; Andriulli, N; Barone, M; Corritore, G; Cozzolongo, R; D'Andrea, G; Fasano, M; Fontana, R; Gatti, P; Giannitrapani, L; Gioffreda, D; Ippolito, AM; Latiano, A; Margaglione, M; Milella, M; Morisco, F; Palmieri, O; Santantonio, T; Tundo, P; Valvano, MR | 1 |
| Cheng, HS; Hung, CH; Hung, IW; Hwang, JJ; Lin, CH; Lo, CC; Tsai, WJ | 1 |
| Castro, JA; Cifuentes, C; González-Candelas, F; Homar, F; López-Labrador, FX; Matas, M; Moya, A; Payeras, A; Picornell, A; Ramon, C | 1 |
| Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA | 1 |
| Andreone, P; Berg, T; De Meyer, S; DeMasi, R; Diago, M; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Lonjon-Domanec, I; Luo, D; Picchio, G; Pol, S; Roberts, S; Younossi, Z; Zeuzem, S | 1 |
| Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA | 1 |
| Alqahtani, SA; Dhingra, A; Kapoor, S | 1 |
| Andrade, RJ; Buti, M; Casado, MA; Gros, B; Oyagüez, I; Serra, MA; Turnes, J | 1 |
| Stirnimann, G | 1 |
| Chang, CS; Cho, SF; Chuang, WL; Hsiao, HH; Hsiao, SY; Hsu, JF; Lin, SF; Liu, TC; Liu, YC; Tsai, HJ; Wang, HC; Wu, CH; Yu, ML | 1 |
| Davis, JS; Ianna, E; Jones, T; Silva, C | 1 |
| Bialas, K; Holysz, M; Kmieciak, D; Migdalski, P; Trzeciak, WH | 2 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Ho, HJ; Hsu, YC; Huang, YT; Lin, JT; Wang, HH; Wu, CY; Wu, MS | 1 |
| Charlton, MR; Gallegos-Orozco, JF | 1 |
| Arena, U; Boldrini, B; Fabbrizzi, A; Fognani, E; Gragnani, L; Iannacone, C; Laffi, G; Monti, M; Piluso, A; Ranieri, J; Stasi, C; Urraro, T; Zignego, AL | 1 |
| Bridges, GG; Dorholt, M; Frazee, SG; Henderson, RR; Levin, RJ; Visaria, J | 1 |
| Chusri, P; Kumthip, K; Maneekarn, N; O'Brien, A; Pantip, C; Thongsawat, S | 1 |
| Benjelloun, S; Ezzikouri, S; Inoue, K; Kino, Y; Kohara, M; Matsumori, A; Nishimura, T; Tsukiyama-Kohara, K | 1 |
| Jensen, BE; Smith, AA; Wohl, BM; Zelikin, AN | 1 |
| Aghemo, A; Donato, MF | 1 |
| Qi, W; Qin, S; Wang, J; Wang, X; Xu, Y; Zhang, Q; Zhang, Y; Zhao, P | 1 |
| Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS | 1 |
| de los Santos-Gil, I; Haubitz, S; Ingiliz, P; Lutz, T; Márquez, M; Mira, JA; Munteanu, D; Neukam, K; Pineda, JA; Rauch, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S | 1 |
| Khorrami, S; Merat, S; Mohammadpour, H; Poustchi, H; Shahzamani, K; Sharifi, AH; Zarif, MN | 1 |
| Benstead, TJ; Chalk, CH; Parks, NE | 1 |
| Kim, MJ; Koenigsmann, C; Moorjani, H; Spaulding, AC | 1 |
| Gattei, V; Mauro, E; Mazzaro, C | 1 |
| Färkkilä, M | 3 |
| Marqués-Lespier, J; Miranda-Avalo, EI; Morales-Vásquez, L; Muñoz-Acabá, J; Pastrana, R; Pérez-Cardona, CM; Quiñones-Badillo, Y; Rodríguez-Medina, JR; Torres, EA; Yamamura, Y | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Carey, L | 1 |
| Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M | 1 |
| Abdel-aal, AM; Abdou, MA; Eltayeb, AA; Othman, MH | 1 |
| Agarwal, K; Barnabas, A | 1 |
| Akamatsu, N; Aoki, T; Harada, N; Hasegawa, K; Ishizawa, T; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T; Yamaguchi, T | 1 |
| Benschop, KS; Duizer, E; Koopmans, MP; van der Avoort, HG | 1 |
| Gutierrez, J; Martin, P; Trivella, JP | 1 |
| Aldaz, A; Aumente-Rubio, MD; Beunza, M; Calvo, MV; Cano-Marron, M; Comas-Sugrañes, D; Conesa-Zamora, P; Cortijo, J; Díaz-Ruíz, P; García, M; García-Simón, MS; Gimenez-Manzorro, A; Herrero, JI; Jiménez-Mutiloa, E; Margusino-Framiñan, L; Martin-Barbero, M; Más-Serrano, P; Merino, E; Milara, J; Montero-Alvarez, JL; Outeda-Macias, M; Padullés-Zamora, N; Pastor-Clerigues, A; Saavedra-Aldrich, M; Saval, A; Schoenenberger, JA; Tévar-Alfonso, E | 1 |
| Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Kozlov, VK; Skipsky, IM; Stelmakh, VV; Sukhanov, DS | 1 |
| Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Akhtar, N; Bilal, M; Khan, A; Khan, MA; Rizwan, M | 1 |
| Eguchi, S; Hidaka, M; Kuroki, T; Miyaaki, H; Nakao, K; Soyama, A; Takatsuki, M; Yamashita, M | 1 |
| Pan, Q; van der Laan, LJ; Verstegen, MM | 1 |
| Arena, U; Boldrini, B; Corti, G; Laffi, G; Marra, F; Milani, S; Montalto, P; Monti, M; Piluso, A; Salomoni, E; Stasi, C; Zignego, AL | 1 |
| Akker, Dv; Berry, SM; Broglio, KR; Daar, ES; Detry, MA; Kalsekar, A; Le, T; Lewis, RJ; Quintana, M; Spellberg, B; Yuan, Y | 1 |
| Aguilar, R; Ampuero, J; Calleja, JL; Casado, MA; Crespo, J; Cuenca, B; Diago, M; Garcia-Samaniego, J; Gonzalez-Garcia, J; Leal, S; Muñoz-Molina, B; Oyagüez, I; Planas, R; Romero-Gómez, M; Sola, R; Turnes, J | 1 |
| Basevitz, A; Levit, S; Malnick, S; Sheidvasser, V | 1 |
| Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P | 1 |
| Bañares, R; Berenguer, J; Catalina, MV; López, JC; Miralles, P; Pérez-Latorre, L; Rincón, D; Sánchez-Conde, M | 1 |
| Aikata, H; Chayama, K; Fujino, H; Fukuhara, T; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Ishiyama, K; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Naeshiro, N; Ochi, H; Ohdan, H; Tashiro, H; Tsuge, M | 1 |
| Huarte, MP; Lacruz, B; Quispe, I; Tiberio, G; Torroba, L | 1 |
| Augustyniak-Bartosik, H; Bednarz, Z; Jakuszko, K; Klinger, M; Krajewska, M; Penar, J; Rukasz, D | 1 |
| Feld, JJ; Hoofnagle, JH; Pawlotsky, JM; Zeuzem, S | 1 |
| Qadir, A | 1 |
| Agrawal, S; Kwo, PY | 1 |
| Bakker, JA; Bierau, J; de Knegt, RJ; Leers, MP; Peltenburg, NC; Verbon, A; Vroemen, WH | 1 |
| Gao, Y; Li, H; Liu, Z; Su, H; Sun, Y; Tang, R; Zhang, D; Zhang, M; Zhou, S; Zhou, X | 1 |
| Devaki, P; Jencks, D; Nguyen, MH; Yee, BE | 1 |
| Bahnasy, K; El Gohary, E; Fouad, A; Ghoraba, D; Hafez, T; Hassan, H; Kamal, SM; Kassim, S; Nabegh, L | 1 |
| Chen, TY; Jain, MK | 1 |
| Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B | 1 |
| Ahmad, J; Bach, N; Chang, C; Chernyiak, M; Doucette, JT; Fiel, MI; Florman, SS; Grewal, P; Khaitova, V; Kim-Schluger, L; Lim, KB; Liu, L; Odin, J; Perumalswami, P; Schiano, TD; Sima, HR | 1 |
| Pár, A | 3 |
| Tornai, I | 1 |
| Hunyady, B; Makara, M | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Cope, R; Faulds, S; Glowa, T; Pickering, A; Prasad, R; Veldkamp, P | 1 |
| Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S | 1 |
| Baldelli, S; Cattaneo, D; Gervasoni, C; Milazzo, L; Peri, AM; Rizzardini, G | 1 |
| Aqel, BA; Chervenak, AE; Keaveny, AP; Leise, M; McLemore, R; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Bassiony, MM; El-Shabrawi, A; El-Shafeey, M; Fouad, E; Raya, Y; Yousef, A | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Dusheiko, G; Kalafateli, M; Manousou, P | 1 |
| Ianna, EA; Jones, TL; Reeves, GE; Tran, HA | 1 |
| Akhtar, M; Gititu, E; Jalluri, C; Ramirez, J; Wilkins, T | 1 |
| Ascione, A; Bruno, S; Coppola, C; Deodato, B; Mangia, A; Orlandini, A; Puoti, M; Schmitz, M | 1 |
| Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Fatiguso, G; Mohamed Abdi, A | 1 |
| Alshuth, U; Böker, K; Buggisch, P; Christensen, S; Hofmann, WP; Hüppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Schott, E | 1 |
| Abad-Fernández, M; Casado, JL; Dronda, F; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Vallejo, A | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CJ; Tseng, TC | 1 |
| Afzal, MS; Ahmad, T; Raza, H | 1 |
| Kao, JH | 1 |
| Cheetham, TC; Chiang, K; Hay, JW; Hechter, R; Kalsekar, A; Niu, F; Nyberg, L; Yuan, Y | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T | 1 |
| Cheli, S; Clementi, E; Falvella, FS; Landonio, S; Lombardi, A; Magni, C; Mazzali, C; Mondelli, MU; Rizzardini, G | 1 |
| Antón, JJ; Caylà, JA; de Juan, J; Faraco, I; Marco, A; Saíz de la Hoya, P; Trujols, J | 1 |
| Nair, S; Pai, G; Prabhu, RA; Reddy, NP; Suvarna, D | 1 |
| Chang, JJ; Chien, CH; Chien, RN; Hu, CC; Lin, CL | 1 |
| Aerssens, J; Darling, JM; Fanning, G; Fried, MW; Johansson, S; Scholliers, A; Talloen, W; Tuefferd, M | 1 |
| Aerssens, J; Darling, J; Fanning, G; Fried, MW; Johansson, S; Talloen, W; Tuefferd, M | 1 |
| Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
| Cheng, PN; Hsu, SJ; Huang, CF; Lai, HC; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, CW; Su, WW; Tsai, WL; Tseng, KC; Wang, CH; Yang, CC; Yu, ML | 1 |
| Enomoto, N; Higuchi, M; Itakura, J; Itakura, Y; Izumi, N; Kurosaki, M; Maekawa, S; Nakakuki, N; Nakanishi, H; Suzuki, S; Takada, H; Takahashi, Y; Tamaki, N; Tsuchiya, K; Yasui, Y | 1 |
| Arai, M; Haga, Y; Imazeki, F; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Shirasawa, H; Yasui, S; Yokosuka, O | 1 |
| Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E | 1 |
| Bhangui, P; Choudhary, NS; Gautam, D; Goja, S; Lipi, L; Menon, PB; Ramachandra, SK; Rastogi, A; Saigal, S; Saraf, N; Soin, AS | 1 |
| Bieńkowska-Szewczyk, K; Chmielewska, AM; Król, E; Rychłowska, M; Solarz, K | 1 |
| Ayoub, WS; Lutchman, GA; Nguyen, MH; Nguyen, NH; Yee, BE; Yip, B; Zhang, B | 1 |
| Banhegyi, D; Bergin, C; Chernova, O; DeMasi, R; Doroana, M; Gori, A; Hadacek, B; Liu, C; Nelson, M; Rockstroh, JK; Verucchi, G | 1 |
| Benhaim, S; Borentain, P; Colson, P; Dhiver, C; Gerolami, R; Tamalet, C | 1 |
| Pol, S; Vallet-Pichard, A | 1 |
| Erickson, CP; Kalimullah, FA; Peng, LS; Smith, JA | 1 |
| García-Álvarez, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Vázquez-Morón, S | 1 |
| Badiani, B; Messori, A; Trippoli, S | 1 |
| Kilvert, L; Lee, SS; Liu, H; Trepanier, J | 1 |
| Wyles, DL | 2 |
| Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Yeh, ML; Yu, ML | 1 |
| Baumgarten, A; Bhagani, S; Boesecke, C; Guiguet, M; Ingiliz, P; Lutz, T; Mauss, S; Nelson, M; Page, E; Reiberger, T; Rockstroh, JK; Stellbrink, HJ; Valantin, MA; Vogel, M; Voigt, E | 1 |
| Azzola, E; Boldrini, A; Bruzzone, B; Cenderello, G; De Leo, P; Di Biagio, A; Grasso, A; Icardi, G; Lorusso, C; Nicolini, LA; Prinapori, R; Rappazzo, E; Sartini, M; Setti, M; Sticchi, L; Valle, C | 1 |
| Cascella, R; Ceccherini-Silberstein, F; Cento, V; Colabattista, C; Di Candilo, F; Di Giammartino, D; Di Maio, VC; Giardina, E; Manzoli, L; Monarca, R; Parruti, G; Perno, CF; Polilli, E; Prinapori, R; Rastrelli, E; Sciotti, M; Tontodonati, M; Trave, F; Vecchiet, J | 1 |
| Jordan, S; Lang, M; Lohse, AW; Nashan, B; Pischke, S; Polywka, S; Proske, VM; Sterneck, M | 1 |
| Chou, WW; Chuang, WL; Dai, CY; Hsi, E; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Juo, SH; Tsai, PC; Tsai, WL; Tsai, YS; Yeh, ML; Yu, ML | 1 |
| El-Abhar, HS; Mohamed, WA; Schaalan, MF | 1 |
| Brown, RS; Darling, JM; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Jacobson, IM; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Reddy, KR; Stewart, TG; Sulkowski, MS; Vargas, HE | 1 |
| Brainard, DM; Chan, HL; Han, LL; Knox, SJ; Lai, CL; Mo, H; Wong, VW; Yang, JC; Yuen, MF | 1 |
| Cai, Q; Deng, H; Gao, Z; Guan, Y; Guo, F; Hu, F; Huang, M; Lan, Y; Lin, C; Lin, G; Liu, Y; Lu, L; Luo, Q; Mei, Y; Ren, Z; Shao, X; Shi, H; Wei, M; Xu, M; Zhang, X; Zhao, Z; Zhu, J | 1 |
| Gabr, HA; Marzaban, RN; Mokhles, MA; Salama, ZA; Seyam, MS; Soliman, AF | 1 |
| Andolina, A; Bagaglio, S; Di Serio, C; Hasson, H; Lazzarin, A; Merli, M; Messina, E; Morsica, G; Porrino, L; Trentini, F; Uberti-Foppa, C | 1 |
| Cai, Z; Dang, S; Deng, H; Guo, Y; Huang, N; Ji, F; Jia, X; Li, Z; Liu, L; Wang, Y; Xue, H; Zhang, S | 1 |
| Blanco, J; Clotet, B; Crespo, M; Gómez-Mora, E; Jou, A; Martinez-Picado, J; Montaner, LJ; Morón-López, S; Navarro, J; Ouchi, D; Pérez, M; Puertas, MC; Salgado, M; Tural, C; Urrea, V | 1 |
| Bani-Sadr, F; Dabis, F; Gilbert, C; Loko, MA; Morlat, P; Neau, D; Rosenthal, E; Salmon, D; Simon, A; Valantin, MA; Wittkop, L | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Alric, L; Cacoub, P; Costopoulos, M; Fontaine, H; Guillaud, C; Hezode, C; Izzedine, H; Le Garff-Tavernier, M; Mallet, M; Musset, L; Plaisier, A; Pol, S; Poynard, T; Saadoun, D; Si Ahmed, SN; Thibault, V | 1 |
| Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I | 1 |
| Gonzalez, YS; Huber, C; Juday, T; Saab, S; Wang, A | 1 |
| Chen, DS; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Lo, YC; Sheng, WH; Su, TH; Sun, HY; Yang, HC | 1 |
| Biggins, SW; Burton, JR; Everson, GT; Gralla, J; Nordstrom, EM; Rosen, HR | 1 |
| Asselah, T; Baum, P; Böcher, WO; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Mensa, FJ; Müllhaupt, B; Roberts, SK; Schuchmann, M; Soriano, V; Stern, JO; Voss, F; Zeuzem, S | 1 |
| Carneiro, BM; Frick, DN; Hanson, AM; Mukherjee, S; Nogueira, ML; Provazzi, PJ; Rahal, P | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Arends, JE; Bierman, WF; Claassen, MA; Hullegie, SJ; Koopmans, PP; Lauw, FN; Leyten, EM; Newsum, AM; Posthouwer, D; Richter, C; Rijnders, BJ; van den Berk, GE; van der Meer, JT; van Eeden, A | 1 |
| Felger, JC; Haroon, E; Miller, AH; Raison, CL; Woolwine, BJ | 1 |
| Abuelhassan, W; Blackard, JT; Bowyer, SM; Mahlangu, J; Mahomed, A; Prabdial-Sing, N; Puren, AJ; Vermeulen, M | 1 |
| Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X | 1 |
| Dore, GJ; Martinello, M | 1 |
| Bellefquih, AM; Benani, A; Essalhi, M; Fayssel, N; Khyatti, M; Serghini, FZ; Trimbitas, RD; Wakrim, L | 1 |
| Agarwal, K; Brown, NW; Morgan, PE; Tredger, JM | 1 |
| Chen, X; Cheng, J; Han, T; Heo, J; Hoeben, E; Kalmeijer, R; Kim, JH; Lenz, O; Li, M; Ouwerkerk-Mahadevan, S; Peeters, M; Scott, J; Shang, J; Sinha, R; Verbinnen, T; Wei, L; Witek, J; Xie, Q; Yang, D | 1 |
| Cooke, GS; Hill, A; Riley, RD; Saleem, J; Simmons, B | 1 |
| Applegate, T; Dore, GJ; Grebely, J; Haber, P; Hellard, M; Iser, D; Lloyd, A; Maire, L; Martinello, M; Matthews, GV; Petoumenos, K; Sasadeusz, J; Shaw, D; Thompson, A; Yeung, B | 1 |
| Chen, TM; Huang, PT; Li, YC | 1 |
| Brennan, BJ; Eng, S; Gane, EJ; Hassanein, T; Kupcova, V; Le Pogam, S; Mazur, W; Morcos, PN; Rouzier, R; Scalori, A; Stedman, CA; Thommes, J; Voulgari, A | 1 |
| Gonzalez, HC; Nair, S; Satapathy, SK | 1 |
| Hasselblad, V; Muir, A; Saraswathula, A; Wilder, J | 1 |
| Chen, F; Chen, Z; Hu, Y; Liu, Y; Wang, J; Wu, S; Xue, J; Yang, F; Yang, Y; Zheng, M; Zhou, X; Zhu, H | 1 |
| Li, CX; Li, W; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW | 1 |
| Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N | 1 |
| Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM | 1 |
| Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R | 1 |
| Abunimeh, M; Bennett, M; Bernstein, DE; Cohen, DE; Cohen, E; Khatri, A; Lawitz, E; Mantry, PS; Pockros, PJ; Podsadecki, T; Reddy, KR; Shulman, NS; Sulkowski, MS; Wang, D | 1 |
| Cooper, C; Gill, J; Hull, M; Klein, MB; Moqueet, N; Platt, RW | 1 |
| Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G | 1 |
| Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H | 1 |
| Kim, KA | 1 |
| Jung, YK | 1 |
| Gwak, GY | 1 |
| Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Alshuth, U; Buggisch, P; Galle, PR; Grimm, D; Hueppe, D; Mauss, S; Pfeiffer-Vornkahl, H; Zimmermann, T | 1 |
| Fukuda, Y; Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Koike, K; Matsumoto, N; Matsunaga, K; Nakahara, K; Noguchi, Y; Okuse, C; Shigefuku, R; Shima, J; Suzuki, M; Watanabe, T; Yamamoto, H; Yasuda, H; Yotsuyanagi, H | 1 |
| Aghemo, A; Colombo, M | 1 |
| Alkhouri, N; Apfel, T; Hanouneh, IA; Hanouneh, M; Jackson, WE; John, BV; Zein, NN; Zervos, X | 1 |
| Arini, A; Bavetta, MG; Cabibbo, G; Calvaruso, V; Cammà, C; Conte, E; Craxì, A; Di Marco, V; Ferraro, D; Grimaudo, S; Peralta, S; Pipitone, RM; Simone, F | 1 |
| Ide, K; Kawasaki, Y; Masaki, N; Yamada, H | 1 |
| Araújo, FS; Coral, GP; Marcon, Pdos S; Mattos, AA; Tovo, CV | 1 |
| Belyakov, NA; Kizlo, SN; Mednikov, RV; Rabinovich, VI; Sokolov, AA | 1 |
| Anand, BS; Aytaman, A; Brau, N; Chang, KM; Cheung, R; Cozen, ML; Kaplan, DE; Monto, A; Morgan, T; Pedrosa, M; Pocha, C; Ryan, JC; Schmidt, WN; Shen, H | 1 |
| Carrieri, MP; Cotte, L; Fournier, I; Marcellin, F; Poizot-Martin, I | 1 |
| Abutidze, A; Bolokadze, N; Chkhartishvili, N; Sharvadze, L; Tsertsvadze, T | 1 |
| Ahmad, I; Chishti, MA; Nawaz, A; Nazar, H; Sheikh, ZA; Usmanghani, K | 1 |
| Doyle, JS; Hellard, ME; Veronese, V; Wade, AJ | 1 |
| Gaus, B; Hoffmann, M; Lemmenmeier, E; Schmid, P | 1 |
| Eguchi, S; Haraguchi, M; Hidaka, M; Ichikawa, T; Miuma, S; Miyaaki, H; Nakao, K; Shibata, H; Soyama, A; Takatsuki, M; Tamada, Y; Taura, N | 1 |
| Ridler, C | 1 |
| Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C | 1 |
| Afridi, JZ; Ahmad, B; Ali, I; Ali, S; Anwar, N; Mahmood, N; Saeedi, I | 1 |
| Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES | 1 |
| Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N | 1 |
| Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D | 1 |
| Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Alberi, G; Crocè, SL; Crovella, S; Masutti, F; Moratelli, G; Polesello, V; Pozzato, G; Segat, L; Zupin, L | 1 |
| Abdel Ghany, HM; Abdelraheem, WM; Abdelwahab, SF; Abuloyoun, SM; Hassuna, NA; Rizk, HA | 1 |
| Alavi, M; Dore, GJ; Doyle, JS; Grebely, J; Hellard, ME; Matthews, GV; Spelman, T; Thompson, AJ | 1 |
| Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O | 1 |
| Bayer, J; Gardner, EM; Johnson, S; Langness, J; Rogers, M; Rowan, SE; Smith, L | 1 |
| Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R | 1 |
| Agüero, F; Ambrosioni, J; Costa, J; Forner, A; Laguno, M; Lligoña, A; Londoño, MC; Manzardo, C; Miró, JM; Moreno, A; Rimola, A; Ruiz, P | 1 |
| Gountas, I; Hatzakis, A; Papatheodoridis, G; Razavi, H; Souliotis, G; Sypsa, V | 1 |
| Bajaj, JS; Betrapally, NS; Daita, K; Fuchs, M; Ganapathy, D; Gillevet, PM; Heuman, DM; Hylemon, PB; Nixon, DE; Sikaroodi, M; Sterling, RK; White, MB | 1 |
| Asselah, T; Buggisch, P; Buti, M; Craxí, A; Foster, GR; Gschwantler, M; Lenz, O; Lonjon-Domanec, I; Moreno, C; Ryan, R; Sarrazin, C; Schlag, M; Scott, J; Van Dooren, G | 1 |
| Castelli, F; Di Filippo, E; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Gagliardini, R; Gori, A; Maggiolo, F; Pan, A; Postorino, MC; Prosperi, M; Quiros Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Aguilar, H; Asatryan, A; Gane, E; Hassanein, T; Kort, J; Kwo, PY; Lalezari, J; Lin, CW; Liu, R; Maliakkal, B; Mensa, FJ; Ng, TI; Poordad, F; Wang, S; Wyles, DL | 1 |
| Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H | 1 |
| D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M | 1 |
| Kanda, T; Nakamoto, S; Shirasawa, H; Win, NN; Yokosuka, O | 1 |
| Feld, JJ; Jacobson, IM; Pawlotsky, JM; Poordad, F; Sulkowski, MS; Tatsch, F | 1 |
| Antoniazzi, S; Bolis, M; Carnovale, C; Clementi, E; Gentili, M; Landonio, S; Magni, C; Niero, F; Radice, S | 1 |
| Javed, A; Kausar, S; Mansoor, A; Mansoor, S; Muhammad Din, S; Riaz, S; Sultan, A | 1 |
| Abu Freha, N; Ben Yakov, G; Dizingof, V; Etzion, O; Fich, A; Monitin, S; Montano, D; Mushkalo, A; Shwarts, D; Sikuler, E; Takchick, A; Zilberman, D | 1 |
| Ampuero, J; Romero-Gómez, M | 1 |
| Alain, S; Dao, T; Deny, P; Gagnieu, MC; Loustaud-Ratti, V; Lunel-Fabiani, F; Marquet, P; Maynard, M; Picard, N; Pradat, P; Rousseau, A; Silvain, C; Thevenon, S; Tran, A; Trepo, C; Zublena, I | 1 |
| Boo, SJ; Cho, YK; Choi, EK; Jeong, SU; Kim, BS; Kim, HU; Lee, SJ; Na, SY; Song, BC; Song, HJ | 1 |
| Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A | 1 |
| Baribwira, C; Kiromera, A; Musabeyezu, E; Riedel, DJ; Sebeza, J; Simango, R; Taylor, S | 1 |
| Fortune, BE; Lim, JK; McCarty, TR; Njei, B | 1 |
| Hawke, P; Ide, K; Imai, T; Kawasaki, Y; Masaki, N; Sato, I; Yamada, H | 1 |
| Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S | 1 |
| Lanzetta, G; Puoti, C; Scotti, E | 1 |
| Jeong, SH; Kim, SM; Kim, YS; Lee, JS; Lee, JW; Lee, MS; Lim, YS; Park, SH; Shin, SR; Sohn, JH | 1 |
| Anthony, DD; Bonomo, RA; Chandar, AK; Compan, A; Davitkov, P; Falck-Ytter, Y; Gideon, C; Hirsch, A; Silveira, MG; Smith, S | 1 |
| Alric, L; Besson, C; Bonnet, D; Cacoub, P; Canioni, D; Davi, F; Hermine, O; Jeannel, J; Lapidus, N; Michot, JM; Pol, S; Rabiega, P; Ysebaert, L | 1 |
| Baouchi, F; Keniston, A; Martinez-Camacho, A; Nordstrom, EM | 1 |
| Berry, K; Green, PK; Ioannou, GN; Su, F | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Ardeshna, K; Maciocia, N; O'Brien, A | 1 |
| Arcaini, L; Carli, G; Merli, M; Visco, C | 1 |
| Moiseev, S; Mukhin, N; Novikov, P | 1 |
| Carrero, A; Cervantes, M; Cifuentes, C; Cruceta, A; de Lazzari, E; Deig, E; Gómez-Sirvent, JL; Guardiola, JM; Jou, A; Laguno, M; López-Calvo, S; Mallolas, J; Martínez-Rebollar, M; Montes, ML; Murillas, J; Navarro, J; Pineda, JA; Ruiz-Mesa, JD; Tapiz, A; Van den Eynde, E; Veloso, S; Von Wichmann, MA | 1 |
| Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K | 1 |
| Bramness, JG; Dalgard, O; Haukeland, JW; Midgard, H; Skurtveit, S | 1 |
| Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R | 1 |
| Arker, SH; Banerjee, D; Hlaing, NK; Mitrani, R; Reddy, KR; Thant, Z; Tun, NL; Win, KM; Win, KS | 1 |
| Liu, H; Yan, Y; Zhang, T | 1 |
| Acevedo, P; Bernal Blanco, G; Gentil Govantez, MA; Gonzalez Roncero, FM; Gonzalez-Corvillo, C; Perez Valdivia, MA; Sousa, JM; Suarez Benjumea, A; Suñer Poblet, M | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Chen, W; Dang, P; Feng, J; Ma, Y; Wang, L; Xi, W; Yu, Y | 1 |
| Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S | 1 |
| Hernandez, D; McPhee, F; Zhou, N | 1 |
| Asselah, T; Bicer, C; Buggisch, P; Buti, M; Craxí, A; Foster, GR; Gschwantler, M; Lenz, O; Lonjon-Domanec, I; Moreno, C; Nalpas, C; Sanai, F; Sarrazin, C; Schlag, M; Van Dooren, G | 1 |
| Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P | 1 |
| Aherfi, S; Brouqui, P; Colson, P; Dhiver, C; Meddeb, L; Menard, A; Mokhtari, S; Ravaux, I; Stein, A; Tissot-Dupont, H | 1 |
| Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z | 1 |
| Beck, R; Berg, CP; Dietz, J; Klag, T; Lauer, UM; Malek, NP; Sarrazin, C; Schwarz, JM; Werner, CR | 1 |
| Burra, P; Zanetto, A | 1 |
| Yu, ML | 1 |
| Abad, S; Albalate, M; de Sequera, P; Hernández, E; López-Gómez, JM; Macías, N; Mérida, E; Milla, M; Vega, A | 1 |
| Barbati, ZR; Dieterich, DT; El Sayed, A; Fierer, DS; Foster, AL; Morey, T; Turner, SS | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Akutagawa, M; Ide, K; Kawasaki, A; Kawasaki, Y; Masaki, N; Yamada, H | 1 |
| Lim, SG | 1 |
| Gong, G; Jiang, Y; Peng, F; Peng, M; Xiao, X; Zhang, M | 1 |
| Aziz, T; Hanif, FM; Laeeq, SM; Luck, NH; Mandhwani, RK; Mehdi, SH | 1 |
| Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B | 1 |
| Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN | 1 |
| Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C | 1 |
| Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Enquist, R; Glaumann, H; Hollander, A; Lindahl, K; Lindh, G; Mattsson, L; Quist, A; Schvarcz, R; Weiland, O | 1 |
| Gasztonyi, B; Lombay, B; Szalay, F | 1 |
| Akyol, G; Dalgic, B; Egritas, O; Sari, S; Vural, C | 1 |
| Ishii, S; Koziel, MJ | 1 |
| Borisov, AS; Massung, B; Miller, AH; Raison, CL; Vogt, G; Woolwine, BJ | 1 |
| Katagiri, S; Tokushige, K; Yamamoto, M | 1 |
| Camacho, F; Cooper, CL; Costiniuk, CT | 1 |
| Kasturi, KS; Mummadi, RR; Sood, GK | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 4 |
| Fischer, R; Giardina, PJ; Harmatz, P; Jonas, MM; Kwiatkowski, JL; Neufeld, EJ; Olivieri, N; Porter, J; Vichinsky, E; Wright, EC | 1 |
| Hopwood, M; Treloar, C | 1 |
| Arends, JE; Hoepelman, AI; Mudrikova, T; Schaar, CG; Schrover, IM | 1 |
| Egawa, H; Haga, H; Ito, T; Takada, Y; Tanaka, K; Ueda, Y; Uemoto, S | 1 |
| Obołończyk, L; Siekierska-Hellmann, M; Sworczak, K | 1 |
| Cacoub, P; Delluc, A; Ghillani-Dalbin, P; Piette, JC; Saadoun, D; Sene, D | 1 |
| Anselmo, M; De Leo, P; Grasso, A; Malfatti, F; Menardo, G; Toscanini, F | 1 |
| Hamada, N; Hara, K; Honda, H; Ide, T; Iwahashi, J; Kashiwagi, T; Kohara, M; Kumashiro, R; Ogata, K; Sata, M; Watanabe, H | 1 |
| Balan, V; Gallegos-Orozco, JF; Rakela, J; Rosati, MJ; Vargas, HE | 1 |
| Arizcorreta, A; Gutierrez-Valencia, A; Jimenez, L; Lopez-Cortes, LF; Ruiz-Valderas, R; Terrón, A; Valera-Bestard, B; Viciana, P | 1 |
| Pár, A; Pár, G | 1 |
| Diepolder, H; Gruener, NH; Heeg, M; Jung, MC; Loehe, F; Nitschko, H; Raziorrouh, B; Schirren, CA; Thiel, M; Ulsenheimer, A; Zachoval, R | 1 |
| Bonkovsky, HL; Chung, RT; Fontana, RJ; Ghany, MG; Lambrecht, RW; Lee, WM; Morgan, TR; Naishadham, D; O'Brien, TR; Sterling, RK; Wright, EC | 1 |
| Fragopanagou, E; Giannakoulas, NC; Lampropoulou-Karatza, Ch; Mimidis, K; Pallasopoulou, M; Thomopoulos, K; Tsamandas, AC | 1 |
| Bassetti, M; Beltrame, A; Dentone, C; Di Biagio, A; Lindstrom, V; Mazzarello, G; Ratto, S; Righi, E; Viscoli, C | 1 |
| Hamer, C | 1 |
| Chatelut, E; Dubois, M; Izopet, J; Lafont, T; Legrand-Abravanel, F; Nicot, F; Pasquier, C; Sauné, K | 1 |
| Barreiro, P; García-Gascó, P; Labarga, P; Maida, I; Martín-Carbonero, L; Morello, J; Rodriguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Gagnieu, MC; Maynard, M; Pradat, P; Souvignet, C; Trepo, C | 1 |
| Fasano, M; Santantonio, T | 1 |
| Burroughs, A; Calvaruso, V; Corbani, A; Leandro, G; Manousou, P; Patch, D; Sigalas, A; Triantos, C; Xirouchakis, E | 1 |
| Garattini, S | 1 |
| Bruno, S; D'Agostino, D; De Renzo, A; La Mura, V; Masarone, M; Perna, F; Persico, M; Romano, M; Torella, R | 1 |
| Conway, B; deVlaming, S; Duncan, F; Grebely, J; Viljoen, M | 1 |
| Lettmeier, B; Mühlberger, N; Schwarzer, R; Siebert, U; Sroczynski, G; Wright, D; Zeuzem, S | 1 |
| McGilvray, I; Selzner, N | 1 |
| Cupelli, L; Di Bisceglie, AM; Duff, F; Fried, MW; Jensen, DM; Lin, A; Morgan, TR; Nelson, DR; Nyberg, LM; Pockros, PJ; Rodriguez-Torres, M; Wang, K | 1 |
| Eason, J; Lipscomb, J; Nair, S | 1 |
| Bärthel, E; Habrecht, O; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Lapointe, N; Lemay, M; Martin, SR; Quesnel-Vallières, M; Soudeyns, H | 1 |
| Anand, B; Barange, K; Diago, M; Govindarajan, S; Hooper, G; Lin, A; Morgan, T; Rodriguez-Torres, M; Shiffman, M; Suter, F | 1 |
| Abbas, G; Hussain, S; Shafi, T | 1 |
| Cha, CH; Folk, WR; Hong, SP; Kim, KM; Kim, SO; Oh, HB; Suh, DJ | 1 |
| Altice, FL; Basu, S; Bruce, RD; Maru, DS | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Torres-Puente, M; Wrobel, B | 2 |
| Charlton, MR; Hay, JE; Heimbach, JK; Kremers, WK; Poterucha, JJ; Rosen, CB; Veldt, BJ; Watt, KD; Wiesner, RH | 1 |
| Smith, JP | 1 |
| Chuang, WL; Dai, CY; Huang, JF; Yu, ML | 1 |
| Agnelli, F; Arosio, E; Colombo, M; Donato, MF; Rigamonti, C | 1 |
| Andreone, P; Andriulli, A; Bacca, D; Cozzolongo, R; Cursaro, C; Iacobellis, A; Mangia, A; Minerva, N; Montalto, G; Scuteri, A; Stanzione, M; Valvano, MR | 1 |
| de Felipe, B; Gutiérrez, A; Leal, M; López-Cortés, L; Molina-Pinelo, S; Soriano-Sarabia, N; Vallejo, A | 1 |
| Fried, MW; Hadziyannis, SJ; Jensen, DM; Messinger, D; Reau, N | 1 |
| Capodiferro, S; Giuliani, M; Lajolo, C; Sartorio, A; Scivetti, M; Tumbarello, M | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Nelson, D; Nyberg, L; Pockros, P; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Arduino, R; Barnett, B; Bolcic, F; Bull, L; Martinez, L; Quarleri, J; Reynoso, R; Salomon, H | 1 |
| Deng, Q; Gao, DY; Gong, QM; Hou, G; Jin, GD; Kong, XF; Ling, Y; Lu, ZM; Yao, BL; Yu, DM; Zhan, Q; Zhang, DH; Zhang, XX | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Hsu, CS; Hsu, SJ; Kao, JH; Lai, MY; Liang, CC; Lin, CL; Liu, CH; Liu, CJ; Tseng, TC; Wang, CC; Yang, SS | 1 |
| Dev, AT; Heller, K; Kauf, TL; McHutchison, JG; Patel, K; Schulman, KA; Zekry, A | 1 |
| Azlarova, A; Bonetto, S; Chub, E; Fanning, LJ; Izopet, J; Kamitsukasa, H; Kurbanov, F; Legrand-Abravanel, F; Maruyama, I; Mizokami, M; Moreau, I; Naoumov, N; Netesov, S; Ohno, T; Shimada, T; Tanaka, Y | 1 |
| Bujan, L; Daudin, M; Moinard, N; Pasquier, C; Pecou, S; Walschaerts, M | 1 |
| Czerwionka-Szaflarska, M; Figlerowicz, M; Gronkowska, A; Kupś, J; Liberek, A; Pawłowska, J; Szaflarska-Popławska, A; Woźniakowska-Gesicka, T; Łoś-Rycharska, E | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Fehér, J; Lengyel, G; Wimmer, A | 1 |
| Edenberg, HJ; Kwo, P; McClintick, JN; Taylor, MW; Tsukahara, T | 1 |
| Dahari, H; Perelson, AS; Ribeiro, RM; Shudo, E | 1 |
| Godeau, B | 1 |
| McHutchison, JG; Patel, K; Thompson, A; Tillman, H | 1 |
| Thompson, AJ; Tillmann, HL | 1 |
| Brinkmann, K; Sabranski, M; Stoehr, A | 1 |
| Bader, T; Fazili, J; Le, V | 1 |
| Andriulli, A; Iacobellis, A; Ippolito, A | 1 |
| Aikata, H; Aimitsu, S; Chayama, K; Imamura, M; Ito, H; Jeong, SC; Kawakami, H; Kawakami, Y; Kawaoka, T; Kitamoto, M; Takahashi, S; Tsuji, K | 1 |
| Hoffman, CJ; Ray, SC | 1 |
| Bittar, C; Carareto, CM; de Queiróz, AT; Jardim, AC; Mello, IM; Pinho, JR; Rahal, P; Yamasaki, LH | 1 |
| Gault, E; Girard, PM; Gozlan, J; Lacombe, K; Raguin, G | 1 |
| Chung, RT; Tai, AW | 1 |
| Chaudhary, I; Collett, M; Douglas, D; Gao, T; Howe, AY; Immermann, F; Kneteman, NM; Lewis, J; Lund, G; Mercer, DF; O'Connell, J; Pevear, D; Speth, J; Tyrrell, DL; Villano, SA | 1 |
| Bacon, BR; Brunt, EM; Di Bisceglie, AM; George, SL; Hoffmann, J; Mihindukulasuriya, KL | 1 |
| Liebman, HA | 1 |
| Brandão-Mello, CE; Coelho, HS; de Segadas-Soares, JA; Nabuco, LC; Perez, RM; Villela-Nogueira, CA | 1 |
| Bhattacharyya, I; Cohen, DM; Islam, N; Katz, J; Ojha, J; Stewart, CM | 1 |
| Chao, YC; Chen, CL; Chen, DS; Chen, PJ; Chuang, WL; Jeng, YM; Kao, JH; Kuo, HT; Lee, CM; Liao, LY; Lin, CL; Liu, CH; Liu, CJ; Lu, SN; Su, WW; Tung, SY; Wu, SS; Yang, SS; Yu, ML | 1 |
| Bhatti, L; Dieterich, DT; Edlin, BR; Fishbein, DA; Goetz, MB; Wagner, GJ; Weiss, JJ; Yu, K | 1 |
| Buck, M; Feldstein, A; Kleiner, D; Kravetz, D | 1 |
| Duncea, I; Pepene, CE | 1 |
| Gordon, SC; Sherman, KE | 1 |
| Cassidy, W; Chen, H; Howell, CD; Huang, C | 1 |
| Cross, LB; Foard, JC; Gross, BN; Wood, YA | 1 |
| Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S | 1 |
| Pozza, R | 1 |
| Clavien, PA; Dinges, S; Dufour, JF; Giostra, E; Heim, M; Mentha, G; Morard, I; Müllhaupt, B; Negro, F | 1 |
| Bernard, PH; Castéra, L; Chanteloup, E; Couzigou, P; de Lédinghen, V; Foucher, J; Merrouche, W; Terrebonne, E; Tournan, R; Vergniol, J | 1 |
| Cosgrove, DO; Goldin, RC; Grier, S; Kuo, YT; Lim, AK; Patel, N; Taylor-Robinson, SD; Thomas, HC | 1 |
| Gordon, FD; Kwo, P; Vargas, HE | 1 |
| Fiel, MI; Schiano, T | 1 |
| Lu, Y; Robinson, M; Zhang, FJ | 1 |
| Baker, D; Dore, GJ; Haber, P; Hellard, M; Kaldor, J; Lloyd, A; Marks, P; Matthews, GV; McCaughan, G; Rawlinson, W; Sasadeusz, J; White, P; Yeung, B | 1 |
| Aberle, JH; Gangl, A; Holzmann, H; Kohrgruber, N; Kundi, M; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Cirera, I; Clotet, B; Coll, S; Galeras, JA; García-Retortillo, M; Giménez, D; Márquez, C; Planas, R; Rey-Joly, C; Salas, A; Sirera, G; Solà, R; Tor, J; Tural, C; Videla, S | 1 |
| Chkhartishvili, NI; Gogichaishvili, ShSh; Sakandelidze, TsG; Sharvadze, LG; Zhamutashvili, MT | 1 |
| Farnik, H; Mihm, U; Zeuzem, S | 1 |
| Carrión, JA; Crespo, G; Forns, X; García-Valdecasas, JC; Martínez-Bauer, E; Navasa, M; Pérez-del-Pulgar, S; Ramírez, S | 1 |
| de los Santos-Gil, I; del Valle, J; Fernández-Fuertes, E; González-Serrano, M; Macías, J; Merchante, N; Merino, D; Mira, JA; Moro, A; Pineda, JA; Ruiz-Morales, J; Sanz-Sanz, J | 1 |
| Roche, B; Samuel, D | 3 |
| Kleppinger, EL; Ragan, AP | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Olmo, JD; Ortega, E; Torres-Puente, M | 1 |
| Balistreri, W; Barton, B; González-Peralta, RP; Haber, B; Jonas, MM; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Robuck, P; Rodrigue, JR; Rosenthal, P; Schwarz, KB; Smith, LJ | 1 |
| Daiter, J; John-Baptiste, A; Krahn, M; Lingley, M; Nedd-Roderique, T; Teplin, D; Tomlinson, G; Varenbut, M | 1 |
| Blum, JS; Daniel, AL; Houlihan, JL; Walsh, JP | 1 |
| Ebner, N; Fischer, G; Jachmann, CA; Matzenauer, C; Thau, K; Wanner, C; Winklbaur, B | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Foltzer, A; Gerard, L; Lapidus, N; Perronne, C; Pol, S; Rosenthal, E | 1 |
| Azzazy, HM; Badreldin, NG; El Awady, MK; Fahmy, AM; Goueli, SA; Omran, MH; Shawky, SM; Yossef, SS; Zekri, AR | 1 |
| Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Yu, ML | 2 |
| Ghany, MG; Seeff, LB; Strader, DB; Thomas, DL | 1 |
| Esposito, L; Guitard, J; Kamar, N; Ribes, D; Rostaing, L | 1 |
| Freedman, K; Nathanson, J | 1 |
| Francis, M; Ganeshalingam, Y; Suleman, S | 1 |
| Piroth, L | 1 |
| Agoglia, L; Balbi, E; Cariús, LP; Covelo, MC; Enne, M; Gonzalez, AC; Leal, CR; Oliveira, PV; Pacheco-Moreira, LF; Pousa, FS; Roma, J | 1 |
| Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 3 |
| Afdhal, NH; Di Bisceglie, AM; Lok, AS | 1 |
| Babany, G; Gagnieu, MC; Jourdil, JF; Marquet, P; Sauvage, FL; Stanke-Labesque, F | 1 |
| Barbarini, G; Barlattani, A; Bellis, L; Bonaventura, ME; Dell'Unto, C; Dell'Unto, O; Guarisco, R; Mazzoni, E; Mecenate, F; Mitidieri, O; Morrone, A; Nosotti, L; Paffetti, A; Paglia, F; Pellicelli, AM; Picardi, A; Puoti, C; Romano, M; Soccorsi, F; Spilabotti, L; Villani, R | 1 |
| Bracho, MA; Cuevas, JM; García-Robles, I; Gonzalez, M; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Torres-Puente, M | 1 |
| Cotler, SJ; Dahari, H; Layden, TJ; Perelson, AS; Shudo, E | 1 |
| Szaflarska-Popławska, A; Łoś-Rycharska, E | 1 |
| Afzal, M; Manzoor, S; Rizvi, F; Shafi, MS; Sheikh, NI | 1 |
| Baden, LR; Hamel, MB; Wilck, MB | 1 |
| Charlton, M; Veldt, B; Watt, K | 1 |
| Dintsios, CM; Gerlach, T; Haverkamp, A; Krauth, C; Manns, MP; Pape, G; Wedemeyer, H; Wiegand, J | 1 |
| Balk, H; Berg, T; Buggisch, P; Gerlach, T; Hinrichsen, H; Klinker, H; Möller, B; Neumann, K; Rasenack, J; Sarrazin, C; Spengler, U; Teuber, G; Weich, V; Zankel, M; Zeuzem, S | 1 |
| Asselah, T; Aupérin, A; Bedossa, P; Boyer, N; Cardoso, AC; Castelnau, C; Giuily, N; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Pouteau, M; Ripault, MP; Stern, C | 1 |
| de Knegt, RJ; Drenth, JP; Lamers, MH; Roomer, R; Slavenburg, S; van Oijen, MG | 1 |
| Gold, J; Hellard, M; Sacks-Davis, R | 1 |
| Alavian, SM; Tabatabaei, SV | 1 |
| Poll, R | 1 |
| Gao, J; Kang, P; Li, SC; Sun, LJ; Yu, JW; Zhao, YH | 1 |
| Pockros, PJ | 1 |
| Pockros, PJ; Shields, WW | 1 |
| Abradelo, M; Colina, F; Fernández, I; Gimeno, A; Jiménez, C; Lumbreras, C; Meneu, JC; Moreno, E; Solís-Herruzo, JA; Ulloa, E | 1 |
| Ahya, SN; Baker, T; Levitsky, J; Norvell, JP; Van Wagner, LB; Wang, E | 1 |
| Barut, S; Basak, AN; Eken, AG; Karaer, H; Oksuz, E | 1 |
| Gale, M; Jain, M; Lee, WM; Snow, KK; Yuan, HJ | 1 |
| Conrads-Frank, A; Esteban, E; Mühlberger, N; Schwarzer, R; Siebert, U; Sroczynski, G; Wright, D; Zeuzem, S | 1 |
| Asada, M; Fukunaga, T; Ito, H; Kato, Y; Kawaguchi, K; Kou, T; Kudo, Y; Nakamura, T; Oda, Y; Ohashi, S; Sakuma, Y; Sugiura, Y; Taguchi, N; Watanabe, M; Yamauchi, A; Yazumi, S | 1 |
| Chen, TM; Tung, JN | 1 |
| Berenguer, J; Girón, JA; González-Serrano, M; Iribarren, JA; Japón, MA; López-Cortés, LF; Macías, J; Mira, JA; Miralles, P; Moreno, A; Ortega, E; Pineda, JA; Rivero, A | 1 |
| Birch, CE; Bowen, MJ; Chung, RT; Kim, AY; McGovern, BH; Nagami, EH; Reyor, LL | 1 |
| Adams-Huet, B; Attar, N; Carney, DS; Gale, M; Jain, MK; Lee, WM; Neumann, AU; Reeck, A; Shelton, J; Yuan, HJ; Zhang, S | 1 |
| Houlihan, DD; Lee, JM; Storan, ER | 1 |
| Theiler, RN | 1 |
| Abe, Y; Fujita, K; Iida, H; Inamori, M; Kirikoshi, H; Kobayashi, N; Kubota, K; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Sasaki, H; Shinohara, Y; Takahashi, H; Yoneda, M | 2 |
| Floreani, A | 1 |
| Marcellin, P; Moucari, R | 1 |
| Nelson, M; Page, E; Rockstroh, JK; Vogel, M | 1 |
| Cadranel, JF; Lahmek, P; Morin, T; Pariente, A; Rabaud, C; Silvain, C | 1 |
| Bach, N; Chang, C; Elsiesy, H; Grewal, P; Khaitova, V; Liu, L; Massoumi, H; Norkus, E; Peterson, B; Schiano, TD | 1 |
| Alvarez-Uria, G; Day, JN; Nasir, AJ; Russell, SK; Vilar, FJ | 1 |
| Al-ahmadi, M; Al-hamoudi, W; Ather, HM; Batwa, F; Dahlan, Y | 1 |
| Abderrahim, E; Ben Abdallah, T; Ben Hamida, F; Ben Maïz, H; Bezzine, H; Hedri, H; Khaled, S; Kheder, A; Ounissi, M; Trabelsi, S | 1 |
| Berenguer, J; Catalán, P; Cosín, J; González-Nicolás, J; López, JC; Lorente, R; Micheloud, D; Miralles, P; Muñoz-Fernández, M; Resino, S | 1 |
| Chen, TM; Ho, KS; Huang, PT; Lin, CH; Lin, LF; Liu, CC; Tsai, MH; Tung, JN | 1 |
| Adorni, F; Antinori, S; Caramma, I; Cesari, M; Galli, M; Milazzo, L | 1 |
| Nelson, DR | 2 |
| Gomollón García, F; Moreno López, R; Sicilia Aladrén, B | 1 |
| Ku, JY; Sharma, A | 1 |
| Avidan, NU; Buti, M; Fauci, AS; Ferenci, P; Goldstein, D; Kottilil, S; Masur, H; McLaughlin, M; Polis, MA; Rozenberg, L | 1 |
| Bahra, M; Bayraktar, S; Berg, T; Neuhaus, P; Neumann, U; Pratschke, J; Schmeding, M; Schmidt, SC | 1 |
| Cabrera, R; Chen, C; Clark, VC; Firpi, RJ; Levy, C; Michaels, A; Morelli, GG; Nelson, DR; Soldevila-Pico, C; Suman, A | 1 |
| Aghemo, A; Colombo, M; Rumi, MG | 1 |
| Aghemo, A; Agnelli, F; Colombo, M; Donato, MF; Iavarone, M; Lampertico, P; Rumi, MG; Viganò, M | 1 |
| Bédossa, P; Cacoub, P; Carrat, F; Halfon, P; Lambert, J; Pénaranda, G; Pol, S | 1 |
| Barreiro, P; García-Samaniego, J; Jiménez-Nácher, I; Labarga, P; Madejón, A; Martín-Carbonero, L; Medrano, J; Resino, S; Rodríguez, V; Soriano, V; Tuma, P; Vispo, E | 1 |
| Crawford, RI; Mistry, N; Shapero, J | 1 |
| Breilh, D; Chêne, G; Djabarouti, S; Dupon, M; Fleury, H; Le Bail, B; Neau, D; Ragnaud, JM; Saux, MC; Thiébaut, R; Trimoulet, P | 1 |
| El-Zayadi, AR | 1 |
| Corrêa, ME; de Moraes, PC; Mautoni, MC; Noce, CW; Thomaz, LA | 1 |
| Berg, T; Potthoff, A; Wedemeyer, H | 1 |
| Bischof, M; Brunner, H; Datz, C; Ferenci, P; Gschwantler, M; Hofer, H; Laferl, H; Löschenberger, K; Maieron, A; Scherzer, TM; Stauber, R; Steindl-Munda, P; Strasser, M; Vogel, W; Wenisch, C | 1 |
| Dantzer, R; Kelley, KW; Lawson, MA; Miller, AH; Raison, CL; Saito, K; Spivey, JR; Vogt, G; Woolwine, BJ | 1 |
| Bruno, S; Gane, EJ; Hadziyannis, SJ; Marcellin, P; Messinger, D; Roberts, SK; Shiffman, ML | 1 |
| Alaeus, A; Falconer, K; Reichard, O; Sandberg, JK | 1 |
| Samuel, D | 2 |
| Dionne-Odom, J; Grakoui, A; Osborn, MK; Radziewicz, H; Workowski, K | 1 |
| Adler, M; Deltenre, P; Henrion, J; Mathurin, P; Moreno, C; Pawlotsky, JM | 1 |
| Adeyi, O; Girgrah, N; Herath, C; Kashfi, A; Levy, GA; Lilly, L; Renner, EL; Selzner, M; Selzner, N; Therapondos, G | 1 |
| Fischler, B; Friman, S; Gerdén, B; Josephson, F; Karlström, O; Lagging, M; Sangfelt, P; Schvarz, R; Uhnoo, I; Weiland, O; Wejstål, R | 1 |
| Flisiak, R; Parfieniuk, A | 1 |
| Mallat, ME; Sharara, AI | 1 |
| Cingolani, A; De Luca, A; Donato, C; Pinnetti, C | 1 |
| Hagan, JJ; Hostetter, JE; Martin, CK | 1 |
| Andreone, P; Anticoli, S; Balsano, C; Bernardi, M; Cursaro, C; Furlini, G; Galli, S; Gramenzi, A; Loggi, E; Margotti, M; Salerno, M; Spaziani, A | 1 |
| Leifeld, L; Nattermann, J; Spengler, U | 1 |
| Kaneko, J; Kokudo, N; Makuuchi, M; Sugawara, Y; Tamura, S; Yamashiki, N | 1 |
| Bunim, AL; Feuerstadt, P; Gaglio, PJ; Garcia, H; Karlitz, JJ; Massoumi, H; Pellecchia, A; Reinus, JF; Thosani, AJ; Wolkoff, AW | 1 |
| Alajos, P; Béla, H; Ferenc, S; Gábor, H; István, T; Judit, G; László, T; Mihály, M | 1 |
| Kimura, H; Matsuyama, Y; Minota, S; Nagashima, T; Onishi, S; Yoshio, T | 1 |
| Chiu, MW; Farshidi, D | 1 |
| Alsiö, A; Buhl, MR; Christensen, PB; Färkkilä, M; Haagmans, BL; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Maida, I; Martin-Carbonero, L; Soriano, V; Sotgiu, G; Vispo, E | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E; Xirouchakis, E | 1 |
| Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D | 1 |
| Chow, DC; Khawcharoenporn, T; Suwantarat, N; Tice, AD | 1 |
| Cacoub, P; Landau, DA; Resche-Rigon, M; Saadoun, D; Scerra, S; Sene, D | 1 |
| Chiba, T; Egawa, H; Marusawa, H; Takada, Y; Ueda, Y; Uemoto, S | 1 |
| Abe, H; Araoka, T; Doi, T; Fukatsu, A; Iehara, N; Kishi, F; Kishi, S; Kita, T; Kondo, N; Matsubara, T; Matsuura, M; Mima, A; Murakami, T; Nagai, K; Shigeta, R; Takahashi, T; Yamamoto, S; Yoshikawa, K | 1 |
| Szalay, F | 1 |
| Hierro, L; Jara, P | 1 |
| Aurora, R; Cannon, NA; Di Bisceglie, AM; Donlin, MJ; Li, J; Tavis, JE; Wahed, AS | 1 |
| Costelloe, SJ; Dusheiko, G; Jacobs, M; Morris, C; Schulz, J; Thomas, M; Vaghijiani, T; Vanderpump, MP; Wassef, N; Whiting, S | 1 |
| Arcaini, L; Bruno, R | 1 |
| Christofi, M; Chung, RT; Delgado-Borrego, A; Healey, D; Jordan, SH; Kamegaya, Y; Lin, W; Lok, AS; Ludwig, DA; Negre, B | 1 |
| Ferzli, P; Halpern, AV; Heymann, WR; Peikin, SR | 1 |
| Brack, J; Deibler, P; Dilg, C; Haasen, C; Isernhagen, K; Reimer, J; Schulte, B; Schütt, S; Verthein, U | 1 |
| Colić Cvrlje, V; Filipec Kanizaj, T; Mrzljak, A; Ostojić, R | 1 |
| Fassio, E; Sordá, J; Terg, R | 1 |
| Jmelnitzky, AC; Jorge, O; Manero, E | 1 |
| Fainboim, H; García, D; Muñoz, A | 1 |
| Curciarello, J; Fernández, JL; Silva, M | 1 |
| Nilsson, J; Weiland, O | 1 |
| Broussolle, C; Faurie, P; Sève, P; Trepo, C; Zoulim, F | 1 |
| Michaels, AJ; Nelson, DR | 1 |
| Bruix, J; Forns, X | 1 |
| Chan, KM; Cheng, SS; Chou, HS; Lee, CF; Lee, WC; Wu, TJ | 1 |
| Fukuhara, T; Ikegami, T; Maehara, Y; Okano, S; Shirabe, K; Soejima, Y; Taketomi, A | 1 |
| Asselah, T; Bedossa, P; Boyer, N; Cardoso, AC; Carvalho-Filho, RJ; Castelnau, C; Figueiredo-Mendes, C; Giuily, N; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Ripault, MP; Valla, D | 1 |
| Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
| Berg, KT; Harrison, AR; Lee, MS; McLoon, LK; Nelson, B | 1 |
| Araya, V; Bingaman, A; Grewal, KS; Horton, J; Olson, MR; Ortiz, J; Stewart, S; Zaki, R | 1 |
| Azwa, A; Bhagani, S; Dominguez, S; Guiguet, M; Katlama, C; Nelson, M; Page, E; Rockstroh, JK; Valantin, MA; Vogel, M | 1 |
| Calabrese, L; Ferri, C; Govoni, M | 1 |
| Benito, JM; Goldstein, D; McHutchison, J; Medrano, J; Naggie, S; Rallón, NI; Restrepo, C; Shianna, KV; Soriano, V; Thompson, A; Vispo, E | 1 |
| Balart, LA; Hamzeh, FM; Kwok, A; Lentz, E; Lisker-Melman, M; Rodriguez-Torres, M | 1 |
| Conway, B; DeVlaming, S; Duncan, F; Elliott, D; Gallagher, L; Genoway, KA; Grebely, J; Khara, M; Knight, E; Raffa, JD; Storms, M; Viljoen, M | 1 |
| Almasio, PL; Cacopardo, B; Cosentino, S; Fatuzzo, F; Foti, G; Frugiuele, P; Galdieri, A; Guadagnino, V; Russello, M; Sapienza, M; Scalisi, I; Scifo, G; Spadaro, A; Stroffolini, T | 1 |
| Inati, A; Musallam, KM; Sharara, AI; Taher, AT | 1 |
| Barreiro, P; Jiménez-Nacher, I; Labarga, P; Madejón, A; Martín-Carbonero, L; Medrano, J; Resino, S; Rodriguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E | 1 |
| Egawa, H; Hata, K; Hori, T; Nguyen, JH; Nishikiori, M; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Uemoto, S | 1 |
| Hirai, Y; Kadoya, H; Matsuda, J; Moriwaki, T; Namba, T; Shiba, R; Takeji, M; Yamada, Y; Yamamoto, T; Yamauchi, A; Yoshihara, H | 1 |
| Alcaide, N; Aller, R; Almansa, R; Bermejo-Martin, JF; Caro-Paton, A; de la Fuente, C; de Lejarazu, RO; Gonzalez, JM; Jimenez-Sousa, MA; Largo, P; Resino, S; Ruiz, L; Sanchez-Antolín, G | 1 |
| Breitenecker, F; Gangl, A; Kosi, L; Maresch, J; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Wrba, F | 1 |
| Arnholm, B; Buhl, MR; Eilard, A; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Mørch, K; Nilsson, S; Norkrans, G; Pedersen, C; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Alam, I; Cecil, B; Kistler, KD; Stainbrook, T | 1 |
| Berenguer, J; Catalán, P; Cosín, J; López, JC; Miralles, P; Resino, S; Ryan, P; Vargas, A | 1 |
| Adrover, R; Cocozzella, D; Fernández, N; Reggiardo, MV; Ridruejo, E | 1 |
| Autran, B; Blanco, J; Bofill, M; Clotet, B; Garcia, E; Jou, A; Massanella, M; Papagno, L; Tural, C | 1 |
| Berenguer, M; Rubin, A | 1 |
| Hunt, DR; McClune, A; Saab, S; Stone, MA; Tong, MJ | 1 |
| Malcolm, JK; Raina, D; Schade, RR; Wilkins, T | 1 |
| Cao, F; Cheng, X; Donlin, MJ; Tavis, JE; Turner, K | 1 |
| Cheng, W; Flexman, JP; Hammond, T; Lee, S; Price, P; Watson, MW | 1 |
| Barbarini, G; Barlattani, A; Bellis, L; Bonaventura, ME; Costanza, OM; Dell' Unto, O; Elmo, MG; Guarisco, R; Mecenate, F; Nicolini, AM; Nosotti, L; Pellicelli, A; Picardi, A; Puoti, C; Romano, M; Soccorsi, F; Spilabotti, L | 1 |
| El-Azab, IA; ElHefnawi, MM; Zada, S | 1 |
| Brennan, CS | 1 |
| Kim, SJ; Kornek, M; Schuppan, D; Shimada, M; Yoshida, S | 1 |
| Cooper, C | 1 |
| Affonso de Araujo, ES; Barone, AA; Cotler, SJ; Dahari, H; Haagmans, BL; Layden, TJ; Neumann, AU | 1 |
| Aqel, B; Balan, V; Byrne, T; Carey, E; Douglas, D; Heilman, RL; Mekeel, K; Rakela, J; Reddy, K; Vargas, HE; Werner, T | 1 |
| Berenguer, J; Catalán, P; Cosín, J; Gutiérrez, I; López, JC; Miralles, P; Moreno, S; Ramírez, M; Resino, S; Ryan, P | 1 |
| Oriñuela, I; Ortiz de Zárate, Z; Sanjuán, AZ; Velasco, J | 1 |
| Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M | 1 |
| Adams, LA; Bulsara, M; Cheng, W; Flexman, JP; Lee, S; Price, P; Rossi, E; Varano, J; Watson, MW | 1 |
| Conway, B; Dore, GJ; Duncan, F; Gallagher, L; Genoway, KA; Grebely, J; Knight, E; Krajden, M; Ngai, T; Raffa, JD; Storms, M | 1 |
| Cheng, WS; Crawford, D; Dore, GJ; Marks, PS; McCaughan, G; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Thommes, J; Weltman, M; Yoshihara, M | 1 |
| Bacca, D; Carretta, V; Goldstein, DB; Mangia, A; McHutchison, JG; Minerva, N; Mottola, L; Patel, K; Petruzzellis, D; Piazzolla, V; Santoro, R; Shianna, KV; Thompson, AJ; Tillmann, HL | 1 |
| Andersen, J; Bhattacharya, D; Carrat, F; Chung, RT; Currier, JS; Peters, MG; Torriani, F; Umbleja, T | 1 |
| Jensen, DM | 1 |
| Alavian, SM; Behnava, B; Elizee, PK; Keshvari, M; Lankarani, KB; Miri, SM; Tabatabaei, SV | 1 |
| Abe, H; Chayama, K; Hayashida, Y; Hayes, CN; Kubo, M; Kumada, H; Maekawa, T; Nakamura, Y; Nakano, R; Ochi, H; Tsunoda, T | 1 |
| Doucette, K; Hartling, L; Hu, J; Robinson, J; Tjosvold, L | 1 |
| Furusyo, N; Hayashi, J | 1 |
| Alonso, S; Bárcena, R; Fernandez, I; Fernández-Rodríguez, CM; Forns, X; Fuente, J; Garcia-Samaniego, J; Martinez, SM; Moreno-Otero, R; Planas, R; Rincón, D; Rodriguez-Caravaca, G; Romero-Gómez, M; Sanchez-Tapias, JM; Serra, MA; Solá, R | 1 |
| Ceccherini-Silberstein, F; Cento, V; Di Masi, F; Manzoli, L; Mazzotta, E; Mercurio, F; Parruti, G; Perno, CF; Pieri, A; Polilli, E; Sozio, F; Tontodonati, M | 1 |
| Hattori, T; Inoue, Y; Kodama, EN; Li, S; Matsuura, Y; Tanaka, T; Tani, H; Zhang, J | 1 |
| Castañeda-Hernández, G; Jiménez-Méndez, R | 1 |
| Marroni, CA | 1 |
| Lerias de Almeida, PR | 1 |
| Black, M; Burke, M; Jain, AB; Singhal, A | 1 |
| Deutsch, M; Papatheodoridis, GV | 1 |
| Dahari, H; Guedj, J; Perelson, AS; Rong, L | 1 |
| de Almeida, PR; de Mattos, AA; de Mattos, AZ; Tovo, CV | 1 |
| Araújo, ES; Barone, AA; Cotler, SJ; Dahari, H; de Melo, ES; de Paula Cavalheiro, N; Layden, TJ; Melo, CE; Neumann, AU | 1 |
| Brown, GR; Cubillas, R; Grumbeck, C; Hale, T; Phillips, FH; Prebis, M | 1 |
| Abou-Zahra, SB; El Sayed, ZM; Ghal, MF; Mansour, FA | 1 |
| Andriulli, A; Mangia, A | 2 |
| Barreiro, P; Cuenca, L; Jiménez-Nácher, I; Labarga, P; Madejón, A; Medrano, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Flisiak, I; Flisiak, R | 1 |
| Hickman, M; Martin, N; Vickerman, P | 1 |
| Ahlenstiel, G; Cherepanov, V; El-Diwany, R; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Koh, C; Liang, TJ; Modi, AA; Park, Y; Rotman, Y; Thomas, E; Titerence, R | 1 |
| Alston, B; Andersen, JW; Butt, AA; Chung, RT; Goodman, ZD; Koziel, MJ; Peters, MG; Sherman, KE; Sulkowski, M; Umbleja, T | 1 |
| Bacon, BR; Schoenfeld, PS; Shiffman, M; Singal, AG; Waljee, AK | 1 |
| Fischler, B; Psaros-Einberg, A | 1 |
| Ardèvol, M; Castellví, P; Costa, J; Diago, M; Diez-Quevedo, C; Giménez, D; Giner, P; Martín-Santos, R; Masnou, H; Morillas, RM; Navinés, R; Planas, R; Pretel, J; Solà, R | 1 |
| Mangia, A | 1 |
| Aftab, M; Akram, M; Ali, L; Ali, M; Awan, Z; Badar, S; Butt, S; Fatima, Z; Hussain, A; Idrees, M; Khubaib, B; Munir, S; Naudhani, M; Rauff, B; Saleem, S; Tariq, A | 1 |
| Aparicio, E; Clotet, B; Franco, S; Martínez, MA; Parera, M; Pérez-Alvarez, N; Tural, C | 1 |
| DeVoss, A; Elsen, C; Jensen, D; Mohanty, S; Reau, N; Reddy, G; Satoskar, R; Te, H | 1 |
| Poordad, F | 1 |
| Sarrazin, C; Vermehren, J | 1 |
| Lee, VS; Levitsky, J; Pillai, AA; Rinella, ME; Wang, E | 1 |
| Arakawa, T; Fujimori, M; Hisanaga, Y; Hosokawa, T; Kanamori, A; Kiriyama, S; Kumada, T; Tada, T; Tanikawa, M; Toyoda, H | 1 |
| Dore, GJ; Grebely, J | 1 |
| Christodoulou, DK; Katsanos, KH; Tsianos, EV; Tsianos, VE; Vagias, I; Zervou, E; Zioga, H; Zois, CD | 1 |
| Alric, L; Barange, K; Gandia, P; Houin, G; Izopet, J; Lavit, M; Nicot, F; Séraissol, P; Trancart, S | 1 |
| Cacoub, P; Halfon, P | 1 |
| Lawson, A | 1 |
| Benhamou, Y; Berg, T; Boecher, WO; Bonacini, M; Bourlière, M; Calleja, JL; Kukolj, G; Manns, MP; Pol, S; Scherer, J; Steinmann, G; Stern, JO; Trepo, C; White, PW; Wright, D; Yong, CL | 1 |
| Alavi, M; Dore, GJ; Grebely, J; Haber, PS; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Shaw, D; van Beek, I; Yeung, B | 1 |
| Bao, S; Dong, Z; Guo, Q; Lu, J; Tao, W; Xiang, X; Xie, Q; Zhong, J; Zhou, H; Zhou, X | 1 |
| Doehring, A; Geisslinger, G; Hofmann, WP; Lötsch, J; Sarrazin, C; Schlecker, C; Susser, S; Zeuzem, S | 1 |
| Abe, H; Aikata, H; Chayama, K; Hatakeyama, T; Hayes, CN; Hiraga, N; Imamura, M; Kawakami, Y; Kawaoka, T; Kitamura, S; Mitsui, F; Mori, N; Ochi, H; Ohishi, W; Saneto, H; Takahashi, S; Takaki, S; Tsuge, M | 1 |
| Ardèvol, M; Ausina, V; Bracho, MA; González-Candelas, F; Martró, E; Planas, R; Saludes, V; Valero, O | 1 |
| Burger, DM; Dofferhoff, TS; Drenth, JP; Huntjens-Fleuren, HW; Koopmans, PP; Richter, C; Slavenburg, S; Verwey-Van Wissen, CP | 1 |
| Aftab, M; Afzal, S; Akram, M; Awan, Z; Badar, S; Fatima, Z; Hussain, A; Idrees, M; Khubaib, B | 1 |
| Alter, HJ; Haynes-Williams, V; Heller, T; Herrine, SK; Hoofnagle, JH; Liang, TJ; Loomba, R; McBurney, R; Park, Y; Rehermann, B; Rivera, MM | 1 |
| Chayama, K; Hayes, CN | 1 |
| McHutchison, JG | 3 |
| Craxì, A; Petta, S | 1 |
| Kamal, SM | 1 |
| Fried, MW | 2 |
| Abaalkhail, F; Abdo, A; Al-Hamoudi, W; Al-Jedai, A; Al-Masri, N; Al-Sebayel, M; Al-Sofayan, M; Allam, N; Alqahtani, S; Kamel, Y; Khalaf, H; Mohamed, H | 1 |
| Ahmed, A; Ahmed, H; Ali, L; Ali, M; Idrees, M | 1 |
| Amador, C; Benito, C; Ena, J; Pasquau, F; Ruiz-de-Apodaca, RF | 1 |
| Katayama, K; Miyakawa, Y; Mizui, M; Tanaka, J; Tomoguri, T; Yoshizawa, H; Yugi, H | 1 |
| Pawlotsky, JM | 2 |
| Gonzalez, SA | 1 |
| Fukuda, K; Haruna, Y; Hayashi, N; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inoue, Y; Kanto, T; Kasahara, A; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yoshida, Y | 1 |
| Clark, PJ; Facciorusso, D; Goldstein, DB; Mangia, A; McHutchison, JG; Mottola, L; Muir, AJ; Naggie, S; Patel, K; Petruzzellis, D; Piazzolla, V; Romano, M; Santoro, R; Shianna, KV; Sogari, F; Thompson, AJ; Tillmann, HL | 1 |
| Berenguer, J; Carrero-Gras, A; Catalán, P; Cosín, J; García-Álvarez, M; Guzmán-Fulgencio, M; López, JC; Micheloud, D; Miralles, P; Resino, S | 1 |
| Atzeni, F; Bonacci, E; Bruno, R; Bruno, S; Campanini, M; Candela, M; Castelnovo, L; De Vita, S; Ferri, C; Filippini, D; Gabrielli, A; Gaeta, GB; Galli, M; Marson, P; Mascia, MT; Mazzaro, C; Mazzotta, F; Meroni, P; Montecucco, C; Monti, G; Ossi, E; Piccinino, F; Pietrogrande, M; Pioltelli, P; Prati, D; Puoti, M; Quartuccio, L; Renoldi, P; Riboldi, P; Riva, A; Roccatello, D; Saccardo, F; Sagnelli, E; Sansonno, D; Sarzi-Puttini, P; Scaini, P; Scarpato, S; Sinico, R; Sollima, S; Taliani, G; Tavoni, A; Zignego, AL | 1 |
| Dixit, NM; Krishnan, SM | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Nakamura, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Bagasra, O; Noorali, S; Pace, DG | 1 |
| Blanco, JL; Calvo, M; González, A; Laguno, M; Larrousse, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A | 1 |
| Hama, T; Hayami, S; Ichinose, M; Shigekawa, Y; Takifuji, K; Tamai, H; Uchiyama, K; Ueno, M; Yamaue, H | 1 |
| Balistreri, W; Barton, B; González-Peralta, RP; Haber, B; Jonas, MM; Lobritto, SJ; Mohan, P; Molleston, JP; Murray, KF; Narkewicz, MR; Robuck, PR; Rodrigue, JR; Rosenthal, P; Schwarz, KB; Smith, LJ | 1 |
| Deng, L; El-Shamy, A; Hotta, H; Ide, YH; Kawata, S; Saito, T; Shoji, I; Watanabe, H | 1 |
| Glória, H; Marinho, R; Nunes, J; Serejo, F; Velosa, J | 1 |
| Bolcic, F; Cahn, P; Laufer, N; Martinez, A; Pérez, H; Quarleri, J; Reynoso, R; Rolón, MJ; Salomón, H | 1 |
| Carral Martínez, M; García-Toro, M; Gili Planas, M; Jimeno Beltrán, T; Pradas Guerrero, C; Roca Bennasar, M; Román Ruiz del Moral, Y; Vilella Martorell, A | 1 |
| Eslam, M; Maraver, M; Romero-Gomez, M; Ruiz, A | 1 |
| Cacoub, P; Chousterman, M; Fontanges, T; Lang, JP; Marcellin, P; Melin, P; Ouzan, D; Rotily, M; Varastet, M | 1 |
| Cooper, C; Dalgard, O; Hunyady, B; Jia, J; Ogurtsov, P; Peck-Radosavljevic, M; Shiffman, ML; Sulkowski, MS; Yurdaydin, C | 1 |
| De Knegt, RJ; Desombere, I; Haagmans, B; Hansen, B; Janssen, HL; Leroux-Roels, G; Orlent, H; Schalm, SW; Van Vlierberghe, H | 1 |
| Aldamiz-Echevarría, T; Berenguer, J; Cosín, J; de Castro, IF; Guzmán-Fulgencio, M; López, JC; Lorente, R; Micheloud, D; Miralles, P; Muñoz-Fernández, MÁ; Resino, S | 1 |
| Camacho, A; Macías, J; Merchante, N; Mira, JA; Neukam, K; Pérez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Laguno Centeno, M; Mallolas Masferrer, J; Martínez-Rebollar, M | 1 |
| Berenguer, J; C López, J; Catalán, P; Cosín, J; Fernández de Castro, I; García-Álvarez, M; Guzmán-Fulgencio, M; Micheloud, D; Miralles, P; Resino, S | 1 |
| Doletskiĭ, AA; Fomin, VV; Girina, SS; Moiseev, SV; Nikulkina, EN; Sedov, VP | 1 |
| Gong, QM; Gu, LL; Han, Y; Jin, GD; Li, XH; Liao, XW; Ling, Y; Lu, ZM; Yao, BL; Yu, DM; Zhang, DH; Zhang, SY; Zhang, XX | 1 |
| Pellicelli, AM; Zoli, V | 1 |
| Andrés, C; Aparicio, E; Clotet, B; Franco, S; Martínez, MA; Parera, M; Tural, C | 1 |
| Arvelakis, A; Assis, D; Caldwell, C; Cimsit, B; Emre, S; Kulkarni, S; Schilsky, M; Taddei, T | 1 |
| Hammond, JL; Jagannatha, S; Kantaridis, C; Neelakantan, S; Purohit, VS; Simpson, P; Thompson, R; Troke, PJ; Wagner, F | 1 |
| Albrecht, JK; Bloomer, JR; Boparai, N; Brass, CA; Brown, KA; Galler, GW; Ghalib, RH; Herrine, SK; Jiang, R; King, JW; McCone, J; McHutchison, JG; Melia, MT; Muir, AJ; Mullen, KD; Noviello, S; Nunes, FA; Ravendhran, N; Shiffman, ML; Sulkowski, MS | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Lee, ST; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Bzowej, N; Charlton, MR; Everson, GT; Nelson, DR; Prabhakar, A; Teng, LL; Terrault, NA | 1 |
| Boesecke, C; Rockstroh, JK | 2 |
| Andersen, JW; Butt, AA; Chung, RT; Sherman, KE; Umbleja, T | 2 |
| Kistner-Griffin, E; Pandey, JP | 1 |
| Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Imai, Y; Imanaka, K; Inui, Y; Ishida, H; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Nagase, T; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, A; Yoshida, Y; Yoshihara, H | 1 |
| Alestig, E; Arnholm, B; Eilard, A; Lagging, M; Lindh, M; Nilsson, S; Norkrans, G; Wahlberg, T; Wejstål, R; Westin, J | 1 |
| Camacho, A; Caruz, A; Di Lello, FA; Gómez-Mateos, J; Macías, J; Mesa, P; Neukam, K; Pineda, JA; Rivero, A; Rivero-juárez, A | 1 |
| Chung, TL; Haagmans, BL; Herrmann, E; Kottilil, S; Lempicki, RA; Murphy, AA; Osinusi, AO; Polis, MA; Sachau, W; Wood, BJ; Wu, L; Yang, J | 1 |
| Alain, S; Babany, G; Bourlière, M; Carrier, P; De Ledinghen, V; Di Martino, V; Loustaud-Ratti, V; Marquet, P; Maynard, M; Pinta, A; Pol, S; Rousseau, A; Sautereau, D; Trépo, C; Zarski, JP | 1 |
| Knyazer, B; Kratz, A; Levy, J; Lifshitz, T; Marcus, M; Zlotnik, A | 1 |
| Bahra, M; Berg, T; Biermer, M; Boas-Knoop, S; Eurich, D; Neuhaus, P; Neuhaus, R; Neumann, U | 1 |
| Buhl, MR; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Mørch, K; Nilsson, S; Norkrans, G; Pedersen, C; Westin, J | 1 |
| Heil, PM; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Abe, H; Akuta, N; Chayama, K; Hayes, CN; Kamatani, N; Karino, Y; Kobayashi, M; Kumada, H; Miki, D; Nakamura, Y; Ochi, H; Sezaki, H; Suzuki, F; Toyota, J | 1 |
| Chapman, S; Cozen, M; Cunningham, F; Currie, SL; Monto, A; Shen, H; Tortorice, K; Yee, HS | 1 |
| Lobo, C; López-Pestaña, A; Tuneu, A; Zubizarreta, J | 1 |
| Dougherty, KA; Fried, MW; McGowan, CE | 1 |
| Zaaijer, HL | 1 |
| Drenth, JP; Gevers, TJ; Slavenburg, S; van Oijen, MG | 1 |
| Schlütter, J | 1 |
| Maxmen, A | 1 |
| Doucette, K; Dryden, DM; Durec, T; Fassbender, K; Tandon, P; Vandermeer, B | 1 |
| de Oliveira, IR; Galvão-de Almeida, A; Guindalini, C; Koenen, KC; Lyra, AC; Miranda-Scippa, A; Paraná, R; Parise, CL; Quarantini, LC; Sampaio, AS | 1 |
| Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Hu, TH; Huang, JF; Hung, CH; Kao, JH; Lee, CM; Lin, ZY; Liu, CJ; Lu, SN; Wang, JH; Yeh, ML; Yu, ML | 1 |
| Dahari, H; Guedj, J; Perelson, AS | 1 |
| Ehleben, C; Pearlman, BL | 1 |
| Akuta, N; Arase, Y; Chayama, K; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Nakamura, Y; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Dróżdż, W; Dybowska, D; Halota, W; Kozielewicz, D | 1 |
| Ahlenstiel, G; Edlich, B; Feld, JJ; Hogdal, LJ; Holz, LE; Liang, TJ; Noureddin, M; Rehermann, B; Rotman, Y; Titerence, RH | 1 |
| Arends, JE; van den Berk, GE | 1 |
| Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S | 1 |
| Akahoshi, T; Furusyo, N; Hashizume, M; Hayashi, J; Kawanaka, H; Kinjo, N; Maehara, Y; Nagao, Y; Tomikawa, M; Tsutsumi, N | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG | 1 |
| Carrieri, MP; Dabis, F; Fugon, L; Lacombe, K; Roux, P; Salmon-Céron, D; Sogni, P; Spire, B; Winnock, M | 1 |
| Chapman, J; Cheung, R; Hockemeyer, J; Jones, S; Oser, M; Weitlauf, J | 1 |
| Bonkovsky, HL; Mathew, A; O'Bryan, JM; Potts, JA; Rothman, AL | 1 |
| Ermacora, A; Mauro, E; Mazzaro, C; Pedata, M | 1 |
| McCombs, JS; Saab, S; Shin, J; Yuan, Y | 1 |
| Arora, S; Deming, P | 1 |
| Ding, CB; Jiang, JD; Peng, ZG; Song, DQ; Zhang, JP; Zhao, Y | 1 |
| Aikata, H; Chayama, K; Hashimoto, Y; Hiraga, N; Hiramatsu, A; Imamura, M; Katamura, Y; Kawakami, Y; Kawaoka, T; Miki, D; Nagaoki, Y; Ochi, H; Ohdan, H; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Kwo, PY; Zhao, R | 1 |
| Bacon, BR; Khalid, O | 1 |
| Welzel, TM; Zeuzem, S | 1 |
| Chang, KM; Pelletier, S; Shoukry, NH | 1 |
| George, M; Moore, CM; Van Thiel, DH | 1 |
| Kao, JH; Liu, CH | 1 |
| Bourlière, M; Buggisch, P; Cacoub, P; Dupin, N; Dusheiko, G; Hézode, C; Lübbe, J; Picard, O; Pujol, R; Roujeau, JC; Segaert, S; Thio, B | 1 |
| Alvarez, NP; Clotet, B; González, J; Laguno, M; Moltó, J; Ornelas, A; Paredes, R; Sánchez, M; Solà, R; Téllez, MJ; Tural, C; von Wichmann, MÁ; Zamora, AM | 1 |
| Attili, AF; Biliotti, E; Corradini, SG; Gentili, F; Giannelli, V; Giusto, M; Lionetto, L; Merli, M; Rossi, M; Simmaco, M; Taliani, G | 1 |
| Bruno, R; Fagiuoli, S; Sacchi, P | 1 |
| Bae, SH; Choi, JE; Choi, JY; Choi, SW; Hong, SW; Hur, W; Kim, CW; Lyoo, K; Shin, EC; Song, MJ; Yoon, SK | 1 |
| Chary, A; Holodniy, M | 1 |
| Aikata, H; Chayama, K; Hiraga, N; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Miki, D; Ochi, H; Ohdan, H; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Aparicio, E; Bellido, R; Cañete, N; Clotet, B; Franco, S; García-Retortillo, M; Martínez, MA; Paredes, R; Solà, R; Tural, C | 1 |
| Adda, N; Adler, M; Afdhal, NH; Everson, GT; Flamm, SL; Fried, MW; George, S; Kauffman, RS; Martin, M; Nelson, DR; Poordad, F; Reesink, HW; Sankoh, AJ; Sherman, KE; Sulkowski, MS; Wright, CI | 1 |
| Baily, G; Buckland, M; Dorward, J; Garrett, N; Orkin, C; Scott, D | 1 |
| Amorosa, VK; Gross, R; Kaplan, DE; Lo Re, V; Localio, AR; Teal, V | 2 |
| Abd-Rabou, AA; Eskander, EF; Mohamed, MS; Shaker, OG; Yahya, SM | 1 |
| Eslam, M; López-Cortés, LF; Romero-Gomez, M | 1 |
| Razonable, RR | 1 |
| Colomba, C; Mazzola, G; Rubino, R; Siracusa, L; Titone, L | 1 |
| Chiba, T; Fujiwara, T; Inokuma, T; Marusawa, H; Nasu, A; Nishijima, N; Osaki, Y; Sato, F; Shimizu, K; Takahashi, K; Tamada, T; Ueda, Y; Yamashita, Y | 1 |
| Kaczmarek, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Sikora, J; Zeromski, J | 1 |
| Lou, M; Park, SH; Wackernah, RC | 1 |
| Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H | 1 |
| Camacho Espejo, A; Caruz, A; García-Lázaro, M; Mesa, P; Mira, JA; Neukam, K; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juárez, A; Torre-Cisneros, J | 1 |
| Bergin, C; Dillon, A; Farrell, G; Jackson, A; Kieran, J; Mulcahy, F; Norris, S | 1 |
| Boesecke, C; Vogel, M | 1 |
| Chung, RT; Dayyeh, BK; de Bakker, PI; Gupta, N; Sherman, KE | 1 |
| Agarwal, K; Arterburn, S; Buggisch, P; Foster, GR; Horsmans, Y; Klinker, H; Knox, S; Manns, MP; Marcellin, P; McHutchison, JG; Mo, H; Moreno, C; Oldach, D; Sereni, D; Zarski, JP; Zeuzem, S | 1 |
| Buonsenso, D; Ceccarelli, M; Gargiullo, L; Ranno, O; Serranti, D; Valentini, P | 1 |
| Arends, JE; Fransen, JH; Hoepelman, AI; Mudrikova, T; Schellens, IM; Spijkers, SN; Sprenger, HG; Stek, CJ; van Assen, S; van Baarle, D; Wensing, AM | 1 |
| Berg, T; Dusheiko, G; Flisiak, R; Lenz, O; Manns, M; Marcellin, P; Meyvisch, P; Moreno, C; Peeters, M; Reesink, H; Sekar, V; Simmen, K; Verloes, R | 1 |
| Andoh, A; Bamba, S; Fujiyama, Y; Nakahara, T; Nakajo, S; Nishimura, T; Okumura, Y; Osaki, R; Shioya, M; Takeuchi, T | 1 |
| Hemmati, I; Shojania, K; Yoshida, E | 1 |
| Otón Nieto, E | 1 |
| Chen, CH; Hu, TH; Huang, CM; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Anagnostis, P; Aristidis, D; Aristidis, S; Deliyiannidis, A; Eleni, OK; Eugenidis, N; Georgios, N; Grammatikos, N; Kaliopi, P; Kargiotis, K; Konstantinos, K; Konstantinos, S; Nalmpantidis, G; Nikolaos, E; Nikolaos, G; Orfanou-Koumerkeridou, E; Panagiotis, A; Patsiaoura, K; Slavakis, A; Soufleris, K; Themistoklis, V; Vasiliadis, T | 1 |
| Arnsten, JH; Berg, KM; Hidalgo, J; Li, X; Litwin, AH | 1 |
| Chee, GM; Poordad, F | 1 |
| Brook, RA; Corey-Lisle, PK; Iloeje, UH; Kleinman, NL; Su, J | 1 |
| Bourke, NM; Hegarty, JE; Keogh, CA; Murphy, AG; O'Farrelly, C; Stevenson, NJ | 1 |
| Doehring, A; Geisslinger, G; Hofmann, WP; Lötsch, J; Schlecker, C; Ultsch, A; Zeuzem, S | 1 |
| Beem, LW; Morse, ML | 1 |
| Hopwood, M; Newland, J; Rance, J; Treloar, C | 1 |
| Alavi, M; Day, C; Dore, GJ; Grebely, J; Haber, PS; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Van Beek, I; Yeung, B | 1 |
| Kudo, M | 2 |
| Arizumi, T; Chung, H; Hagiwara, S; Hayaishi, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Sakurai, T; Takita, M; Ueda, T; Ueshima, K; Yada, N | 1 |
| Butt, AA; Kanwal, F | 1 |
| Liu, J; Luo, G; Shi, S; Zhuang, H | 1 |
| Gallay, PA | 1 |
| Croner, R; Demir, R; Hohenberger, W; Müller, V; Perrakis, A; Schellerer, V; Schuhmann, S; Yedibela, S | 1 |
| Benito, JM; Camacho, A; Caruz, A; Gómez-Mateos, J; López-Cortés, LF; Macías, J; Nattermann, J; Neukam, K; Pineda, JA; Rallón, N; Rivero, A; Rockstroh, JK; Soriano, V; Torres-Cornejo, A | 1 |
| Dieterich, D | 2 |
| Chen, SC; Chuang, WL; Dai, CY; Hsi, E; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, ZY; Wang, LY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Abbas, Z | 1 |
| Abe, H; Agata, R; Aizawa, Y; Chiba, K; Fujise, K; Furihata, T; Ika, M; Namiki, Y; Shimada, N; Tada, N; Tsubota, A; Yoshizawa, K; Yumoto, Y | 1 |
| Al Alwan, AM; Al Balwi, MA; Al Flaiw, AI; Al Ghamdi, GA; Al Hejaili, FF; Al Qurashi, SH; Al Sayyari, AA; Al Traif, IH; Aljumah, AA; Saeed, MA | 1 |
| Castilho, MC; Ferreira Júnior, Oda C; Figueiredo, FA; Horbach, IS; Lima, DB; Martins, AN; Nabuco, LC; Perez, Rde M; Pinto, Pde T; Porto, LC; Tanuri, A | 1 |
| Acosta, A; Altice, FL; Bruce, RD; Eiserman, J; Gote, C; Lim, JK | 1 |
| Bárcena, R; Cañete, N; García-Samaniego, J; Gutiérrez, ML; Manzano, ML; Morano, L; Pérez-Álvarez, R; Pérez-López, R; Planas, R; Rodrigo, L; Solá, R | 1 |
| Cheiab, B; Ioniţă-Radu, F; Raşcanu, A | 1 |
| Corouge, M; Mallet, VO; Pol, S; Vallet-Pichard, A | 1 |
| Izopet, J; Kamar, N; Rostaing, L; Weclawiak, H | 1 |
| Ferenci, P; Hadziyannis, S; Jensen, D; Marcellin, P; Messinger, D; Reau, N; Tatsch, F | 1 |
| Jablonowska, E; Nocun, M; Wojcik, K | 1 |
| Aparicio, E; Clotet, B; de Castellarnau, M; Franco, S; Martínez, MA; Parera, M; Tural, C | 1 |
| Altamura, S; Crowe, J; Devitt, E; Lawless, MW; Muckenthaler, MU; Mullins, S; Ryan, JD | 1 |
| Barili, V; Fasano, M; Ferrari, C; Missale, G; Molinari, A; Orlandini, A; Penna, A; Pilli, M; Ravanetti, L; Santantonio, T; Zerbini, A | 1 |
| Demetrashvili, MF; Liu, S; Manatunga, A; McNutt, MD; Miller, AH; Musselman, DL; Raison, CL; Royster, EB; Woolwine, BJ | 1 |
| Abe, M; Hiasa, Y; Ikeda, Y; Kumagi, T; Mashiba, T; Matsuura, B; Onji, M; Tokumoto, Y; Uesugi, K; Watanabe, T | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E | 1 |
| Mouch, A; Nimer, A | 1 |
| Abbott, D; Lee, HK; Trask, LE | 1 |
| Camacho, A; Caruz, A; Di Lello, FA; Gonzalez, R; Mesa, P; Neukam, K; Peña, J; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Torre-Cisneros, J | 1 |
| Bouvier-Alias, M; Cassard, B; Dominguez, S; Ghosn, J; Katlama, C; Lascaux, AS; Lévy, Y; Melica, G; Peytavin, G; Poizot-Martin, I; Solas, C | 1 |
| Loulergue, P; Mir, O; Sogni, P | 1 |
| Ayala, CE; Bacchetti, P; Brandman, D; Khalili, M; Maher, JJ | 1 |
| Baietto, L; Bonora, S; Calcagno, A; Cariti, G; Ciancio, A; Cusato, J; de Requena, DG; Di Perri, G; DʼAvolio, A; Marucco, DA; Rizzetto, M; Sciandra, M; Siccardi, M; Simiele, M; Smedile, A; Troshina, G | 1 |
| Takeda, T | 1 |
| Rifai, MA; Sabouni, MA | 1 |
| Alberti, AB; Belli, LS; Burra, P; Burroughs, AK; Cillo, U; De Carlis, L; De Martin, E; Fagiuoli, S; Graziadei, I; Gridelli, B; Guido, M; Lerut, J; Pasulo, L; Pinzello, G; Starkel, P; Vogel, W; Volpes, R | 1 |
| Blanco, JL; Calvo, M; Costa, J; Gatell, JM; González-Cordón, A; Laguno, M; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A; Perez, I | 1 |
| Bachmeyer, C; Pellen, JC | 1 |
| Voelker, R | 1 |
| Bai, XF; Hao, CQ; Jia, ZS; Kang, WZ; Li, B; Ma, L; Pan, L; Peng, XJ; Wei, X; Xie, YM; Zhang, Y | 1 |
| Babudieri, S; Fois, AG; Madeddu, G; Molicotti, P; Mura, MS; Muredda, AA; Murino, M; Pirina, P; Soddu, A; Zanetti, S | 1 |
| Aoki, T; Hasegawa, K; Kaneko, J; Kokudo, N; Sakamoto, Y; Sugawara, Y; Tamura, S; Yamashiki, N | 1 |
| Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH | 1 |
| Imawari, M; Kato, T; Masaki, T; Matsumura, T; Murayama, A; Sugiyama, N; Tasaka-Fujita, M; Wakita, T | 1 |
| Chia, C; Cunanan, RJ; Dorrell, J; Martin, S; Moore, CD; Pauly, MP; Russell, M; Witt, G | 1 |
| Freedberg, KA; Kim, AY; Linas, BP; Schackman, BR; Wong, AY | 1 |
| Adinolfi, LE; Guerrera, B; Restivo, L; Ruggiero, L; Zampino, R | 1 |
| Agnesod, D; Baietto, L; Boglione, L; Bonora, S; Calcagno, A; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Sciandra, M; Simiele, M; Turini, S | 1 |
| Bonten, MJ; de Wit, GA; de Wit, NJ; Hellinga, HL; Helsper, CW; Hoepelman, AI; Richter, C; van Erpecum, KJ; van Essen, GA | 1 |
| Durmaz, O | 1 |
| Bukh, J | 1 |
| Sperati, CJ | 1 |
| Applegate, T; Dore, GJ; Feld, JJ; George, J; Grebely, J; Hellard, M; Kaldor, JM; Lloyd, AR; Matthews, GV; Petoumenos, K; Rawlinson, W; Yeung, B | 1 |
| Bruce, MG; Bruden, DL; Deubner, H; Gove, JE; Gretch, DR; Homan, CE; Livingston, SE; McMahon, BJ; Robinson, RF; Townshend-Bulson, LJ | 1 |
| Enomoto, N; Sakamoto, M | 1 |
| Chen, Y; Liu, XX; Mahato, RI; Wang, LJ; Xu, HX; Zhao, YR | 1 |
| Ghany, MG; Liang, TJ; Thomas, E | 1 |
| Barros, C; Bellón, JM; Berenguer, J; Esteban, H; Galindo, MJ; Gaspar, G; González-García, J; Guardiola, JM; Jou, A; Jusdado, JJ; López-Aldeguer, J; Mallolas, J; Miralles, P; Montes, ML; Ortega, E; Pulido, F; Quereda, C; Rodríguez, E; Rubio, R; Santos, I; Sanz, J; Téllez, MJ; Van Den Eynde, E; Von Wichmann, MA | 1 |
| Fontana, RJ; Rangnekar, AS | 1 |
| Boillot, O; Botta-Fridlund, D; Boudjema, K; Calmus, Y; Chazouillères, O; Dharancy, S; Durand, F; Duvoux, C; Gugenheim, J; Néau-Cransac, M; Pageaux, G; Rostaing, L; Samelson, L; Samuel, D; Vanlemmens, C; Wolf, P | 1 |
| Albrecht, JK; Bacon, BR; Boparai, N; Brass, CA; Bronowicki, JP; Burroughs, MH; Gordon, SC; Goteti, VS; Jacobson, IM; Molony, C; Morgan, TR; Pedicone, LD; Poordad, F; Poynard, T; Sings, HL; Sniukiene, V; Sulkowski, MS; Zeuzem, S | 1 |
| Aikata, H; Chayama, K; Hayes, CN; Imamura, M | 1 |
| Cameron, S | 1 |
| Birnkrant, D; Florian, J; Jadhav, PR; Liu, J; Murray, J | 1 |
| Baumert, TF; Dill, MT; Duong, FHT; Filipowicz, M; Heim, MH; Makowska, Z; Merkofer, F; Terracciano, L; Tornillo, L | 1 |
| de Los Santos-Gil, I; del Mar Viloria, M; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA | 1 |
| Goto, H; Katano, Y; Kumada, T; Toyoda, H | 1 |
| Brown, KA; Brown, RS; Chaudhri, E; Crippin, J; Ghalib, R; Gordon, FD; Kwo, P; Pedicone, LD; Schiano, T; Vargas, HE | 1 |
| Alvarez, MA; Baños, F; Calleja, JL; de la Revilla, J; Erdozaín, JC; Espinosa, MD; García-Samaniego, J; Morillas, R; Romero-Gómez, M; Ruiz-Antorán, B; Solá, R; Suárez, D; Trapero, M | 1 |
| Abbas, Z; Hamid, S; Jafri, W; Raza, S | 1 |
| Arends, JE; Huisman, EJ; Siersema, PD; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H | 1 |
| Anthony, DD; Blanton, RE; Conry, SJ; Falck-Ytter, Y; Landay, AL; Lederman, MM; Medvik, K; Rodriguez, B; Sandberg, JK; Sandhya Rani, MR | 1 |
| Carter, JA; Gao, X; Haider, S; Rustgi, VK; Stephens, JM | 1 |
| Andreone, P; Bertuzzo, VR; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; Dazzi, A; Del Gaudio, M; Di Gioia, P; Ercolani, G; Lorenzini, S; Morelli, MC; Pinna, AD; Ravaioli, M; Tamè, M | 1 |
| Chen, J; Lin, Y; Shi, J; Xie, WF; Zeng, X | 1 |
| Ackefors, M; Gjertsen, H; Weiland, O; Wernerson, A | 1 |
| Liu, N; Liu, P; Sun, C; Wen, Y | 1 |
| Bessede, T; Buffet, C; Charpentier, B; Durrbach, A; Hassan, Q; Roche, B; Samuel, D | 1 |
| de Bruijne, J; Fanning, G; Lenz, O; Peeters, M; Picchio, G; Reesink, H; Simmen, K; Van Marck, H; Vandenbroucke, I; Verbinnen, T; Verloes, R; Vijgen, L; Weegink, C | 1 |
| Mutimer, D | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Cacopardo, B; Fatuzzo, F; Montineri, A; Nunnari, G; Portelli, V; Savalli, F | 1 |
| Bataille, S; Chiche, L; Jourde, N; Kaplanski, G | 1 |
| Berg, CP; Egetemeyr, DP; Königsrainer, A; Lauer, UM; Malek, NP; Nadalin, S; Werner, CR | 1 |
| Hu, HD; Hu, P; Liu, JY; Ren, H; Sheng, YJ; Tong, SW; Wang, J; Zhang, DZ; Zhong, Q; Zhou, Z | 1 |
| Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Connell, EV; Harrison, SA; Mazur, W; McKenna, M; Messinger, D; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Tatsch, F | 1 |
| de los Santos-Gil, I; García-Rey, S; Girón-González, JA; López-Cortés, LF; Macías, J; Márquez, M; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Chen, DS; Chen, HL; Huang, WH; Lai, MY; Liu, WL; Su, WC; Wang, CC; Wang, HY; Yang, HC | 1 |
| Bahra, M; Boas-Knoop, S; Eurich, D; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, UP; Puhl, G; Trautwein, C; Wasmuth, H; Yahyazadeh, A | 1 |
| Cachay, ER | 1 |
| Alfaleh, FZ; Alghamdi, AS; Alghamdi, H; Alqutub, A; Alswat, K; Altraif, I; Ismail, M; Sanai, FM; Shah, H | 1 |
| Aguilera, V; Berenguer, M; de la Mata, M; Duclos-Vallée, JC; Navarro, L; Pons, JA; Prieto, M; Roche, B; Rubín, A; Samuel, D | 1 |
| Beinhardt, S; Ferenci, P; Rutter, K; Stättermayer, AF | 1 |
| Bernstein, D; Craxi, A; Diago, M; Hadziyannis, S; Lin, A; Marcellin, P; Pockros, P; Rajender Reddy, K; Rizzetto, M; Rodríguez-Torres, M; Shiffman, ML; Tatsch, F; Zeuzem, S | 1 |
| Andersen, JW; Butt, AA; Chung, RT; Hua, L; Kemmer, N; Sherman, KE | 1 |
| John-Baptiste, A; Krahn, M; Leung, V; van der Velde, G; Yeung, MW | 1 |
| Hirase, K; Nagao, Y; Sata, M; Shimoda, T; Shirahama, S; Tomohiro, M; Yamasaki, K | 1 |
| Asensi, V; Cartón, JA; Collazos, J; de la Fuente, B | 1 |
| Pascale, A; Serfaty, L | 1 |
| Camacho, A; Caruz, A; Macias, J; Mira, JA; Neukam, K; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Torre-Cisneros, J | 1 |
| Bárcena, R; Casado, JL; Del Campo, S; Dronda, F; Mateos, ML; Montes, M; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Bizzaro, N; Calise, SJ; Carcamo, WC; Ceribelli, A; Chan, EK; Daves, M; Krueger, C; Liu, C; Satoh, M; Villalta, D | 1 |
| Charlebois, A; Cooper, E; Lee, L; Mason, K; Powis, J | 1 |
| Egashira, T; Kobayashi, M; Kumada, H; Nagano, M; Suzuki, F; Tadokoro, K; Tanaka, C; Yamaguchi, T | 1 |
| Arnedo, M; Auguet, T; Cifuentes, C; Gallart, L; Gatell, JM; Hernandez, P; Laguno, M; López-Dupla, M; Mallolas, J; Murillas, J; Payeras, A; Richart, C; Sampériz, G; Veloso, S; Vidal, F | 1 |
| Flexner, C; Kiser, JJ | 1 |
| Camacho, A; Caruz, A; Gutierrez-Valencia, A; Lopez-Cortes, LF; Marquez-Solero, M; Pineda, JA; Rivero, A; Rivero-Juárez, A; Ruiz-Valderas, R; Torre-Cisneros, J; Torres-Cornejo, A | 1 |
| Aguilar Marucco, D; Baietto, L; Bonora, S; Calcagno, A; Cariti, G; Caviglia, GP; Ciancio, A; Cusato, J; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Rizzetto, M; Sciandra, M; Siccardi, M; Simiele, M; Smedile, A; Troshina, G | 1 |
| Driver, TH; Saxena, V; Terrault, N | 1 |
| Biliotti, E; Gallinaro, V; Giusto, M; Grieco, S; Merli, M; Spaziante, M; Taliani, G; Zacharia, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Suk-Fong Lok, A | 1 |
| Espinales, JC; Lawitz, EJ; Membreno, FE | 1 |
| Ginba, H; Ide, T; Izumi, N; Kumada, T; Matsuyama, K; Sata, M; Shimada, N; Takaguchi, K; Toyoda, H | 1 |
| Alder, L; Gumbo, T; Jain, MK; Lee, WM; Pasipanodya, JG | 1 |
| Andreone, P; Beumont, M; De Meyer, S; Diago, M; Foster, GR; George, S; Lawitz, EJ; Lonjon-Domanec, I; Luo, D; Picchio, G; Pockros, PJ; Pol, S; Roberts, S; Younossi, Z; Zeuzem, S | 1 |
| Albrecht, JK; Bacon, B; Brass, CA; Bruno, S; Burroughs, MH; Esteban, R; Goodman, Z; Gottesdiener, K; Nyberg, LM; Pedicone, LD; Poordad, F; Tanno, H; Thompson, S; Vierling, JM | 1 |
| Lemon, M | 1 |
| Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Leroy, V; Marcellin, P; Pérusat, S; Poynard, T; Trimoulet, P | 1 |
| Feld, JJ | 1 |
| Bastiampillai, AJ; Donato, MF; Manini, M; Monico, S | 1 |
| Des Jarlais, DC; Dimova, RB; Hagan, H; Jacobson, IM; Talal, AH; Zeremski, M | 1 |
| Grant, PR; Nicholson, L; Tedder, RS; Tuke, P; Wallis, N; Wright, M | 1 |
| Tillmann, HL | 1 |
| Ignatova, TM; Mukhin, NA | 1 |
| Egle, A; Greil, R; Grundbichler, M; Melchardt, T; Strasser, M; Taylor, N | 1 |
| Dimova, RB; Jacobson, IM; Makeyeva, J; Rennert, H; Sipley, JD; Talal, AH; Zeremski, M | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Juo, SH; Kao, JH; Lin, ZY; Liu, CH; Tseng, TC; Wang, LY; Yu, ML | 1 |
| Choi, Y; Li, K; Rahal, H; Saab, S; Tong, M | 1 |
| Coilly, A; Roche, B; Samuel, D | 1 |
| Sulkowski, MS | 2 |
| Clark, VC; Nelson, DR; Peter, JA | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Arai, M; Fujiwara, K; Imazeki, F; Kanda, T; Kato, K; Maruoka, D; Mikami, S; Miyamura, T; Nakamoto, S; Nishino, T; Takada, N; Tanaka, T; Tsubota, A; Wu, S; Yokosuka, O | 1 |
| Wedemeyer, H | 1 |
| Aerssens, J; Andreone, P; Beumont, M; Botfield, M; De Meyer, S; Focaccia, R; Foster, GR; Horban, A; Lawitz, EJ; Luo, D; Picchio, G; Pockros, PJ; Pol, S; Roberts, S; Van Heeswijk, RP; Younossi, Z; Zeuzem, S | 1 |
| Khudyakov, Y; Lara, J | 1 |
| Chao, YC; Chen, CL; Chen, DS; Chen, PJ; Chuang, WL; Kao, JH; Kuo, HT; Lee, CM; Liao, LY; Lin, CL; Liu, CH; Liu, CJ; Lu, SN; Su, WW; Tung, SY; Wu, SS; Yang, HC; Yang, SS; Yu, ML | 1 |
| Alejji, K; Alkaabi, S; Almohanadi, M; Butt, M; Derbala, M; Eldweik, N; John, A; Rizk, N; Sharma, M; Shebl, F; Yaqoob, R | 1 |
| Baruch, Y; Hassoun, G; Kramskay, R; Lorber, M; Maor, C; Pollack, S; Shahar, E; Veitsman, E | 1 |
| Baumert, TF; Doffoël, M; Donlin, MJ; Erba, AC; Fafi-Kremer, S; Fofana, I; Gut, JP; Habersetzer, F; Moenne-Loccoz, R; Murray, JM; Schvoerer, E; Stoll-Keller, F; Tavis, JE; Turek, M; Velay, A; Zeisel, MB | 1 |
| Baur, K; Geier, A; Rau, M | 1 |
| Bruno, S; Mangia, A | 1 |
| Bartolucci, GB; Chemello, L; Rinaldi, R; Scaggiante, R; Trevisan, A | 1 |
| Cornberg, M; Kirschner, J; Maasoumy, B; Manns, MP; Markova, AA; Mix, C; Port, K; Rogalska-Taranta, M; Serrano, BC; Sollik, L; Wedemeyer, H | 1 |
| Ho, HJ; Hsu, YC; Lin, JT; Wu, CY; Wu, MS | 1 |
| Golenberg, EM; Holland-Staley, CA; Kovari, LC; Mayers, DL; Pobursky, KJ | 1 |
| Bruno, R; Carosi, G; Filice, G; Puoti, M; Sacchi, P | 1 |
| Craven, DE; Nunes, DP | 1 |
| Barel, C; Bilger, K; Dumortier, J; Ninet, J; Scoazec, JY | 1 |
| Bessis, D; Blanc, P; Chapoutot, C; Guilhou, JJ; Guillot, B; Larrey, D; Luong, MS | 1 |
| Maier, I; Wu, GY | 1 |
| Perlemuter, G | 1 |
| Lucidarme, D | 1 |
| Benhamou, Y; Bernard, B; Di Martino, V; Moussalli, J; Myers, RP; Poynard, T; Ratziu, V; Regimbeau, C; Thabut, D | 1 |
| Cacoub, P | 3 |
| Feray, C; Roche, B; Samuel, D | 1 |
| Grangé, JD | 2 |
| Dhumeaux, D; Lerebours, E; Marcellin, P | 1 |
| Duclos-Vallée, JC | 1 |
| Arora, M; Mishra, D; Sibal, A | 1 |
| Grube, T; Hommann, M; Kornberg, A; Scheele, J; Schotte, U; Tannapfel, A | 1 |
| Abshire, TC; Davis, PC; Fried, MW; Gaglio, PJ; Hoots, K; Key, NS; Lindblad, L; Peter, J; Rickles, FR; Talbut, D; White, GC | 1 |
| Borczuk, AC; Brown, M; Brown, RS; Esposito, SP; Jacobson, IM; Kumar, KS; Lobritto, SJ; Russo, MW | 1 |
| Durández Lazaro, R; Fábregas Puigtió, S; Planas Vilà, R; Vega Palomares, R | 1 |
| Montes Ramírez, ML; Rodríguez Zapata, M | 1 |
| Gane, E | 2 |
| Balan, V; Brass, C; Conjeevaram, H; Crippin, J; Demetris, AJ; Gish, R; Kwo, P; McGuire, B; Rakela, J; Shakil, AO; Teperman, L; Wright, TL | 1 |
| Misery, L | 1 |
| Miller, SK | 1 |
| El-Nahas, AM; Fox, S; Grabowska, A; Irving, WL; Kudesia, G; Sabry, AA; Sheaashaa, HA; Sobh, MA; Wagner, BE; Wild, G | 1 |
| Di Bisceglie, AM; Hoofnagle, JH | 1 |
| Lindsay, KL | 1 |
| Davis, GL | 2 |
| Bacon, BR | 2 |
| Wright, TL | 3 |
| Alberti, A; Benvegnù, L; Boccato, S; Vario, A | 1 |
| Carlsson, T; Reichard, O; Weiland, O | 1 |
| Abdelmalek, MF; Crawford, JM; Davis, GL; Firpi, RJ; Hemming, A; Howard, R; Lauwers, G; Liu, C; Nelson, DR; Reed, A; Soldevila-Pico, C; Van Der Werf, W | 1 |
| Dvorchik, I; Eghtesad, B; Fontes, PA; Fung, JJ; Jain, AB; Kashyap, R; Kingery, L; Shakil, AO; Venkataramanan, R | 1 |
| Bruchfeld, A; Lindahl, K; Schvarcz, R; Ståhle, L | 3 |
| Allen, S; Berzin, T; Feller, E; Rich, J; Taylor, L | 1 |
| Cornberg, M; Manns, MP; Wedemeyer, H; Wiegand, J | 1 |
| Barnard, D | 1 |
| Diamond, C; Lee, JH | 1 |
| Craven, DE; Fleming, CA; Nunes, D; Thornton, D; Tumilty, S | 1 |
| Auchincloss, H; Baid, S; Chung, R; Colvin, RB; Cosimi, AB; Delmonico, FL; Pascual, M; Saidman, S; Tolkoff-Rubin, N; Williams, WW | 1 |
| Gonvers, JJ; Pache, I | 1 |
| Chung, RT; Cosimi, AB; Pascual, AM; Sikaneta, T; Williams, WW | 1 |
| Kermack, D; Senosier, M; Sherker, AH | 1 |
| Ahmed, SN; Baulieux, J; Bizollon, T; Chevallier, M; Chevallier, P; Ducerf, C; Guichard, S; Parvaz, P; Radenne, S; Trepo, C; Zoulim, F | 1 |
| Dikman, SH; Gorevic, PD; Widman, D; Wilson, LE | 1 |
| Jasin, HE; Medhekar, S; Nutt, A; Raufman, JP | 1 |
| Adams, P | 1 |
| Levenson, D | 2 |
| Chen, DS; Chen, PJ; Jeng, YM; Kao, JH; Lai, MY; Liu, CJ | 1 |
| Bandi, L | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Hu, R; Ibrahim, AB; Kunder, G; Lassman, C; Saab, S; Yersiz, H | 1 |
| García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Castedal, M; Friman, S; Olausson, M; Siewert-Delle, A | 1 |
| Heathcote, J; Krahn, M; Scully, L; Wang, P; Yi, Q | 1 |
| Nicolas, I; Pons, JA | 1 |
| Gopal, DV; Rosen, HR | 1 |
| Blazek, J; Eason, J; Khan, S; Lipscomb, J; Loss, G; Mason, A; Nair, S | 1 |
| Karnam, US; Reddy, KR | 1 |
| Fried, MW; McHutchison, JG | 1 |
| De Francesco, R; Rice, CM | 1 |
| Brenner, B; Campeol, N; Klein, MB; Lalonde, RG; Wainberg, MA | 1 |
| Bailly, F; Chevallier, M; Chevallier, P; Rocca, P; Trépo, C; Zoulim, F | 1 |
| Hernández, ML | 1 |
| Poo, JL | 1 |
| Abou Ayache, R; Bridoux, F; Goujon, JM; Provôt, F; Touchard, G | 1 |
| Enomoto, N; Nakagawa, M; Sakamoto, N | 1 |
| Yano, K; Yano, M; Yatsuhashi, H | 2 |
| Durand, D; Izopet, J; Kamar, N; Rostaing, L; Sandres-Saune, K; Selves, J | 1 |
| Hierro Llanillo, L | 1 |
| Benech, H; Bonnet, E; Bouvier-Alias, M; Chêne, G; Goujard, C; Lassalle, R; Morlat, P; Payan, C; Pérusat, S; Pruvost, A; Salmon-Céron, D; Sogni, P; Tréluyer, JM; Zoulim, F | 1 |
| Baio, P; Bellavita, P; Bertani, T; Caldara, R; Luliri, P; Mazzucco, G; Misiani, R; Rossi, P; Tengattini, F | 1 |
| Monarch, A | 1 |
| Allen, S; Jacobs, G; Mitty, J; Schwartzapfel, B; Taylor, LE | 1 |
| Herrmann, E; Lee, JH; Marinos, G; Modi, M; Zeuzem, S | 1 |
| Layden, TJ; Layden-Almer, JE; Perelson, AS; Ribeiro, RM; Wiley, T | 1 |
| Abraczinskas, DR; Bhan, AK; Chung, RT; Cosimi, AB; Leung, JY; Pascual, M; Terella, AM | 1 |
| Howard, L; Walker, B | 1 |
| Berthillon, P; Marcellin, P; Martinot, M; Maynard, M; Picchio, G; Pradat, P; Trepo, C; Voirin, N | 1 |
| Connor, K; Davis, L; Heffron, TG; Martinez, E; Smallwood, GA; Stieber, AC | 1 |
| Albrecht, J; Goodman, Z; Manns, M; McHutchison, J; Poynard, T; Ratziu, V; Younossi, Z; Zeuzem, S | 1 |
| Smith, C | 1 |
| Barbare, JC | 1 |
| de Man, RA; Orlent, H; Schalm, SW; Vrolijk, JM | 1 |
| Backmund, M; Diepolder, HM; Gerlach, JT; Gruener, NH; Jung, MC; Pape, GR; Schirren, CA; Schraut, WW; Ulsenheimer, A; Waechtler, M; Zachoval, R | 1 |
| Abi-Nassif, S; Fogel, RB; Hallisey, RK; Mark, EJ | 1 |
| Saab, S; Wang, V | 1 |
| Albrecht, J; Manns, M; McHutchison, J; Myers, RP; Poynard, T | 1 |
| Bica, I; McGovern, B | 1 |
| Butt, AA | 2 |
| Gerber, JG; Glesby, MJ | 1 |
| Bruchfeld, A; Lindahl, K; Schvarcz, R; Söderberg, M; Ståhle, L | 1 |
| Shobokshi, OA | 1 |
| Al-Jaser, NM; Serebour, FE; Shobokshi, OA; Skakni, LI | 1 |
| Bon, C; Castera, L; Dény, P; Grando, V; Morice, Y; Roulot, D | 1 |
| Baracetti, S; Bianchini, D; Comar, C; Donada, C; Donadon, V; Mazzaro, C; Nascimben, F; Pozzato, G; Zorat, F | 1 |
| de la Mata, M; Feliu, A; Forns, X; García-Retortillo, M; García-Valdecasas, JC; Navasa, M; Rimola, A; Rodés, J; Serrano, T; Suarez, F | 1 |
| Betancourt-González, A; de la Serna-Higuera, C; Martín-Arribas, MI; Martínez-Moreno, J; Pérez-Villoria, A; Rodríguez-Gómez, SJ | 1 |
| Maier, KP | 1 |
| Harkness, GA | 1 |
| He, JW; Lai, MM; Lee, KJ; Lindsay, KL; Liu, WC; Milstein, SL; Young, KC | 1 |
| Banks, A; Castro, O; Giday, S; Hasan, S; Hassan, M; Smoot, D | 1 |
| Cruz, CN; Ferraz, ML; Kirsztajn, GM; Lopes, EP; Silva, AE; Valente, LM | 1 |
| Shimotohno, K | 1 |
| Dwyer, JT; Paul, SM | 1 |
| Holmes, R; Jensen, SL | 1 |
| Cheng, IK; Kuok, UI; Leung, VK; Mao Chan, T; Neng Lai, K; Tang, AW; Tang, S; Wing Ho, Y | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lunel-Fabiani, F | 1 |
| Everson, GT; Shiffman, ML; Vargas, HE | 1 |
| Sorrell, M; Villamil, F; Wiesner, RH | 1 |
| Rosen, HR | 1 |
| Everson, GT | 1 |
| Terrault, NA | 1 |
| Neuberger, J | 1 |
| Balliram, DB; Johanson, FD | 1 |
| Clauson, M; Gilbert, TL; Pacheco, DM; Perelson, AS; Ribeiro, RM; Schrenk, UM; Torriani, FJ | 1 |
| Lai, MM; Levine, AM; Shimodaira, S | 1 |
| Avérous, K; Bonsch, M; Eugène, C; Le Corguillé, M; Rocher, P | 1 |
| Bui, DP; Disston, AR; Sylvestre, DL | 1 |
| Si, CW | 1 |
| Copley, L | 1 |
| Frost, SD; Lake-Bakaar, G | 1 |
| Bacon, BR; Di Bisceglie, AM; Lyra, AC; Ramrakhiani, S | 1 |
| Bruno, R; Filice, G; Sacchi, P | 1 |
| Cotler, SJ; Harb, G; Jensen, DM; Lam, H; Shillington, A | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Mukherjee, S; Rogge, J; Schafer, DF; Weaver, L | 1 |
| Ackrill, AM; Diago, M; Hassanein, T; Rodés, J; Sedarati, F | 1 |
| Germer, JJ; Hoskin, TL; Metwally, MA; Patel, R; Scott Harmsen, W; Smith, TF; Zein, NN | 1 |
| Chatelut, E; Izopet, J; Kamar, N; Lafont, T; Manolis, E; Rostaing, L | 1 |
| Balan, V; De Petris, G; Douglas, DD; Hansen, K; Khatib, A; Moss, A; Mulligan, D; Ortiz, J; Rakela, J; Rodriguez-Luna, H; Sharma, P; Vargas, HE; Williams, JW | 1 |
| Bonino, F; Brunetto, MR; Campa, M; Ciccorossi, P; Civitano, L; Coco, B; Colombatto, P; Flichman, D; Oliveri, F | 1 |
| Bruning, B; de Jong, MD; Kroes, AC; Schinkel, J; Spaan, WJ; van Hoek, B | 1 |
| Abdelmalek, MF; Crawford, JM; Davis, GL; Firpi, RJ; Hemming, AW; Liu, C; Nelson, DR; Reed, AI; Soldevila-Pico, C | 1 |
| Arroyo, J; Castro, FJ; González, H; Muñoz, H; Ríos, ME; Torres, EA | 1 |
| Wilde, JT | 1 |
| Buckwold, VE | 1 |
| Delforge, ML; Deviere, J; Golstein, PE; Marcellin, P | 1 |
| Drusano, GL; Preston, SL | 1 |
| Benedict Cosimi, A; Bhan, AK; Chung, RT; Pascual, M; Ross, AS; Thiim, M | 1 |
| Chen, CH; Enomoto, N; Kakinuma, S; Kanazawa, N; Kurosaki, M; Maekawa, S; Nakagawa, M; Sakamoto, N; Tanabe, Y; Ueda, E; Watanabe, M; Yamashiro, T | 1 |
| Diamond, C | 1 |
| Smoot, DT | 1 |
| Antela, A; Bárcena, R; Casado, JL; Dronda, F; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Navas, E; Perez-Elías, MJ; Quereda, C | 1 |
| Alric, L; Cacoub, P; Péron, JM; Piette, JC; Plaisier, E; Pourrat, J; Ronco, P; Rostaing, L; Thébault, S | 1 |
| Clavien, PA; Egger, HP; Fried, R; Giostra, E; Hadengue, A; Keller, W; Kraehenbuhl, S; Kullak-Ublick, GA; Locher, S; Mentha, G; Morel, P; Negro, F; Vanlemmens, C | 1 |
| Alric, L; Barange, K; Desmorat, P; Izopet, J; Legrand-Abravanel, F; Moreau, J; Sandres-Sauné, K; Vinel, JP | 1 |
| Manns, MP | 1 |
| Afdhal, NH | 1 |
| Dev, AT; McHutchison, JG | 1 |
| Gish, RG | 1 |
| Brandimarte, G; Torello, M; Tursi, A | 1 |
| Cacoub, P; Cargnel, A; Dieterich, D; Hatzakis, A; Mauss, S; Puoti, M; Rockstroh, J; Soriano, V; Sulkowski, M | 1 |
| Acosta, L; Ballesteros, AL; Clotet, B; Franco, S; Fuster, D; Martínez, MA; Planas, R; Rey-Joly, C; Salas, A; Sirera, G; Tor, J; Tural, C | 1 |
| Anty, R; Benzaken, S; Rampal, P; Tran, A; Vanbiervliet, G | 1 |
| Boxwell, D; Fleischer, R; Sherman, KE | 1 |
| Parini, S | 1 |
| Bogomolov, BP; Gromova, NI | 1 |
| Bejarano, PA; Cirocco, R; de Medina, M; Hill, MA; Khaled, AS; Montalbano, M; Neff, GW; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Tzakis, AG | 1 |
| Boyle, B | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, T; Younossi, Z | 1 |
| Adeyemi, OM; Attar, B; Cotler, SJ; Gallagher, M; Ghaoui, R; Jensen, D; Wolen, D | 1 |
| Mukherjee, S | 2 |
| Kryczka, W; Zarebska-Michaluk, D | 1 |
| Furne, JK; Ho, SB; Levitt, MD; Virtue, MA | 1 |
| Lehmann, M; Manns, MP; Meyer, MF; Monazahian, M; Tillmann, HL; Wedemeyer, H | 1 |
| Berthillon, P; Buti, M; Esteban, JI; Manns, MP; Marcellin, P; Martinot, M; Maynard, M; Picchio, G; Pradat, P; Tillmann, HL; Trepo, C; Voirin, N; Wiegand, J | 1 |
| Pariente, A | 1 |
| Calvit, TB; Cash, BD; Holtzmuller, KC; Hwang, I | 1 |
| Buti, M | 1 |
| Dusheiko, GM; Gotto, J | 1 |
| de Knegt, RJ; Orlent, H; Schalm, SW; Veldt, BJ; Vrolijk, JM | 1 |
| Alarcón, C; Arambarri, M; Echarri, R; Fernández Lucas, M; Merino, JL; Ortuño, J; Teruel, JL | 1 |
| Chang, HR; Chen, CH; Cheng, CH; Lan, JL; Lee, WC; Lian, JD; Shu, KH; Wu, MJ | 1 |
| Trivedi, HS; Trivedi, M | 1 |
| Ashworth, A; Contos, M; Cotterell, AH; Fisher, RA; Heuman, DM; Luketic, VA; Maluf, D; Mills, AS; Posner, MP; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Gajjar, NA; Ghobrial, RM; Goldstein, LI; Han, S; Hiatt, J; Kalmaz, D; Lassman, CR; Saab, S; Yersiz, H | 1 |
| Alter, H; Heller, T; Herrine, S; Hoofnagle, J; Liang, TJ; Mizukoshi, E; Nascimbeni, M; Rahman, F; Rehermann, B; Sobao, Y | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Erim, Y; Frilling, A; Gerken, G; Malago, M; Zhang, X | 1 |
| Rockstroh, JK; Vogel, M | 1 |
| Ahmed, P; Patel, D; Taylor, D; Tyms, AS; Whitby, K | 1 |
| Reich, B | 1 |
| Santantonio, T | 1 |
| Afeltra, A; Amoroso, A; D'Avola, D; Gentilucci, UV; Picardi, A; Zardi, EM | 1 |
| Bianca, S | 1 |
| Mbow, ML; Sarisky, RT | 1 |
| Barozzi, P; Luppi, M; Morselli, M; Potenza, L; Riva, G; Torelli, G | 1 |
| Blanche, P; Bouscary, D; Calmus, Y; Christoforov, B; Dreyfus, F; Kelaidi, C; Park, S; Podevin, P; Rollot, F; Sogni, P; Tulliez, M | 1 |
| Alric, L; Boulestin, A; Izopet, J; Kamar, N; Legrand-Abravanel, F; Rostaing, L; Sandres-Saune, K; Vinel, JP | 1 |
| Jones, WN; Mangin, EF | 1 |
| Pearlman, BL | 1 |
| Sterling, RK; Sulkowski, MS | 1 |
| Cheng, SX; Dhar, AD; Klaus, SN; Werchniak, AE | 1 |
| Gale, M; He, Y; Huang, Y; Tan, SL | 1 |
| Main, J; Thomas, H | 1 |
| Dillon, JF | 1 |
| Omata, M | 1 |
| Chayama, K; Ohishi, W | 1 |
| Kawamura, A; Kukita, K; Saitou, M; Tuyuguchi, M | 1 |
| Iino, S | 3 |
| Okuno, T; Shindo, M | 1 |
| Imawari, M; Nakamura, I; Ochiai, K | 1 |
| Kumada, H; Tsubota, A | 1 |
| Enomoto, N; Kanazawa, N; Nakagawa, M; Sakamoto, N; Watanabe, H | 1 |
| Iwasaki, Y; Shiraha, H; Shiratori, Y | 1 |
| Matsumori, A | 2 |
| Iitsuka, T; Kanzaki, S; Murakami, J; Nagata, I; Okamoto, M; Shiraki, K | 1 |
| Kobayashi, Y; Matsumoto, E; Sakaguchi, K; Shiratori, Y | 1 |
| Teruya, K | 2 |
| Bain, C; Dubois, V; Duverger, B; Gebuhrer, L; Inchauspé, G; Komurian-Pradel, F; Lavergne, JP; Paranhos-Baccala, G; Parroche, P; Penin, F; Trépo, C; Vieux, C | 1 |
| Homma, M; Inoue, Y; Ito, T; Kohda, Y; Matsumura, T; Matsuzaki, Y; Mitamura, K; Shibata, M; Tanaka, N | 1 |
| Blum, HE; Moradpour, D | 2 |
| Friedman, JA; Miller, EB | 1 |
| Hayes, P; Teo, M | 1 |
| Durantel, D; Escuret, V; Zoulim, F | 1 |
| Ahn, J; Flamm, S | 1 |
| Abdo, AA; Lee, SS | 1 |
| Anderson, JP; Daifuku, R; Loeb, LA | 1 |
| Berenguer, J; Berenguer, M; Calvo, F; Carrasco, D; Palau, A; Prieto, M; Rayón, JM | 1 |
| Abergel, A; Bommelaer, G; Bonny, C; Bronowicki, JP; Canva, V; Chevallier, M; Darcha, C; de Ledinghen, V; Dechelotte, P; Henquell, C; Lafeuille, H; Martineau, N; Pol, S; Tran, A; Ughetto, S | 1 |
| Kostman, JR; Lo Re, V | 1 |
| Chung, RT; Yachimski, P | 1 |
| Simon, K; Szymczak, A | 1 |
| Gaudy, C; Goudeau, A; Lunel, F; Payan, C; Veillon, P | 1 |
| Lunel, F; Payan, C; Pivert, A | 1 |
| Bagheri, H; Barange, K; Fouladi, A; Lapeyre-Mestre, M; Montastruc, JL; Payen, JL; Vinel, JP | 1 |
| Cuthbertson, FM; Davies, M; McKibbin, M | 1 |
| Bejarano, PA; De Medina, M; Khaled, AS; Lee, M; Montalbano, M; Neff, GW; Nery, J; Nishida, S; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Slapak-Green, G; Tzakis, A | 1 |
| Gładysz, A; Inglot, M | 1 |
| Agarwal, K; Dieterich, DT; Kontorinis, N | 2 |
| Bozorg, B; Rifai, MA; Rosenstein, DL | 1 |
| Asnis, GM; De La Garza, R; Henderson, MA; Rego, SA; Reinus, JF | 1 |
| Beissner, R; Carpenter, J; Hurley, D; Midturi, J; Sierra-Hoffman, M; Winn, R | 1 |
| Franchini, M | 2 |
| Beld, MG; den Hollander, JG; Ruys, TA; van der Ende, ME; van der Meer, JT | 1 |
| Baldelli, F; Canovari, B; Conte, ME; Di Candilo, F; Francisci, D; Sfara, C; Stagni, G; Valente, M | 1 |
| Dixit, NM; Layden, TJ; Layden-Almer, JE; Perelson, AS | 1 |
| Bernard, EJ | 2 |
| Ascher, NA; Bollinger, K; Khalili, M; Roberts, JP; Shergill, AK; Straley, S; Terrault, NA | 1 |
| de Gruijl, TD; Janssen, HL; Kölgen, W; Molling, JW; Mulder, CJ; Nishi, N; Scheper, RJ; Stam, AG; van den Eertwegh, AJ; van der Vliet, HJ; van Nieuwkerk, CJ; von Blomberg, BM | 1 |
| Ide, T; Kawaguchi, T; Kumashiro, R; Nagao, Y; Sata, M | 1 |
| Antela, A; Bárcena, R; Blázquez, J; del Campo, S; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, L; Moreno, S; Perez-Elías, MJ; Quereda, C; Sánchez, J | 1 |
| Moreno-Otero, R | 1 |
| Anselmi, E; Arcaini, L; Arcari, AL; Bernuzzi, P; Bertè, R; Callea, V; Cavanna, L; Lazzarino, M; Lazzaro, A; Marasca, R; Moroni, C; Sacchi, S; Trabacchi, E; Vallisa, D | 1 |
| Alberti, A | 1 |
| Borisov, AS; Broadwell, SD; Capuron, L; Jacobson, IM; Miller, AH; Nemeroff, CB; Raison, CL; Woolwine, BJ | 1 |
| Armour, K; Lowe, P | 1 |
| Carrat, F; Perronne, C | 1 |
| Kirkegaard, K; Pfeiffer, JK | 1 |
| Lyden, E; McCashland, TM; Mukherjee, S; Schafer, DF | 1 |
| Antonaci, S; Antonelli, G; Dentico, P; Giannelli, G; Guadagnino, G | 1 |
| Chung, RT; Horn, PS; James Koziel, M; Peters, MG; Rouster, SD; Sherman, KE; Shire, NJ | 1 |
| delaGarza, J; Madariaga, J; Neff, GW; Nishida, S; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, E; Shire, N | 1 |
| Gaudy, C; Goudeau, A; Lambelé, M; Lunel, F; Moreau, A; Veillon, P | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Pradat, P; Trepo, C; Zoulim, F | 1 |
| Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM | 1 |
| Aora, S; Gish, R; Lau, D; Lin, CC; Peterson, J; Rossi, S; Teng, A; Xu, C; Yeh, LT | 1 |
| Sax, PE | 1 |
| Camino, N; Sheldon, J; Soriano, V | 1 |
| Baumgarten, A; Bieniek, B; Bogner, JR; Hoffmann, C; Jessen, H; Kroidl, A; Rockstroh, JK; Schewe, CK; Spengler, U; Vogel, M | 1 |
| Armor, JF; Fazili, J; Kamble, R; Kern, W; Kharfan-Dabaja, MA; Toubia, N | 1 |
| Ferenci, P; Gangl, A; Gasche, C; Grundtner, P; Hofer, H; Neufeld, JB; Oesterreicher, C; Wrba, F | 1 |
| Cacoub, P; Lidove, O; Limal, N; Piette, JC; Saadoun, D; Sene, D | 1 |
| Taylor, LE | 1 |
| García-Buey, L; Gisbert, JP; Moreno-Otero, R; Pajares, JM | 1 |
| Begović, V; Dokić, M | 1 |
| den Hollander, JG; Rijnders, BJ; van der Ende, ME; van Doornum, GJ | 1 |
| Bernard, N; Beylot, J; Bonarek, M; Bonnet, F; Dramé, M; Lacoste, D; Lafon, ME; Morlat, P; Ramanampamonjy, R; Rambeloarisoa, J; Seydi, M; Trimoulet, P | 1 |
| Levin, J | 1 |
| Bennett, TJ; Fracht, HU; Harvey, TJ | 1 |
| Lumb, J | 1 |
| Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Minisini, R; Pirisi, M; Toniutto, P | 1 |
| Kato, T; Levi, D; Madariaga, J; Martinez, E; Moon, J; Nishida, S; Ruiz, P; Sadfar, K; Schiff, E; Selvaggi, G; Tzakis, A; Yoshida, H | 1 |
| Heathcote, J; Main, J | 1 |
| Husa, P | 1 |
| Changchien, CS; Chen, CH; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Boullosa Graña, E; Cuervas-Mons Martínez, V; Fernández Ruiz, M; Jiménez Garrido, M; Lucena de la Poza, JL; Martínez Arrieta, F; Molina Miliani, C; Moreno Planas, JM; Rubio González, E; Sánchez Turrión, V | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, R; Guardia, J; Luis Lázaro, J; Margarit, C; Vargas, V | 1 |
| Biglia, A; Blanco, JL; de Lazzari, E; García, F; García, M; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J | 1 |
| de Rave, S; Schalm, SW; Vrolijk, JM | 1 |
| Aziz, S | 1 |
| Chawla, S; Rivkin, AM | 1 |
| Bárcena, R; Blázquez, J; Foruny, JR; García, M; Gil-Grande, L; Moreno, A; Moreno, J; Otón, E; Sánchez, J | 1 |
| Calabrese, LH; Cooper, SM; Fessler, BJ; Gota, C; Levine, JW | 1 |
| Chen, DS; Chen, PJ; Hsieh, TH; Kao, JH; Lai, MY | 1 |
| Barrios Peinado, C; Boullosa Graña, E; Cuervas-Mons Martinez, V; Garrido Botella, A; Jiménez Garrido, M; Lucena Poza, JL; Moreno Planas, JM; Rubio Gonzalez, E; Sanchez Turrion, V | 1 |
| Alric, L; Izopet, J; Kamar, N; Rostaing, L | 1 |
| Baz, P; Daniel, F; Haddad, F; Koussa, S; Sayegh, R; Yaghi, C | 1 |
| Barylski, C; Bernstein, D; Hoffman-Terry, M; Khalili, M; Lentz, E | 1 |
| Mazzaro, C; Spina, M; Tirelli, U | 1 |
| Babatin, M; Burak, KW; Schindel, L | 1 |
| Romero Gómez, M | 1 |
| Barreiro, P; García-Samaniego, J; González-Lahoz, J; Jiménez-Nácher, I; Martín-Carbonero, L; Núñez, M; Rendón, AL; Romero, M; Soriano, V | 1 |
| Alvarez, D; Bini, EJ; Bräu, N; Dejesus, E; Dieterich, DT; Leitz, GJ; Sulkowski, MS | 1 |
| Boggio, L; Green, D; Herman, C | 1 |
| Berg, T; Frey, UH; Gerken, G; Mueller, T; Roggendorf, M; Sarrazin, C; Siffert, W; Weich, V; Zeuzem, S | 1 |
| Bellis, L; Dell' Unto, O; Durola, L; Galossi, A; Guarisco, R; Martellino, F; Puoti, C | 1 |
| Ferenci, P | 1 |
| Bunnapradist, S; Fabrizi, F; Martin, P | 1 |
| Chun, S; Sherman, KE | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Sato, J; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Alric, L; Boulestin, A; Dubois, M; Izopet, J; Pipy, B; Sandres-Saune, K; Vinel, JP | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J | 1 |
| Berns, GS; Capuron, L; Demetrashvili, M; Miller, AH; Nemeroff, CB; Pagnoni, G; Woolwine, BJ | 1 |
| Balderson, K; Sockalingam, S | 1 |
| Asahina, Y; Enomoto, N; Hamano, K; Itakura, J; Izumi, N; Kakinuma, S; Kurosaki, M; Maekawa, S; Sakamoto, N; Tanabe, Y; Ueda, E; Watanabe, H; Watanabe, M | 1 |
| Feld, JJ; Hoofnagle, JH | 1 |
| Andreadis, C; Downs, LH; Miller, WT; Schuster, SJ; Svoboda, J; Tsai, DE | 1 |
| Fukunaga, K; Kusaka, T; Matoba, Y; Ohnishi, K; Sawada, K | 1 |
| Asboe, D; Atkins, M; Bower, M; Browne, RE; Gazzard, BG; Gilleece, YC; Mandalia, S; Nelson, MR | 1 |
| Bani-Sadr, F; Bentata, M; Cacoub, P; Carrat, F; Goujard, C; Hor, R; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E; Salmon-Ceron, D | 1 |
| Chang, WY; Chuang, WL; Dai, CY; Hou, NJ; Yu, ML | 1 |
| Helbling, B; Mülhaupt, B; Telser, H; Zweifel, P | 1 |
| Barreiro, P; Garcia-Samaniego, J; Gonzalez-Lahoz, J; Maida, I; Nunez, M; Ramos, B; Soriano, V | 1 |
| Perronne, C | 1 |
| Lapiński, TW; Michalewicz, M; Nowacka, B | 1 |
| Bolewska, B; Juszczyk, J; Przedwojewski, M; Wojtacha, A | 1 |
| Jeong, SH; Suh, DJ | 1 |
| Lai, CL; Yuen, MF | 1 |
| Chung, RT; Yeung, E | 1 |
| Chu, CM; Lin, SM | 1 |
| Friedrich-Rust, M; Sarrazin, C; Zeuzem, S | 1 |
| Tien, PC | 1 |
| Allen, TM; Casson, DR; Chung, RT; Day, CL; Gandhi, RT; Kim, AY; Klenerman, P; Lauer, GM; Li, B; Lucas, M; Ouchi, K; Paranhos-Baccala, G; Reiser, M; Schulze Zur Wiesch, J; Sheridan, I; Timm, J; Walker, BD | 1 |
| Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K | 1 |
| Cianciara, J; Horban, A; Jabłońska, J; Walewska-Zielecka, B | 1 |
| Gładysz, A; Inglot, M; Rymer, W | 1 |
| Podlasin, RB | 1 |
| Arruga-Ginebreda, J; Castillo-Campillo, L; Mesa-Toledo, E; Miserachs-García, S | 1 |
| Grattagliano, I; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S | 1 |
| Carter, M | 1 |
| Cengiz, C; Dieterich, DT; Park, JS; Saraf, N | 1 |
| Au, WY; Lam, CC; Liu, CL; Yuen, MF | 1 |
| Aguilera, A; Castroagudín, JF; Delgado, MB; Martinez, SM | 1 |
| Fung, J; Jain, A; Kashyap, R; Marcos, A; Vekatramanan, R; Yelochan, B | 1 |
| Makuuchi, M; Sugawara, Y | 3 |
| Keeffe, EB; Nguyen, MH | 1 |
| Cummings, OW; Knox, KS; Weyer, P | 1 |
| Ołdakowska-Jedynak, U; Paczek, L | 1 |
| Peng, L; Qu, F; Wan, J; Wu, Q; Xia, Y | 1 |
| Dieterich, DT; Gorman, JM; Reichenberg, A | 1 |
| Tedaldi, EM | 1 |
| Sherman, KE; Shire, NJ | 1 |
| Amick, C; Andalkar, A; Bica, I; Bradley, M; Drewniak, S; Fiore, J; Galvin, S; Libone, G; McGovern, B; Molinaro-Gudas, V; Ramsey, J; Scheft, H; Taglienti, P; Wurcel, A | 1 |
| Sylvestre, DL | 2 |
| Alberti, A; Bortoletto, G; Dal Pero, F; Fagiuoli, S; Ferrari, A; Gerotto, M; Pistis, R; Realdon, S; Sebastiani, G | 1 |
| Encke, J; Kraus, T; Mehrabi, A; Sauer, P; Stremmel, W | 1 |
| Bani-Sadr, F; Bonarek, M; Cacoub, P; Carrat, F; Colin de Verdiere, N; Lunel-Fabiani, F; Morand, P; Perronne, C; Pialoux, G; Piroth, L; Pol, S; Rosenthal, E | 1 |
| Friman, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sato, J; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Gonçales, FL; Macedo-de-Oliveira, A; Pavan, MH; Pedro, MN; Vigani, AG | 1 |
| Clotet, B; Force, L; Fuster, D; Gómez, G; González García, J; Huertas, JA; Pedrol, E; Planas, R; Sirera, G; Solà, R; Tor, J; Tural, C; Videla, S; Vilaró, J | 1 |
| Akamatsu, N; Kaneko, J; Kishi, Y; Kokudo, N; Makuuchi, M; Sugawara, Y; Tamura, S | 1 |
| Bodenheimer, H; Bodian, C; Branch, AD; Cheng, B; Chung, RT; Fiel, MI; Gutierrez, JA; Schiano, TD; Schwartz, ME; Thung, SN; Walewski, JL | 1 |
| Cozzolongo, R; Cuppone, R; Manghisi, OG; Petruzzi, J; Stroffolini, T | 1 |
| Thomas, DL | 1 |
| Bertholom, C | 1 |
| Delić, D; Nesić, Z; Prostran, M; Simonović, J; Svirtlih, N | 1 |
| Duvnjak, M; Lerotić, I; Pavić, T; Tomasić, V; Virović, L | 1 |
| Kekez, AJ | 1 |
| Bruno, M; Coccoli, P; Cordone, G; Parrilli, G | 1 |
| Caprio, N; Iannicelli, P; Martini, S; Mogavero, AR; Pasquale, G | 1 |
| Bartlett, JG | 2 |
| Adeleine, P; Bailly, F; Maynard, M; Nemoz, C; Pradat, P; Rozier, F; Si Ahmed, SN; Trépo, C | 1 |
| Hodo, Y; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Tsuji, K; Yamashita, T | 1 |
| Kakizaki, S; Mori, M; Sato, K; Sohara, N; Takagi, H | 1 |
| Cacoub, P; Carrat, F; Deshayes, J; Fafi-Kremer, S; Lunel, F; Morand, P; Payan, C; Perronne, C; Pivert, A; Pol, S | 1 |
| Blot, C; d'Arondel, C; Messous, D; Morra, R; Moussalli, J; Munteanu, M; Naveau, S; Poynard, T; Simon, A; Thibault, V | 1 |
| Boyanova, Y; Calmus, Y; Conti, F; Pissaia, A; Soubrane, O | 1 |
| Ferenci, P; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Peck-Radosavljevic, M; Sieghart, W | 1 |
| Dixit, NM; Perelson, AS | 1 |
| El Riachy, E; Filoche, B; Gonzalez, F; Khalil, A; Lucidarme, D | 1 |
| Dieterich, DT; Park, JS; Saraf, N | 1 |
| Batisse, D; Chaix, ML; Dupont, C; Fontaine, H; Piketty, C; Pol, S; Rouveix, E; Rouzioux, C; Serpaggi, J; Vallet-Pichard, A; Viard, JP; Weiss, L | 1 |
| Alric, L; Kamar, N; Rostaing, L | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Doherty, MC; Gretch, DR; Koziel, MJ; Lindsay, KL; Malet, PF; Morishima, C; Polyak, SJ; Ray, R; Rothman, AL; Sullivan, DG | 1 |
| Atripaldi, L; Bellopede, P; Conca, P; Patarino, T; Perrella, A; Perrella, O; Ruggiero, L; Sbreglia, C; Sorrentino, P; Tarantino, G | 1 |
| Laurence, J | 1 |
| Batool, U; Qureshi, S | 1 |
| Beylot, J; Blanco, P; Bonnet, F; Cazanave, C; Morlat, P; Rakotondravelo, S | 1 |
| Bini, EJ; Mehandru, S | 1 |
| Hamidah, A; Jamal, R; Thambidorai, CR | 1 |
| Carreño, V; Castillo, I; López-Alcorocho, JM; Pardo, M; Perez-Mota, A; Rodríguez-Iñigo, E | 1 |
| Mohsen, A; Norris, S | 2 |
| Balogh, P; Berki, T; Halász, M; Hegedus, G; Hunyady, B; Miseta, A; Mózsik, G; Pálinkás, L; Pár, A; Pár, G; Szekeres-Barthó, J; Szereday, L | 1 |
| Longo, DL; Manns, MP; McHutchison, JG | 1 |
| Bergin, C; Clarke, S; Farrell, G; Hennessy, M; Hopkins, S; Lambourne, J; McCullagh, L; Mulcahy, F | 1 |
| Gubler, C; Müllhaupt, B; Renner, EL; Wilhelmi, M | 1 |
| Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S | 1 |
| Battegay, M; Bernasconi, E; Furrer, H; Hirschel, B; Ledergerber, B; Opravil, M; Rickenbach, M; Schmid, P; Tarr, PE; von Wyl, V; Weber, R; Zinkernagel, AS | 1 |
| Benhamou, Y; Bonnard, P; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Pialoux, G; Schruniger, A; Simon, A; Thibault, V; Valantin, MA | 1 |
| Barrufet, P; Castro, ER; Clotet, B; Coll, S; Force, L; Fuster, D; Galeras, JA; Giménez, MD; Montoliu, S; Montull, S; Planas, R; Sirera, G; Solà, R; Torra, S; Tural, C | 1 |
| Bettoli, V; Boccia, S; Mantovani, L; Virgili, A | 1 |
| García-Buey, L; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| de los Santos Gil, I; González Cerrajero, M; Pazos García, A; Sanz Sanz, J | 1 |
| Bryce, AH; Dispenzieri, A; Gertz, MA; Kyle, RA | 1 |
| Boninsegna, S; Brolese, A; Burra, P; Canova, D; D'Aloiso, C; Fagiuoli, S; Germani, G; Guido, M; Masier, A; Pevere, S; Targhetta, S; Tomat, S | 1 |
| Anderson, MH; Balan, V; Rakela, J; Rosati, MJ | 1 |
| Cullen, C; Grace, M; Hussain, M; Markatou, M; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH | 1 |
| Arakawa, Y; Fujiwara, K; Imazeki, F; Kato, N; Komine, F; Moriyama, M; Omata, M; Shiratori, Y; Tanaka, N; Yokosuka, O; Yoshida, H | 1 |
| Lyden, E; Mukherjee, S | 1 |
| Bräu, N; Dieterich, DT; Green, J; Hornberger, J; Patel, K; Sulkowski, MS; Torres, MR; Torriani, FJ | 1 |
| Bain, VG; Campbell, P; Zeman, M | 1 |
| Pazgan-Simon, M; Simon, K | 1 |
| Antela, A; Bárcena, R; Diz, S; García-Garzón, S; Mateos, ML; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Pérez-Elías, MJ; Quereda, C; Zamora, J | 1 |
| Furukawa, H; Ota, M; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S; Yamashita, K | 1 |
| Chung, RT; O'Leary, JG | 1 |
| Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG | 1 |
| Andreone, P; Berardi, S; Bernardi, M; Biselli, M; Bontadini, A; D'Errico, A; Gramenzi, A; Grazi, G; Lenzi, M; Lodato, F; Mazzella, G; Morelli, MC; Pinna, AD; Piscaglia, F; Sama, C; Tamè, MR | 1 |
| Gibofsky, A; Niewold, TB | 1 |
| Ko, HH; Marra, CA; Richardson, K; Wang, CS; Yoshida, EM | 1 |
| Sjogren, MH | 1 |
| Capra, F; Franchini, M; Nicolini, N | 1 |
| Dudley, T; Haydon, G; Höroldt, B; Mutimer, D; Nightingale, P; O'Donnell, K | 1 |
| Changchien, CS; Chen, CH; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH | 1 |
| Ballesteros, AL; Cervantes, M; Clotet, B; Force, L; Fuster, D; García, I; Gonzalez, J; Pedrol, E; Planas, R; Roget, M; Salas, A; Sirera, G; Tor, J; Tural, C; Videla, S; Vilaró, J | 1 |
| Bárcena, R; Blázquez, J; Foruny, JR; Gil-Grande, LA; Manzano, R; Moreno, A; Nuño, J | 1 |
| Cohen, L; Cooper, MA; Elkashab, M; Feinman, V; Fletcher, D; Girgrah, N; Heathcote, J; Levstik, M; McNaull, WB; Sherman, M; Wong, D; Wong, F; Yim, C | 1 |
| Bessone, F; Corti, M; Findor, J | 1 |
| Daruich, J; Fainboim, H; Frider, B | 1 |
| Barcena, R; Barrios, C; Blesa, C; Boullosa-Graña, E; Cuervas-Mons, V; Garcia-Garzon, S; Garcia-Gonzalez, M; Mateos, ML; Moreno, A; Moreno-Planas, JM; Moreno-Zamora, A; Oton, E; Rubio-Gonzalez, EE | 1 |
| Stribling, R; Sussman, N; Vierling, JM | 1 |
| Andrade, R; Bárcena, R; Crespo, J; Diago, M; Enríquez, J; Escartín, P; García-Bengoechea, M; Garcia-Samaniego, J; Martínez-Bauer, E; Moreno-Otero, R; Muñoz-Sánchez, M; Pérez, R; Planas, R; Romero-Gómez, M; Sánchez-Tapias, JM; Solá, R; Testillano, M | 1 |
| Afdhal, N; Belle, SH; Brown, RS; Conjeevaram, HS; Fried, MW; Hoofnagle, JH; Howell, CD; Jeffers, LJ; Kleiner, DE; Terrault, NA; Wiley-Lucas, TE | 1 |
| Asselah, T; Marcellin, P; Martinot, M; Rautou, PE; Saadoun, D; Valla, D | 1 |
| Abergel, A; Bommelaer, G; Bonny, C; Bourlière, M; Bronowicki, JP; Fontaine, H; Guillemard, C; Henquell, C; Hézode, C; Larrey, D; Marcellin, P; Merle, P; Nicolas, C; Poynard, T; Randl, K; Roche, C; Sapey, T; Ughetto, S; Zarski, JP | 1 |
| Andriulli, A; Bjøro, K; Dalgard, O; Mangia, A | 1 |
| Mallet, VO; Pol, S | 1 |
| Burioni, R; Carletti, S; Clementi, M; Craxì, A; Craxì, RD; Mancini, N; Perotti, M; Romanò, L; Zanetti, AR | 1 |
| Dar Santos, A; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Diepolder, HM; Gruener, NH; Klenerman, P; Loughry, A; Lucas, M; Pape, GR; Seth, NP; Tilman Gerlach, J; Ulsenheimer, A; Wucherpfennig, KW | 1 |
| Borzio, M; Cargnel, A; Fargion, S; Maraschi, A | 1 |
| Agyemang, AF; Hu, Z; Kottilil, S; McLaughlin, MM; Pau, AK; Polis, MA | 1 |
| Bongiovanni, M; Casanova, F; Ferrero, S; Monforte, Ad; Ranieri, R | 1 |
| Dogan, S; Gulec, S; Nuhoglu, A; Urganci, N | 1 |
| Buffet, C | 1 |
| Al Kaabi, SR; Al-Marri, A; Amer, AM; Bener, A; Butt, MT; Derbala, MF; El Dweik, NZ; Morad, N; Pasic, F; Yakoob, R | 1 |
| Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Takeda, Y; Umeshita, K | 1 |
| Berggren, R; Doyle, MK; Magnus, JH | 1 |
| Andrade, Z; Codes, L; Cruz, M; de Freitas, LA; Paraná, R; Schinoni, MI; Trepo, C | 1 |
| Gorman, JM; Weiss, JJ | 1 |
| Izopet, J; Kamar, N; Ribes, D; Rostaing, L | 1 |
| Borovicka, J; Cerny, A; Dinges, S; Esteban, A; Gonvers, JJ; Helbling, B; Jochum, W; Knöpfli, M; Meyer-Wyss, B; Müllhaupt, B; Renner, EL; Stamenic, I; Wilhelmi, M | 1 |
| Eyster, ME; Horn, PS; Rouster, SD; Sherman, KE; Shire, NJ; Stanford, S | 1 |
| Casane, D; Cristina, J; López, L; Moreno, MP | 1 |
| Lindhardt, BØ; Peters, L | 2 |
| Nelson, M; Waters, L | 1 |
| Daniel, J; Hari, P; Knox, J; Saeian, K; Surapaneni, SN | 1 |
| Blanco, JL; Costa, J; de Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martinez, E; Milinkovic, A; Murillas, J; Sánchez-Tapias, JM | 1 |
| Backus, LI; Boothroyd, DB; Mole, LA; Phillips, BR | 2 |
| Conceição, I; Couto, M; de Carvalho, M | 1 |
| Abradelo, M; Castellano, G; Colina, F; Fernández, I; Fuertes, A; García, I; Lumbreras, C; Meneu, JC; Moreno, E; Muñoz, R; Solís-Herruzo, JA | 1 |
| Carrilho, FJ; da Silva, LC; de Carvalho Mello, IM; de Mello Malta, F; Medeiros-Filho, JE; Neumann, AU; Pinho, JR | 1 |
| Hu, Z; Kleiner, DE; Koratich, C; Kottilil, S; Lempicki, R; Masur, H; McLaughlin, M; Polis, MA; Rehm, CA; Reitano, KN; Wood, B; Wu, L; Yang, J | 1 |
| Shah, BB; Wong, JB | 1 |
| Muir, AJ; Ramamurthy, M | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Gerken, G | 1 |
| Baulieux, J; Bizollon, T; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C | 1 |
| Frank, I; Gross, R; Kostman, JR; Lo Re, V; Mounzer, K; Putt, M; Reddy, KR; Rennert, H; Stieritz, DD; Strom, BL; Zemel, BS | 1 |
| Akuta, N; Kobayashi, M; Kumada, H; Matsuo, Y; Okamoto, K; Tazawa, H | 1 |
| Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D | 1 |
| Ferrari, C; Hansen, BE; Hellstrand, K; Lagging, M; Lukasiewicz, E; Neumann, AU; Pawlotsky, JM; Schalm, SW; Veldt, BJ; Verhey-Hart, E; Westin, J; Zeuzem, S | 1 |
| Dore, GJ | 1 |
| Bull, J; Chua, F; Galhenage, S; Hulse, G; Jeffrey, GP; MacQuillan, G; O'Neil, G; Young, E | 1 |
| Carneiro, F; Chaves, L; Coelho, H; Dias, N; Duarte, M; Fortes, O; Horta, A; Mendez, J; Pinho, L; Pires, N; Recalde, C; Sarmento-Castro, R; Seabra, J; Tavares, AP; Vasconcelos, O; Ventura, A | 1 |
| Addario, L; Ascione, A; Calise, F; Cuomo, O; De Luca, M; Di Costanzo, GG; Lampasi, F; Lanza, AG; Marsilia, GM; Picciotto, FP; Tartaglione, MT; Tritto, G | 1 |
| Aguilar Marucco, D; Bonora, S; Calcagno, A; Cariti, G; Cavecchia, I; de Requena, DG; De Rosa, FG; Di Perri, G; Sinicco, A; Veronese, L | 1 |
| Hofmann, WP; Sarrazin, C; Wohnsland, A | 1 |
| Shafran, SD | 1 |
| Sherman, KE | 2 |
| Schiff, ER | 1 |
| Alves de Mattos, A; Ferrari de Oliveira Rigo, J; Galperim, B; Lerias de Almeida, PR; Ribeiro de Souza, A; Riegel Santos, B; Valle Tovo, C | 1 |
| Bolkhir, A; Brunt, EM; Hayashi, PH; Solomon, HS | 1 |
| Jacobson, I; Sigal, S | 1 |
| Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L | 1 |
| Hauser, P; Indest, DW; Loftis, JM; Moles, JK; Morasco, BJ; Rifai, MA | 1 |
| Korochkina, OV; Sobchak, DM; Sobolevskaia, OL | 1 |
| Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Padmanabhan, L; Shiffman, ML | 1 |
| Dar Santos, AE; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, JI; Esteban, R; Guardia, J; Len, O; Margarit, C; Pahissa, A; Piron, M; Ribera, E; Sauleda, S; Vargas, V | 1 |
| Manz, M; Steuerwald, M | 1 |
| Ciuffreda, D; Fontana, M; Moradpour, D; Pascual, M | 1 |
| Angelico, M; Burra, P; Donato, MF; Lenci, I; Lionetti, R; Merli, M; Petrolati, A; Strazzabosco, M; Tisone, G | 1 |
| Grifols, JR; Ribera, JM; Serrano, A; Xicoy, B | 1 |
| Bitetto, D; Fabris, C; Fornasiere, E; Rapetti, R; Toniutto, P | 1 |
| Mátyus, J; Tornai, I | 1 |
| Sallie, R | 1 |
| Askari, F; Conjeevaram, H; Fontana, RJ; Greenson, JK; Lok, AS; Marrero, JA; Sharma, P; Su, GL; Sullivan, P | 1 |
| Sherman, KE; Shire, NJ; Welge, JA | 1 |
| Highleyman, L | 1 |
| Albo Castaño, MI; Casallo Blanco, S; Marcos Sánchez, F | 1 |
| Cairns, G | 1 |
| Javed, U; Lanford, J; Liu, R; Paul, S; Tevendale, R | 1 |
| Brown, QB; Cunningham-Rundles, S; Dorante, G; Markatou, M; Talal, AH; Zeremski, M | 1 |
| Dollarhide, AW; Endow-Eyer, R; Leckband, SG; Loh, C; Meyer, JM; Robinson, S | 1 |
| Tursi, A | 1 |
| Barreiros, AP; Biesterfeld, S; Böcher, WO; Galle, PR; Greif-Higer, G; Kanzler, S; Lohse, AW; Mönch, C; Otto, G; Schuchmann, M; Sprinzl, MF; Wörns, MA; Zimmermann, A; Zimmermann, T | 1 |
| Farrell, GC | 1 |
| Amarapurkar, D; Bowden, S; Chow, WC; Chutaputti, A; Dore, G; Gane, E; Guan, R; Hamid, SS; Hardikar, W; Hui, CK; Jafri, W; Jia, JD; Lai, MY; Leung, N; McCaughan, GW; Omata, M; Piratvisuth, T; Sarin, S; Sollano, J; Tateishi, R; Wei, L | 1 |
| Koike, K; Yotsuyanagi, H | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Denoeud, L; Lunel-Fabiani, F; Morand, P; Perronne, C; Pol, S | 1 |
| Encke, J; Stremmel, W; Weigand, K | 1 |
| Aguilar-Reina, J; Barroso, N; Garcia-Lozano, JR; Gonzalez-Escribano, MF; Montes-Cano, MA; Nunez-Roldan, A; Romero-Gomez, M | 1 |
| Bosch, J; Bruguera, M; Carrión, JA; Crespo, G; Forns, X; García-Pagan, JC; García-Retortillo, M; Navasa, M | 1 |
| Layden, TJ; Perelson, AS | 1 |
| Brillet, R; Chevaliez, S; Hézode, C; Lázaro, E; Pawlotsky, JM | 1 |
| Arazo, P; Barreiro, P; Berdún, MA; Echevarría, S; Garcia-Samaniego, J; Guardiola, JM; Labarga, P; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Ramos, B; Rendón, A; Romero, M; Santos, I; Soriano, V | 1 |
| Benhamou, Y; Sulkowski, MS | 1 |
| Benhamou, Y | 1 |
| Aurora, R; Belle, SH; Cannon, NA; Di Bisceglie, AM; Donlin, MJ; Li, J; Tavis, JE; Taylor, MW; Wahed, A; Yao, E | 1 |
| Kowala-Piaskowska, A | 1 |
| Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K | 1 |
| Lunel-Fabiani, F | 1 |
| Cross, JT; Devine, EB; Kowdley, KV; Sullivan, SD | 1 |
| Ahlenstiel, G; Berg, T; Biermer, M; Bueren, K; Grünhage, F; Nattermann, J; Nischalke, HD; Rockstroh, J; Sauerbruch, T; Spengler, U; Vogel, M | 1 |
| Belair, ML; Jun, AS; Kedhar, SR; Sulkowski, M; Thorne, JE | 1 |
| Lang, L | 1 |
| Chowaniec, E; Radziszewski, A; Sułowicz, W | 1 |
| Brodsky, LI; Li, J; Tavis, JE; Taylor, MW; Tsukahara, T; Wahed, AS | 1 |
| Dahari, H; Perelson, AS | 1 |
| Baba, HA; Beckebaum, S; Broelsch, CE; Cicinnati, VR; Erim, Y; Gerken, G; Hilgard, P; Iacob, S; Klein, CG; Sotiropoulos, GC | 1 |
| Dahari, H; Perelson, AS; Ribeiro, RM | 1 |
| Bosco, G; de Gennaro, M; Fiorini, I; Luchi, S; Meini, M; Moneta, S; Ricciardi, L; Scasso, A | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Ibrahim, AB; Oh, MK; Saab, S; Tong, MJ; Yersiz, H | 1 |
| Bracho, MA; Carnicer, F; Cuevas, JM; Del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Torres-Puente, M | 2 |
| Bacon, BR; Barange, K; Harley, H; Lin, A; Nelson, D; Shafran, SD; Shiffman, ML; Solá, R; Soman, A; Suter, F; Zeuzem, S | 1 |
| Liang, TJ | 1 |
| Batista, RS; Gomes, AP; Massumoto, CM; Moura, LH; Rego, TC; Soares, LM | 1 |
| Fytili, P; Manns, MP; Schaffer, S; Schulz, S; Tiemann, C; Wang, C; Wedemeyer, H | 1 |
| Buckton, AJ; Fisher, M; James, R; Kulasegaram, R; Ngui, SL; Rangarajan, S; Teo, CG | 1 |
| Belle, SH; Burton, JR; Erlich, H; Im, K; Klarquist, J; Rosen, HR; Weston, SJ; Yang, H | 1 |
| Axel, B; Berg, T; Bienek, B; Bruno, R; Clotet, B; Danta, M; Grünhage, F; Haerter, G; Klausen, G; Lutz, T; Mayr, C; Nattermann, J; Nischalke, HD; Rausch, M; Rockstroh, JK; Sauerbruch, T; Schewe, K; Spengler, U; Tural, C; Vogel, M | 1 |
| Dzierzanowska-Fangrat, K; Jankowska, I; Kaliciński, P; Kluge, P; Pawłowska, J; Socha, J; Teisseyre, J; Teisseyre, M; Woynarowski, M | 1 |
| Aoki, FH; Gonçalves, FL; Pavan, MH; Velho, PE; Vigani, AG | 1 |
| Balan, V; Krahn, LE; Martin, KA; Rosati, MJ | 1 |
| Dybowska, D; Halota, W | 1 |
| Bischof, T; Gonvers, JJ; Mullhaupt, B; Renner, EL; Wenger, C | 1 |
| Fukushima, K; Inoue, J; Iwasaki, T; Kakazu, E; Kido, O; Kimura, O; Kogure, T; Matsuda, Y; Nagasaki, F; Nakagome, Y; Obara, N; Shimosegawa, T; Ueno, Y; Wakui, Y | 1 |
| Dewar, R; Haagmans, B; Jackson, J; Koratich, C; Kottilil, S; Masur, H; McLaughlin, M; Neumann, A; Polis, M; Reitano, K; Rozenberg, L | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Miyakawa, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H | 1 |
| Alagna, L; De Bona, A; Galli, L; Gallotta, G; Guzzo, A; Lazzarin, A; Uberti-Foppa, C | 1 |
| Bieber, T; Bräuninger, W; Proelss, J; Scheler, M; Wenzel, J | 1 |
| Batista-Neves, S; Bressan, RA; Galvão, A; Miranda-Scippa, A; Paraná, R; Quarantini, LC | 1 |
| Gjertsen, H; Hörnfeldt, E; Weiland, O | 1 |
| Conway, B; DeVlaming, S; Duncan, F; Elliott, D; Genoway, K; Grebely, J; Khara, M; Raffa, JD; Viljoen, M | 1 |
| Dore, GJ; Hellard, ME; Kaldor, JM; Nguyen, OK | 1 |
| Chevaliez, S; Pawlotsky, JM | 1 |
| Aida, K; Kurihara, H; Mikami, M; Nagashima, I; Shiga, J; Takikawa, H; Tanaka, A; Uegaki, S | 1 |
| Bader, P; Bourcier, T; Lenoble, P; Nasica, X; Sauer, A; Speeg-Schatz, C | 1 |
| Elloumi, H; Gargouri, D; Ghorbel, A; Hadj, NB; Houissa, F; Kharrat, J; Romani, M | 1 |
| Han, SH; Smith, J | 1 |
| Afdhal, N; Becker, S; Bernstein, D; Brass, CA; Brown, RS; Flamm, S; Freilich, B; Godofsky, E; Griffel, LH; Jacobson, IM; Kwo, PY; Mukhopadhyay, P; Pauly, MP; Pound, D; Santoro, J; Strauss, R; Wakil, AE | 1 |
| Albert, C; Araya, V; Black, M; Brass, CA; Brown, RS; Dragutsky, MS; Freilich, B; Galler, GW; Griffel, LH; Hargrave, T; Harvey, J; Jacobson, IM; Kwo, PY; Lambiase, L; McCone, J; Siddiqui, FA | 1 |
| Chuang, WL; Dai, CY; Hsieh, MY; Huang, JF; Yu, ML | 1 |
| Wakita, T | 1 |
| Lengyel, G; Tulassay, Z | 1 |
| Rockstroh, J; Vogel, M | 1 |
| Fiel, MI; Saraf, N; Schiano, TD; Shukla, D; Xu, R | 1 |
| Esteban, JI; Ferrari, C; Germanidis, G; Haagmans, BL; Hezode, C; Homburger, Y; Lagging, M; Lukasiewicz, E; Lurie, Y; Missale, G; Negro, F; Neumann, AU; Orlandini, A; Pawlotsky, JM; Penna, A; Pilli, M; Schalm, SW; von Wagner, M; Zerbini, A; Zeuzem, S | 1 |
| Doros, A; Fazakas, J; Fehér, J; Fehérvári, I; Gálffy, Z; Gerlei, Z; Görög, D; Járay, J; Lengyel, G; Lotz, G; Máthé, Z; Nagy, P; Nemes, B; Németh, A; Pár, A; Sárváry, E; Schaff, Z; Schuller, J; Telegdy, L | 1 |
| Carrillo-Gómez, R; Collado, A; García-García, JA; Gil, Ide L; Girón-González, JA; Gómez-Mateos, J; González-Serrano, M; López-Cortés, LF; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Valera-Bestard, B | 1 |
| Chen, DS; Kao, JH; Liu, CH | 1 |
| Beaugrand, M; Braks, RE; Fontaine, H; Ganne-Carrie, N; Grando-Lemaire, V; Paries, J; Pol, S; Trinchet, JC | 1 |
| Benito, JM; Rallón, NI; Soriano, V | 1 |
| Barone, AA; Cavalheiro, Nde P; de Araújo, ES; Filgueiras, TC; Melo, CE; Morimitsu, SR; Tengan, FM | 1 |
| Basgoz, N; Bica, I; Birch, C; Davis, B; Gandhi, RT; Graeme-Cook, F; McGovern, BH; Quirk, JR; Stone, D; Zachary, K; Zaman, MT | 1 |
| Alobeid, B; Gaglio, PJ; Mears, JG; Schecter, JM | 1 |
| Berg, T; Hadziyannis, SJ; Jorga, K; Marcellin, P; Puoti, C; Snoeck, E; Swain, MG; Zarski, JP; Zeuzem, S | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Wu, CM; Yen, YH | 1 |
| Bjornsson, E; Bjøro, K; Dalgard, O; Florholmen, J; Frydén, A; Hellum, K; Holberg-Petersen, M; Myrvang, B; Reichard, O; Ring-Larsen, H; Ritland, S; Skovlund, E; Sundelöf, B; Verbaan, H | 1 |
| Bracho, A; Carnicer, F; Castro, JA; Del Olmo, J; García-Robles, I; González-Candelas, F; Jiménez-Hernández, N; Moya, A; Ortega, E; Sentandreu, V; Torres-Puente, M | 1 |
| Morelli, J; Senecal, DL | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Cummings, OW; Kwo, PY; Saxena, R; Tector, AJ | 1 |
| Hoefs, JC; Morgan, TR | 1 |
| Ariyarantha, K; Mukherjee, S | 1 |
| Abergel, A; Henquell, C; Nevens, F; Peigue-Lafeuille, H; Ross, RS; Van der Merwe, S; Van Ranst, M; Verbeeck, J | 1 |
| Andriulli, A; Bacca, D; Carretta, V; Cozzolongo, R; Cristofaro, G; Mangia, A; Minerva, N; Montalto, G; Mottola, L; Ricci, GL; Romano, M; Scotto, G; Spirito, F; Vinelli, F | 1 |
| Duvnjak, M; Virovic Jukic, L; Wu, CH; Wu, GY | 1 |
| Hayashi, N; Iino, S; Kiyosawa, K; Kumada, H; Okuno, T; Omata, M; Sakai, T; Yamada, G | 1 |
| Abbate, I; Capobianchi, MR; D'Offizi, G; Dianzani, F; Martini, F; Narciso, P; Rozera, G | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Duclos-Vallée, JC; Féray, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M; Teicher, E; Vittecoq, D | 1 |
| Clotet, B; Clumeck, N; Cooper, DA; Depamphilis, J; Dieterich, DT; Montaner, J; Opravil, M; Rockstroh, JK; Sasadeusz, J; Torriani, FJ | 1 |
| Dellamonica, P; Freedberg, KA; Gastaut, JA; Marimoutou, C; Poizot-Martin, I; Pradier, C; Rosenthal, E; Tran, A; Valerio, L; Yazdanpanah, Y | 1 |
| Riley, TR | 1 |
| Carriero, D; Dieterich, DT; Rafiq, N; Uriel, A | 1 |
| Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
| Cerulli, MA; Iqbal, S; Mansour, M | 1 |
| Cainelli, F | 1 |
| Brann, T; Dewar, RL; Highbarger, HC; Imamichi, T; Koratich, C; Kottilil, S; Lempicki, RA; Masur, H; McLaughlin, M; Neumann, AU; Nussenblatt, V; Polis, MA; Proschan, M; Rehm, CA; Yang, J | 1 |
| Freshwater, DA; Mutimer, DJ; O'Donnell, K | 1 |
| Avidan, B; Bar-Meir, S; Bashari, D; Lurie, Y; Maor, Y; Martinowitz, U; Paritsky, M; Rachlis, Z; Safadi, R; Schapiro, JM; Segol, O | 1 |
| Alvarez, M; Butt, G; Hill, WD; Krajden, M | 1 |
| Bergmann, JF; de Knegt, RJ; Drenth, JP; Roomer, R; Slavenburg, S | 1 |
| Bergin, C; Codd, M; Farrell, G; Mulcahy, F; Norris, S; Shea, DO; Tuite, H | 1 |
| Aguilar Marucco, D; Baietto, L; Bonasso, M; Bonora, S; Cariti, G; D'Avolio, A; De Blasi, T; Di Perri, G; Gonzalez de Requena, D; Sciandra, M; Siccardi, M; Sinicco, A; Tettoni, C; Trentini, L | 1 |
| Crespo, M; Curran, A; Esteban, JI; Falcó, V; Feijoo, M; Lopez, R; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sauleda, S; Villar del Saz, S | 1 |
| Cacoub, P; Saadoun, D; Sène, D | 1 |
| Cogliano-Shutta, NA; Connors, M; Davey, RT; Hallahan, CW; Johnson, AJ; Kottilil, S; Lempicki, RA; Lifson, JD; Luskin, MR; Manion, MM; Metcalf, JA; Mican, JM; Patamawenu, AA; Tilton, JC | 1 |
| Annable, L; Benkelfat, C; Brouillette, MJ; Cooper, C; Klein, MB; Kraus, D; Sheehan, NL; Singer, J; Weston, F | 1 |
| De Tullio, D; Falasca, K; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Chougnet, C; Fichtenbaum, CJ; Lages, CS; Shata, MT; Velilla, PA; Ying, J | 1 |
| Bahra, M; Berg, T; Kahl, A; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, U; Puhl, G; Schmitz, V | 1 |
| Dinihan, I; Freiman, J; Yan, KK; Zekry, A | 1 |
| Campos, R; Di Lello, F; Garcia, G; Kott, V; Sookoian, S | 1 |
| Ammassari, A; Giuliani, M; Lacaita, MG; Lajolo, C; Sartorio, A; Scivetti, M; Tamburrini, E; Tumbarello, M | 1 |
| Bani-Sadr, F; Bensalem, M; Cacoub, P; Carrat, F; Lapidus, N; Melchior, JC; Perronne, C; Pol, S; Ravaux, I; Rosa, I | 1 |
| Akazawa, K; Aoyagi, Y; Nakamura, J; Toyabe, SI | 1 |
| Abenavoli, L; Abenavoli, SM; De Maria, V; De Siena, M; Di Salvo, S; Giancotti, F; Gravina, T | 1 |
| Brown, RS; Jacobson, IM | 1 |
| Saunders, JC | 1 |
| Eguchi, S; Hamasaki, K; Hidaka, M; Ichikawa, T; Kanematsu, T; Miyazaki, K; Soyama, A; Tajima, Y; Takatsuki, M; Tokai, H | 1 |
| Akarca, U; Ersoz, G; Gunsar, F; Karasu, Z; Tekin, F | 1 |
| Borum, M; Stephen, S | 1 |
| Llopis-González, A; Márquez-Peiró, JF; Morales-Suárez-Varela, MM; Pérez-Peiró, C; Valero-Alcocer, VE | 1 |
| Chiba, T; Egawa, H; Haga, H; Ito, T; Marusawa, H; Nabeshima, M; Takada, Y; Tanaka, K; Ueda, Y; Uemoto, S | 1 |
| Ahmed, MS; Kapoor, N; Pandya, BK; Shawki, H; Wong, CF | 1 |
| Buxton, JA; Hill, WD; Hsu, PC; Krajden, M; Tu, AW; Yu, A | 1 |
| Angarano, G; Di Tullio, R; Fazio, V; Fornabaio, C; Saracino, A; Scotto, G; Tartaglia, A | 1 |
| Fried, MW; Thomas, E | 1 |
| Ferrari, C; Herrmann, E; Homburger, Y; Negro, F; Neumann, AU; Pawlotsky, JM; Pugnale, P; Schalm, SW; Zeuzem, S | 1 |
| Chosidow, O; Descamps, V; Francès, C; Landry, J; Marinho, E; Ratziu, V | 1 |
| Casado, J; Gila, A; León, J; Muñoz de Rueda, P; Palacios, A; Patón, R; Quiles, R; Quintero, D; Ruiz-Extremera, A; Salmerón, J | 1 |
| Bátyi, E; Szegedi, J | 1 |
| Cheung, R; Cunningham, F; Iqbal, SU; Kazis, L; Lee, A; Li, NC; Miller, DR | 1 |
| Bischof, M; Brunner, H; Ferenci, P; Fischer, G; Gschwantler, M; Hofer, H; Laferl, H; Löschenberger, K; Maieron, A; Scherzer, TM; Stauber, R; Staufer, K; Steindl-Munda, P; Strasser, M | 1 |
| Aurora, R; Cannon, NA; Donlin, MJ; Fan, X; Tavis, JE | 1 |
| Bauer, B; Bischof, M; Brunner, H; Datz, C; Ferenci, P; Formann, E; Gschwantler, M; Laferl, H; Löschenberger, K; Maieron, A; Scherzer, TM; Stauber, R; Staufer, K; Steindl-Munda, P | 1 |
| Seeff, LB | 1 |
| Conjeevaram, HS; Di Bisceglie, AM; Fried, MW; Hoofnagle, JH; Kleiner, DE; Mahaney, K; Park, Y; Sallie, R; Swain, M; Yurdaydin, C | 1 |
| Barbara, L; Brillanti, S; Deaville, R; Foli, M; Garson, J; Masci, C; Miglioli, M; Whitby, K | 1 |
| Bresters, D | 1 |
| Davis, GL; Lau, JY; Lim, HL | 1 |
| Gane, EJ; Portmann, BC; Ramage, JK; Tibbs, CJ; Williams, R | 1 |
| James, DG | 2 |
| Schvarcz, R; Sönnerborg, A; Weiland, O; Yun, ZB | 1 |
| Conte, PE; Ferrara, S; Mangano, A; Scotto, G; Tantimonaco, G | 1 |
| Main, J | 2 |
| Di Bisceglie, AM; Hoofnagle, JH; Krawczynski, K | 1 |
| Bacon, BR; Di Bisceglie, AM; Hoofnagle, JH; Kleiner, DE | 1 |
| Koskinas, J; McFarlane, IG; Pereira, LM; Saleh, MG; Tibbs, C; Williams, R | 1 |
| Chevallier, P; Chossegros, P; Daoud, S; Dubernard, JM; Garnier, JL; Touraine, JL | 1 |
| Braconier, JH; Frydén, A; Norkrans, G; Weiland, O | 1 |
| Ebeling, F | 1 |
| Giostra, E; Malè, PJ | 1 |
| Reichard, O | 1 |
| Dhumeaux, D; Marcellin, P; Pawlotsky, JM; Trépo, C | 1 |
| Bailly, F; Berby, F; Berthillon, P; Habersetzer, F; Pichoud, C; Trépo, C; Vitvitski, L | 2 |
| Sherlock, S | 3 |
| Camps, J; Civeira, MP; García, N; Prieto, J; Riezu-Boj, JI | 1 |
| Reichard, O; Sönnerborg, A; Weiland, O; Yun, ZB | 1 |
| Higashi, Y; Ishikawa, T; Kakumu, S; Takayanagi, M; Wakita, T; Yoshioka, K | 1 |
| Dusheiko, GM; Zuckerman, AJ | 1 |
| Pirotte, J | 1 |
| Cameron, R; Cattral, MS; Chung, SW; Greig, PD; Krajden, M; Levy, GA; Rezig, M; Wanless, IR | 1 |
| Braconier, JH; Engman, K; Paulsen, O; Widell, A | 1 |
| Alberti, A; Bernardinello, E; Cavalletto, L; Chemello, L; Guido, M; Pontisso, P | 1 |
| Barbara, L; Brillanti, S; Miglioli, M | 1 |
| Bizollon, T; Ducerf, C; Trépo, C | 1 |
| Ando, Y; Schvarcz, R; Sönnerborg, A; Weiland, O | 1 |
| Dusheiko, GM | 1 |
| Benhamou, JP; Boyer, N; Castelnau, C; Erlinger, S; Marcellin, P; Martinot, M; Pouteau, M | 1 |
| Acero, D; Adrados, M; Figa, M; González-Huix, F | 1 |
| Andersson, J; Aschan, J; Björkstrand, B; Hägglund, H; Ljungman, P; Lönnqvist, B; Ringdén, O; Winiarski, J | 1 |
| Chinitz, MA | 1 |
| Chan, KW; Chen, DS; Chen, PJ; Chu, JS; Kao, JH; Lai, MY; Wang, JT; Yang, PM | 1 |
| Adahm, M; Baulieux, J; Bizollon, T; Ducerf, C; Trepo, C | 1 |
| Conjeevaram, H; Di Bisceglie, AM; Hoofnagle, JH; Kleiner, D; Lau, D | 1 |
| Bailly, F; Bizollon, T; Trepo, C | 1 |
| Lopes, E; Lopes, LV; Silva, AE | 1 |
| Bassendine, M; Cuypers, T; Dhillon, A; Dusheiko, G; Fryden, A; Lee, C; Lelie, N; Main, J; Norkrans, G; Rassam, S; Reesink, H; Reichard, O; Sillikens, P; Telfer, P; Thomas, H; Watson, J; Weegink, C; Weiland, O | 1 |
| Alberti, A; Bellobuono, A; Brouwer, JT; Chemello, L; Ideo, G; Schalm, SW; Schwartz, R; Weiland, O | 1 |
| Bruguera, M | 1 |
| Erhard, A; Häussinger, D; Heintges, T; Hensel, F; Niederau, C; Niederau, CM; Petry, W; Wenning, M | 1 |
| Clarysse, C; Suwandhi, W; Verslype, C; Yap, SH | 1 |
| Davis, GL; González-Peralta, RP; Lau, JY; Liu, WZ; Qian, KP | 1 |
| Fazio, V; Scotto, G; Tantimonaco, G | 1 |
| Najm, W | 1 |
| Dieterich, D; Diflo, T; Harren, P; Rudow, DL; Teperman, LW | 1 |
| Bellobuono, A; Idéo, G; Mondazzi, L; Silini, E; Tempini, S; Vicari, F | 1 |
| Alberti, A; Bellobuono, A; Brouwer, JT; Cavalletto, L; Chemello, L; Hansen, BE; Ideo, G; Schalm, SW; Schvarcz, R; Weiland, O | 1 |
| Brouwer, JT; Schalm, SW | 1 |
| Collins, ML; Davis, GL; Detmer, J; Kolberg, JA; Lau, JY; Mizokami, M; Orito, E; Qian, K; Urdea, MS | 1 |
| Clarke, G; Crowe, J; Fielding, JF; Sachithanandan, S | 1 |
| Bodenheimer, HC; Davis, GL; Lewis, JH; Lindsay, KL; Seeff, LB; Thung, SN | 1 |
| Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Elliott, M; Palazzo, U; Pouyet, M; Trepo, C | 1 |
| Almasio, P; Cammà, C; Craxì, A; Di Marco, V; Giunta, M | 1 |
| He, Y; Liu, W; Zeng, L | 1 |
| Bongini, A; Busi, C; Colonna, FP; Di Stefano, G; Fiume, L; Mattioli, A | 1 |
| Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T | 1 |
| Cattral, MS; Greig, PD; Hemming, AW; Levy, G; Lilly, LB; Philosophe, B; Superina, RA | 1 |
| Belleannee, G; Beylot-Barry, M; Brudieux, E; Couzigou, P; de Ledinghen, V; Doutre, MS | 1 |
| Sharara, AI | 1 |
| Reichard, O; Schvarcz, R; Weiland, O | 1 |
| Brouwer, JT; Fattovich, G; Schalm, SW | 1 |
| Garson, JA; Grant, PR; Hoffbrand, AV; Telfer, PT; Whitby, K; Wonke, B; Yardumian, A | 1 |
| Ashur, Y; Ilan, Y; Safadi, R; Shouval, D; Tur-Kaspa, R | 1 |
| Abdulla, A; al-Sebayel, M; al-Traif, I; Hammad, A; Kizilisik, TA; Ramirez, CG | 1 |
| Blanche, P; Bouscary, D | 1 |
| Gane, EJ; Lau, JY; Lo, SK; Naoumov, NV; Portmann, BC; Riordan, SM; Williams, R | 1 |
| Opolon, P; Poynard, T | 1 |
| Lee, JH; Roth, WK; Schmidt, JM; Teuber, G; von Wagner, M; Zeuzem, S | 1 |
| Bouloux, P; Hoffbrand, AV; Jensen, C; Telfer, P; Wonke, B | 1 |
| Gross, JB | 1 |
| Berg, T; Götz, G; Haefker, A; Hopf, U; Neuhaus, P; Neuhaus, R; Schön, MR | 1 |
| Chossegros, P; Claudy, A; Faure, M; Forestier, JY; Ghohestani, R; Kanitakis, J; Misery, L; Thiery, S; Trepo, C | 1 |
| Azoulay, D; Charpentier, B; Debuire, B; Ducret, F; Féray, C; Gigou, M; Lemoine, A; Paradis, V; Pham, HP; Samuel, D | 1 |
| Hug, B | 1 |
| Hill, N | 1 |
| Delwaide, J | 1 |
| Cooksley, WG | 1 |
| Brenard, R; Closon, ML; Fevery, J; Hautekeete, M | 1 |
| Batey, RG; Sievert, W | 1 |
| Daghestani, L; Pomeroy, C | 1 |
| Clay, CM | 1 |
| Newman, TB | 1 |
| Bricaire, F | 1 |
| Bolondi, L; Brillanti, S; Di Tomaso, M; Foli, M; Gramantieri, L; Masci, C | 1 |
| Baio, P; Bellavita, P; Caldara, R; Ferruzzi, S; Misiani, R; Rossi, P; Tengattini, F | 1 |
| Cohen, J | 1 |
| Shneider, BL | 1 |
| Agarwal, K; Jones, DD | 1 |
| Patrick, L | 1 |
| Albillos, A; Cacho, G; Calleja, JL; Domper, F; Escartín, P; Moreno-Otero, R; Rossi, I; Yebra, M | 1 |
| Silvain, C | 1 |
| Fabrizi, F; Locatelli, F | 1 |
| Görög, D; Horányi, M; Schaff, Z; Telegdy, L | 1 |
| MacConnachie, AM | 1 |
| Poynard, T | 1 |
| al-Muzairai, IM; Costandi, JN; Gupta, RK; Johny, KV; Mousawi, M; Nampoory, MR; Ninan, VT; Samhan, M | 1 |
| Lavezzo, B; Rizzetto, M | 1 |
| Lawrence, SP | 1 |
| Antonaci, S; Caccavo, D; Jirillo, E; Pellegrino, NM; Piazzolla, G | 1 |
| Catalina, G; Navarro, V | 1 |
| Hoofnagle, JH; Liang, TJ; Rehermann, B; Seeff, LB | 1 |
| Britnell, T; Muir, D; Mutimer, DJ; Roberts, A; Shields, PL; Skidmore, S; Wilde, JT | 1 |
| Akesson, A; Christensson, B; Widell, A; Wiebe, T | 1 |
| Faure, I; Leng, B; Lifermann, F; Mercié, P; Pellegrin, JL; Trimoulet, P; Viallard, JF; Vital, A | 1 |
| Ebel, M; Erhardt, A; Häussinger, D; Heintges, T; Jablonowski, H; Petry, W | 1 |
| Mast, EE; Seeff, LB; Sulkowski, MS; Thomas, DL | 1 |
| Cervera, R; Font, J; García-Carrasco, M; Ramos-Casals, M; Trejo, O | 1 |
| McHutchison, J; Pianko, S | 1 |
| Bruch, K; Kornetzky, I; Kronenberger, B; Lee, JH; Roth, WK; Rüster, B; Sarrazin, C; Zeuzem, S | 1 |
| Fukumoto, T; Iwasaki, T; Ku, Y; Kuroda, Y; Kusunoki, N; Muramatsu, S; Tominaga, M; Yoon, S | 1 |
| Castro, FJ; Dragon, EA; Esteban, JI; Esteban, R; Guardia, J; Sauleda, S; Viladomiu, L | 1 |
| Bar-Nathan, N; Ben-Ari, Z; Mor, E; Shaharabani, E; Shapira, Z; Tur-Kaspa, R | 1 |
| Hoepelman, AI | 1 |
| Trepo, C | 1 |
| Yamabe, H | 1 |
| Barnes, E; Brown, D; Dusheiko, G; Webster, G | 1 |
| Bréchot, C; Chaix, ML; Fontaine, H; Lagneau, JL; Pol, S | 1 |
| Balistreri, WF; Schwimmer, JB | 1 |
| Altisent, C; Esteban, JI; Esteban, R; Guardia, J; Puig, L; Sauleda, S | 1 |
| Barnes, E; Dusheiko, G; Webster, G; Whalley, S | 1 |
| Stachowski, J | 1 |
| Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C | 1 |
| Main, J; Thomas, HC; Wright, M | 1 |
| Layden, TJ; Mika, B; Wiley, TE | 1 |
| Bouvier-Alias, M; Darthuy, F; Dhumeaux, D; Hezode, C; Pawlotsky, JM; Remire, J | 1 |
| Carithers, RL; Gretch, DR; Larson, AM; Nousbaum, J; Polyak, SJ; Ray, SC; Sullivan, DG | 1 |
| Batisse, D; Jian, R; Kazatchkine, MD; Landau, A; Piketty, C | 1 |
| Keren, D; Naschitz, JE; Rosner, I; Rozenbaum, M; Sabo, E; Slobodin, G; Toubi, E; Tsykounov, I; Yeshurun, D; Zuckerman, E | 1 |
| Cruz, CN; Felipe, M; Ferraz, LG; Figueiredo, VM; Granero, L; Lanzoni, V; Lopes, EP; Oliveira, PM; Silva, AE | 1 |
| Kennedy, M | 1 |
| Beergabel, M; Lurie, Y; Malnick, SD | 1 |
| Agarwal, S; Rosse, WF; Swaim, MW | 1 |
| Balija, M; Bingulac-Popović, J; Drazić, V; Grahovac, B; Grgicević, D; Hrstić, I; Ostojić, R; Vucelić, B | 1 |
| Bruno, S; Crosignani, A; Pinzello, GB | 1 |
| Aguilar, C; Lucia, JF; Simón, MA | 1 |
| Codes, L; Cruz, M; Cruz, T; Ferreira, K; Paraná, R; Santos-Jesus, R | 1 |
| Bekkering, FC; Brouwer, JT; McHutchison, JG; Perelson, AS; Stalgis, C | 1 |
| Chadapaud, S; Hittinger, G; Lafeuillade, A | 1 |
| Berk, BS; Chou, S; Corless, CL; Gopal, DV; Olyaei, A; Orloff, SL; Rabkin, JM; Rosen, HR | 1 |
| Billaud, G; Maertens, G; Querenghi, F; Trépo, C; Yu, Q; Zoulim, F | 1 |
| Fontana, RJ | 1 |
| Berenguer, M; Wright, TL | 1 |
| Davis, L; De Vera, ME; Heffron, TG; Martinez, E; Rosado, K; Sharma, S; Smallwood, GA; Stieber, AC | 1 |
| Berntorp, E; Lethagen, S; Lindgren, S; Verbaan, H; Widell, A | 1 |
| Brabant, G; Horn, R; Jaeckel, E; Manns, MP; Ockenga, J; Tillmann, HL; von zur Mühlen, A; Wedemeyer, H; Widjaja, A | 1 |
| Shermock, KM; Temple, ME; Younossi, ZM | 1 |
| Baker, R | 1 |
| Roehr, B | 1 |
| Powell, J | 1 |
| Stoia, J | 1 |
| Norton, M | 1 |
| Grinberg, L | 1 |
| James, JS | 1 |
| Fontaine, H; Pol, S | 2 |
| Burroughs, AK; Papatheodoridis, GV; Teixeira, R | 1 |
| Bunce, M; Chapman, R; Collier, J; Harcourt, G; Hellier, S; Klenerman, P; Phillips, R; Satsangi, J | 1 |
| Goodman, Z; Gramlich, T; Mayes, J; Ong, JP; Sarbah, S; Yen-Lieberman, B; Younossi, ZM | 1 |
| Fontaine, H; Pol, S; Vallet-Pichard, A | 1 |
| Seeff, LB; Strader, DB | 1 |
| Abad, S; Chauvelot-Moachon, L; Salmon-Céron, D; Silbermann, B; Sogni, P | 1 |
| Backmund, M; Eichenlaub, D; Meyer, K; Von Zielonka, M | 1 |
| Lauer, GM; Walker, BD | 1 |
| Boulet, JM; Causse, X; Djarech, H; Labarriere, D; Lagasse, JP; Ripault, MP | 1 |
| Hubbard, MJ | 1 |
| Baud, M; Burnichon, J; Dutertre, N; Minazzi, H; Morand, P; Pernollet, M; Seigneurin, JM; Zarski, JP | 1 |
| Brown, PJ; Neuman, MG | 1 |
| Raufman, JP; Satoor, S | 1 |
| Lemon, MD; Meade, F | 1 |
| Blendis, L; Konikoff, FM | 1 |
| Cotler, SJ; Jensen, DM | 1 |
| Jonas, MM | 1 |
| Bain, VG | 1 |
| Dieterich, DT; Jones, JS | 1 |
| Cunningham-Rundles, C; Jonas, MM; Razvi, S; Schneider, L | 1 |
| Allegri, L; Buzio, C; Carnevali, L; Catellani, W; Garini, G; Manganelli, P | 1 |
| Higashi, MK; Phillips, KA; Veenstra, DL | 1 |
| Chen, DS; Chen, PJ; Cheng, YM; Kao, JH; Lai, MY | 1 |
| Addesa, JA; Navarro, VJ | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Cavallari, A; Cursaro, C; D'Errico, A; Di Giammarino, L; Galli, S; Gramenzi, A; Grazi, GL; Jovine, E; Mazziotti, A | 1 |
| Di Bisceglie, AM; McHutchison, J; Rice, CM | 1 |
| Bacon, BR; Di Bisceglie, AM | 1 |
| de Knegt, RJ; van den Berg, AP | 1 |
| Rodés, J; Sánchez Tapias, JM | 1 |
| Colombo, M; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E | 1 |
| Murphy, MJ | 1 |
| Schulman, S | 1 |
| Hwang, SJ | 1 |
| Canchis, PW; Jacobson, I; Talal, AH | 1 |
| Ramrakhiani, S; Sponseller, CA | 1 |
| Amarapurkar, A; Amarapurkar, D; Dhorda, M; Kankonkar, S; Kirpalani, A | 1 |
| Lu, Z; Xu, X | 1 |
| Ma, H; Wang, H | 1 |
| Bonacini, M | 1 |
| Farah, A | 1 |
| Giostra, E; Hadengue, A; Mentha, G; Negro, F; Pawlotsky, JM; Perrin, L; Quadri, R; Roskams, T; Rubbia-Brandt, L | 1 |
| Buti, M; Esteban, R; Lurie, Y; Martell, M; Sanchez-Avila, F; Stalgis, C; Valdés, A | 1 |
| Benson, L; Birkel, A; Caldwell, L; Casarico, B; Stafford-Fox, V | 1 |
| Amati, L; Amoroso, A; Caccavo, D; Caradonna, L; Cozzolongo, R; Cuppone, R; Jirillo, E; Magrone, T; Manghisi, OG; Mastronardi, ML | 1 |
| Amati, L; Amoroso, A; Caccavo, D; Caradonna, L; Cozzolongo, R; Cuppone, R; Jirillo, E; Magrone, T; Manghisi, OG; Mastronardi, ML; Pellegrino, NM | 1 |
| Fernández, I; Lumbreras, C; Rubio, R | 1 |
| Nguyen, MH; Wright, TL | 1 |
| Cooper, DA; Dore, GJ | 1 |
| Cameron, CE; Castro, C | 1 |
| Charlton, MR; Crippin, JS; McCashland, T; Sheiner, P; Terrault, N | 1 |
| Berenguer, M | 1 |
| Dev, A; Sievert, W | 1 |
| Iosue, K | 1 |
| Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
| Dieterich, DT | 1 |
| Gebo, K | 1 |
| Bruno, R; Ciappina, V; Cotler, S; Filice, G; Rondanelli, M; Sacchi, P | 1 |
| Rockstroh, JK | 1 |
| Chung, M; Gretch, DR; Perelson, AS; Ribeiro, RR; Rosen, HR; Weinberger, L; Wolf, S | 1 |
| Fabrizi, F; Martin, P; Poordad, FF | 1 |
| Chung, RT; Kobayashi, M; Moriguchi, H; Sato, C; Uemura, T | 1 |
| Watson, J | 1 |
| Grube, T; Hommann, M; Kornberg, A; Scheele, J; Schotte, U; Tannapfel, A; Voigt, R; Wagner, T | 1 |
| Barrera, JM; Campistol, JM; Esforzado, N; Morales, JM | 1 |
| Fevery, J; Moshage, H; Willems, M; Yap, SH | 1 |
| Axiotis, CA; Bergasa, NV; Di Bisceglie, AM; Fong, TL; Fried, MW; Hoofnagle, JH; Park, Y; Shindo, M; Swain, MG; Waggoner, JG | 1 |
| Andersson, J; Reichard, O; Schvarcz, R; Weiland, O | 1 |
| Andersson, J; Reichard, O | 1 |
| Métreau, JM | 1 |
508 review(s) available for ribavirin and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
[From treating in the dark towards eliminating hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin | 2021 |
Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Treatment Outcome | 2022 |
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Management of Hepatitis C in Children - A New Paradigm.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Ribavirin; Treatment Outcome | 2023 |
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Topics: Antiviral Agents; Chronic Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2023 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization | 2020 |
Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Patient Selection; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2021 |
Hepatitis C Virus and Hepatitis B Virus Co-Infection.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Interferons; Mice; Microbial Interactions; Ribavirin; Risk Factors; Virus Activation; Virus Replication | 2020 |
Association between inosine triphosphatase rs1127354 polymorphisms and ribavirin-induced anaemia and outcome in hepatitis C virus-infected patients: A meta-analysis.
Topics: Anemia; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Inosine Triphosphatase; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2020 |
A PRISMA-compliant systematic review and meta-analysis of integrated Chinese and Western medicine in treating hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Combined Modality Therapy; Drug Therapy, Combination; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Medicine, Chinese Traditional; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum Albumin | 2020 |
Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2020 |
Hepatitis C virus-related cryoglobulinemic vasculitis.
Topics: Antiviral Agents; Blood Component Removal; Colchicine; Cryoglobulinemia; Female; Glucocorticoids; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis | 2021 |
Hepatitis C virus-associated non-Hodgkin lymphomas: the endless history.
Topics: Antiviral Agents; Cryoglobulinemia; Hepacivirus; Hepatitis C; Humans; Interferons; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Ribavirin | 2021 |
Genotype 3-hepatitis C virus' last line of defense.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome | 2021 |
Hepatitis C in Tunisia from 1991 to 2019: A systematic review.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Tunisia | 2021 |
Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus.
Topics: Antiviral Agents; Cell Line; COVID-19; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Mutation; Ribavirin; RNA, Viral; Sequence Analysis; Viral Nonstructural Proteins; Virus Replication | 2021 |
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Renal Insufficiency, Chronic; Ribavirin | 2017 |
Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Topics: Antiviral Agents; CTLA-4 Antigen; Genome-Wide Association Study; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Ribavirin; Viral Load; Viral Proteins | 2017 |
Direct-acting antivirals: the endgame for hepatitis C?
Topics: Antiviral Agents; Disease Eradication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2017 |
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2017 |
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.
Topics: Antiviral Agents; Drug Therapy, Combination; Fluorescein Angiography; Fundus Oculi; Glucocorticoids; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Tomography, Optical Coherence; Uveomeningoencephalitic Syndrome | 2019 |
Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; India; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Treatment of hepatitis C in special populations.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Immunocompromised Host; Interferons; Liver Transplantation; Postoperative Period; Protease Inhibitors; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.
Topics: Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C; Humans; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin | 2018 |
Identifying causal variants at the interferon lambda locus in case-control studies: Utilizing non-synonymous variant rs117648444 to probe the role of IFN-λ4.
Topics: Antiviral Agents; Chromosome Mapping; Drug Resistance; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon Regulatory Factors; Interferons; Interleukins; Linkage Disequilibrium; Polymorphism, Single Nucleotide; Ribavirin | 2018 |
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Ribavirin | 2018 |
Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Inflammation; Interferon-alpha; Lichen Planus, Oral; Liver Diseases; Male; Middle Aged; Prevalence; Ribavirin | 2018 |
Interferon-Free Regimen for Hepatitis C: Insight and Management.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Protease Inhibitors; Ribavirin; Serine Proteases; Viral Nonstructural Proteins | 2018 |
Pharmacological interventions for acute hepatitis C infection.
Topics: Acute Disease; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Network Meta-Analysis; Randomized Controlled Trials as Topic; Ribavirin; Viral Hepatitis Vaccines | 2018 |
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Substitution; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Guanine; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
Treatment decisions and contemporary versus pending treatments for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2013 |
[Biochemical and pharmacological features of telaprevir].
Topics: Administration, Oral; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Food-Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Humans; Inactivation, Metabolic; Interferons; Interleukins; Intestinal Absorption; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2013 |
Optimizing DAA management in daily practice.
Topics: Antiviral Agents; Checklist; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Medication Adherence; Oligopeptides; Patient Education as Topic; Polyethylene Glycols; Proline; Ribavirin | 2013 |
Optimizing treatment in HIV/HCV coinfection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin | 2013 |
Emerging treatments for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2013 |
Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Virus Activation | 2014 |
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals.
Topics: Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2013 |
[Hepatitis C virus: 25 years-old, the end?].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Protease Inhibitors; Ribavirin | 2013 |
Hepatitis C virus NS3 inhibitors: current and future perspectives.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins | 2013 |
Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin | 2013 |
Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
How to optimize current treatment of genotype 2 hepatitis C virus infection.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Standard of Care; Time Factors; Treatment Outcome | 2014 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins | 2014 |
Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Meta-Analysis as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.
Topics: Anti-Retroviral Agents; Comorbidity; Disease Management; Disease Progression; End Stage Liver Disease; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
What is the future of ribavirin therapy for hepatitis C?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin | 2014 |
New antiviral agents for the treatment of hepatitis C: ABT-450.
Topics: Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2014 |
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Species Specificity; Treatment Outcome | 2014 |
Review article: HCV genotype 3 – the new treatment challenge.
Topics: Animals; Antiviral Agents; Cyclophilins; Cyclosporine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Viral Nonstructural Proteins | 2014 |
Factors influencing adherence in Hepatitis-C infected patients: a systematic review.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Medication Adherence; Polyethylene Glycols; Ribavirin | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Antiviral treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
[Future perspectives of hepatitis C therapeutics].
Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Enzyme Inhibitors; Genome-Wide Association Study; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Liver Neoplasms; Polymorphism, Genetic; Ribavirin; Viral Nonstructural Proteins | 2014 |
Efficacy of daclatasvir in hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Valine; Viral Nonstructural Proteins | 2014 |
Treating hepatitis C in the elderly: the future is near?
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Medication Adherence; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Randomized Controlled Trials as Topic; Ribavirin; Young Adult | 2014 |
Decade in review-HCV: hepatitis C therapy-a fast and competitive race.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2014 |
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.
Topics: Adult; Aged; Cohort Studies; Female; Gene Frequency; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Linkage Disequilibrium; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Recent advances in the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Cyclophosphamide; Hepacivirus; Hepatitis C; Humans; Immunologic Factors; Interferon-alpha; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Ribavirin; Rituximab | 2014 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
[New drugs for hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferons; Oligopeptides; Recurrence; Ribavirin; Risk Factors | 2014 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Ribavirin; Thiazoles | 2015 |
Antivirals against enteroviruses: a critical review from a public-health perspective.
Topics: Amantadine; Antiviral Agents; Child; Clinical Trials as Topic; Coinfection; Drug Resistance, Viral; Enterovirus; Enterovirus Infections; Epidemiological Monitoring; Hepatitis C; Humans; Immunocompromised Host; Influenza, Human; Public Health; Ribavirin | 2015 |
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome | 2015 |
Gene therapies for hepatitis C virus.
Topics: Animals; Antiviral Agents; Drug Delivery Systems; Genetic Therapy; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Ribavirin; RNA Interference; RNA, Small Interfering | 2015 |
A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.
Topics: Algorithms; Antiviral Agents; Bayes Theorem; Comparative Effectiveness Research; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2015 |
From non-A, non-B hepatitis to hepatitis C virus cure.
Topics: Clinical Trials as Topic; Hepatitis C; Hepatitis, Viral, Human; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin | 2015 |
[Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Topics: Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Oligopeptides; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Ribavirin; Simeprevir; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
[Financial burden of hepatitis C infection and its treatment].
Topics: Administration, Oral; Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Early Diagnosis; Hepatitis C; Humans; Hungary; Interferons; Protease Inhibitors; Quality of Life; Quality-Adjusted Life Years; Ribavirin | 2015 |
Diagnosis and Management of Hepatitis C.
Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Humans; Interferon-alpha; Liver Diseases; Mass Screening; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Viral Load; Viral Nonstructural Proteins | 2015 |
Perspectives on dual hepatitis B and C infection in Taiwan.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome | 2016 |
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Withholding Treatment | 2015 |
[Novel methods of hepatitis C treatment and prevention].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Oligopeptides; Protease Inhibitors; Ribavirin; Simeprevir | 2015 |
Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.
Topics: Acute Disease; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Topics: Aged; Anemia, Hemolytic; Antiviral Agents; Female; Genetic Variation; Genotype; Haplotypes; Hemoglobins; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Metabolism, Inborn Errors; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome | 2015 |
Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Liver Neoplasms; Observational Studies as Topic; Outcome Assessment, Health Care; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2015 |
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins | 2015 |
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir | 2015 |
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Antiviral Agents; Coinfection; Drug Users; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sustained Virologic Response; Viral Load; Young Adult | 2016 |
A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; Humans; North America; Patient Participation; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Indications for Treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Practice Guidelines as Topic; Republic of Korea; Ribavirin | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Republic of Korea; Ribavirin; Sofosbuvir | 2016 |
A systematic review of community based hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Tertiary Care Centers; Treatment Outcome | 2016 |
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine | 2016 |
Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
Topics: Antiviral Agents; Delayed-Action Preparations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin | 2017 |
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.
Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepatitis C; Humans; Interferons; Lymphoma, B-Cell; Ribavirin; Treatment Outcome | 2016 |
Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Tissue Donors; Viral Load | 2017 |
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Network Meta-Analysis; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Viral Hepatitis Vaccines | 2017 |
[Clinical aspects of hepatitis C in women of child-bearing age].
Topics: Adolescent; Adult; Antiviral Agents; Contraindications; Female; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Infectious; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Viremia | 2008 |
Immune responses during acute and chronic infection with hepatitis C virus.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Recombinant Proteins; Ribavirin; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic | 2008 |
[Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Risk Factors; Thyroid Diseases; Thyroiditis | 2007 |
Therapy of acute hepatitis C: a review of literature.
Topics: Acute Disease; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2008 |
Current approaches to HCV infection in current and former injection drug users.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Patient Care Team; Recurrence; Ribavirin; Substance Abuse, Intravenous | 2008 |
Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Pharmacists; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2008 |
Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature.
Topics: Antiviral Agents; Diagnosis, Differential; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lichen Planus, Oral; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Ribavirin | 2008 |
Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
Topics: Antiviral Agents; Biomedical Research; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2009 |
Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Hypertension, Portal; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome; Viral Load | 2008 |
Treatment failure in hepatitis C: mechanisms of non-response.
Topics: Drug Resistance, Viral; Hepatitis C; Humans; Immunity, Innate; Interferon Type I; Interferons; Ribavirin; Treatment Failure; Viral Interference | 2009 |
Clinical management of HIV/hepatitis C virus coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Health Services Needs and Demand; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Medication Adherence; Nurse Practitioners; Nurse's Role; Ribavirin; Risk Factors; Severity of Illness Index; Social Support | 2008 |
Treatment of hepatitis C in liver transplant recipients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Optimal therapy in genotype 1 patients.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Type B insulin resistance developing during interferon-alpha therapy.
Topics: Autoantibodies; Hepatitis C; Humans; Hyperglycemia; Immunoprecipitation; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Receptor, Insulin; Ribavirin | 2009 |
Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chronic Disease; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opioid-Related Disorders; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retention, Psychology; Ribavirin; Young Adult | 2009 |
Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Mental Disorders; Polyethylene Glycols; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2009 |
Influence of selected HLA tissue compatibility antigens on the course and efficacy of viral hepatitis C treatment--actual knowledge position.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Evidence-Based Practice; Haplotypes; Hepacivirus; Hepatitis C; HLA Antigens; Humans; Interferons; Major Histocompatibility Complex; Ribavirin; Treatment Outcome | 2009 |
A practical guide to the management of HCV infection following liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2009 |
Hepatitis C treatment for injection drug users: a review of the available evidence.
Topics: Antiviral Agents; Drug Users; Hepatitis C; Humans; Interferons; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2009 |
The role of the community nurse in hepatitis C diagnosis and treatment.
Topics: Antiviral Agents; Community Health Nursing; Depression; Drug Monitoring; Fatigue; Hepatitis C; Humans; Infection Control; Interferon alpha-2; Interferon-alpha; Neutropenia; Nurse's Role; Nursing Assessment; Patient Education as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Social Support; United Kingdom | 2009 |
Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges?
Topics: Acute Disease; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2009 |
Use of agents stimulating erythropoiesis in digestive diseases.
Topics: Anemia; Erythropoiesis; Erythropoietin; Hematinics; Hepatitis C; Humans; Inflammatory Bowel Diseases; Ribavirin | 2009 |
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.
Topics: Alopecia; Antiviral Agents; Drug Eruptions; Drug Therapy, Combination; Eczema; Hepatitis C; Humans; Interferons; Psoriasis; Ribavirin; Sarcoidosis | 2009 |
Acute hepatitis C and HIV coinfection.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
Topics: Acute Disease; Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sweden | 2009 |
Investigational drugs for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Drugs, Investigational; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2010 |
Treatment and prevention of hepatitis B and C in thalassemia.
Topics: Antiviral Agents; Hemolysis; Hepatitis B; Hepatitis C; Humans; Ribavirin; Thalassemia; Transfusion Reaction | 2009 |
Host genetic factors and treatment of hepatitis C.
Topics: Antiviral Agents; Chemokines; Cytokines; Hepatitis C; HLA Antigens; Humans; Interferons; Polymorphism, Genetic; Ribavirin | 2008 |
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Topics: Amantadine; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Randomized Controlled Trials as Topic; Recurrence; Ribavirin | 2010 |
Treatment of hepatitis C in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell, Marginal Zone; Ribavirin | 2010 |
New therapies in the management of hepatitis C virus.
Topics: Hepatitis C; HIV Protease Inhibitors; Humans; Ribavirin | 2010 |
[Hepatitis C virus infection--after 20 years].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Viral Nonstructural Proteins; Viral Structural Proteins | 2010 |
The A, B, Cs of viral hepatitis in the biologic era.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Ribavirin; Rituximab | 2010 |
[When and how should hepatitis C be treated?].
Topics: Age Factors; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Finland; Hepacivirus; Hepatitis C; Humans; Interferons; Patient Selection; Protease Inhibitors; Ribavirin; Treatment Outcome | 2010 |
Hepatitis C: diagnosis and treatment.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a.
Topics: Amino Acid Sequence; Antiviral Agents; Biomarkers; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Sequence Data; Mutation; Ribavirin; Viral Nonstructural Proteins | 2010 |
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.
Topics: Animals; Antiviral Agents; Carboxylic Acids; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Protease Inhibitors; Remission Induction; Ribavirin; Thiophenes; Treatment Outcome | 2010 |
Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sex Factors | 2010 |
Treatment of hepatitis C in children: a systematic review.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Genotype; Hepatitis C; Humans; Infant; Infant, Newborn; Interferons; Randomized Controlled Trials as Topic; Ribavirin | 2010 |
[Epidemiological and clinical study for hepatitis C virus infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HTLV-I Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Japan; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2010 |
Acute hepatitis C treatment.
Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Selection; Ribavirin; Treatment Outcome | 2010 |
A perspective on modelling hepatitis C virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
Albinterferon-alpha 2b: a new treatment option for hepatitis C.
Topics: Albumins; Animals; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Viral Load | 2010 |
Boceprevir.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Microbial Sensitivity Tests; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2010 |
Telaprevir.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Microbial Sensitivity Tests; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Proteins | 2010 |
Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Patient Selection; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Hepatitis C treatment: current and future perspectives.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
New HCV therapies on the horizon.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2011 |
Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Female; Greece; Hepatitis B; Hepatitis C; Humans; Inflammatory Bowel Diseases; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Ribavirin; Tenofovir; Treatment Outcome | 2010 |
[New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Protease Inhibitors; Ribavirin | 2010 |
Hepatitis C virus: How genetic variability affects pathobiology of disease.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2011 |
The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.
Topics: Age Factors; Antiviral Agents; Genetic Markers; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin; Sex Factors | 2011 |
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Standard of Care | 2011 |
Hepatitis C virus genotype 4 therapy: progress and challenges.
Topics: Antiviral Agents; Drug Administration Schedule; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Pharmacogenetics; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Ribavirin | 2011 |
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2011 |
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Blood Component Removal; Cryoglobulinemia; Drug Therapy, Combination; Evidence-Based Medicine; Expert Testimony; Glucocorticoids; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Precision Medicine; Recombinant Proteins; Ribavirin; Rituximab; Virus Replication | 2011 |
Of lives and livers: emerging responses to the hepatitis C virus.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Ribavirin; Risk Factors; Time Factors | 2011 |
[Current status of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Asymptomatic Diseases; Comorbidity; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Risk Factors; RNA, Viral; Sexual Behavior; Spain; Substance Abuse, Intravenous; Viremia | 2011 |
Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.
Topics: Genetic Variation; Genome-Wide Association Study; Hepatitis C; HLA Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2011 |
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
[Treatment of hepatitis C virus in HIV-positive patients].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Outbreaks; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Patient Dropouts; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2011 |
Treatment of acute hepatitis C infection in HIV-infected patients.
Topics: Antiviral Agents; Australia; Cohort Studies; Drug Monitoring; Europe; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferons; Male; Ribavirin; Treatment Outcome; United States | 2011 |
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin; Viral Load | 2011 |
Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review.
Topics: Antiviral Agents; Confidence Intervals; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome | 2011 |
Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Taribavirin in the treatment of hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Prodrugs; Ribavirin | 2011 |
Boceprevir: a user's guide.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.
Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Mixing and matching drugs: what makes sense?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2011 |
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Topics: Antiviral Agents; Drug Eruptions; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Ribavirin; Skin Diseases | 2012 |
Interferon combination therapy for HIV/hepatitis C virus coinfection.
Topics: Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
The role of insulin resistance in HIV/hepatitis C virus-coinfected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Insulin Resistance; Interferon-alpha; Polyethylene Glycols; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
NK cells prevalence, subsets and function in viral hepatitis C.
Topics: Adaptive Immunity; Animals; Antiviral Agents; Cytotoxicity, Immunologic; DNA-Binding Proteins; Genes, RAG-1; Hepacivirus; Hepatitis C; Hepatocytes; HLA-C Antigens; Humans; Immune Tolerance; Immunity, Innate; Interferon-alpha; Interferon-gamma; Interleukin-12; Interleukin-15; Killer Cells, Natural; Liver; Lymphocyte Subsets; Mice; Prognosis; Receptors, KIR2DL3; Ribavirin | 2011 |
HIV and hepatitis C co-infection: acute HCV therapy.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child?
Topics: Age Factors; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Evidence-Based Medicine; Hepatitis C; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Patient Selection; Practice Guidelines as Topic; Ribavirin; Treatment Outcome | 2011 |
Relapsing polychondritis associated with hepatitis C virus infection.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Polychondritis, Relapsing; Ribavirin; Treatment Outcome | 2012 |
Interferon free hepatitis C treatment regimens: the beginning of another era.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2012 |
Tailor-made therapy for viral hepatitis: recent advances.
Topics: Hepatitis B; Hepatitis C; Humans; Inosine Triphosphatase; Interferon alpha-2; Interferon-alpha; Plasmapheresis; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin | 2011 |
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2012 |
Recent advance in antiviral drugs for hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; RNA-Dependent RNA Polymerase; Viral Nonstructural Proteins | 2011 |
Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.
Topics: Animals; Antiviral Agents; Cyclophilins; Drug Delivery Systems; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin | 2012 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2011 |
Hepatitis C: epidemiology, diagnosis, natural history and therapy.
Topics: Antiviral Agents; Chronic Disease; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prevalence; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2012 |
Treatment of hepatitis C virus infection after kidney transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Transplantation; Ribavirin | 2012 |
[Progress in blood purification medicine in 2011].
Topics: Antiviral Agents; Bone Diseases, Metabolic; Cardiovascular Diseases; Chronic Disease; Hepatitis C; HIV Infections; Humans; Interferons; Kidney Diseases; Practice Guidelines as Topic; Renal Dialysis; Ribavirin | 2012 |
Utilizing genomic polymorphisms to personalize hepatitis C therapies.
Topics: Antiviral Agents; Depressive Disorder, Major; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Pharmacogenetics; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Animal models for the study of hepatitis C virus infection and related liver disease.
Topics: Animals; Antibodies, Neutralizing; Antiviral Agents; Carcinoma, Hepatocellular; Cercopithecidae; Disease Models, Animal; Disease Susceptibility; Hepatitis Antibodies; Hepatitis C; Humans; Immunity, Innate; Interferon-alpha; Liver Diseases; Liver Neoplasms; Mice; Mice, SCID; Pan troglodytes; Platyrrhini; Ribavirin; Virus Replication | 2012 |
[Anti HCV drugs--ribavirin, telaprevir].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin | 2012 |
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
The application and mechanism of action of ribavirin in therapy of hepatitis C.
Topics: Animals; Antiviral Agents; Hepatitis C; Humans; Ribavirin | 2012 |
Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Genetics of IL28B and HCV--response to infection and treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Acute hepatitis C in patients with HIV.
Topics: Antiviral Agents; Australia; Coinfection; Europe; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; United States | 2012 |
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Health Care Costs; Hepatitis C; Humans; Interferons; Protease Inhibitors; Quality of Life; Ribavirin | 2012 |
Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2012 |
The place of immunotherapy in the management of HCV-induced vasculitis: an update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis | 2012 |
The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.
Topics: Antiviral Agents; Asian People; Hepatitis B; Hepatitis C; Humans; Interferons; Ribavirin | 2012 |
Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis C; Humans; Interferons; Mass Screening; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Substance Abuse, Intravenous | 2012 |
Direct-acting antiviral agents for hepatitis C virus infection.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2013 |
Acute hepatitis C in an HIV-infected patient: a case report and review of literature.
Topics: Acute Disease; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2013 |
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Cyclophilin inhibitors for hepatitis C therapy.
Topics: Antiviral Agents; Cyclophilins; Cyclosporine; Cyclosporins; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2013 |
Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.
Topics: Acute Disease; Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin | 2012 |
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.
Topics: Adult; Antiviral Agents; Drug Users; Female; Hepatitis C; Humans; Interferons; Male; Medication Adherence; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2013 |
[Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell; Ribavirin; Rituximab; Vasculitis | 2012 |
Current management and perspectives for HCV recurrence after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2013 |
HCV therapy in HIV-infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
New therapeutic strategies in HCV: second-generation protease inhibitors.
Topics: Animals; Antiviral Agents; Carrier Proteins; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Viral Nonstructural Proteins | 2013 |
Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Patient Selection; Phenotype; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.
Topics: Antiviral Agents; Biological Evolution; Drug Resistance, Viral; Drug Therapy, Combination; Epistasis, Genetic; Genetic Markers; Genetic Variation; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Host genetic variants in the pathogenesis of hepatitis C.
Topics: Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Disease Susceptibility; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferons; Interleukins; Membrane Transport Proteins; Pyrophosphatases; Receptors, Calcitriol; Ribavirin; Treatment Outcome | 2012 |
Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
Topics: Antiviral Agents; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferons; Protease Inhibitors; Ribavirin | 2013 |
Management of hepatitis C in human immunodeficiency virus-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Interactions; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin | 2002 |
[Treatment of hepatitis C. Consensus conference].
Topics: Alcohol Drinking; Antiviral Agents; Drug Administration Schedule; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Patient Selection; Ribavirin; Severity of Illness Index | 2002 |
Hepatitis C and HIV co-infection: a review.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Immunity, Cellular; Interferons; Male; Ribavirin | 2002 |
[Hepatitis C and alcohol].
Topics: Alanine Transaminase; Alcoholism; Antiviral Agents; Apoptosis; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Odds Ratio; Prevalence; Ribavirin; Risk Factors; Time Factors; Viral Load | 2002 |
[Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; France; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferons; Prevalence; Prisons; Prognosis; Prospective Studies; Recurrence; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders; Time Factors | 2002 |
[Management of patients with hepatitis C virus infection. Virological tests].
Topics: Acute Disease; Adult; Algorithms; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Biomarkers; Capsid; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Male; Monitoring, Physiologic; Polymerase Chain Reaction; Prognosis; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2002 |
[What are the indications for treatment of acute hepatitis C?].
Topics: Acute Disease; Adult; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Meta-Analysis as Topic; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors; Transaminases; Transfusion Reaction | 2002 |
[Treatment of extrahepatic manifestations associated with hepatitis C virus infection].
Topics: Antiviral Agents; Autoantibodies; Cryoglobulinemia; Drug Therapy, Combination; Fatigue; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Lymphoproliferative Disorders; Male; Middle Aged; Odds Ratio; Porphyria Cutanea Tarda; Pruritus; Ribavirin; Sjogren's Syndrome; Surveys and Questionnaires; Thrombocytopenia; Time Factors; Vascular Diseases | 2002 |
[Treatment of hepatitis C after liver transplantation].
Topics: Acute Disease; Animals; Drug Therapy, Combination; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunoglobulins; Immunosuppression Therapy; Interferons; Liver Transplantation; Pan troglodytes; Postoperative Care; Postoperative Complications; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Virus Replication | 2002 |
[Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Liver Transplantation; Male; Multicenter Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; Time Factors; Transaminases | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Treatment of acute hepatitis C].
Topics: Acute Disease; Adult; Antiviral Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Interferon-beta; Male; Meta-Analysis as Topic; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors | 2002 |
[Treatment of hepatitis C virus associated extrahepatic manifestations].
Topics: Antiviral Agents; Autoantibodies; Clinical Enzyme Tests; Clinical Trials as Topic; Cryoglobulinemia; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferons; Lichen Planus; Lymphoma, Non-Hodgkin; Porphyria Cutanea Tarda; Prospective Studies; Purpura, Thrombocytopenic; Retrospective Studies; Ribavirin; Sjogren's Syndrome; Thyroid Diseases; Time Factors; Transaminases | 2002 |
Hepatitis C in childhood.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Ribavirin; Serologic Tests | 2002 |
[Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Topics: Acute Disease; Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Depression; Drug Evaluation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Hyperbilirubinemia; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Thyroiditis; Viral Load; Viremia | 2002 |
Treatment of recurrent hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Optimal therapy of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Introduction to therapy of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2002 |
Monitoring of viral levels during therapy of hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Monitoring, Physiologic; Ribavirin; Viral Load | 2002 |
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Reference Values; Ribavirin; Transaminases | 2002 |
Treatment of patients with hepatitis C and cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver; Liver Cirrhosis; Liver Transplantation; Ribavirin | 2002 |
Therapy of acute hepatitis C.
Topics: Acute Disease; Antiviral Agents; Hepatitis C; Humans; Interferons; Ribavirin | 2002 |
Side effects of therapy of hepatitis C and their management.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Polyethylene glycol-interferon: current status in hepatitis C virus therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Viramidine (Ribapharm).
Topics: Animals; Clinical Trials as Topic; Hepatitis C; Humans; Ribavirin; Technology, Pharmaceutical | 2002 |
Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.
Topics: Adult; Antibodies, Antineutrophil Cytoplasmic; Cryoglobulins; Drug Therapy, Combination; Glucocorticoids; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney Glomerulus; Lupus Nephritis; Male; Middle Aged; Ribavirin | 2002 |
Pegylated interferons.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Current therapy for hepatitis C: pegylated interferon and ribavirin.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2003 |
New therapies on the horizon for hepatitis C: are we close?
Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Ribavirin; RNA, Antisense; RNA, Catalytic; Viral Proteins; Virus Replication | 2003 |
[Screening and treatment of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C; Humans; Interferon-alpha; Mass Screening; Ribavirin; Risk Factors; Treatment Outcome | 2003 |
[Drug therapy of hepatitis B and C].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2003 |
[Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Recurrence; Ribavirin | 2002 |
[Renal damage during type II cryoglobulinemia].
Topics: Acute Disease; Adrenal Cortex Hormones; Antiviral Agents; Biopsy; Cryoglobulinemia; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Diseases; Male; Microscopy, Electron; Middle Aged; Nephritis; Nephrotic Syndrome; Plasma Exchange; Prognosis; Ribavirin | 2003 |
[Hepatitis C virus infection].
Topics: Animals; Drug Therapy, Combination; Genes, vif; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Replicon; Ribavirin; Viral Proteins | 2003 |
[Hepatitis C].
Topics: Acute Disease; Chronic Disease; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Japan; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2003 |
The silent dragon--hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Middle Aged; Perioperative Nursing; Ribavirin | 2003 |
[The treatment of hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Synergism; Hepatitis C; HIV Infections; Humans; Metabolic Clearance Rate; Pancreatitis; Ribavirin | 2003 |
The role of the laboratory in the diagnosis and management of chronic hepatitis C patients.
Topics: Acute Disease; Biopsy, Needle; Clinical Laboratory Techniques; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Saudi Arabia; Sensitivity and Specificity | 2003 |
[Hepatitis C virus genotype 4: epidemiology and treatment].
Topics: Antiviral Agents; Genotype; Global Health; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2003 |
HCV in sickle cell disease.
Topics: Anemia, Sickle Cell; Antiviral Agents; Chronic Disease; Comorbidity; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Prevalence; Ribavirin; Transfusion Reaction; United States | 2003 |
[How can we improve the system to analyze HCV replication system?].
Topics: Animals; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genetic Therapy; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferons; Replicon; Ribavirin; RNA, Viral; Virus Replication | 2003 |
HIV and hepatitis C co-infection.
Topics: Antiviral Agents; Comorbidity; Contraindications; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Patient Selection; Practice Guidelines as Topic; Recurrence; Reoperation; Ribavirin; Risk Factors | 2003 |
Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury.
Topics: Antibody Formation; Antigens, Viral; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dendritic Cells; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Killer Cells, Natural; Liver; Ribavirin; RNA, Viral; T-Lymphocytes | 2003 |
Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2003 |
Treatment of hepatitis C virus infection in the allograft.
Topics: Antiviral Agents; Contraindications; Cost of Illness; Drug Therapy, Combination; Graft Survival; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous | 2003 |
New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation.
Topics: Animals; Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral; Secondary Prevention; Virus Replication | 2003 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index | 2003 |
HIV and HCV coinfection in haemophilia.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Ribavirin; Transaminases; Viremia | 2004 |
Managing hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States | 2004 |
Care of patients with hepatitis C and HIV co-infection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
[Treatment of hepatitis C. Different modalities based on viral genotype].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Patient Care Planning; Ribavirin | 2003 |
[Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
Topics: Acute Disease; Antiviral Agents; Forecasting; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Remission, Spontaneous; Ribavirin; RNA, Viral; Viral Load; Viremia | 2004 |
Hepatitis C and treatment with pegylated interferon and ribavirin.
Topics: Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Replication | 2004 |
The treatment of hepatitis C: history, presence and future.
Topics: Amantadine; Antiviral Agents; Chronic Disease; Consensus; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Ribavirin | 2004 |
Therapy of hepatitis C in HIV-coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Europe; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Ribavirin; United States | 2004 |
Treatment of acute hepatitis C.
Topics: Acute Disease; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Interferons; Ribavirin | 2004 |
The role of ribavirin in the combination therapy of hepatitis C virus infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2004 |
What is disrupting IFN-alpha's antiviral activity?
Topics: Cytokines; Drug Resistance; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Repressor Proteins; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transcription Factors; Tumor Necrosis Factors | 2004 |
Hepatitis C treatment update.
Topics: Acute Disease; Adjuvants, Immunologic; Algorithms; Antiviral Agents; Chronic Disease; Decision Trees; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; United States; Viral Load | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Strategies for hepatitis C therapeutic intervention: now and next.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Protein Prenylation; Ribavirin; Viral Hepatitis Vaccines; Virus Replication | 2004 |
Hepatitis C: How should we manage the patient?
Topics: Delivery of Health Care; Hepatitis C; Humans; Interferons; Patient Education as Topic; Ribavirin | 2004 |
Hepatitis C: What is the best treatment?
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2004 |
[Present status of therapy for viral hepatitis in Japan].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Japan; Liver Neoplasms; Prognosis; Ribavirin | 2004 |
[Detection of hepatitis C virus RNA].
Topics: Antiviral Agents; Biomarkers; Hepacivirus; Hepatitis C; Humans; Interferons; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2004 |
[Epidemiology of hepatitis C in Japan].
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Global Health; Hepatitis C; Humans; Incidence; Interferons; Japan; Prevalence; Ribavirin; Seroepidemiologic Studies; Time Factors | 2004 |
[Prevalence of hepatitis C virus infection among chronic hemodialysis patients].
Topics: Antiviral Agents; Biomarkers; Chronic Disease; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Prevalence; Renal Dialysis; Ribavirin; Risk; RNA, Viral; Time Factors; Transfusion Reaction | 2004 |
[Guidelines for treatment of hepatitis C].
Topics: Antiviral Agents; Biomarkers; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
[Clinical, virologic and pathologic features of asymptomatic hepatitis C virus carriers].
Topics: Antiviral Agents; Carrier State; Cost-Benefit Analysis; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Ribavirin; RNA, Viral; Time Factors; Viral Proteins | 2004 |
[Clinical management of asymptomatic HCV carriers].
Topics: Alanine Transaminase; Antiviral Agents; Biomarkers; Carrier State; Contraindications; Drug Therapy, Combination; Fibrosis; Hepatitis C; Humans; Interferons; Liver; Practice Guidelines as Topic; Ribavirin | 2004 |
[Therapeutic strategies for hepatitis C].
Topics: Antiviral Agents; Cysteine; Drug Combinations; Drug Therapy, Combination; Genotype; Glycine; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferons; Oleanolic Acid; Pharmacogenetics; Phlebotomy; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Ursodeoxycholic Acid | 2004 |
[Virus factors determining the outcome of IFN treatment for chronic hepatitis C].
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins; Viral Proteins | 2004 |
[Evaluating the efficacy of interferon therapy on hepatitis C patients].
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Neoplasms; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Effect of IFN treatment for extrahepatic manifestations].
Topics: Antiviral Agents; Cardiomyopathies; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Middle Aged; Myositis; Ribavirin; Thyroid Diseases; Treatment Outcome | 2004 |
[Hepatitis C in childhood--natural history and therapy].
Topics: Adolescent; Antiviral Agents; Biomarkers; Child; Child, Preschool; Disease Transmission, Infectious; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Infant; Infant, Newborn; Interferons; Liver; Mother-Child Relations; Prognosis; Ribavirin; RNA, Viral; Transfusion Reaction | 2004 |
[Recurrence of hepatocellular carcinoma associated with hepatitis C virus after tumor ablation].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Drug Therapy, Combination; Ethanol; Hepatectomy; Hepatitis C; Humans; Injections, Intralesional; Interferon-alpha; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Ribavirin; Risk Factors; Time Factors | 2004 |
[Hepatitis C in the HIV-infected person].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Prognosis; Ribavirin; Temperance | 2004 |
[Hepatitis C].
Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors | 2004 |
Management of hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Immunotherapy; Interferon-beta; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin | 2004 |
Current and emerging therapeutic approaches to hepatitis C infection.
Topics: Animals; Genotype; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2003 |
Peginterferon-alpha(2b) and ribavirin.
Topics: Animals; Antiviral Agents; Drug Interactions; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2004 |
Management of hepatitis C virus genotype 4.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin | 2004 |
Viral error catastrophe by mutagenic nucleosides.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Models, Genetic; Mutagenesis; Nucleosides; Ribavirin; RNA Viruses | 2004 |
Anemia during treatment of hepatitis C in HIV-infected patients.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
[Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
[Treatment strategies of acute and chronic hepatitis C].
Topics: Acute Disease; Antiviral Agents; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2002 |
HIV/HCV coinfection in clinical practice.
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States | 2004 |
Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
Topics: Aged; Antiviral Agents; Female; Granuloma; Hepatitis C; Humans; Interferons; Lung Diseases, Interstitial; Ribavirin | 2004 |
Hepatitis C in haemophiliacs.
Topics: Female; Genotype; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; Time Factors; Treatment Outcome | 2004 |
[HIV infections].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Transmission, Infectious; Hepatitis C; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Interferons; Patient Compliance; Ribavirin; Treatment Failure | 2004 |
Therapeutic modalities in hepatitis C: challenges and development.
Topics: Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Quality of Life; Ribavirin | 2005 |
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels.
Topics: Alanine Transaminase; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Liver; Reference Values; Ribavirin | 2005 |
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin | 2005 |
Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Update on hepatitis C treatment in HIV-coinfected patients.
Topics: Algorithms; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2004 |
Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.
Topics: Antiviral Agents; Gene Order; Genes, bcl-2; Hepatitis C; Humans; Interferon-alpha; Lymphoproliferative Disorders; Remission Induction; Ribavirin | 2005 |
Treatment of hepatitis C.
Topics: Acute Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Maximum Tolerated Dose; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2005 |
Hepatitis C virus infection: the new global epidemic.
Topics: Antiviral Agents; Drug Therapy, Combination; Global Health; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Health Care Costs; Hepatitis C; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
[Treatment of hepatitis C virus infection].
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Meta-Analysis as Topic; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Viral Load | 2005 |
Treatment of hepatitis C in potential kidney and heart transplant patients.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Heart Failure; Heart Transplantation; Hepatitis C; Humans; Interferon Type I; Kidney Failure, Chronic; Kidney Transplantation; Recombinant Proteins; Renal Dialysis; Ribavirin | 2005 |
Treatment of hepatitis C virus/HIV coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Treatment Refusal | 2005 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Transaminases; Treatment Failure; Viral Envelope Proteins; Viral Hepatitis Vaccines | 2005 |
Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Signal Transduction | 2005 |
Current status of hepatitis C virus infection in Korea.
Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Child; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Korea; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Prevalence; Ribavirin; Risk Factors; RNA, Viral; Species Specificity | 2006 |
Secondary prevention of hepatitis C virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin | 2005 |
Current therapy for hepatitis C.
Topics: Algorithms; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Recurrence; Ribavirin | 2007 |
[Experimental therapy in HCV infection].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrones; Recombinant Proteins; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Catalytic; RNA, Small Interfering; RNA, Viral; Treatment Outcome; Viral Nonstructural Proteins | 2005 |
[Hepatitis C infections in dialyzed patients].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors | 2005 |
HIV and liver diseases: recent clinical advances.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Ribavirin | 2005 |
Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.
Topics: Antiviral Agents; Drug Therapy, Combination; Genes, Viral; Genotype; Global Health; Hepacivirus; Hepatitis C; Humans; Interferons; Prevalence; Ribavirin | 2005 |
[The course of hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Genotype; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Treatment of hepatitis C virus in HIV patients: a review.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
New drug targets for HIV and hepatitis C virus coinfection.
Topics: Drug Delivery Systems; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferons; Ribavirin; Viral Hepatitis Vaccines; Virus Replication | 2005 |
Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Treatment of hepatitis C virus reinfection after liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
Hepatitis C virus infection, cryoglobulinemia, and peripheral neuropathy: a case report.
Topics: Antiviral Agents; Cryoglobulinemia; Electromyography; Hepacivirus; Hepatitis C; Humans; Immunoenzyme Techniques; Interferon-alpha; Male; Middle Aged; Polyneuropathies; Ribavirin | 2005 |
Options for treatment of hepatitis C in HIV-infected persons.
Topics: Antiviral Agents; Drug Carriers; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Treatment algorithm for the management of hepatitis C in HIV-coinfected persons.
Topics: Algorithms; Anti-Retroviral Agents; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Hepatitis C--treatment of untreated (naive) patients].
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[HCV reinfection after liver transplantation for HCV cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Treatment Outcome | 2005 |
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin | 2006 |
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Topics: Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Treatment of hepatitis C-virus-related glomerulonephritis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Proteinuria; Renal Insufficiency; Renin-Angiotensin System; Ribavirin; Rituximab | 2006 |
Chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Definition and management of anemia in patients infected with hepatitis C virus.
Topics: Anemia; Antiviral Agents; Cardiovascular System; Cognition Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Topics: Acute Disease; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Is interferon-beta an alternative treatment for chronic hepatitis C?
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Randomized Controlled Trials as Topic; Ribavirin | 2006 |
[Rules of management and treatment the patients with recurrent hepatitis C after liver transplantation].
Topics: Antiviral Agents; Graft Rejection; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Liver Transplantation; Ribavirin; RNA, Viral; Secondary Prevention | 2005 |
Management of hepatitis C virus coinfection in HIV-infected persons.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Ribavirin | 2006 |
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Ribavirin; Treatment Outcome | 2006 |
Treatment of hepatitis C in hemophiliacs.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon Type I; Liver Transplantation; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Topics: Algorithms; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Living donor liver transplantation to patients with hepatitis C virus cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Living Donors; Postoperative Complications; Recombinant Proteins; Ribavirin; Risk Factors; Secondary Prevention; Tissue and Organ Procurement | 2006 |
Treatment of hepatitis C infection.
Topics: Antiviral Agents; Contraindications; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Improving anti-hepatitis C virus therapy.
Topics: Algorithms; Animals; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Patient Selection; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2006 |
Hepatitis C (chronic).
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Acute hepatitis. Biological hepatic anomalies in asymptomatic persons].
Topics: Acute Disease; Adult; Antiviral Agents; Cholestasis; Chronic Disease; Clinical Enzyme Tests; Diagnosis, Differential; France; Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Hepatitis D; Hepatitis D, Chronic; Hepatitis, Viral, Human; Humans; Infectious Disease Transmission, Vertical; Interferon-alpha; Phosphoric Monoester Hydrolases; Prevalence; Ribavirin; Transaminases | 2006 |
Liver transplantation for hepatitis C.
Topics: Hepatitis C; Humans; Immunosuppression Therapy; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2006 |
Interferon-induced sarcoidosis.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Ribavirin; Sarcoidosis, Pulmonary | 2006 |
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV.
Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Patient Compliance; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2006 |
Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Kidney Failure, Chronic; Kidney Transplantation; Liver Function Tests; Prevalence; Recombinant Proteins; Renal Replacement Therapy; Ribavirin; Waiting Lists | 2006 |
[Acute hepatitis C virus infection--clinical manifestations, diagnosis and treatment].
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
New therapeutic options for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Viral Hepatitis Vaccines | 2006 |
The economics of hepatitis C virus.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mass Screening; Polyethylene Glycols; Public Health; Recombinant Proteins; Ribavirin | 2006 |
Treatment of hepatitis C in special populations.
Topics: Adult; Antiviral Agents; Asian; Black or African American; Hepacivirus; Hepatitis C; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?].
Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Cholestasis, Intrahepatic; Disease-Free Survival; Follow-Up Studies; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Incidence; Interferon-alpha; Liver Diseases; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Middle Aged; Patient Compliance; Prognosis; Recurrence; Ribavirin; Risk Factors; Time Factors | 2006 |
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome | 2006 |
Viral determinants of resistance to treatment in patients with hepatitis C.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2007 |
Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon Type I; Recombinant Proteins; Ribavirin | 2007 |
New paradigms in the management of hepatitis C virus co-infections.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Virus Replication | 2007 |
Emerging strategies for pegylated interferon combination therapy.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Viral Vaccines; Virus Replication | 2007 |
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Topics: Anemia; Chemotherapy, Adjuvant; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; Humans; Interferons; MEDLINE; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Case Management; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
Updates on antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Interferon alpha-2; Interferon-alpha; Models, Biological; Recombinant Proteins; Ribavirin | 2007 |
[Treatment of hepatitis C in patients on renal replacement therapy].
Topics: Antiviral Agents; Cross Infection; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2007 |
Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
Topics: Antiviral Agents; Bayes Theorem; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2007 |
[Drugs for hepatitis B and C infection].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Lamivudine; Mutation; Oligopeptides; Organophosphonates; Proline; Ribavirin; Serine Proteinase Inhibitors | 2007 |
[Mechanisms of drug resistance in hepatitis viruses B and C].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferons; Lamivudine; Mutation; Organophosphonates; Ribavirin; Viral Nonstructural Proteins | 2007 |
[Interferon therapy for hepatitis B and C].
Topics: Antiviral Agents; Biomarkers; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Treatment of hepatitis C virus infection.
Topics: Acute Disease; Amantadine; Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Therapeutic issues in HIV/HCV-coinfected patients.
Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
[Hepatitis C virus--structure, replication and therapeutical opportunities and the phenomenon of resistance].
Topics: Drug Resistance, Viral; Genes, Viral; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Species Specificity; Viral Proteins; Virion; Virus Replication | 2006 |
Hepatitis C virus infection in dialysis patients.
Topics: Antiviral Agents; Europe; Genome, Viral; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Japan; Liver Cirrhosis; Renal Dialysis; Ribavirin; RNA, Viral | 2007 |
Interferon-based therapy of hepatitis C.
Topics: Animals; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Hepatitis C; Humans; Interferon-alpha; Interferons; Models, Biological; Ribavirin | 2007 |
[Treatment of recurrent hepatitis C virus infection after liver transplantation].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
[Adaptive cell immune response against the hepatitis C virus infection].
Topics: Acute Disease; Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferon-alpha; Killer Cells, Natural; Mutation; Pan troglodytes; Ribavirin; T-Lymphocytes; T-Lymphocytes, Helper-Inducer; Time Factors; Virus Replication | 2007 |
Hepatitis C virus infection: a current review.
Topics: Acute Disease; Antiviral Agents; Chronic Disease; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors | 2007 |
Hepatitis C virus infection in the elderly: epidemiology, natural history and management.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Geriatrics; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin | 2008 |
[Cryoglobulinemia].
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C; Humans; Immunologic Factors; Interferon-alpha; Liver Cirrhosis; Male; Recurrence; Ribavirin; Rituximab; Sex Factors; Vasculitis | 2008 |
Neuropsychiatric symptoms of hepatitis C.
Topics: Antiviral Agents; Anxiety Disorders; Brain; Chronic Disease; Cognition Disorders; Depressive Disorder, Major; Hepatitis C; Humans; Neuropsychological Tests; Ribavirin | 2008 |
T-cell non-Hodgkin's lymphoma presenting after clearance of hepatitis C: a case report and review of the literature.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Function Tests; Lymphoma, T-Cell; Male; Middle Aged; Ribavirin | 2008 |
Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature.
Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Biopsy; Creatinine; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Glucocorticoids; Hepatitis C; Humans; Immunoglobulin M; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Failure, Chronic; Male; Methylprednisolone; Nephrotic Syndrome; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Immunoprophylaxis and treatment of viral hepatitis B.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; gamma-Globulins; Hepatitis B; Hepatitis B Antibodies; Hepatitis C; Humans; Immunization; Immunization, Passive; Injections; Interferons; Nucleic Acid Synthesis Inhibitors; Ribavirin; Sexually Transmitted Diseases; Vidarabine | 1981 |
Hepatitis C treatment.
Topics: Hepatitis C; Humans; Interferon-alpha; Interferons; Ribavirin | 1994 |
Therapy for chronic hepatitis C.
Topics: Chronic Disease; DNA, Viral; Dose-Response Relationship, Drug; Hepatitis C; Humans; Interferons; Recurrence; Ribavirin; RNA, Viral; Time Factors | 1994 |
Hepatitis C: clinical aspects.
Topics: Acute Disease; Chronic Disease; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 1995 |
[Treatment of viral hepatitis C: what are the perspectives?].
Topics: Acetylcysteine; Adult; Age Factors; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Ketoprofen; Male; Middle Aged; Prognosis; Ribavirin; Sex Factors; Time Factors; Ursodeoxycholic Acid | 1994 |
[Treatment of viral hepatitis C].
Topics: Acute Disease; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon Type I; Interferon-beta; Recombinant Proteins; Ribavirin | 1994 |
Interferon therapy for hepatitis C.
Topics: Alanine Transaminase; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hepatitis C; Humans; Interferon-alpha; Patient Selection; Ribavirin | 1994 |
Treatment of chronic viral hepatitis.
Topics: Acute Disease; Adrenal Cortex Hormones; Chronic Disease; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Interferon-alpha; Ribavirin | 1993 |
[Current knowledge in the treatment of chronic hepatitis C].
Topics: Age Factors; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Prognosis; Ribavirin; Risk Factors | 1995 |
Treatment options for chronic hepatitis C infection.
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Thymosin | 1995 |
Antiviral therapy for chronic hepatitis C viral infection.
Topics: Antiviral Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Liver Cirrhosis; Liver Neoplasms; Patient Selection; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral | 1995 |
Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Research Design; Ribavirin | 1995 |
Summary: antiviral treatment of hepatitis C virus.
Topics: Acute Disease; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Ribavirin | 1996 |
[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver; Male; Recurrence; Ribavirin; Sex Factors | 1995 |
[Treatment of hepatitis C].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 1995 |
New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin.
Topics: Adult; Antiviral Agents; Diagnosis, Differential; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral | 1996 |
Treatment of chronic hepatitis C: another therapeutic option.
Topics: Antiviral Agents; Chronic Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1996 |
Interferon-ribavirin combination therapy for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Randomized Controlled Trials as Topic; Ribavirin | 1996 |
[Treatment of chronic hepatitis C: still many problems pending].
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cholagogues and Choleretics; Chronic Disease; Clinical Enzyme Tests; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Indomethacin; Interferons; Ofloxacin; Phlebotomy; Recurrence; Ribavirin; Time Factors; Ursodeoxycholic Acid | 1997 |
[Outcomes research in therapy of chronic hepatitis C].
Topics: Combined Modality Therapy; Contraindications; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; Hepatitis, Chronic; Humans; Interferons; Liver Function Tests; Ribavirin; Treatment Outcome | 1996 |
Hepatitis C: seven years after the discovery of the causative agent.
Topics: Antiviral Agents; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Diseases; Ribavirin; RNA, Viral | 1997 |
Viral hepatitis: how to manage type C and D infections.
Topics: Acute Disease; Aged; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1997 |
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.
Topics: Adult; Alanine Transaminase; Chronic Disease; Drug Synergism; Drug Therapy, Combination; Female; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral | 1997 |
Antiviral therapy of hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 1997 |
Moving towards the optimal treatment of chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin | 1997 |
Chronic hepatitis C.
Topics: Antiviral Agents; Blood Transfusion; Carcinoma, Hepatocellular; Cryoglobulinemia; Disease Progression; Forecasting; Genotype; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Porphyria Cutanea Tarda; Ribavirin; Risk Factors; Treatment Outcome | 1997 |
Therapy of hepatitis C: alpha interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Postoperative Care; Randomized Controlled Trials as Topic; Ribavirin | 1997 |
Therapy of hepatitis C: patients with cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Prognosis; Ribavirin; RNA, Viral | 1997 |
New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.
Topics: Antiviral Agents; beta-Thalassemia; Child; Endocrine System Diseases; Female; Growth; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Osteoporosis; Pregnancy; Pregnancy Complications; Ribavirin; Sex Characteristics | 1998 |
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)].
Topics: Acute Disease; Antiviral Agents; Chronic Disease; Combined Modality Therapy; Cross Infection; Disease Progression; Hepatitis C; Humans; Interferons; Ribavirin | 1998 |
[Hepatitis C virus infection and cardiomyopathy].
Topics: Antiviral Agents; Cardiomyopathies; Genome, Viral; Heart; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; RNA, Viral | 1999 |
Renal manifestations of hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Hepatitis C; Humans; Interferon-alpha; Kidney; Prognosis; Ribavirin | 1999 |
Two options for hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1999 |
Hepatitis C. Shedding light on the shadow epidemic.
Topics: Hepatitis C; Humans; Interferons; Ribavirin; Substance Abuse, Intravenous; Transfusion Reaction; United States | 1999 |
Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.
Topics: Antioxidants; Antiviral Agents; Catechin; Complementary Therapies; Disease Progression; Glycyrrhizic Acid; Hepacivirus; Hepatitis C; Humans; Phytosterols; Plant Extracts; Ribavirin; Silymarin | 1999 |
[Antiviral treatment of hepatitis C virus infection].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Protease Inhibitors; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 1999 |
Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist.
Topics: Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Failure, Chronic; Nephrology; Ribavirin | 1999 |
[International consensus conference on hepatitis C. Conclusions. Organized under the auspices of the European Association for the Study of the Liver (EASL)].
Topics: Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Alcoholism; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Diagnosis, Differential; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Substance-Related Disorders; Viral Hepatitis Vaccines | 1999 |
Current and evolving therapies for hepatitis C.
Topics: Adjuvants, Immunologic; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ribavirin; Vaccines | 1999 |
[Hepatitis C: natural history, biology, treatment monitoring].
Topics: Antiviral Agents; Biomarkers; France; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 1999 |
Treatment of recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 1999 |
Advances in the treatment of hepatitis C.
Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin | 2000 |
Hepatitis C virus infection: immune responsiveness and interferon-alpha treatment.
Topics: Arachidonic Acid; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2000 |
Hepatitis C: a challenge for the generalist.
Topics: Algorithms; Antiviral Agents; Biopsy; Combined Modality Therapy; Decision Trees; Hepatitis C; Humans; Interferons; Primary Health Care; Primary Prevention; Ribavirin; Risk Factors; Severity of Illness Index; United States | 2000 |
Pathogenesis, natural history, treatment, and prevention of hepatitis C.
Topics: Antibody Formation; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Immunity, Cellular; Interferons; Ribavirin; United States; Viral Hepatitis Vaccines | 2000 |
[Antiviral therapy of hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin | 2000 |
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Hepatitis C; Humans; Interferon-alpha; Recurrence; Ribavirin | 2000 |
Mixed cryoglobulinemia: new concepts.
Topics: Antiviral Agents; Autoimmune Diseases; Cryoglobulinemia; Hepatitis C; Humans; Interferon-alpha; Lupus Erythematosus, Systemic; Ribavirin; Sjogren's Syndrome | 2000 |
Genotype and viral load as prognostic indicators in the treatment of hepatitis C.
Topics: Algorithms; Antiviral Agents; Drug Resistance, Microbial; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Prognosis; Recombinant Proteins; Ribavirin | 2000 |
HCV genotypes--role in pathogenesis of disease and response to therapy.
Topics: Antiviral Agents; Genotype; Global Health; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral | 2000 |
Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population.
Topics: Adult; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Hepatitis C; Humans; Infant; Infectious Disease Transmission, Vertical; Interferons; Male; Pregnancy; Prevalence; Prognosis; Ribavirin; Risk Factors; Treatment Outcome; United States | 2000 |
[Hepatitis C virus infection in renal diseases: state of knowledge, therapeutic problems and perspectives].
Topics: Antiviral Agents; Cytokines; Hepatitis C; Humans; Interferon-alpha; Kidney Diseases; Ribavirin; T-Lymphocytes | 2000 |
Drug-resistant viral hepatitis.
Topics: Amantadine; Antiviral Agents; Drug Resistance, Microbial; Hepacivirus; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Ribavirin | 2000 |
Hepatitis C kinetics: mathematical modeling of viral response to therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Half-Life; Hepacivirus; Hepatitis C; Humans; Interferons; Models, Theoretical; Ribavirin; Viral Load | 2000 |
Treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C; Humans; Interferons; Phlebotomy; Ribavirin | 2000 |
An emerging role for interferon in haemophiliacs with chronic hepatitis C?
Topics: Antiviral Agents; Chronic Disease; Hemophilia A; Hepatitis C; Humans; Interferons; Ribavirin | 2001 |
Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.
Topics: Antiviral Agents; Anxiety; Chronic Disease; Cognition; Depression; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Sleep Initiation and Maintenance Disorders | 2000 |
Treatment strategies for recurrent hepatitis C after liver transplantation.
Topics: Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Reoperation; Ribavirin | 1999 |
A pharmacoeconomic appraisal of therapies for hepatitis B and C.
Topics: Antiviral Agents; Costs and Cost Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2001 |
Side effects of interferon-alpha in treating hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2001 |
Management of recurrent hepatitis C after liver transplantation.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Cyclosporine; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Ribavirin; Secondary Prevention; Tacrolimus | 2001 |
[Treatments for hepatitis virus C infections].
Topics: Amantadine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Prognosis; Ribavirin | 2001 |
Hepatitis C: a brief clinical overview.
Topics: Antiviral Agents; Black People; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Public Health; Remission, Spontaneous; Ribavirin | 2001 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Transplantation; Prevalence; Ribavirin; Transfusion Reaction | 2001 |
Evaluation and management of the patient co-infected with human immunodeficiency virus and hepatitis C.
Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin | 2001 |
Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C.
Topics: Antiviral Agents; Congresses as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2001 |
Treatment of hepatitis C.
Topics: Algorithms; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Quality of Life; Ribavirin | 2001 |
The basics of new treatment for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Patient Education as Topic; Recombinant Proteins; Ribavirin; United States | 2001 |
Treatment of hepatitis C virus and HIV co-infections.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; Time Factors | 2001 |
Challenges in the treatment of hepatitis C in children.
Topics: Antiviral Agents; Child; Female; Hepatitis C; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferons; Pregnancy; Ribavirin; United States | 2001 |
The kinetics of hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Kinetics; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viremia; Virus Replication | 2001 |
Effect of HCV viral dynamics on treatment design: lessons learned from HIV.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Viremia | 2001 |
[HVB and HVC infections in nephrology].
Topics: Antiviral Agents; Comorbidity; Contraindications; Graft Rejection; Hepatitis B; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Lamivudine; Liver Cirrhosis; Postoperative Complications; Renal Dialysis; Ribavirin; Vaccination; Viral Hepatitis Vaccines; Viremia | 2001 |
Concise review of the management of hepatitis C.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Risk Factors | 2001 |
New therapeutic strategies for hepatitis C.
Topics: Animals; Antiviral Agents; Cell Culture Techniques; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; IMP Dehydrogenase; Interferons; Liver Diseases; Ribavirin; Virus Replication | 2002 |
[Prevention and treatment of viral hepatitis in renal insufficiency conditions].
Topics: Antiviral Agents; Biopsy; Comorbidity; Contraindications; Cryoglobulinemia; Female; Graft Rejection; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Lamivudine; Liver; Male; Renal Dialysis; Ribavirin; Severity of Illness Index | 2001 |
Hepatitis C virus infection: an overview.
Topics: Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Models, Genetic; Ribavirin; RNA, Viral | 2001 |
The HCV and HIV coinfected patient: what have we learned about pathophysiology?
Topics: Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; RNA, Viral | 2002 |
Treatment of hepatitis B and C following liver transplantation.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Interferon-alpha; Lamivudine; Liver Transplantation; Organophosphonates; Prognosis; Ribavirin; Secondary Prevention; Survival Rate | 2002 |
[Hepatic transplantation and HBV reinfection].
Topics: Antiviral Agents; Chemoprevention; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Liver Transplantation; Ribavirin; Secondary Prevention | 2002 |
[Long-acting interferon: studies on pegylated interferon].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Advances in the treatment of hepatitis C: combination antiviral therapy with interferon alfa-2b and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Monitoring, Physiologic; Patient Education as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2000 |
Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin.
Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Interferon-gamma; Interleukin-10; Nitric Oxide; Ribavirin; Th1 Cells; Th2 Cells | 2002 |
Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection.
Topics: Autoantibodies; Cytokines; Drug Therapy, Combination; Endotoxemia; Hepatitis C; Humans; Interferon-alpha; Lactoferrin; Lipopolysaccharides; Ribavirin | 2002 |
Hepatitis C in HIV-infected patients--therapeutic approach.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Ribavirin | 2002 |
Therapeutic advances in the management of hepatitis B and hepatitis C.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Ribavirin | 2001 |
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Liver; Ribavirin; Viremia | 2001 |
The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase.
Topics: Antiviral Agents; Genome, Viral; Hepatitis C; Mutagenesis; Ribavirin; RNA-Dependent RNA Polymerase | 2001 |
[Treatment of recurrent hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2000 |
Hepatitis C advances in antiviral therapy: what is accepted treatment now?
Topics: Antiviral Agents; Gastroenterology; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Chronic hepatitis C: latest treatment options.
Topics: Algorithms; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferons; Quality of Life; Ribavirin; Risk Factors | 2002 |
Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2002 |
Challenges for hepatitis C patients coinfected with HIV.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Ribavirin | 2002 |
Hepatitis C infection and the patient with end-stage renal disease.
Topics: Cross Infection; Graft Survival; Hepatitis C; Humans; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Renal Dialysis; Ribavirin; Survival Rate; Tissue Donors; Treatment Outcome | 2002 |
Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin.
Topics: Antiviral Agents; Hepatitis C; Humans; Ribavirin; Stereoisomerism | 2002 |
[Kidney transplantation in patients positive for hepatitis C virus].
Topics: Algorithms; Antiviral Agents; Cross Infection; Follow-Up Studies; Glomerulonephritis; Graft Survival; Hepatitis C; Humans; Interferons; Kidney Diseases; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Prevalence; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Survival Analysis; Tissue Donors; Treatment Outcome; Waiting Lists | 2002 |
[Hepatitis C; current developments in diagnosis and therapy].
Topics: Blood Donors; Enzyme-Linked Immunosorbent Assay; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Hepatitis C Antibodies; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin | 1992 |
[Treatment of chronic active B and non A-non B hepatitis].
Topics: Acyclovir; Adrenal Cortex Hormones; Hepatitis B; Hepatitis C; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Interferons; Ribavirin | 1989 |
363 trial(s) available for ribavirin and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Cell Line; Crystallography, X-Ray; Drug Resistance, Viral; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Oligopeptides; Phenotype; Viral Nonstructural Proteins; Virus Replication | 2008 |
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2023 |
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Neoplasms; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam | 2020 |
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutation; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2020 |
Novel combined single dose anti-hepatitis C therapy: a pilot study.
Topics: Adult; Antiviral Agents; Catechin; Female; Genotype; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; Sofosbuvir | 2021 |
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Uracil; Viral Load | 2017 |
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir | 2017 |
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2017 |
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opiate Substitution Treatment; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Self Administration; Treatment Outcome | 2017 |
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk-Taking; Secondary Prevention; Substance Abuse, Intravenous; Young Adult | 2017 |
DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Topics: Adult; Aged; Analgesics, Opioid; Antiviral Agents; Community Pharmacy Services; Feasibility Studies; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Opiate Substitution Treatment; Pharmacists; Ribavirin; Substance Abuse, Intravenous; Young Adult | 2017 |
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.
Topics: Acetylcysteine; Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lactoferrin; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Resveratrol; Ribavirin; Sleep Wake Disorders; Stilbenes; Surveys and Questionnaires | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Immunogenicity of branched polyethylene glycol modified interferon alpha.
Topics: Antibodies, Neutralizing; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2018 |
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quality of Life; Regression Analysis; Ribavirin; Ritonavir; Severity of Illness Index; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Liver; Male; Mass Spectrometry; Middle Aged; Ribavirin; Sofosbuvir | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Genotype; Germany; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mutant Proteins; Mutation, Missense; Oligopeptides; Prevalence; Ribavirin; Treatment Failure; United Kingdom; Viral Nonstructural Proteins | 2018 |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2018 |
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult | 2018 |
Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
Topics: Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Genotype; Hepatitis C; Humans; Interleukins; Liver; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus.
Topics: Antiviral Agents; Cohort Studies; Drug Costs; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Pakistan; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2018 |
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; England; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Prospective Studies; Ribavirin; Ritonavir; RNA, Viral; Safety; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2018 |
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2019 |
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2019 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Guanosine Monophosphate; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Coinfection; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Young Adult | 2013 |
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Topics: Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interdisciplinary Communication; Interferon-alpha; Male; Markov Chains; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Self-Help Groups; Treatment Outcome; Young Adult | 2013 |
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Epoxy Compounds; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Sulfonamides | 2013 |
Measuring ribavirin concentrations during the earliest stages of antiviral therapy for hepatitis C: potential relevance for treatment outcome.
Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Treatment Outcome | 2013 |
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2013 |
Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Behavior Therapy; Female; Germany; Hepatitis C; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Viral Load; Young Adult | 2013 |
A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Fatty Acids, Monounsaturated; Fluvastatin; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2013 |
Hepatitis C virus genotype 5: prospective evaluation of peginterferon/ribavirin treatment efficacy and predictive value of on-treatment virological responses for sustained virological response.
Topics: Aged; Alanine Transaminase; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Memory, Episodic; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Viral Load | 2014 |
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Incidence; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Stroke; Taiwan; Treatment Outcome | 2014 |
Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antiviral Agents; Biomarkers; Canada; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Infliximab; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2014 |
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Topics: Adult; Age Factors; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; RNA, Viral; White People | 2014 |
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
Topics: Antiviral Agents; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
Topics: Adolescent; Adult; Aged; Female; Hepatitis C; Humans; Incidence; Infections; Interferon alpha-2; Interferon-alpha; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Young Adult | 2014 |
Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2014 |
CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Demography; Female; Gene Expression Regulation; Hepatitis C; Humans; Integrin alpha2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome | 2014 |
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Asia; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; North America; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2014 |
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; In Vitro Techniques; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; STAT4 Transcription Factor; Treatment Outcome | 2014 |
Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Risk Factors; Viral Load | 2014 |
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Topics: Adolescent; Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Quinolines; Recombinant Proteins; Ribavirin; RNA, Viral; Thiazoles; Viral Nonstructural Proteins; Young Adult | 2014 |
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2014 |
Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Failure | 2014 |
Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; Humans; Interferon-alpha; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Failure; Viral Load; Young Adult | 2014 |
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Topics: Adult; Aged; Cyclopropanes; Deoxycytidine; Electrocardiography; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides | 2015 |
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Puerto Rico; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2014 |
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.
Topics: Antiviral Agents; Clinical Trials Data Monitoring Committees; Data Interpretation, Statistical; Drug Therapy, Combination; Guideline Adherence; Guidelines as Topic; Hepatitis C; Humans; Information Dissemination; Interferon-alpha; Manuscripts, Medical as Topic; Peer Review, Research; Periodicals as Topic; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Time Factors; Treatment Outcome; United States | 2014 |
High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.
Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2015 |
eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?
Topics: Age Factors; Antiviral Agents; ErbB Receptors; Hepatitis C; Humans; Interferon-alpha; Kidney; Linear Models; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Factors | 2015 |
OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Topics: Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Italy; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2015 |
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Topics: Compassionate Use Trials; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Spain | 2015 |
Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin.
Topics: 5' Untranslated Regions; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Point Mutation; Regulatory Sequences, Ribonucleic Acid; Ribavirin; RNA, Viral; Viral Tropism | 2014 |
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists | 2015 |
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Topics: Amides; Carbamates; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin; Sulfonamides | 2014 |
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2015 |
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Topics: Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Lipoproteins, LDL; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Regression Analysis; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.
Topics: Antiviral Agents; Cohort Studies; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors | 2015 |
Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
Topics: Adult; Case-Control Studies; China; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2014 |
Vitamin D status and viral response to therapy in hepatitis C infected children.
Topics: Adolescent; Alkaline Phosphatase; Antiviral Agents; Biomarkers; Bone Density; Calcifediol; Calcium; Case-Control Studies; Child; Dietary Supplements; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Parathyroid Hormone; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Vitamin D; Vitamin D Deficiency | 2015 |
Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients.
Topics: Anemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Japan; Leukopenia; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transplant Recipients; Treatment Outcome | 2014 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2016 |
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Oligopeptides; Ribavirin; RNA, Viral; Young Adult | 2015 |
Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2016 |
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Italy; Kinetics; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult | 2015 |
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hong Kong; Humans; Male; Middle Aged; Ribavirin; RNA; Sofosbuvir; Treatment Outcome | 2016 |
24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; China; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2015 |
Evaluation of fluvastatin in combination with the standard of care therapy (PEG-IFN/Ribavirin) in Egyptian patients with hepatitis C virus.
Topics: Adult; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Egypt; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C; Humans; Indoles; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Standard of Care; Treatment Outcome | 2015 |
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.
Topics: Adult; Antiviral Agents; Body Fluid Compartments; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis | 2016 |
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Topics: Acrylates; Aminoisobutyric Acids; Anemia; Antiviral Agents; Benzimidazoles; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Leucine; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Pyrophosphatases; Quinolines; Real-Time Polymerase Chain Reaction; Ribavirin; Thiazoles | 2015 |
Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carrier Proteins; China; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Patient Reported Outcome Measures; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; RNA, Viral; Simeprevir; Sustained Virologic Response; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure | 2016 |
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Topics: Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure | 2016 |
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Reported Outcome Measures; Quality of Life; Ribavirin; Sofosbuvir | 2016 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2016 |
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Topics: Adolescent; Adult; Antiviral Agents; Biological Availability; Cyclopropanes; Drug Compounding; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Young Adult | 2016 |
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Risk Factors; Smoking; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2016 |
Ways to manage hepatitis C without cirrhosis: Treatment by comparison of coded eastern medicine hepcinal with interferon alpha 2b and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Plant Preparations; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult | 2016 |
Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Pakistan; Prognosis; Ribavirin; RNA, Viral | 2016 |
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cell Adhesion Molecules; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Italy; Lectins, C-Type; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Cell Surface; Ribavirin | 2016 |
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Treatment Outcome; Young Adult | 2016 |
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response | 2016 |
Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepatitis C; Humans; Interferons; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recombinant Proteins; Ribavirin | 2016 |
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
Topics: Anemia; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Oligopeptides; Proline; Ribavirin; Severity of Illness Index; Treatment Outcome | 2016 |
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Spain; Treatment Outcome; Viral Nonstructural Proteins | 2016 |
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Viral Load; Young Adult | 2017 |
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
Topics: Adult; Aged; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Ribavirin; Treatment Outcome; Valine; Viral Load | 2017 |
Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior.
Topics: Adrenocorticotropic Hormone; Adult; Antiviral Agents; Circadian Rhythm; Cytokines; Depression; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Hepatitis C; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Pituitary-Adrenal System; Ribavirin; Statistics as Topic; Statistics, Nonparametric | 2010 |
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Thalassemia | 2008 |
Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pilot Projects; Plasmapheresis; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2008 |
Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Virus Replication | 2008 |
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Withholding Treatment | 2009 |
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Female; Follow-Up Studies; Hemoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Asian People; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Asian People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2009 |
HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Topics: Animals; Antiviral Agents; Benzofurans; Disease Models, Animal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Liver; Mice; Mice, SCID; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; Sulfonamides; Viral Nonstructural Proteins | 2009 |
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Topics: Adult; Antibodies, Viral; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome; Viral Interference; Viral Load | 2009 |
Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Rate; Treatment Outcome | 2009 |
Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2009 |
Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.
Topics: Adolescent; Adult; Antiviral Agents; Caregivers; Child; Child Behavior; Cognition; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Legal Guardians; Male; Parents; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sickness Impact Profile; Stress, Psychological | 2009 |
Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Chronic Disease; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opioid-Related Disorders; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retention, Psychology; Ribavirin; Young Adult | 2009 |
Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy.
Topics: Drug Therapy, Combination; gamma-Glutamyltransferase; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Topics: Anemia; Antiviral Agents; Chronic Disease; Creatinine; Darbepoetin alfa; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Liver Transplantation; Male; Pilot Projects; Postoperative Care; Prospective Studies; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Branched DNA Signal Amplification Assay; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nucleic Acid Amplification Techniques; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2009 |
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2009 |
Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.
Topics: Acute Disease; Adult; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Young Adult | 2009 |
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2009 |
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Topics: Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tacrolimus | 2010 |
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2009 |
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome; Virus Replication | 2010 |
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study.
Topics: 2',5'-Oligoadenylate Synthetase; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Ketoprofen; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Treatment Outcome; Young Adult | 2009 |
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Urban Health | 2010 |
Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
Topics: Adult; Age Factors; Antibodies; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Topics: Adult; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance.
Topics: Adult; Antiviral Agents; Female; Genotype; Germany; Health Status; Hepacivirus; Hepatitis C; Heroin; Heroin Dependence; Humans; Interferons; Male; Mental Health; Middle Aged; Narcotics; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous; Viral Load; Young Adult | 2010 |
Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Europe; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2010 |
Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Topics: ADP-ribosyl Cyclase 1; Antiviral Agents; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets; Treatment Outcome; Viral Load | 2010 |
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2010 |
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Italy; Logistic Models; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Iran; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin.
Topics: Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; Depression; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Self Report; Surveys and Questionnaires; Texas; Time Factors; Treatment Outcome; Veterans; Viral Load | 2010 |
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
Topics: Adult; Aged; Antiviral Agents; Cell Line, Tumor; Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression Regulation; Genotype; GTP-Binding Proteins; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Myxovirus Resistance Proteins; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Polyethylene Glycols; Proteins; Recombinant Proteins; Ribavirin; RNA, Messenger; RNA, Viral; S-Adenosylmethionine; Signal Transduction; STAT1 Transcription Factor; Time Factors; Treatment Failure; Ubiquitins; Viral Load | 2011 |
Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C).
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antiviral Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carrier Proteins; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leucine; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quinolines; Recombinant Proteins; Ribavirin; Thiazoles; Viral Load; Viral Nonstructural Proteins | 2011 |
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2011 |
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Topics: Adult; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Linear Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.
Topics: Adolescent; Antiviral Agents; Behavior; Child; Child, Preschool; Cognition; Drug Therapy, Combination; Emotions; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin | 2011 |
Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Biomarkers; Carrier Proteins; Decision Support Techniques; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Logistic Models; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Failure; Viral Nonstructural Proteins; Young Adult | 2010 |
Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrones; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Triazoles; Viral Nonstructural Proteins | 2011 |
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Biopsy; End Stage Liver Disease; Female; Fibrosis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
Topics: Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sweden; Treatment Outcome; Viral Core Proteins | 2011 |
Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Black or African American; Drug Administration Schedule; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication; Young Adult | 2011 |
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Linear Models; Male; Middle Aged; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
Topics: Demography; DNA, Viral; Female; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Time Factors | 2011 |
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Topics: Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Nonstructural Proteins | 2011 |
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome | 2011 |
Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.
Topics: Alanine Transaminase; Antigens, CD; Aspartate Aminotransferases; Drug Therapy, Combination; Flow Cytometry; Hepatitis C; Humans; In Situ Hybridization, Fluorescence; Interferon-alpha; Ribavirin; T-Lymphocytes; Telomere; Viral Load | 2011 |
Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure; Treatment Outcome | 2011 |
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Response-guided telaprevir combination treatment for hepatitis C virus infection.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Exanthema; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Young Adult | 2011 |
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Japan; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2012 |
IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.
Topics: Alleles; Cohort Studies; Coinfection; Drug Synergism; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Probability; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Purines; Pyridazines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Bilirubin; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Viral Load | 2011 |
Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2011 |
Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Drug Users; Employment; Female; Hepatitis C; HIV Seropositivity; Humans; Interferon-alpha; Logistic Models; Male; Mental Health; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Social Participation; Substance Abuse, Intravenous; Surveys and Questionnaires; Viral Load; Young Adult | 2012 |
Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Kinetics; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Taiwan; Treatment Outcome | 2012 |
Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Self Administration; Viral Load | 2012 |
Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.
Topics: Adult; Aged; Antimicrobial Cationic Peptides; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hemochromatosis Protein; Hepatitis C; Hepcidins; Histocompatibility Antigens Class I; Humans; Interferon-alpha; Interferons; Interleukins; Iron; Iron Deficiencies; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; STAT3 Transcription Factor; Viral Load | 2012 |
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antiviral Agents; Double-Blind Method; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Mood Disorders; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Dietary Supplements; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Vitamin D | 2012 |
Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action.
Topics: Adolescent; Adult; Antiviral Agents; Female; Glucose; Hepacivirus; Hepatitis C; Humans; Insulin Resistance; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome; Young Adult | 2012 |
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
[Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Ribavirin; Splenectomy; Treatment Outcome | 2012 |
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Interferon-alpha; Male; Metformin; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.
Topics: Adult; Analysis of Variance; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon-alpha; Lipid Metabolism; Lipoproteins; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin | 2012 |
Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Topics: Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Induction Chemotherapy; Interferon-alpha; Kidney; Liver Cirrhosis; Liver Transplantation; Logistic Models; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome; Viral Load | 2012 |
Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Topics: Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proline; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; United States; Viral Load | 2012 |
Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult | 2012 |
Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2012 |
Preventive versus "on-demand" nutritional support during antiviral treatment for hepatitis C: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Digestive System; Digestive System Diseases; Female; Hand Strength; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nutrition Therapy; Nutritional Status; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.
Topics: Adult; Antiviral Agents; CD56 Antigen; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Killer Cells, Natural; Lipopolysaccharide Receptors; Male; Polyethylene Glycols; Receptors, IgG; Recombinant Proteins; Ribavirin | 2012 |
Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Darbepoetin alfa; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Mutation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Viral Load | 2012 |
Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.
Topics: Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Effects and outcomes of interferon treatment in Japanese hepatitis C patients.
Topics: Aged; Antiviral Agents; Asian People; Cause of Death; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Interferon-beta; Life Expectancy; Male; Middle Aged; Prognosis; Ribavirin; Survival Rate; Treatment Outcome | 2012 |
Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin | 2012 |
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.
Topics: Adult; Female; Gene Expression Regulation, Viral; Genetic Variation; Genotype; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Models, Genetic; Models, Statistical; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Ribavirin; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins | 2012 |
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
Topics: Adult; Antiviral Agents; Coinfection; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Salvage Therapy; Treatment Failure | 2013 |
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral | 2013 |
Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; France; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Polymorphism, Genetic; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Platelet Count; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Risk Assessment; Treatment Outcome | 2013 |
Side effects. Bone problems may occur with hepatitis treatment.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Osteoporosis; Ribavirin | 2000 |
Combination therapy/prophylaxis with interferon and ribavirin for recurrent hepatitis C after liver transplantation: long-term effects on graft function and morphology.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Function Tests; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2002 |
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Dropouts; Pilot Projects; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2002 |
Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Time Factors; Treatment Outcome | 2002 |
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2002 |
Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.
Topics: Adult; Algorithms; Antiviral Agents; Chromatography, High Pressure Liquid; Creatinine; Drug Monitoring; Female; Glomerular Filtration Rate; Hepatitis C; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Models, Biological; Prospective Studies; Ribavirin; Spectrophotometry, Ultraviolet | 2002 |
Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2003 |
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Least-Squares Analysis; Male; Middle Aged; Nonlinear Dynamics; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
Topics: Adult; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin | 2003 |
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Remission, Spontaneous; Ribavirin; Treatment Outcome | 2003 |
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Topics: Adult; Algorithms; Antiviral Agents; Biomarkers; Biopsy; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2003 |
Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.
Topics: Adult; Antiviral Agents; Biopsy; Complementarity Determining Regions; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2003 |
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recombinant Proteins; Ribavirin; Secondary Prevention; Viral Load | 2003 |
Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Binding Sites; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Molecular Sequence Data; Mutation; Ribavirin; RNA, Viral; Viral Nonstructural Proteins; Virus Replication | 2003 |
[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].
Topics: Adenosine Triphosphate; Anemia; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Glutathione; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Virus Replication | 2003 |
Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2004 |
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Probability; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Viral Load | 2004 |
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2004 |
Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy.
Topics: Adult; Aged; Antiviral Agents; Female; Gastric Mucosa; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Comparative efficacy of combined treatment with intron A and pegintron in combination with ribavirin of patients with chronic hepatitis C].
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Function Tests; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Male; Ribavirin; RNA, Viral; Safety | 2004 |
Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study.
Topics: Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.
Topics: Antiviral Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Hemoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phosphoric Monoester Hydrolases; Phosphorylation; Recombinant Proteins; Reproducibility of Results; Ribavirin | 2004 |
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2004 |
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Growth Substances; Hepatitis C; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Tacrolimus; Time Factors | 2005 |
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2005 |
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2005 |
Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutation; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins | 2005 |
Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Analysis | 2005 |
Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
Topics: Administration, Oral; Adult; Antiviral Agents; Erythrocytes; Female; Hepatitis C; Humans; Male; Middle Aged; Prodrugs; Ribavirin | 2005 |
Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Daclizumab; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2005 |
Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2005 |
Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial.
Topics: Adult; Antiviral Agents; Cohort Studies; Double-Blind Method; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Anterior cingulate activation and error processing during interferon-alpha treatment.
Topics: Adult; Antiviral Agents; Attention; Brain Mapping; Female; Gyrus Cinguli; Hepatitis C; Humans; Interferon-alpha; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Reaction Time; Ribavirin; Space Perception | 2005 |
Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin.
Topics: Acute Disease; Adult; Antiviral Agents; Disease Transmission, Infectious; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Seropositivity; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; London; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Failure | 2005 |
Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
Topics: Antiviral Agents; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C; Hong Kong; Humans; Interferon-alpha; Ribavirin; RNA, Viral; Species Specificity; Treatment Outcome; Viremia | 2006 |
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Topics: Adult; Area Under Curve; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Zidovudine | 2005 |
High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain.
Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Prevalence; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Spain | 2005 |
Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection.
Topics: Adult; Aged; Antiviral Agents; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.
Topics: Adult; Aged; Antiviral Agents; Cognition Disorders; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin | 2005 |
Approaching treatment for hepatitis C virus infection in substance users.
Topics: Adolescent; Adult; Disease Management; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2005 |
Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Topics: Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Hepacivirus; Hepatitis C; Hepatitis C Antigens; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Reagent Kits, Diagnostic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins | 2006 |
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
Topics: Alanine Transaminase; alpha-Macroglobulins; Antiviral Agents; Apolipoprotein A-I; Bilirubin; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Haptoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Case-Control Studies; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet Activation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polyethylene Glycols; Recombinant Proteins; Ribavirin; von Willebrand Factor | 2006 |
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Neutralization Tests; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2006 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Ribavirin; Tenofovir | 2006 |
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Topics: Acute Disease; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
Topics: Adult; Antiviral Agents; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Topics: Adult; Aged; Biopsy; Cohort Studies; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.
Topics: Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Liver Transplantation; Living Donors; Middle Aged; Pilot Projects; Plasmapheresis; Ribavirin; RNA, Viral | 2006 |
Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2006 |
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2006 |
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Black or African American; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United States; White People | 2006 |
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Topics: 5' Untranslated Regions; Adult; Antibody Specificity; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Epitopes; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Neutralization Tests; Polyethylene Glycols; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Envelope Proteins; Viremia | 2006 |
Triple antiviral therapy in HCV positive patients who failed prior combination therapy.
Topics: Adolescent; Adult; Aged; Amantadine; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin | 2006 |
Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Administration Schedule; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.
Topics: Adult; Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Schistosoma; Schistosomiasis; Treatment Outcome | 2006 |
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Viremia | 2006 |
HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Antiviral Agents; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Remission Induction; Ribavirin; RNA, Viral; Viral Load | 2006 |
Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cholesterol, LDL; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Core Proteins | 2007 |
Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
Topics: Adolescent; Adult; Antiviral Agents; Drug Implants; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Prospective Studies; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Secondary Prevention; Survival Rate; Treatment Outcome | 2007 |
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Paroxetine; Personality Inventory; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans | 2007 |
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Diabetes Mellitus; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2006 |
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemokines, CXC; Drug Administration Schedule; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chemokine CCL2; Female; Genotype; Hepatitis C; Humans; Interferon Type I; Liver; Male; Middle Aged; Multivariate Analysis; Mutation; Receptors, CCR2; Receptors, Chemokine; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2007 |
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Darbepoetin alfa; Disease Progression; Dose-Response Relationship, Drug; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Endpoint Determination; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Spain; Species Specificity; Treatment Outcome | 2007 |
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Black or African American; Drug Carriers; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Open Reading Frames; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sequence Alignment; Sequence Analysis, DNA; White People | 2007 |
The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.
Topics: Adult; Aged; Antiviral Agents; Cytosine; Drug Therapy, Combination; Female; Genotype; GTP-Binding Protein beta Subunits; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Thymine; Treatment Outcome | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2007 |
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Cell Line, Tumor; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-6; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; STAT3 Transcription Factor; Treatment Outcome | 2007 |
[Preliminary results and complications of HCV treatment after liver transplantation].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study.
Topics: Adolescent; Adult; Aged; Amantadine; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure; Treatment Outcome | 2007 |
Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Panic Disorder; Polyethylene Glycols; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Failure | 2007 |
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2008 |
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
Topics: Adult; Antiviral Agents; Australia; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interviews as Topic; Male; Middle Aged; Patient Care Team; Patient Compliance; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Research Design; Ribavirin; Socioeconomic Factors; Substance Abuse, Intravenous; Time Factors; Treatment Outcome | 2007 |
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2007 |
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Europe; Hepacivirus; Hepatitis Antigens; Hepatitis C; Humans; Immunity, Cellular; Interferon alpha-2; Interferon-alpha; Kinetics; Lymphocyte Activation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Treatment Outcome; Virus Replication | 2007 |
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2008 |
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; Serologic Tests; Time Factors; Treatment Outcome | 2007 |
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Placebos; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2008 |
CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
Topics: Antidepressive Agents, Second-Generation; Antiviral Agents; Canada; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Psychometrics; Recombinant Proteins; Ribavirin; Sample Size; Severity of Illness Index; Treatment Outcome | 2008 |
Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Topics: Adult; Age Factors; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Weight Loss | 2008 |
Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2008 |
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Plasma; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2008 |
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Immunoprophylaxis and treatment of viral hepatitis B.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; gamma-Globulins; Hepatitis B; Hepatitis B Antibodies; Hepatitis C; Humans; Immunization; Immunization, Passive; Injections; Interferons; Nucleic Acid Synthesis Inhibitors; Ribavirin; Sexually Transmitted Diseases; Vidarabine | 1981 |
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antiviral Agents; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; RNA, Viral | 1995 |
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Chronic Disease; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Male; Middle Aged; Pilot Projects; Ribavirin; RNA | 1994 |
Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.
Topics: Adult; Aged; Alanine Transaminase; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Ribavirin; RNA, Viral | 1995 |
Treatment with ribavirin+alpha interferon in HCV chronic active hepatitis non-responders to interferon alone: preliminary results.
Topics: Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1995 |
Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients.
Topics: Adult; Aspartate Aminotransferases; Base Sequence; Drug Resistance, Microbial; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leukocytes, Mononuclear; Liver; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Virus Replication | 1995 |
A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C.
Topics: Adult; Chronic Disease; Female; Hepacivirus; Hepatitis C; Humans; Interferon-beta; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral | 1993 |
A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral | 1996 |
Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Pilot Projects; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 1995 |
The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Recombinant Proteins; Reference Values; Ribavirin | 1995 |
Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
Topics: Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Italy; Liver; Male; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Reference Values; Ribavirin; RNA, Viral | 1995 |
Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
Topics: Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Sweden; Time Factors | 1995 |
Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 1996 |
Prolonged therapy of chronic hepatitis C with ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Bile Duct Diseases; Biopsy; Cholelithiasis; Fatigue; Female; Headache; Hematocrit; Hepacivirus; Hepatitis C; Humans; Liver; Male; Middle Aged; Ribavirin; RNA, Viral | 1996 |
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Chronic Disease; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome | 1996 |
Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Follow-Up Studies; Genetic Heterogeneity; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Ribavirin; RNA, Viral; Viral Envelope Proteins | 1997 |
Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis, Chronic; Humans; Interferon Type I; Male; Pilot Projects; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 1996 |
Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.
Topics: Adult; Aged; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 1997 |
Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chronic Disease; DNA, Viral; Drug Therapy, Combination; Female; Flaviviridae; Genetic Techniques; Hepatitis C; Hepatitis, Viral, Human; Humans; Interferon Type I; Liver; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Viremia | 1997 |
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Chronic Disease; Double-Blind Method; Female; Hepatitis C; Humans; Male; Middle Aged; Ribavirin | 1997 |
Hepatitis C recurrence in liver transplant recipients.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Drug Therapy, Combination; Follow-Up Studies; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time Factors | 1997 |
A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Aspartate Aminotransferases; Female; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 1998 |
Hepatitis C: somber views of natural history and optimistic views of interferon treatment?
Topics: Hepatitis C; Humans; Interferons; Ribavirin | 1998 |
Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Cohort Studies; Drug Combinations; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Models, Biological; Recombinant Proteins; Ribavirin; Virus Replication | 1998 |
Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1998 |
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.
Topics: Adult; Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Statistics, Nonparametric | 1999 |
Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa.
Topics: Alanine Transaminase; Antiviral Agents; Biopsy; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polymerase Chain Reaction; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Standardization of hepatitis C virus RNA quantification.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Techniques; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Reference Standards; Ribavirin; RNA, Viral | 2000 |
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Sequence Data; Mutation; Ribavirin; Viral Nonstructural Proteins | 2000 |
Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.
Topics: Adult; Aged; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2000 |
A prospective and randomized study using ribavirin as monotherapy for the treatment of naïve patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy.
Topics: Adult; Age Distribution; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Leptin; Male; Middle Aged; Multivariate Analysis; Probability; Prognosis; Radioimmunoassay; Reference Values; Regression Analysis; Ribavirin; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution | 2001 |
Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: a clinical trial of interferon relapsers and non-responders.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Viral Load | 2001 |
Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hemophilia A; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Treatment Outcome | 2002 |
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors | 2002 |
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Selection; Pilot Projects; Probability; Recombinant Proteins; Ribavirin; RNA, Viral; Safety; Viral Load; Waiting Lists | 2002 |
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Ribavirin treatment for chronic hepatitis C.
Topics: Administration, Oral; Adult; Alanine Transaminase; Drug Administration Schedule; Drug Evaluation; Female; Hepatitis C; Hepatitis, Chronic; Humans; Male; Middle Aged; Pilot Projects; Ribavirin | 1991 |
1464 other study(ies) available for ribavirin and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
Topics: Antiviral Agents; Benzazepines; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Nucleosides; Virion | 2005 |
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Cyclophilins; Cyclosporine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Replicon; Ribavirin; Viral Nonstructural Proteins | 2009 |
Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
Topics: Antiviral Agents; Cell Line, Tumor; DNA Helicases; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Interferon-gamma; Models, Molecular; Mutation; Ribavirin; RNA Helicases; RNA, Viral; Tropolone; Viral Nonstructural Proteins; Virus Replication | 2010 |
A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
Topics: Antiviral Agents; Cell Line, Tumor; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver; Pyrimidine Nucleosides | 2012 |
Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
Topics: Antiviral Agents; Biphenyl Compounds; Carboxylic Acids; Drug Design; Hepacivirus; Hepatitis C; Humans; PPAR delta; RNA, Viral | 2013 |
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
Topics: Antiviral Agents; Cell Line; Deoxyadenosines; Deoxyribonucleosides; Halogenation; Hepacivirus; Hepatitis C; Humans; Structure-Activity Relationship | 2014 |
Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Cyclophilin A; Drug Synergism; Glycine; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Indoleacetic Acids; Mice, Inbred NOD; Mice, SCID; Models, Molecular; Protein Binding; Replicon; Structure-Activity Relationship; Virus Replication | 2015 |
Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
Topics: Amides; Antiviral Agents; Cell Survival; Cyclophilin A; Dose-Response Relationship, Drug; Drug Design; Hepacivirus; Hepatitis C; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Surface Plasmon Resonance; Tumor Cells, Cultured | 2020 |
Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Hepacivirus; Hepatitis C; Humans; Nucleosides; Ribavirin; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2022 |
U.S. veterans' experience with rebetron in a nonstudy environment: success or failure?
Topics: Adult; Aged; Drug Combinations; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; United States; Veterans | 2002 |
[Acute hepatitis C].
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2002 |
Feasibility and outcome of HCV treatment in a Canadian federal prison population.
Topics: Adult; British Columbia; DNA, Viral; Drug Combinations; Feasibility Studies; Federal Government; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Methadone; Middle Aged; Multivariate Analysis; Narcotics; Prevalence; Prisons; Program Evaluation; Retrospective Studies; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Treatment Outcome | 2005 |
Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm.
Topics: Adult; Drug Combinations; Female; Hepatitis C; Humans; Hyperthyroidism; Interferon-alpha; Ribavirin | 2000 |
Consensus statement to Schering-Plough Pharmaceuticals from the health care community regarding Rebetron development and marketing.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Drug Combinations; Health Services Accessibility; Hepatitis C; Humans; Interferon-alpha; Interferons; Patient Advocacy; Patient Satisfaction; Ribavirin; United States | 1999 |
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides | 2022 |
Hepatitis E Virus Species C Infection in Humans, Hong Kong.
Topics: Aged; Animals; Hepatitis C; Hepatitis E; Hepatitis E virus; Hong Kong; Humans; Phylogeny; Rats; Ribavirin; RNA, Viral | 2022 |
Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project.
Topics: Aged; Antiviral Agents; Argentina; Carcinoma, Hepatocellular; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin | 2022 |
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Ribavirin; Ritonavir; RNA, Messenger; Sulfonamides; Toll-Like Receptor 2; Treatment Outcome; Uracil; Valine | 2022 |
Defining the key intrahepatic gene networks in HCV infection driven by sex.
Topics: Antiviral Agents; Female; Gene Regulatory Networks; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukins; Male; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2023 |
Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Ribavirin; Treatment Outcome | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Discovery of Novel 3-Hydroxyquinazoline-2,4(1
Topics: Antiviral Agents; Chelating Agents; Hepacivirus; Hepatitis C; Humans; Molecular Docking Simulation; Ribavirin; Viral Nonstructural Proteins | 2022 |
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
[The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus (Flaviviridae: Hepacivirus: Hepatitis С virus) NS4a antigen].
Topics: Antiviral Agents; Drug Therapy, Combination; Epitopes, B-Lymphocyte; Flaviviridae; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2022 |
Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoprotein(a); Ribavirin; Sustained Virologic Response | 2022 |
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin | 2023 |
Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Precision Medicine; Recombinant Proteins; Ribavirin; Treatment Outcome | 2022 |
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.
Topics: Aged; Antiviral Agents; Brazil; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Effectiveness of Direct-acting Agents After Liver Transplantation A Real-life Study in Rio de Janeiro.
Topics: Antiviral Agents; Aspartic Acid; Biomarkers; Brazil; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA; Transaminases | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Association of interferon-based therapy with risk of autoimmune diseases in patients with chronic hepatitis C virus infection: A population-based Taiwanese cohort study.
Topics: Cohort Studies; Graves Disease; Hashimoto Disease; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Retrospective Studies; Ribavirin; Risk Factors | 2022 |
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir | 2023 |
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir | 2022 |
Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.
Topics: Animals; Dipeptidyl Peptidase 4; Endothelial Cells; Glucagon-Like Peptide 1; Glucose; Hepatitis C; Hepatocytes; Mice; Non-alcoholic Fatty Liver Disease; Ribavirin | 2023 |
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV.
Topics: Antiviral Agents; Brazil; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2023 |
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2023 |
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2023 |
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Spectroscopic study to verify the anti-hepatitis C virus (HCV) treatment through a delivery system of the sofosbuvir drug on chitosan and pycnogenol nanoparticles surface.
Topics: Animals; Antiviral Agents; Chitosan; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Mice; Pharmaceutical Preparations; Ribavirin; Sofosbuvir; Spectrum Analysis | 2023 |
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon.
Topics: Antiviral Agents; Cytokines; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukin-6; Interleukins; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha | 2023 |
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome | 2023 |
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome | 2023 |
How do we treat psoriasis patients with hepatitis C infections in real-world situations? A retrospective analysis of 34 patients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Psoriasis; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2021 |
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
Topics: Adult; Antibodies, Neutralizing; Antirheumatic Agents; Antiviral Agents; Cell Line, Tumor; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Retrospective Studies; Ribavirin; Sustained Virologic Response; Viral Load | 2019 |
Experimental Study of Flakozid Activity in Viral Hepatitis C In Vitro.
Topics: Animals; Antiviral Agents; Cell Line; Hepacivirus; Hepatitis C; Humans; Ribavirin; Swine | 2019 |
Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.
Topics: Antiviral Agents; Child; Child, Preschool; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Hepatitis C; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Viral Load | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
Topics: Adult; Antiviral Agents; Botswana; Carcinoma, Hepatocellular; Cross-Sectional Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Mutation; Phylogeny; Pilot Projects; Retrospective Studies; Ribavirin | 2019 |
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.
Topics: Analgesics, Opioid; Anilides; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Ribavirin; Sustained Virologic Response | 2020 |
Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Treatment Outcome | 2020 |
Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent.
Topics: Antiviral Agents; Cell Culture Techniques; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Viral Nonstructural Proteins; Virus Replication | 2020 |
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Malaysia; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; Viral Load | 2020 |
Elevated serum levels of adiponectin and interlukin-28B after IFN/RIB therapy in hepatitis C virus-infected patients.
Topics: Adiponectin; Adult; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load | 2019 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin | 2021 |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis.
Topics: Adult; Antiviral Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2020 |
Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cost-Benefit Analysis; Hepatitis C; Humans; Limit of Detection; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility | 2020 |
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir | 2020 |
HCV eradication in chronic kidney disease: ready for prime time?
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir | 2020 |
Modeling based response guided therapy in subjects with recent hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis C; Humans; Male; Middle Aged; Models, Theoretical; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult | 2020 |
[Antiviral therapy of chronic hepatitis C: 30 years success story].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Russia | 2019 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Genotype; Glycosylation; Hepacivirus; Hepatitis C; Humans; Immunoglobulin G; Interferon alpha-2; Liver Cirrhosis; Middle Aged; Ribavirin; Treatment Outcome; Viral Envelope Proteins; Viral Load; Young Adult | 2020 |
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Romania; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2020 |
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
Topics: Antiviral Agents; Bone Density; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2021 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
Topics: Alleles; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukins; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir | 2020 |
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2021 |
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2021 |
Achieving Virological Response in Patients With Hepatitis C Is Only Half Way for Effective Care.
Topics: Hepacivirus; Hepatitis C; Humans; Ribavirin | 2021 |
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Sofosbuvir | 2020 |
Ribavirin to the Rescue: Natural Killer-Cell Function After Hepatitis C Virus Treatment in Liver Transplant Recipients.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Killer Cells, Natural; Liver Transplantation; Ribavirin | 2021 |
Fuzzy logic and Lyapunov-based non-linear controllers for HCV infection.
Topics: Antiviral Agents; Fuzzy Logic; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 2021 |
Comparative safety and efficacy of conventional interferon versus pegylated-interferon based therapy for HCV: A retrospective cohort study from Gujranwala, Pakistan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2020 |
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey | 2021 |
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
Topics: Adult; Antiviral Agents; China; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Ribavirin; Rural Population; Sofosbuvir; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Immune Tolerance; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Regulatory; Viral Load | 2021 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C.
Topics: Adult; Antiviral Agents; Coinfection; Depressive Disorder, Major; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
IL-10 and IL-28B gene variants as predictors of sustained response to peginterferon and ribavirin therapy in chronic HCV infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Interleukin-10; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome | 2022 |
Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Coinfection; Drug Combinations; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lamivudine; Lopinavir; Male; Models, Immunological; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Ribavirin; Ritonavir; Time-to-Treatment; Zidovudine | 2017 |
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Propensity Score; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lichen Planus; Lip; Lip Diseases; Male; Middle Aged; Ribavirin; Sofosbuvir | 2017 |
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
[Clinical timing and benefit of antiviral treatment for hepatitis C].
Topics: Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors; Treatment Outcome | 2017 |
Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sustained Virologic Response | 2017 |
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Immunologic Factors; Prednisolone; Recurrence; Ribavirin; Rituximab; Sofosbuvir; Viral Load | 2017 |
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Topics: Adult; Antiviral Agents; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Immunoassay; Male; Middle Aged; Molecular Diagnostic Techniques; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sustained Virologic Response; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia | 2017 |
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome | 2017 |
PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PREDICTORS OF THE EFFECTIVENESS OF PEGYLATED INTERFERON IN PATIENTS WITH HEPATITIS C IN GEORGIA.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Georgia (Republic); Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Young Adult | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-Authors' reply.
Topics: Antiviral Agents; Child; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation.
Topics: Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2017 |
Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Logistic Models; Male; Odds Ratio; Oligopeptides; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2017 |
Editorial: is ribavirin needed in the treatment of post-transplant hepatitis C recurrence?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin | 2017 |
HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study.
Topics: Adult; Hepatitis C; Hepatitis C Antigens; HIV Infections; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sensitivity and Specificity | 2017 |
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load; Young Adult | 2018 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Health Services; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Program Development; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Ukraine; Young Adult | 2017 |
Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.
Topics: Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2017 |
Lymphoproliferative disease with mixed cryoglobulinemia and hyperviscosity syndrome in an HIV-infected patient: HCV is the only culprit.
Topics: Antiviral Agents; Cryoglobulinemia; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Ribavirin | 2017 |
The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Pakistan; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Sustained virological response after 4-week ritonavir-boosted paritaprevir, ombitasvir and dasabuvir plus ribavirin treatment in a kidney transplant recipient.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Hepatitis C; Humans; Kidney Transplantation; Macrocyclic Compounds; Male; Middle Aged; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil | 2017 |
A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Topics: Antiviral Agents; Developing Countries; District of Columbia; Genotype; Health Resources; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; India; Pilot Projects; Poverty; Ribavirin | 2017 |
Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Treatment Outcome | 2018 |
Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFα α(Etanercept) Therapy.
Topics: Adult; Antiviral Agents; Etanercept; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Male; Psoriasis; Ribavirin; RNA, Viral; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study.
Topics: Aged; Antiviral Agents; Cohort Studies; Elasticity; Elasticity Imaging Techniques; Female; Hepatitis C; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sustained Virologic Response; Time Factors; Treatment Outcome | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2018 |
Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
Topics: Adult; Antiviral Agents; Autoantibodies; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Risk Factors; Thyroid Diseases; Thyroid Gland; Young Adult | 2017 |
Reply to "cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation".
Topics: Cost-Benefit Analysis; Hepacivirus; Hepatitis C; Humans; Ribavirin | 2017 |
Increased hope following successful treatment for hepatitis C infection.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hope; Humans; Interferon-alpha; Male; Middle Aged; Norway; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sweden; Viral Load | 2018 |
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load | 2018 |
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis Antibodies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Viral Load | 2017 |
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir | 2018 |
Cost effectiveness evaluation of hepatitis C therapy in Lahore.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hospital Costs; Hospitals, Private; Hospitals, Public; Humans; Interferon alpha-2; Interferon-alpha; Pakistan; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2017 |
Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Virus Activation | 2018 |
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
Case report: bilateral Mooren ulcer in association with hepatitis C.
Topics: Aged; Antiviral Agents; Conjunctival Diseases; Corneal Ulcer; Eye Infections, Viral; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2017 |
HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lymphoma; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2018 |
Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Thailand; Treatment Outcome; Viral Load | 2018 |
Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; Disease Reservoirs; DNA, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; Viral Load | 2018 |
Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.
Topics: Adult; Antiviral Agents; Depression; Diagnostic and Statistical Manual of Mental Disorders; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Ribavirin; Time Factors; Withholding Treatment | 2018 |
Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin.
Topics: Adolescent; Antiviral Agents; Hepatitis C; Humans; Male; Psoriasis; Ribavirin; Sofosbuvir | 2017 |
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate | 2018 |
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; Hepatitis C; Humans; Interferon-alpha; Models, Economic; Monte Carlo Method; Norway; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin | 2018 |
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Phylogeny; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2018 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.
Topics: 2-Naphthylamine; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil | 2018 |
Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies.
Topics: Aged; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Female; Fluorescent Antibody Technique, Indirect; Hepatitis C; Humans; Immunoassay; Immunoprecipitation; Interferon-alpha; Laboratories; Middle Aged; Mitochondria; Reference Standards; Ribavirin | 2018 |
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2018 |
Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
Topics: Antiviral Agents; Cells, Cultured; Drug Resistance, Viral; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Mutagenesis; Mutation; Ribavirin; RNA, Viral; Viral Nonstructural Proteins; Virus Replication | 2018 |
Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2018 |
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
Transient improvement of skin symptoms in an adult patient with pediatric-onset cutaneous mastocytosis treated with interferon-α.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Infant; Interferon-alpha; Male; Ribavirin; Severity of Illness Index; Urticaria Pigmentosa | 2018 |
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Portugal; Postoperative Complications; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
Topics: Antiviral Agents; Benzofurans; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Italy; Markov Chains; Quality-Adjusted Life Years; Quinoxalines; Ribavirin; Sofosbuvir | 2018 |
The association of CCL3 and CCL4 polymorphisms with HCV clearance in Chinese Han population.
Topics: Adult; Asian People; Chemokine CCL3; Chemokine CCL4; China; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2018 |
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2018 |
Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein | 2018 |
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.
Topics: Adult; Biomarkers; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Proteomics; Ribavirin; Treatment Outcome | 2019 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2018 |
Rescue for interferon failures in HCV genotype 1/HBV dually infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis C; Humans; Interferons; Proline; Ribavirin; Taiwan | 2018 |
Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Topics: Aged; Antiviral Agents; Chemokines; Cytokines; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Interferon-alpha; Male; Middle Aged; Neutralization Tests; Polyethylene Glycols; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Viral Load | 2019 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Two novel SNPs in the promoter region of PKR gene in hepatitis C patients and their impact on disease outcome and response to treatment.
Topics: Adult; Alleles; Antiviral Agents; Case-Control Studies; eIF-2 Kinase; Female; Genotype; Hepatitis C; Humans; Interferons; Male; Middle Aged; Nucleic Acid Amplification Techniques; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Ribavirin; Sustained Virologic Response; Treatment Failure | 2018 |
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Hand-foot syndrome due to hepatitis C therapy.
Topics: Antiviral Agents; Hand-Foot Syndrome; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirin.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Tissue Donors; Transplant Recipients; Viremia | 2019 |
[Treatment of Hepatitis C: State of the Art 2018].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Creatinine; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sodium; Sulfonamides; Uracil; Valine | 2019 |
Getting more out of meta-analyses: a new approach to meta-analysis in light of unexplained heterogeneity.
Topics: Antidepressive Agents; Data Interpretation, Statistical; Depression; Hepatitis C; Humans; Hypericum; Meta-Analysis as Topic; Models, Statistical; Plant Extracts; Ribavirin; Treatment Outcome | 2019 |
A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis C; Humans; Interferons; Male; Metabolic Clearance Rate; Middle Aged; Research Design; Retrospective Studies; Ribavirin; ROC Curve | 2018 |
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir | 2019 |
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Topics: Aged; Animals; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cell Line; Chimera; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Guanosine Monophosphate; Hepacivirus; Hepatitis C; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Male; Mice; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sequence Deletion; Serine Proteases; Simeprevir; Valine; Viral Nonstructural Proteins | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2019 |
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2019 |
Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Erythrocytes; Female; Genotype; Hepatitis C; Humans; Inosine Triphosphatase; Male; Middle Aged; Polyphosphates; Pyrophosphatases; Ribavirin | 2019 |
[Hepatitis C facing the challenge of healing].
Topics: Adult; Antiviral Agents; Child; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Ribavirin | 2018 |
Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Leukemia, Myeloid, Acute; Male; Ribavirin; Treatment Outcome | 2019 |
No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Hepatitis E; Humans; Liver; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Viral; Sustained Virologic Response; Transplant Recipients | 2019 |
Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Topics: Antiviral Agents; Diabetes Mellitus; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Treatment Outcome; Veterans | 2020 |
Utility of viral kinetics in HCV therapy - It is not over until it is over?
Topics: Duration of Therapy; Hepacivirus; Hepatitis C; Humans; Kinetics; Liver Cirrhosis; Ribavirin | 2019 |
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Assessment of cognitive functions and psychiatric symptoms in hepatitis C patients receiving pegylated interferon alpha and ribavirin: A prospective cohort study.
Topics: Adult; Antiviral Agents; Anxiety; Cognition; Depression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neuropsychological Tests; Polyethylene Glycols; Prospective Studies; Ribavirin | 2019 |
Cluster of hepatitis C in a family: a twenty-year follow-up.
Topics: Antiviral Agents; Child; Disease Transmission, Infectious; Family; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Needle Sharing; Ribavirin | 2019 |
Follow-up Results of
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2019 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International St
Topics: Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmaceutical Preparations; Ribavirin; Substance Abuse, Intravenous; Sustained Virologic Response | 2020 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Genetic variants in RIG-I-like receptor influences HCV clearance in Chinese Han population.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Asian People; Aspartate Aminotransferases; DEAD Box Protein 58; Disease Resistance; Ethnicity; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Immunologic; Remission, Spontaneous; Ribavirin; Treatment Outcome; Young Adult | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Treatment Outcome; Virus Activation | 2013 |
Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes.
Topics: Adult; Age Distribution; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Population Surveillance; Ribavirin; Self Report; Sex Distribution; Social Perception; Social Support; Surveys and Questionnaires; Treatment Outcome; United States | 2013 |
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2013 |
Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunity, Active; Interferon-alpha; Lymph Nodes; Ribavirin | 2013 |
UNITAID can address HCV/HIV co-infection.
Topics: Anti-Retroviral Agents; Antiviral Agents; Developing Countries; Financial Support; Hepatitis C; HIV Infections; Humans; Interferon-alpha; International Agencies; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study.
Topics: Adult; Aftercare; Anorexia; Antiviral Agents; Attitude of Health Personnel; Chronic Disease; Cognition Disorders; Depression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neurotoxicity Syndromes; New South Wales; Patient Education as Topic; Qualitative Research; Quality of Life; Recurrence; Ribavirin; Sarcoidosis; Self Report; Severity of Illness Index; Treatment Outcome; Victoria | 2013 |
HCV IRES-mediated core expression in zebrafish.
Topics: Animals; Antiviral Agents; Biomarkers; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Viral; Genes, Reporter; Green Fluorescent Proteins; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Larva; Liver; Mutant Chimeric Proteins; Recombinant Proteins; Ribavirin; RNA, Messenger; Viral Core Proteins; Vitamin B 12; Zebrafish | 2013 |
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; United Kingdom; Viral Load; Young Adult | 2013 |
Pegylated interferon induced myasthenia crisis--a case report.
Topics: Hepatitis C; Humans; Immunoglobulins, Intravenous; Interferon-alpha; Male; Middle Aged; Myasthenia Gravis; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2013 |
Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin.
Topics: Acute Disease; Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Proteomic characterization of hepatitis C eradication: enzyme switch in the healing liver.
Topics: Adult; Alcoholism; Antiviral Agents; Diabetes Complications; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Proteome; Proteomics; Recombinant Proteins; Ribavirin | 2013 |
Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.
Topics: Adenosine Kinase; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Liver Neoplasms; Phenotype; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients.
Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferases; Cohort Studies; Cross-Sectional Studies; Egypt; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multivariate Analysis; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Severity of Illness Index; Sex Factors; Viral Load | 2013 |
Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.
Topics: Adult; Alleles; Female; Genotype; Hepacivirus; Hepatitis C; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome; Young Adult | 2013 |
Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Bilirubin; Biopsy; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Our experience about the particular surgical management of total hip replacement in two patients with severe haemophilic arthropathy: case report.
Topics: Antiviral Agents; Arthropathy, Neurogenic; Arthroplasty, Replacement, Hip; Drug Therapy, Combination; Hemophilia A; Hepatitis C; Hip; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Male; Middle Aged; Polyethylene Glycols; Radiography; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2013 |
[Thrombotic thrombocytopenic purpura associated with interferon therapy in a HIV and HCV co-infected woman].
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Ribavirin | 2013 |
Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
Topics: Adenosine Kinase; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Ribavirin | 2013 |
Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Viral Load; Vitamin D | 2013 |
Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Blood Chemical Analysis; China; Cryoglobulinemia; Cryoglobulins; Female; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Hot Temperature; Humans; Interferon alpha-2; Interferon-alpha; Methylprednisolone; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombotic Microangiopathies | 2013 |
Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization Review; Female; Germany; Guideline Adherence; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response.
Topics: Antibodies, Antinuclear; Cross-Sectional Studies; Egypt; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique, Indirect; Hepatitis C; Humans; Prevalence; Retrospective Studies; Ribavirin; Transaminases | 2013 |
Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
Topics: Adult; Alleles; Cohort Studies; Coinfection; Female; Gene Frequency; Genetic Loci; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunity, Innate; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, KIR; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2013 |
Interferon for hepatitis C: where it has been and where it is going.
Topics: Animals; Antiviral Agents; Biomarkers, Pharmacological; Consensus Development Conferences, NIH as Topic; Evidence-Based Medicine; Hepacivirus; Hepatitis C; Humans; Immunotherapy; Interferons; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome; United States | 2013 |
Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Models, Biological; Models, Statistical; Multivariate Analysis; Phylogeny; Ribavirin; Treatment Outcome; Viral Envelope Proteins | 2013 |
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Genotype; Hepatitis C; Humans; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribavirin; Spain; Treatment Outcome | 2013 |
Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment.
Topics: Antiviral Agents; Diffusion; Galactose; Hep G2 Cells; Hepatitis C; Humans; Materials Testing; Nanocapsules; Prodrugs; Ribavirin | 2013 |
Validity of aspartate aminotransferase to platelet ratio index as predictor of early viral response in patients with hepatitis C treated by interferon-based therapy.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Chi-Square Distribution; Female; Hepatitis C; Humans; Interferons; Male; Pakistan; Platelet Count; Polymerase Chain Reaction; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome | 2012 |
[Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
Topics: Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Glomerulonephritis; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Vasculitis | 2013 |
DRESS syndrome with suspected Strongyloides infection in a patient treated for hepatitis C.
Topics: Animals; Antiparasitic Agents; Antiviral Agents; Drug Hypersensitivity; Eosinophilia; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Ivermectin; Male; Middle Aged; Oligopeptides; Prednisone; Recombinant Proteins; Ribavirin; Strongyloides; Strongyloidiasis; Syndrome | 2013 |
Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Fatigue; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Mental Health; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.
Topics: Adult; Aged; Antiviral Agents; Endoscopy; Female; Hepatitis C; Histocytochemistry; Humans; Inflammatory Bowel Diseases; Interferons; Male; Middle Aged; Minnesota; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Pakistan; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Hepcidin as a predictor of treatment response in chronic hepatitis C infection.
Topics: Antimicrobial Cationic Peptides; Drug Monitoring; Female; Hepatitis C; Humans; Interferon-alpha; Iron Deficiencies; Male; Polyethylene Glycols; Ribavirin | 2014 |
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2013 |
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis.
Topics: Adult; Aged; Antiviral Agents; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Polypharmacy; Proline; Retrospective Studies; Ribavirin; Viral Load | 2013 |
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C.
Topics: Antiviral Agents; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Ribavirin; Treatment Outcome | 2013 |
Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome; Viral Load | 2013 |
Did postoperative peg-interferon plus ribavirin really reduce recurrence of hepatitis C virus-related hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin | 2014 |
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Virus Activation | 2013 |
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection.
Topics: Anemia; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Viral Load | 2014 |
Reply: To PMID 23389758.
Topics: Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Ribavirin | 2014 |
Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Testing; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Incidence; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2013 |
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Topics: Anemia; Diabetes Mellitus, Type 2; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Multivariate Analysis; Odds Ratio; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Statistics, Nonparametric | 2014 |
Reply: To PMID 22334511.
Topics: Antimicrobial Cationic Peptides; Drug Monitoring; Female; Hepatitis C; Humans; Interferon-alpha; Iron Deficiencies; Male; Polyethylene Glycols; Ribavirin | 2014 |
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
Topics: Antiviral Agents; Contraindications; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Viral Load | 2014 |
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.
Topics: Carrier State; Genotype; Hepatitis C; Humans; Interferon Regulatory Factor-3; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Logistic Models; Muscle Proteins; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Recombinant Proteins; Ribavirin | 2014 |
Longitudinal effects of selective serotonin reuptake inhibitor therapy and cytokine-related depression on hepatitis C viral logs during antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cytokines; Depression; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Inflammation Mediators; Interferons; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2014 |
Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California.
Topics: Antiviral Agents; California; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Male; Medically Underserved Area; Middle Aged; Retrospective Studies; Ribavirin; Telemedicine; Treatment Outcome | 2013 |
Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Interferons; Liver Failure; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.
Topics: Animals; Coinfection; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptor, Interferon alpha-beta; Ribavirin; Signal Transduction | 2014 |
Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing.
Topics: Cluster Analysis; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Sequence Homology; Viral Envelope Proteins; Viremia | 2014 |
Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Japan; Male; Middle Aged; Molecular Sequence Data; Oligopeptides; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Young Adult | 2014 |
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.
Topics: Antiviral Agents; Cohort Studies; Comparative Effectiveness Research; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Thrombocytopenia; United States; Veterans | 2014 |
Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients.
Topics: Adult; Egypt; Female; Fibrosis; Genetic Association Studies; Genotype; Hepatitis C; Humans; Interferons; Interleukin-12 Subunit p40; Liver; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Ribavirin; Sex Factors; Treatment Outcome | 2013 |
Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Practice Patterns, Physicians'; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; CD4-Positive T-Lymphocytes; Coinfection; DNA, Viral; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Viral Load | 2014 |
Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic H
Topics: Adult; Antiviral Agents; Black or African American; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Killer Cells, Natural; Liver Diseases; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.
Topics: Adult; Antigen-Presenting Cells; Antiviral Agents; Case-Control Studies; Cohort Studies; Dendritic Cells; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Monocytes; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2014 |
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin | 2014 |
Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Uridine Monophosphate | 2014 |
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients.
Topics: Antiviral Agents; Calibration; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Hepatitis C; Humans; Least-Squares Analysis; Leukocytes, Mononuclear; Phosphorylation; Reproducibility of Results; Ribavirin; Tandem Mass Spectrometry | 2014 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir.
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Graft Survival; Hepatitis C; Humans; Interferons; Liver Neoplasms; Liver Transplantation; Male; Polyethylene Glycols; Postoperative Complications; Proline; Recurrence; Ribavirin; Severe Combined Immunodeficiency | 2014 |
Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cell Degranulation; Fatty Liver; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Liver; Lymphocytes; Lysosomal-Associated Membrane Protein 1; Male; Middle Aged; Multivariate Analysis; Natural Killer T-Cells; Non-alcoholic Fatty Liver Disease; Polymorphism, Genetic; Ribavirin; RNA, Viral; Viral Load | 2014 |
Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
Topics: Acute Disease; Adult; Age Distribution; Antiviral Agents; Case-Control Studies; Confidence Intervals; Disease Progression; Egypt; Female; GB virus C; Genotype; Hepacivirus; Hepatitis C; Humans; Incidence; Interferons; Interleukins; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribavirin; RNA, Viral; Sex Distribution; Statistics, Nonparametric; Treatment Outcome; Viral Load; Viremia | 2014 |
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2014 |
Severe renal impairment during triple therapy with telaprevir.
Topics: Acute Kidney Injury; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2014 |
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy.
Topics: Algorithms; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Population; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Treatment of chronic viral hepatitis C in children and adolescents: UK experience.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United Kingdom | 2014 |
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Vitamin D; Young Adult | 2014 |
Human immunodeficiency virus (HIV)-associated epidermodysplasia verruciformis eradicated after interferon-α and ribavirin treatment.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Coinfection; Epidermodysplasia Verruciformis; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Papillomaviridae; Ribavirin | 2014 |
Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan.
Topics: Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Female; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Mutation, Missense; Pakistan; Phylogeny; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins; Young Adult | 2014 |
Psychiatric aspects of hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Mood Disorders; Ribavirin | 2013 |
European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; DNA, Mitochondrial; Female; Genotype; Haplotypes; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin; Spain; White People | 2014 |
OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2014 |
A 24-week pegylated interferon alpha-2b versus a 12-week pegylated interferon alpha-2b alone or with ribavirin for patients with acute hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Reply: To PMID 24442928.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2014 |
Reply: To PMID 24519039.
Topics: Antiviral Agents; Female; Genetic Variation; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Pyrophosphatases; Ribavirin | 2014 |
Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3.
Topics: Antiviral Agents; Female; Genetic Variation; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Pyrophosphatases; Ribavirin | 2014 |
Drug induced hypersensitivity syndrome by triple therapy of peginterferon alpha2b, ribavirin and telaprevir in patient with double positive for HBV and HCV.
Topics: Antiviral Agents; Biomarkers; Coinfection; DNA, Viral; Drug Hypersensitivity Syndrome; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Guanine; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prednisolone; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Virus Activation | 2013 |
[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Topics: Algorithms; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Early Diagnosis; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Hungary; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2014 |
Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Statistics, Nonparametric; Tacrolimus; Tandem Mass Spectrometry | 2015 |
Hepatitis C treatment & management.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate | 2014 |
Boceprevir in liver transplant recipients.
Topics: Adult; Aged; Analysis of Variance; Creatinine; Drug Monitoring; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplant Recipients | 2015 |
Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Viral Load | 2014 |
Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferons; Male; Middle Aged; Ribavirin; Saudi Arabia | 2014 |
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.
Topics: Antiviral Agents; Benztropine; Biological Assay; Cell Culture Techniques; Drug Therapy, Combination; Genetics, Population; Genotype; Hepacivirus; Hepatitis C; Humans; Hydroxyzine; Interferon-alpha; Liver; Ribavirin; Small Molecule Libraries; Virus Replication | 2014 |
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression Profiling; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Transplant Recipients; Treatment Outcome; Young Adult | 2014 |
Association between response to pegylated interferon/ribavirin therapy and ribavirin levels.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C; Humans; Male; Pyrophosphatases; Ribavirin | 2015 |
The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2014 |
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Early Diagnosis; Female; Fibrosis; Genetic Variation; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin | 2014 |
Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Recurrence; Ribavirin; Sequence Analysis, RNA; Treatment Failure; Viral Proteins | 2015 |
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.
Topics: Adult; Aged; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; United States | 2014 |
HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Ribavirin | 2014 |
Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
Topics: Antiviral Agents; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin | 2014 |
Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Risk Factors; Skin Diseases; Treatment Outcome; Viral Load; Young Adult | 2014 |
Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Topics: Antiviral Agents; Autoantibodies; Hepatitis C; Humans; Immunoglobulin G; IMP Dehydrogenase; Interferon-alpha; Organelles; Ribavirin | 2014 |
Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Secondary Prevention; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2014 |
Hepatitis C virus-associated neuropathy accompanied by eosinophilic vasculitis and granuloma formation.
Topics: Antiviral Agents; Eosinophilia; Granuloma; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Peripheral Nervous System Diseases; Purpura; Ribavirin; Sural Nerve; Vasculitis; Viral Load | 2014 |
Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection.
Topics: Adolescent; Adult; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Hepatitis C: Treatment triumphs.
Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; beta 2-Glycoprotein I; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2014 |
Reply: To PMID 24449403.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Hepatitis C; Humans; Male; Pyrophosphatases; Ribavirin | 2015 |
[Treatment of hepatitis C: current status and perspectives].
Topics: Antiviral Agents; Drug Therapy, Combination; Evidence-Based Medicine; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin; Treatment Outcome | 2014 |
HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study.
Topics: Acute Disease; Adult; Asian People; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
[Multidisciplinary approach as a model for detection and monitoring of psychiatric morbidity in patients treated with interferon and ribavirin].
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Male; Mental Disorders; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Ribavirin | 2014 |
Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Depression; Disease Progression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Multivariate Analysis; Ribavirin; Schizophrenia | 2014 |
Elimination on the agenda for hepatitis C.
Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
[Treatment of recurrent HCV infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2013 |
Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
Topics: Adult; Aged; Amino Acid Substitution; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2015 |
Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Egypt; Female; Genetic Association Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Kidney Failure, Chronic; Male; Middle Aged; Renal Insufficiency, Chronic; Ribavirin; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Topics: Antiviral Agents; Cost of Illness; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Virus Replication | 2014 |
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
Topics: Adult; Antiviral Agents; Depression; Depressive Disorder, Major; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Personality Inventory; Polyethylene Glycols; Prospective Studies; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2014 |
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
An interferon response gene signature is associated with the therapeutic response of hepatitis C patients.
Topics: Adult; Female; Genetic Loci; Hepatitis C; Humans; Interferons; Interleukins; Liver; Male; Models, Statistical; Polymorphism, Single Nucleotide; Ribavirin; Transcriptome; Treatment Failure | 2014 |
Consensus guidelines for the management of hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Saudi Arabia | 2003 |
[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Immunocompromised Host; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexually Transmitted Diseases; Spain | 2015 |
Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
Topics: Antiviral Agents; Cell Line; Gene Expression Regulation, Viral; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Polymethacrylic Acids; Prodrugs; Ribavirin | 2015 |
Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Topics: Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Azerbaijan; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sequence Alignment; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2014 |
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunity, Innate; Interferons; Interleukin-18; Lipopolysaccharide Receptors; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult | 2014 |
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists | 2015 |
Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir.
Topics: Aged; Antiviral Agents; Biopsy; Drug Eruptions; Female; Hepatitis C; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Risk Factors | 2016 |
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Recurrence; Retrospective Studies; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Virus Activation | 2015 |
Different histological sequelae of immune-mediated graft dysfunction after interferon treatment in transplanted dual grafts from living donors.
Topics: Adult; Biopsy; End Stage Liver Disease; Female; Genetic Variation; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immune System; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Japan; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Topics: Adult; Aged; Antiviral Agents; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Italy; Male; Middle Aged; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.
Topics: Adult; Alleles; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-7; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Retrospective Studies; Ribavirin | 2015 |
Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Injections, Intravenous; Kinetics; Models, Biological; Precision Medicine; Ribavirin; RNA, Viral; Silybin; Silymarin; Time Factors | 2015 |
Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
Topics: Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin | 2014 |
Mutant Ninja viruses.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.
Topics: Gene Expression Profiling; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; MicroRNAs; Ribavirin | 2014 |
IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hematologic Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Retrospective Studies; Ribavirin; Taiwan; Thrombocytopenia | 2015 |
Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome | 2014 |
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
[Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Topics: Anemia; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Oligopeptides; Polyethylene Glycols; Prevalence; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; Spain | 2014 |
Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Tissue Donors; Viral Load; Viremia | 2014 |
Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
Topics: Adult; Aged; Case-Control Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2015 |
Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy.
Topics: Amino Acid Sequence; DNA Mutational Analysis; DNA, Complementary; DNA, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Polyethylene Glycols; Ribavirin; Viral Proteins | 2015 |
Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.
Topics: Acute Coronary Syndrome; Adult; Antiviral Agents; Autoimmune Diseases; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Stroke; Treatment Outcome | 2015 |
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Outcome Assessment, Health Care; Patient Compliance; Pharmaceutical Services; Pharmacies; Polyethylene Glycols; Retrospective Studies; Ribavirin; United States | 2014 |
Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Ribavirin; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Drug Synergism; Flavonoids; Hepacivirus; Hepatitis C; Interferon-alpha; Mice; Mice, Transgenic; Oligopeptides; Plant Extracts; Protease Inhibitors; Reactive Oxygen Species; Replicon; Ribavirin; RNA, Viral; Viral Proteins; Virus Replication | 2015 |
Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Chemistry, Pharmaceutical; Drug Carriers; Hepacivirus; Hepatitis C; Hepatocytes; In Vitro Techniques; Macromolecular Substances; Macrophages; Mice; Prodrugs; Ribavirin; RNA, Viral; Structure-Activity Relationship; Virus Replication | 2014 |
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.
Topics: Antiviral Agents; Coinfection; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-α2α and ribavirin.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Combined Modality Therapy; Drug Resistance, Viral; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C; HLA-G Antigens; Humans; Immunotherapy; Interferon-alpha; Interleukin-10; Male; Middle Aged; Ribavirin; Viral Load; Young Adult | 2015 |
Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; New York; Oligopeptides; Pilot Projects; Prisoners; Protease Inhibitors; Ribavirin; Treatment Outcome | 2015 |
Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description.
Topics: Anemia; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Erythropoietin; Glomerulonephritis, Membranoproliferative; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2014 |
Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.
Topics: Adult; Aged; Alleles; Antiviral Agents; Ethnicity; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Puerto Rico; Recombinant Proteins; Registries; Ribavirin; Socioeconomic Factors | 2014 |
Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy.
Topics: Amino Acid Sequence; DNA Mutational Analysis; DNA, Complementary; DNA, Viral; Drug Resistance, Viral; eIF-2 Kinase; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutation; Polyethylene Glycols; Protein Interaction Domains and Motifs; Recombinant Proteins; Ribavirin; Viral Proteins | 2015 |
What is the role of sofosbuvir in treating hepatitis C infection?
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Sofosbuvir | 2015 |
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Polyethylene Glycols; Proline; Ribavirin; RNA-Dependent RNA Polymerase; Sulfonamides; Uracil; Valine | 2015 |
PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; Spain; Viral Load | 2015 |
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Anemia; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Receptors, Calcitriol; Retrospective Studies; Ribavirin; Vitamin D3 24-Hydroxylase | 2015 |
[Pulmonary vasculitis as a clinical mask of HCV infection: efficiency of interferon-free antiviral therapy].
Topics: Acridines; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Leukocytes, Mononuclear; Lung; Lung Diseases; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Vasculitis | 2014 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Prognosis; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Young Adult | 2015 |
[Overwhelming postsplenectomy infection during combination therapy with interferon ribavirin after living donor liver transplantation for hepatitis C: a case report].
Topics: Critical Care; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Transplantation; Living Donors; Middle Aged; Pneumococcal Infections; Postoperative Complications; Recurrence; Ribavirin; Splenectomy | 2015 |
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Proline; Prospective Studies; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2015 |
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Ribavirin | 2015 |
A model for treating HCV hepatitis in patients receiving methadone maintenance therapy.
Topics: Adult; Antiviral Agents; Comorbidity; Hepatitis C; Humans; Interferon-alpha; Methadone; Narcotics; Opiate Substitution Treatment; Ribavirin; Substance-Related Disorders | 2014 |
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin | 2015 |
Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Topics: Aged; Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Tacrolimus; Treatment Outcome | 2015 |
[Helicobacter cinaedi-associated bacteremia in hepatitis C patient under triple therapy].
Topics: Antiviral Agents; Bacteremia; Drug Therapy, Combination; Helicobacter; Helicobacter Infections; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Opportunistic Infections; Recombinant Proteins; Ribavirin | 2015 |
Hepatitis C-associated glomerulonephritis mimicking systemic lupus erythematosus.
Topics: Adult; Antiviral Agents; Diagnosis, Differential; Female; Glomerulonephritis; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Lupus Erythematosus, Systemic; Methylprednisolone; Ribavirin; Treatment Outcome | 2015 |
A Young Lady with Hypertension - Rare Presentation of a Common Disease.
Topics: Antiviral Agents; Blood Transfusion; Cryoglobulinemia; Female; Glomerulonephritis; Hepacivirus; Hepatitis C; Humans; Hypertension; Interferon-alpha; Kidney Diseases; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2015 |
HCV/HIV Coinfection: A New Treatment Paradigm.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Ribavirin; Uridine Monophosphate | 2015 |
Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; DNA; Female; Genotype; Hepatitis C; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Young Adult | 2015 |
Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin | 2015 |
Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.
Topics: Antiviral Agents; Coinfection; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
Topics: Aged; Analysis of Variance; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Safety; Reference Values; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Topics: Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; New York City; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2015 |
[Editorial commentary: Hepatitis C].
Topics: Antiviral Agents; Congresses as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Hungary; Interferons; Liver Cirrhosis; Protease Inhibitors; Research Report; Ribavirin | 2015 |
Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Ritonavir | 2015 |
Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2015 |
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Ribavirin; Simeprevir; Sofosbuvir; Substance Withdrawal Syndrome | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Topics: Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Cognitive impairment in relation to depression, anxiety and virological response in hepatitis C patients in Egypt.
Topics: Adolescent; Adult; Antiviral Agents; Anxiety Disorders; Case-Control Studies; Cognition Disorders; Depressive Disorder; Egypt; Female; Hepatitis C; Humans; Interferons; Male; Middle Aged; Prevalence; Prospective Studies; Ribavirin; Risk Factors; Surveys and Questionnaires; Young Adult | 2015 |
Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation | 2015 |
THE ABSENCE OF THYROID DISEASE IN AN AUSTRALIAN HEPATITIS C COHORT TREATED WITH TRIPLE COMBINATION THERAPY: A PARADIGM SHIFT.
Topics: Adult; Australia; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Retrospective Studies; Ribavirin; Thyroid Diseases | 2015 |
Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; Time Factors; Treatment Outcome; White People; Young Adult | 2014 |
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir.
Topics: Adult; Antiviral Agents; Chromatography, High Pressure Liquid; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Regression Analysis; Retrospective Studies; Ribavirin; Tandem Mass Spectrometry | 2015 |
Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD8-Positive T-Lymphocytes; DNA, Viral; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Human T-lymphotropic virus 2; Humans; Interferon-alpha; Interleukin-6; Male; Middle Aged; Ribavirin; RNA, Viral | 2015 |
HCV, Interferon Therapy Response, Direct Acting Antiviral Therapy Revolution and Pakistan: Future Perspectives.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Ribavirin; RNA, Viral | 2015 |
Hepatitis C virus infection in Taiwan: Past, present, and future.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Public Health; Ribavirin; Taiwan | 2016 |
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System.
Topics: Adult; Age Factors; Antiviral Agents; California; Comorbidity; Delivery of Health Care, Integrated; Drug Therapy, Combination; Female; Genotype; Health Maintenance Organizations; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sex Factors; Treatment Failure | 2015 |
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Pyrophosphatases; Ribavirin | 2015 |
Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Personality Disorders; Polyethylene Glycols; Prisoners; Prisons; Prospective Studies; Recombinant Proteins; Ribavirin; Spain; Treatment Outcome; Young Adult | 2015 |
Clearance of Hepatitis C Virus Improves Insulin Resistance During and After Peginterferon and Ribavirin Therapy.
Topics: Adult; Aged; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Models, Biological; Ribavirin; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Black or African American; Chemokine CXCL1; Chemokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-8; Interleukins; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; White People; Young Adult | 2015 |
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Black or African American; Chemokine CXCL9; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukin-10; Interleukins; Male; Middle Aged; Phenotype; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; United States; Up-Regulation; White People; Young Adult | 2016 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Futility; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Taiwan; Treatment Outcome | 2015 |
Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Mutation, Missense; Ribavirin; Simeprevir; Viral Nonstructural Proteins | 2015 |
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Mutation; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine | 2016 |
Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
Topics: Antiviral Agents; Female; Graft Survival; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.
Topics: Antiviral Agents; Female; Follow-Up Studies; Forecasting; Genotype; Hepatitis C; Humans; Interferon-alpha; Lipoproteins, LDL; Liver Transplantation; Living Donors; Male; Middle Aged; Recurrence; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome | 2015 |
Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Uridine Monophosphate | 2016 |
[Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].
Topics: Antiviral Agents; Biomarkers; Contraindications; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2015 |
Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Scleromyxedema | 2015 |
Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
Topics: Adult; Antiviral Agents; Biomarkers; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Young Adult | 2016 |
Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Viral Core Proteins; Viral Load | 2016 |
MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
Topics: Antiviral Agents; Cell Line; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; MAP Kinase Signaling System; MicroRNAs; Ribavirin; Up-Regulation; Viral Load; Virus Replication | 2016 |
Camel Milk: Potential Utility as an Adjunctive Therapy to Peg-IFN/RBV in HCV-4 Infected Patients in Egypt.
Topics: Adult; Animals; Antioxidants; Antiviral Agents; Apoptosis; Biomarkers; Camelus; Diet; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Inflammation; Interferon-alpha; Male; Middle Aged; Milk; Polyethylene Glycols; Prospective Studies; Ribavirin | 2015 |
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; North America; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2016 |
[Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
Topics: Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; Coinfection; Female; Gene Expression Regulation, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2016 |
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome; Viral Load | 2015 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Economic; Phenotype; Proline; Recurrence; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load; Virus Activation | 2016 |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Odds Ratio; Prospective Studies; Ribavirin; Taiwan; Treatment Outcome; Viral Load | 2015 |
Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2015 |
Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.
Topics: Antiviral Agents; Binding Sites; Biocatalysis; Cell Line, Tumor; DNA; DNA Helicases; Escherichia coli; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Middle Aged; Mutation, Missense; Recombinant Proteins; Recurrence; Ribavirin; RNA; Viral Nonstructural Proteins; Virus Replication | 2015 |
Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin | 2016 |
Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus.
Topics: Adrenocorticotropic Hormone; Adult; Antiviral Agents; Area Under Curve; Corticotropin-Releasing Hormone; Depression; Dexamethasone; Fatigue; Female; Glucocorticoids; Hepatitis C; Humans; Hydrocortisone; Inflammation; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Psychiatric Status Rating Scales; Radioimmunoassay; Receptors, Tumor Necrosis Factor, Type II; Ribavirin; Tumor Necrosis Factor-alpha | 2016 |
Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa.
Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Resistance, Viral; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HLA Antigens; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Ribavirin; RNA, Viral; Sequence Analysis, Protein; South Africa; Viral Core Proteins; Viral Nonstructural Proteins | 2016 |
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2016 |
Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin; Treatment Outcome | 2016 |
Molecular characterization of hepatitis C virus core region in moroccan intravenous drug users.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Disease Reservoirs; Drug Users; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Morocco; Mutation; Phylogeny; Polymerase Chain Reaction; Ribavirin; Sequence Analysis, DNA; Substance Abuse, Intravenous; Viral Core Proteins | 2016 |
Concentration Monitoring of Plasma Ribavirin: Validation of a Liquid Chromatography-Mass Spectrometric Method and Clinical Sample Collection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Chromatography, Liquid; Drug Monitoring; Drug Stability; Drug Storage; Edetic Acid; Hepatitis C; Humans; Middle Aged; Ribavirin; Tandem Mass Spectrometry; Time Factors; Young Adult | 2016 |
Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir | 2016 |
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
MEAN inhibits hepatitis C virus replication by interfering with a polypyrimidine tract-binding protein.
Topics: Antiviral Agents; Cell Death; Cell Line, Tumor; Cytoplasm; Down-Regulation; Drug Synergism; Gene Knockdown Techniques; Green Fluorescent Proteins; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Internal Ribosome Entry Sites; Mutant Proteins; Naphthalimides; Phenylenediamines; Polypyrimidine Tract-Binding Protein; Protein Biosynthesis; Protein Transport; Ribavirin; RNA, Messenger; RNA, Small Interfering; RNA, Viral; Sulfonamides; Virus Replication | 2016 |
Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2016 |
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir | 2016 |
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2016 |
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection.
Topics: Adult; Antiviral Agents; Canada; Cohort Studies; Coinfection; Female; Genotype; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin | 2016 |
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir | 2016 |
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Practice Guidelines as Topic; Republic of Korea; Ribavirin | 2016 |
Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2016 |
No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2016 |
Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
Topics: Aged; Antiviral Agents; Esophageal and Gastric Varices; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Hypertension, Portal; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; Sustained Virologic Response | 2016 |
Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Japan; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Retrospective Studies; Ribavirin | 2016 |
HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2015 |
Double Filtration Plasmapheresis in Treatment of Patients With Co-Infection of Hepatitis C and Human Immunodeficiency Virus.
Topics: Adult; Antiviral Agents; Coinfection; Combined Modality Therapy; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2016 |
Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.
Topics: Adult; Cohort Studies; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Ribavirin; United States; United States Department of Veterans Affairs | 2016 |
From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Protease Inhibitors; Ribavirin; Self Report | 2016 |
INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Georgia (Republic); Hepatitis C; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Retrospective Studies; Ribavirin; Tuberculosis, Pulmonary | 2016 |
A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C.
Topics: Antiviral Agents; Erythema; Hepatitis C; Humans; Male; Middle Aged; Psoriasis; Ribavirin | 2016 |
Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
Topics: Adult; Aged; Biomarkers; DNA Mutational Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunomodulation; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Mutation; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2016 |
Therapy: HCV drugs reduce transplantation need.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Ribavirin | 2016 |
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
Topics: Antiviral Agents; Compassionate Use Trials; Drug Therapy, Combination; France; Hepacivirus; Hepatitis C; Humans; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Drug Pricing Evolution in Hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States | 2016 |
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Egypt; Female; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukin-10; Interleukin-18; Male; Middle Aged; Mutation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin | 2016 |
Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
Topics: Adult; Antiviral Agents; Australia; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Needle Sharing; Patient Compliance; Patient Outcome Assessment; Polyethylene Glycols; Prospective Studies; Quality of Life; Ribavirin; Substance Abuse, Intravenous; Surveys and Questionnaires | 2016 |
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Treatment of Hepatitis C Virus in HIV-Coinfected Individuals in Real-world Clinical Settings: Results From 2 Large HIV Care Clinics.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2016 |
Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Topics: Antiviral Agents; Disease Eradication; Drug Therapy, Combination; Greece; Hepatitis C; Humans; Interferon-alpha; Mass Screening; Morbidity; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Time Factors; World Health Organization | 2017 |
HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Dysbiosis; Female; Hepacivirus; Hepatitis C; Humans; Inflammation; Interferons; Liver Cirrhosis; Male; Microbiota; Middle Aged; Outpatients; Ribavirin | 2016 |
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Longitudinal Studies; Male; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
Hepatitis C virus genotypes in Myanmar.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Epidemiology; Myanmar; Prevalence; Ribavirin | 2016 |
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina.
Topics: Anilides; Antiviral Agents; Breast Diseases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hypertrophy; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2016 |
Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Treatment Outcome; Young Adult | 2016 |
[FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Israel; Male; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2016 |
Pharmacogenetics of ribavirin-induced anemia in hepatitis C.
Topics: Anemia; Antiviral Agents; Equilibrative Nucleoside Transporter 1; Hepatitis C; Humans; Membrane Transport Proteins; Pharmacogenetics; Ribavirin | 2016 |
Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy.
Topics: Abdomen; Antiviral Agents; Drug Therapy, Combination; Endoscopy, Digestive System; Esophageal and Gastric Varices; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenomegaly; Tomography, X-Ray Computed; Ultrasonography | 2016 |
Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hospitals; Humans; Interferons; Middle Aged; Ribavirin; Rwanda; Treatment Outcome; Viral Load | 2016 |
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States | 2016 |
Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2016 |
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2016 |
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2017 |
Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Survival Rate; Treatment Outcome | 2016 |
Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Colorado; Drug Therapy, Combination; Female; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Safety-net Providers; Socioeconomic Factors; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People | 2017 |
Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lymphoma, Follicular; Male; Ribavirin; Sofosbuvir; Viral Load | 2016 |
HCV-associated cryoglobulinemia vasculitis: are its days numbered?
Topics: Cryoglobulinemia; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Vasculitis | 2017 |
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
Topics: Adult; Antipsychotic Agents; Antiviral Agents; Benzodiazepines; Buprenorphine, Naloxone Drug Combination; Disease Notification; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Methadone; Middle Aged; Norway; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Registries; Ribavirin; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous | 2016 |
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Cost-Benefit Analysis; Developing Countries; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Myanmar; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum Albumin; Serum Albumin, Human; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2016 |
Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
Topics: Administration, Oral; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication.
Topics: Adult; Antiviral Agents; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Ribavirin; Sofosbuvir; Tacrolimus | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
Utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
Topics: Adult; Aged; Aged, 80 and over; Disease Management; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Limit of Detection; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Core Proteins; Viral Load; Young Adult | 2017 |
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load | 2017 |
Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2017 |
Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2017 |
Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation.
Topics: Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Recurrence; Ribavirin | 2017 |
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Mutation; Pilot Projects; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database.
Topics: Antiviral Agents; Drug Costs; Health Care Costs; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Quality-Adjusted Life Years; Ribavirin | 2017 |
Differences in IP‑10, TLR4 and IRF5/3 between SVR and non‑SVR HCV‑1 patients treated with PEG‑IFN and ribavirin.
Topics: Adult; Antiviral Agents; Chemokine CXCL10; Female; Hepacivirus; Hepatitis C; Humans; Interferon Regulatory Factor-3; Interferon Regulatory Factors; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Messenger; Toll-Like Receptor 4; Viral Load | 2017 |
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
Topics: Adult; Antiviral Agents; Developing Countries; Drug Therapy, Combination; Female; Genotype; Health Resources; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pakistan; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load | 2017 |
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Granulomatous hepatitis, perihepatic lymphadenopathies, and autoantibody positivity: an unusual association in a child with hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Autoantibodies; Child; Granuloma; Hepatitis C; Humans; Interferons; Liver; Lymphatic Diseases; Male; Ribavirin; RNA, Viral | 2009 |
[Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Hepatectomy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Topics: Adult; Anemia; Antiviral Agents; Cardiovascular Diseases; Female; Hematinics; Hemoglobins; Hepatitis C; Humans; Interferons; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
Neutropenic enterocolitis: An unusual complication of HCV combination therapy with PEG-IFN and ribavirin.
Topics: Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Enterocolitis, Neutropenic; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tomography, X-Ray Computed | 2008 |
Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Amino Acid Substitution; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Factors; Viral Core Proteins | 2008 |
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; Treatment Failure; Treatment Outcome | 2008 |
"Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism.
Topics: Adaptation, Psychological; Adjustment Disorders; Adult; Antiviral Agents; Attitude of Health Personnel; Culture; Decision Making; Denial, Psychological; Depression; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interview, Psychological; Male; Middle Aged; New South Wales; Patient Acceptance of Health Care; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sick Role | 2008 |
Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2008 |
Cryofibrinogen in patients with hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cryoglobulins; Female; Fibrinogens, Abnormal; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Vasculitis | 2008 |
Late occurrence of pleural and peritoneal effusion due to Mycobacterium tuberculosis infection (TB) in a patient with posttransplantation recurrent HCV chronic hepatitis: safety of peginterferon and ribavirin treatment after recovery of TB:- a case report
Topics: Adult; Antiviral Agents; Ascitic Fluid; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Mycobacterium tuberculosis; Pleural Effusion; Postoperative Complications; Ribavirin; Safety; Treatment Outcome; Tuberculosis | 2008 |
A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Ribavirin; Ribosomes; RNA, Viral | 2008 |
Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2008 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome | 2008 |
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-10; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome; White People | 2008 |
Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2008 |
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Demography; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients.
Topics: Aged; Antiviral Agents; Appetite; Body Mass Index; Body Weight; Drug Therapy, Combination; Energy Intake; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Surveys and Questionnaires | 2008 |
Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.
Topics: Adult; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; ROC Curve; Serum; Treatment Outcome | 2008 |
Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
Topics: Adult; Aged; Antiviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Plasma; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; ROC Curve; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2008 |
Is there discrimination in access to therapy for HCV patients?
Topics: Antiviral Agents; Canada; Czech Republic; European Union; Health Services Accessibility; Healthcare Disparities; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prejudice; Recombinant Proteins; Ribavirin | 2008 |
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2008 |
Market uptake of new antiviral drugs for the treatment of hepatitis C.
Topics: Antiviral Agents; Canada; Czech Republic; European Union; Health Care Costs; Healthcare Disparities; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Marketing of Health Services; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Ribavirin; World Health Organization | 2008 |
Can genetic variations predict HCV treatment outcomes?
Topics: Antiviral Agents; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Evolution, Molecular; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Topics: Age Factors; Body Weight; Fatty Liver; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2009 |
Effect of antiviral therapy on hepatitis C virus related glomerulopathy.
Topics: Antibody Formation; Antiviral Agents; Aspartate Aminotransferases; Creatinine; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Hepacivirus; Hepatitis C; Humans; Interferons; Proteinuria; Ribavirin; RNA, Viral | 2008 |
Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism.
Topics: 5' Untranslated Regions; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Korea; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Ribavirin; Sequence Analysis, RNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2008 |
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prisoners; Prisons; Recombinant Proteins; Retrospective Studies; Ribavirin | 2008 |
Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin.
Topics: Antiviral Agents; Complementarity Determining Regions; Evolution, Molecular; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phylogeny; Recombinant Proteins; Ribavirin; Viral Nonstructural Proteins | 2008 |
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.
Topics: Antiviral Agents; Female; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Regression Analysis; Ribavirin; Risk; Treatment Outcome | 2008 |
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Topics: Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin?
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Kinetics; Liver; Liver Transplantation; Odds Ratio; Polyethylene Glycols; Ribavirin; Treatment Outcome | 2008 |
HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2009 |
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2008 |
Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Plasma; Ribavirin; Viral Proteins | 2008 |
Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Child; China; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Statistics as Topic; Viral Core Proteins; Viral Load | 2008 |
Factors influencing the participation of gastroenterologists and hepatologists in clinical research.
Topics: Adult; Aged; Antiviral Agents; Attitude of Health Personnel; Biomedical Research; Clinical Competence; Clinical Trials as Topic; Costs and Cost Analysis; Drug Industry; Ethnicity; Evidence-Based Medicine; Female; Gastroenterology; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Physicians; Research Support as Topic; Ribavirin; Surveys and Questionnaires; United States | 2008 |
Telaprevir phase 3 realize trial starts.
Topics: Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2008 |
Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.
Topics: Adult; Animals; Antiviral Agents; Evolution, Molecular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Mice; Middle Aged; Molecular Epidemiology; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Recombination, Genetic; Ribavirin; Young Adult | 2008 |
Ribavirin and pegylated interferon treatment for hepatitis C was associated not only with semen alterations but also with sperm deoxyribonucleic acid fragmentation in humans.
Topics: Adult; Antiviral Agents; Cell Shape; Chromatin Assembly and Disassembly; Contraceptives, Oral, Hormonal; DNA Fragmentation; Drug Therapy, Combination; Female; Flow Cytometry; Hepatitis C; Humans; In Situ Nick-End Labeling; Interferon alpha-2; Interferon-alpha; Live Birth; Male; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin; Sperm Count; Sperm Motility; Spermatozoa; Time Factors; Treatment Outcome | 2009 |
[The analysis of the hepatitis C virus infection course and efficacy of treatment dependence on HLA A antigens in children and youth].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; HLA-A Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2008 |
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.
Topics: Adult; Aged; Aging; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sex Characteristics; Viral Load; Young Adult | 2009 |
[Successful elimination of hepatitis C virus after hepatic lobectomy in a patient with hepatocellular carcinoma].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepacivirus; Hepatectomy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2008 |
Mathematical modeling of HCV infection and treatment.
Topics: Antiviral Agents; Cell Proliferation; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferons; Kinetics; Models, Biological; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
Shall we treat all patients with hepatitis C, and if not, why? Certainly, injecting drug users must not be an exclusion criterion.
Topics: Antiviral Agents; Drug Users; Hepatitis C; Humans; Interferons; Ribavirin | 2008 |
[HIV and hepatitis C coinfection].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load | 2008 |
A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone.
Topics: Antiviral Agents; Glucocorticoids; Hearing Loss; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin | 2009 |
Severe pruritus after completing pegylated interferon for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hand; Hepatitis C; HIV Infections; Humans; Interferons; Middle Aged; Polyethylene Glycols; Porphyria Cutanea Tarda; Pruritus; Ribavirin; Severity of Illness Index; Time Factors | 2008 |
Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
Topics: Adult; Amino Acid Sequence; Analysis of Variance; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Analysis, Protein; Treatment Outcome; Viral Nonstructural Proteins | 2009 |
Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Viral-associated immune thrombocytopenic purpura.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Bisexuality; Hemorrhage; Hepacivirus; Hepatitis C; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Ribavirin; Risk Factors; Substance Abuse, Intravenous | 2008 |
Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Xerostomia and lichenoid reaction in a hepatitis C patient treated with interferon-alpha: a case report.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lichen Planus, Oral; Male; Middle Aged; Ribavirin; Xerostomia | 2008 |
Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Patient Compliance; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor.
Topics: Antiviral Agents; Apoptosis; Benzofurans; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferons; Liver; Liver Diseases; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Sulfonamides | 2009 |
IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C. Case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Graves Disease; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Thyroidectomy; Thyrotoxicosis; Thyrotropin; Thyroxine | 2008 |
Treatment of HBV/HCV coinfection: releasing the enemy within.
Topics: Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Interference; Viral Load | 2009 |
Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1.
Topics: Adult; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Falsely low hemoglobin A1c levels in a patient receiving ribavirin and peginterferon alfa-2b for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Glycated Hemoglobin; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2009 |
Changes of non-invasive markers and FibroScan values during HCV treatment.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Cohort Studies; Elasticity Imaging Techniques; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome | 2009 |
Perihepatic lymph nodes as markers of disease response in patients with hepatitis C-related liver disease: a prospective clinical evaluation.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Lymph Nodes; Lymphatic Diseases; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Ultrasonography; Viral Load | 2010 |
Jaundice developing in a patient with hepatitis C4 months after liver transplantation.
Topics: Antiviral Agents; Fatal Outcome; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Jaundice; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Tacrolimus | 2009 |
Human immunodeficiency virus and hepatitis C virus co-infection: epidemiology, natural history and the situation in China.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; China; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Australia; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Longitudinal Studies; Male; Prospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Viral Load | 2008 |
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2008 |
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Peritonitis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Safety; Time Factors; Viral Load; Waiting Lists; Young Adult | 2009 |
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results.
Topics: Antiviral Agents; Bacterial Infections; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Safety; Waiting Lists | 2009 |
Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon Type I; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Ribavirin; Transaminases | 2009 |
Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mutation; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
Treatment of hepatitis C infection for current or former substance abusers in a community setting.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2009 |
Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy.
Topics: 5' Untranslated Regions; Adolescent; Adult; Antiviral Agents; Base Sequence; Cloning, Molecular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Ribosomes; RNA, Viral; Young Adult | 2009 |
A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2009 |
Diagnosis, management, and treatment of hepatitis C: an update.
Topics: Biopsy; Counseling; Drug Users; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Treatment Failure | 2009 |
Psychotic mania induced by the withdrawal of pegylated interferon and ribavirin treatment.
Topics: Antiviral Agents; Bipolar Disorder; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Substance Withdrawal Syndrome | 2009 |
[ANRS HC 02 RIBAVIC: histo-pathological impact].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Multivariate Analysis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
[ANRS HC 02 RIBAVIC: from multicenter trial to daily practice].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Comorbidity; Drug Therapy, Combination; France; Government Agencies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
[ANRS HC 02 RIBAVIC: from multicenter trial to daily practice. Conclusions].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Multicenter Studies as Topic; Polyethylene Glycols; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
[HIV-HCV co-infection: where are we now?].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Comorbidity; France; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Interferons; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
Treatment for recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biopsy; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2009 |
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Insulin Resistance; Interferons; Japan; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Core Proteins; Young Adult | 2009 |
Clinical decisions. Management of incidental hepatitis C virus infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biopsy; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Feasibility Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Spectrometry, Mass, Electrospray Ionization | 2009 |
Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carrier State; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
The role of positive selection in hepatitis C virus.
Topics: Amino Acid Sequence; Chi-Square Distribution; Cohort Studies; Complementarity Determining Regions; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Selection, Genetic; Sequence Analysis, Protein; Viral Envelope Proteins; Viral Nonstructural Proteins | 2009 |
Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.
Topics: Antiviral Agents; Cell Count; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Models, Biological; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Virus Replication | 2009 |
Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
Topics: Adult; Aged; Antiviral Agents; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2009 |
Clinical decisions. Management of incidental hepatitis C virus infection--polling results.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Incidental Findings; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Topics: Acute Disease; Adult; Antiviral Agents; Clinical Trials as Topic; Computer Simulation; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Middle Aged; Models, Economic; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Current clinical care compared with new Dutch guidelines for hepatitis C treatment.
Topics: Antiviral Agents; Genotype; Guideline Adherence; Hepacivirus; Hepatitis C; Humans; Netherlands; Practice Guidelines as Topic; Practice Patterns, Physicians'; Ribavirin; Societies, Medical; Surveys and Questionnaires; Viral Load | 2009 |
Therapy of hepatitis C in thalassemia: the influence of iron on achieving sustained viral response.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Iron; Ribavirin; Thalassemia | 2010 |
Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
Novel therapies in Hepatitis C virus. Preface.
Topics: Antiviral Agents; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Ribavirin analogs.
Topics: Anemia, Hemolytic; Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Humans; IMP Dehydrogenase; Mycophenolic Acid; Phenylurea Compounds; Ribavirin | 2009 |
Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Female; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Incidence; Interferons; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Ribavirin; Risk Factors; Treatment Outcome | 2009 |
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
Topics: Antiviral Agents; Case-Control Studies; Female; Graft Survival; Hepatitis C; Humans; Interferon Type I; Kaplan-Meier Estimate; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2009 |
Bell's palsy and choreiform movements during peginterferon alpha and ribavirin therapy.
Topics: Antiviral Agents; Bell Palsy; Chorea; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Cluster Analysis; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Viral Nonstructural Proteins | 2010 |
Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis C; Humans; Interferons; Ribavirin; Treatment Outcome | 2010 |
Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biopsy; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Lymphoma, B-Cell; Magnetic Resonance Imaging; Neoplasm Staging; Radiotherapy, Adjuvant; Ribavirin; Treatment Outcome | 2010 |
Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2009 |
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Cohort Studies; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2009 |
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Molecular Sequence Data; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Nonstructural Proteins; Young Adult | 2009 |
Sustained virologic response following HCV eradication in two brothers with X-linked agammaglobulinaemia.
Topics: Adult; Agammaglobulinemia; Antiviral Agents; Comorbidity; Drug Contamination; Genetic Diseases, X-Linked; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; Siblings | 2009 |
Evidence-based antimicrobial therapy in pregnancy: long overdue.
Topics: Adult; Anti-Infective Agents; Antiviral Agents; Evidence-Based Medicine; Female; Hepatitis C; Humans; Influenza, Human; Pregnancy; Pregnancy Complications, Infectious; Ribavirin; United States; United States Food and Drug Administration | 2009 |
Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Asian People; Cholesterol; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lipoproteins; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Ribavirin; Treatment Outcome; Triglycerides | 2010 |
Hepatitis C: Should antiviral therapy be offered to elderly patients?
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hepatitis C; Humans; Interferons; Life Expectancy; Liver Neoplasms; Middle Aged; Ribavirin; Risk Factors | 2009 |
Hepatitis C: The role of new interferons in the era of STAT-C.
Topics: Albumins; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Belgium; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon Type I; Luxembourg; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Registries; Remission, Spontaneous; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response?
Topics: Adult; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Neutrophils; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Risk Assessment; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Hyalohyphomycosis caused by Paecilomyces lilacinus after kidney transplantation.
Topics: Antifungal Agents; Diabetes Mellitus; Female; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Kidney Transplantation; Middle Aged; Mycoses; Paecilomyces; Polycystic Kidney Diseases; Postoperative Complications; Pyrimidines; Renal Replacement Therapy; Ribavirin; Treatment Outcome; Triazoles; Voriconazole | 2009 |
CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients.
Topics: Adult; Antigens, CD; Antiviral Agents; B-Lymphocytes; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Longitudinal Studies; Lymphocyte Subsets; Male; Ribavirin; RNA, Viral; T-Lymphocytes; Tetraspanin 28; Viral Load | 2010 |
Feasibility of individualized treatment for hepatitis C patients in the real world.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Taiwan; Time Factors; Treatment Outcome; Viral Load | 2010 |
Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Blood Glucose; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Hypercholesterolemia; Hyperglycemia; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Lipodystrophy; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Triglycerides; Viral Load | 2009 |
Hepatitis C drug development at a crossroads.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Pegylated interferon and ribavirin therapy for hepatitis C causing cataract.
Topics: Antiviral Agents; Cataract; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lens, Crystalline; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Visual Acuity | 2009 |
Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Probability; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; ROC Curve; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2009 |
Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2009 |
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2009 |
Hepatitis C comorbidities affecting the course and response to therapy.
Topics: Alcoholism; Antiviral Agents; Comorbidity; Gastroenterology; Hepatitis C; Humans; Interferons; Iron Overload; Polyethylene Glycols; Ribavirin; Schistosomiasis; Smoking; Treatment Outcome | 2009 |
Tongue hyperpigmentation resulting from peginterferon alfa and ribavirin combination therapy: a case report.
Topics: Aged; Antiviral Agents; Brazil; Diagnosis, Differential; Drug Combinations; Female; Hepatitis C; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Skin Pigmentation; Tongue Diseases | 2009 |
CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
Topics: Adult; Antiviral Agents; Chemokine CCL2; Chromatography, High Pressure Liquid; Cytokines; Depression; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C; Humans; Interferon-alpha; Kynurenine; Longitudinal Studies; Male; Middle Aged; Quinolinic Acid; Receptors, Tumor Necrosis Factor, Type II; Ribavirin; Statistics as Topic; Tryptophan | 2010 |
HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment.
Topics: Adult; Ambulatory Care Facilities; Antiviral Agents; Feasibility Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Sweden; Treatment Outcome | 2009 |
Focus.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Ribavirin; Treatment Outcome | 2010 |
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Drug Tolerance; Female; Follow-Up Studies; Genotype; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Tacrolimus; Time Factors; Tissue Donors; Treatment Outcome | 2009 |
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2010 |
New opportunities for the management and therapy of hepatitis C in correctional settings.
Topics: Adolescent; Adult; Antiviral Agents; Female; Health Care Costs; Hepatitis C; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; North Dakota; Prisoners; Prisons; Program Evaluation; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2010 |
Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2010 |
[Protocol for the antiviral therapy of hepatitis C].
Topics: Algorithms; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin | 2010 |
Systemic lupus erythematosus and Sjögren's syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C.
Topics: Antibodies, Antinuclear; Antiviral Agents; Female; Glucocorticoids; Hepatitis C; Humans; Interferon-alpha; Lupus Erythematosus, Systemic; Middle Aged; Ribavirin; Sjogren's Syndrome; Treatment Outcome | 2010 |
Association between phospholipids and free cholesterol in high-density lipoprotein and the response to hepatitis C treatment in Japanese with genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Chromatography, High Pressure Liquid; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Lipoproteins, HDL; Male; Middle Aged; Phospholipids; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hyperpigmentation; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue Diseases | 2010 |
Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome; Up-Regulation | 2010 |
Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment.
Topics: Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Thrombocytopenia; Time Factors; Weight Loss | 2010 |
Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; Severity of Illness Index; Vasculitis; Viral Load | 2010 |
Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2010 |
Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Microscopy, Fluorescence; Middle Aged; Ribavirin; RNA, Viral | 2010 |
[Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States; Viral Load | 2010 |
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Gene Frequency; Genetic Variation; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; MicroRNAs; Middle Aged; Outcome Assessment, Health Care; Phylogeny; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Nonstructural Proteins; White People | 2010 |
Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy.
Topics: Adult; Age of Onset; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Thyroid Diseases; United Kingdom | 2010 |
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial.
Topics: Adult; Aged; Female; Hepatitis C; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2010 |
Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Load; Young Adult | 2010 |
Necrolytic acral erythema: an expanding spectrum.
Topics: Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Erythema; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Necrosis; Ribavirin; Zinc Sulfate | 2009 |
[Treatment of recurrent hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
[Treatment of non-responders].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
[Treatment of HIV-HCV and HBV-HCV co-infection].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin | 2005 |
[Treatment of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Humans; Interferons; Meta-Analysis as Topic; Ribavirin; Viral Load | 2005 |
[Treatment in chronic renal failure].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2005 |
Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Ribavirin; RNA, Viral; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
Sarcoidosis and hepatitis C: clinical description of 11 cases.
Topics: Adrenal Cortex Hormones; Adult; Antiviral Agents; Arthritis; Cohort Studies; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sarcoidosis; Treatment Outcome; Uveitis; Young Adult | 2010 |
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome | 2010 |
Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Multivariate Analysis; Mutation; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Reoperation; Ribavirin | 2010 |
Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy; Female; Follow-Up Studies; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome; Viral Load | 2010 |
Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Tolerance; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Transplantation; Living Donors; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tissue Donors; Viral Nonstructural Proteins; Viral Proteins | 2010 |
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
Pegylated interferon alpha-associated optic neuropathy.
Topics: Antiviral Agents; Atrophy; Blindness; Hepatitis C; Humans; Iatrogenic Disease; Interferon alpha-2; Interferon-alpha; Magnetic Resonance Imaging; Male; Middle Aged; Optic Nerve; Optic Neuropathy, Ischemic; Paresthesia; Peripheral Nerves; Peripheral Nervous System Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Visual Fields | 2010 |
An international survey of the diagnosis, management, and treatment of hepatitis C in patients with end-stage renal disease.
Topics: Antiviral Agents; Biopsy; Evidence-Based Medicine; Guideline Adherence; Health Care Surveys; Hepatitis C; Humans; Informed Consent; Interferons; Kidney Failure, Chronic; Kidney Transplantation; Practice Guidelines as Topic; Practice Patterns, Physicians'; Predictive Value of Tests; Ribavirin; Surveys and Questionnaires; Tissue Donors; Treatment Outcome | 2009 |
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Spain; Treatment Outcome | 2010 |
Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.
Topics: Adult; Antiviral Agents; Drug Carriers; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Interdisciplinary Communication; Interferons; Male; Medical Records; Middle Aged; Odds Ratio; Patient Care Team; Peer Group; Polyethylene Glycols; Retrospective Studies; Ribavirin; Self-Help Groups; Substance-Related Disorders; Treatment Outcome | 2010 |
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
Topics: Body Weight; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2010 |
Current practice of hepatitis C treatment in Southern Italy.
Topics: Adult; Aged; Alanine Transaminase; Alcoholism; Antiviral Agents; Educational Status; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Treatment Refusal | 2010 |
The role of liver iron in hepatitis C antiviral treatment.
Topics: Anemia, Sickle Cell; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV Seropositivity; Humans; Incidence; Interferons; Male; Population Dynamics; Prevalence; Ribavirin; RNA, Viral; Substance Abuse, Intravenous | 2011 |
Hashimoto's encephalopathy after interferon therapy for hepatitis C virus in adult liver transplant recipient accompanied by post-transplant lymphoproliferative disorder related to Epstein-Barr virus infection.
Topics: Antiviral Agents; Brain Diseases; Drug Therapy, Combination; Encephalitis; Epstein-Barr Virus Infections; Female; Hashimoto Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Lymphoproliferative Disorders; Middle Aged; Polyethylene Glycols; Ribavirin | 2010 |
Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy.
Topics: Aged; Antiviral Agents; Biopsy; Combined Modality Therapy; Cryoglobulinemia; Drug Therapy, Combination; Edema; Female; Genotype; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Plasmapheresis; Polyethylene Glycols; Proteinuria; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Down-Regulation; Drug Therapy, Combination; Fibrosis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes, Helper-Inducer; Viral Load | 2010 |
Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Gene Expression Regulation; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; L-Lactate Dehydrogenase; Lactic Acid; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Hepatitis C treatment response kinetics and impact of baseline predictors.
Topics: Adult; Age Factors; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2011 |
Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry.
Topics: Administration, Oral; Adult; Antiviral Agents; Female; Hepatitis C; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Registries; Ribavirin | 2010 |
Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.
Topics: Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Minority Groups; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Urban Population | 2010 |
An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Topics: Antiviral Agents; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Markov Chains; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Recurrence; Ribavirin; RNA-Binding Proteins; RNA, Viral; Viral Nonstructural Proteins | 2011 |
Decreased IFNγ production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy.
Topics: Adult; Aged; Antiviral Agents; Cytokines; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Hepatitis C; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Signal Transduction; Toll-Like Receptors; Trans-Activators; Transcription Factors | 2011 |
Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2011 |
Overcoming barriers to new treatment options for hepatitis C.
Topics: Antiviral Agents; Complementary Therapies; Cost of Illness; Health Behavior; Health Services Accessibility; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Nurse Practitioners; Nursing Assessment; Patient Selection; Practice Guidelines as Topic; Ribavirin; Risk Assessment; Self Care; United States | 2010 |
A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
Topics: Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2010 |
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Treatment of hepatitis C in renal transplantation candidates: a single-center experience.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Basiliximab; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Fusion Proteins; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Waiting Lists | 2010 |
Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2010 |
[Pericardial effusion associated to interferon in an immunocompetent patient].
Topics: Antipsychotic Agents; Antiviral Agents; Drug Therapy, Combination; Dyspnea; Hepatitis C; Humans; Immunocompetence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pericardial Effusion; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Schizophrenia | 2010 |
Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; France; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Mental Disorders; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus.
Topics: Adult; Aged; Algorithms; Antiviral Agents; Area Under Curve; Chemokine CXCL10; Extracellular Matrix Proteins; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Transforming Growth Factor beta; Treatment Outcome; Viral Load | 2010 |
Reinfection with hepatitis C virus following sustained virological response in injection drug users.
Topics: Adult; Antiviral Agents; British Columbia; Community Health Centers; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission, Spontaneous; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load | 2010 |
Treatment duration for genotypes 2 and 3: still confusing after all these years.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2010 |
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genome-Wide Association Study; Hepatitis C; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Treatment Outcome | 2010 |
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Topics: Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome | 2010 |
Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
Topics: Antiviral Agents; Biflavonoids; Catechin; Cell Line, Tumor; Cinnamomum zeylanicum; Drugs, Chinese Herbal; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Proanthocyanidins; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Virus Internalization; Virus Replication | 2010 |
Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Treatment of recurrent hepatitis C post-liver transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Graft Survival; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Practice Guidelines as Topic; Recurrence; Ribavirin; Treatment Outcome | 2010 |
Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
Topics: Adult; Antiviral Agents; Blood Transfusion; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hematinics; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pennsylvania; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cyclopropanes; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Haplorhini; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C; Humans; Immunoglobulin G; Interferon-alpha; Interleukin-8; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; Treatment Outcome | 2011 |
Optimal dosage of ribavirin.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2010 |
Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Equilibrative Nucleoside Transporter 1; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin | 2010 |
Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere.
Topics: Antiviral Agents; Australia; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Methadone; Models, Statistical; Opiate Substitution Treatment; Polyethylene Glycols; Prevalence; Primary Prevention; Recombinant Proteins; Ribavirin; Substance Abuse, Intravenous | 2011 |
Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Diabetes Complications; Female; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Interferons; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Young Adult | 2010 |
The smoldering epidemic. The number of new cases of hepatitis C is down, but millions are chronically infected and may not know it.
Topics: Antiviral Agents; Disease Outbreaks; Drug Therapy, Combination; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2010 |
Pediatric hepatitis C infection: are there missed opportunities for diagnosis and treatment?
Topics: Adolescent; Antiviral Agents; Female; Hepatitis C; Humans; Liver Transplantation; Ribavirin; Risk Factors | 2010 |
IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
Topics: Antiviral Agents; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin; Viral Load | 2010 |
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Big changes are coming in hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; Humans; Interferons; Oligopeptides; Proline; Protease Inhibitors; Ribavirin | 2011 |
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Topics: Aged; Antiviral Agents; Chicago; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serum; Time Factors; Treatment Outcome | 2011 |
Hepatitis C: Enhancing treatment for hepatitis C among drug users.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug Users; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Influence of pre-analytical conditions on plasma ribavirin concentrations.
Topics: Antiviral Agents; Blood Specimen Collection; Centrifugation; Chromatography, High Pressure Liquid; Edetic Acid; Female; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Spectrophotometry, Ultraviolet; Temperature | 2010 |
[IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asia; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; Humans; Infant; Interferon-beta; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; China; Evolution, Molecular; Female; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Open Reading Frames; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Sequence Analysis, RNA; Treatment Failure | 2011 |
Screening for IL28B gene variants identifies predictors of hepatitis C therapy success.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Base Sequence; Case-Control Studies; Cohort Studies; Confidence Intervals; Drug Therapy, Combination; Female; Genetic Association Studies; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prognosis; Recombinant Proteins; Ribavirin; White People; Young Adult | 2010 |
Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Confidence Intervals; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins; Young Adult | 2010 |
Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.
Topics: Adult; Antiviral Agents; Discriminant Analysis; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2010 |
Adding telaprevir improves cure rate in patient with HCV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |
Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Eukaryotic Initiation Factor-2; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Mutation; Pakistan; Protein Structure, Tertiary; Ribavirin; Sequence Alignment; Viral Envelope Proteins | 2010 |
The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2011 |
The role of triple therapy in HCV genotype 1-experienced patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2011 |
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2011 |
Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Pakistan; Prevalence; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Young Adult | 2011 |
Cross-sectional epidemiology of hepatitis C virus detection and treatment in HIV-infected patients.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Educational Status; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medical Records; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Spain; Statistics, Nonparametric | 2011 |
Interferon alone or combined with ribavirin for acute prolonged infection with hepatitis C virus in chimpanzees.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Hepatitis C; Interferon-alpha; Pan troglodytes; Primate Diseases; Ribavirin; RNA, Viral; Serum; Treatment Outcome | 2011 |
The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Patient Selection; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Consensus interferon: tailored therapy and the impact of adherence.
Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Consensus Sequence; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Medication Adherence; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2011 |
Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Neovascularization, Pathologic; Retrospective Studies; Ribavirin | 2011 |
Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.
Topics: Anemia, Hemolytic; Antiviral Agents; Computational Biology; Drug Therapy, Combination; Erythrocyte Aging; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mathematical Concepts; Models, Biological; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Young Adult | 2012 |
A laparoscopic splenectomy allows the induction of antiviral therapy for patients with cirrhosis associated with hepatitis C virus.
Topics: Aged; Antiviral Agents; Blood Loss, Surgical; Contraindications; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Laparoscopy; Length of Stay; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Splenectomy; Thrombocytopenia | 2011 |
Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins | 2011 |
Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.
Topics: Adult; Aging; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin | 2011 |
HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2011 |
[Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antiviral Agents; Anxiety; Depression; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon-alpha; Retrospective Studies; Ribavirin | 2011 |
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.
Topics: Cohort Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Observation; Patient Compliance; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Surveys and Questionnaires | 2011 |
Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Biomarkers; E-Selectin; Endothelial Cells; Female; Hepatitis C; HIV Infections; Humans; Intercellular Adhesion Molecule-1; Interferon-alpha; Male; Middle Aged; P-Selectin; Receptors, Tumor Necrosis Factor, Type I; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Fas Ligand Protein; fas Receptor; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome | 2011 |
[Apical hypertrophic cardiomyopathy associated with HCV infection].
Topics: Adult; Antiviral Agents; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Heart Ventricles; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population.
Topics: Adult; Aged; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin's lymphoma treated with rituximab-containing regimens.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female; Hepatitis C; Humans; Immunologic Factors; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Ribavirin; Rituximab | 2011 |
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Carrier Proteins; Catalysis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Ribavirin; Sequence Analysis, DNA; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2011 |
Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Cohort Studies; Cyclosporine; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Tacrolimus; Treatment Outcome | 2011 |
Racial differences in hepatitis C treatment eligibility.
Topics: Adult; Alcoholism; Antiviral Agents; Black People; Diabetes Complications; Eligibility Determination; Female; Heart Diseases; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Mass Screening; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Substance-Related Disorders; Treatment Outcome; United States; White People | 2011 |
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.
Topics: Aged; Analysis of Variance; Antiviral Agents; Asian People; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis C; Heterozygote; Homozygote; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Zidovudine | 2011 |
Genetic variation at immunoglobulin kappa locus is associated with hepatitis C-treatment-induced viral clearance in African Americans.
Topics: Adult; Alleles; Antiviral Agents; Black or African American; Female; Genetic Loci; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Homozygote; Humans; Immunoglobulin gamma-Chains; Immunoglobulin kappa-Chains; Interferon-alpha; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; White People | 2011 |
Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Female; Genotype; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Predictive Value of Tests; Receptors, LDL; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2011 |
Anterior ischemic optic neuropathy in a patient with hepatitis C treated with interferon-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Glucocorticoids; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Methylprednisolone; Optic Neuropathy, Ischemic; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Visual Acuity | 2011 |
Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Silybin; Silymarin; Time Factors; Treatment Failure; Viral Load | 2011 |
Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Predictive Value of Tests; Pyrophosphatases; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2011 |
Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs; Viral Load | 2011 |
[Sarcoid granulomas in facial cosmetic filler material: induction by interferon-α and ribavirin in a patient with hepatitis C].
Topics: Antiviral Agents; Collagen; Cosmetic Techniques; Female; Granuloma, Foreign-Body; Hepatitis C; Humans; Interferon-alpha; Microspheres; Middle Aged; Polymethyl Methacrylate; Ribavirin | 2011 |
Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
Topics: Acute Disease; Antiviral Agents; Biomarkers; Drug Administration Schedule; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Hepatitis C: many small steps.
Topics: Antiviral Agents; Global Health; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Therapeutics: new drugs hit the target.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin; Simeprevir; Sulfonamides | 2011 |
Pharmacogenomics: playing the odds.
Topics: Female; Genetic Testing; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Ribavirin | 2011 |
Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Brazil; Cross-Sectional Studies; Depression; Depressive Disorder; Female; Genetic Association Studies; Genotype; Hepatitis C; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Ribavirin | 2011 |
Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy.
Topics: Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kinetics; Models, Biological; Ribavirin; RNA, Viral; Taiwan; Viral Load | 2011 |
The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension.
Topics: Antiviral Agents; Black or African American; Drug Therapy, Combination; Genetic Testing; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Predictive Value of Tests; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; White People | 2011 |
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Female; Genetic Variation; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2012 |
Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leukopenia; Male; Middle Aged; Poland; Polymerase Chain Reaction; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2011 |
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
Topics: Adult; Alanine Transaminase; Antigens, Differentiation, Myelomonocytic; Antiviral Agents; Biopsy; Cell Degranulation; Cells, Cultured; Cytokines; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunity, Innate; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lectins; Liver; Male; Maryland; Middle Aged; NK Cell Lectin-Like Receptor Subfamily C; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Viral Load | 2011 |
Sustained viral response after only 6 weeks of peginterferon and ribavirin treatment for acute hepatitis C in a HIV-1-infected patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2011 |
Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Hand-Assisted Laparoscopy; Hepatitis C; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Japan; Laparoscopy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Coinfection; Depression; Drug Therapy, Combination; Ethanol; Female; France; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Logistic Models; Male; Medication Adherence; Middle Aged; Prospective Studies; Ribavirin; Socioeconomic Factors; Substance Abuse, Intravenous; Surveys and Questionnaires | 2012 |
Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.
Topics: Antiviral Agents; California; Cohort Studies; Depressive Disorder; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Ribavirin; Treatment Outcome; Veterans | 2011 |
An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C; Humans; Interferons; Lymphoma, Non-Hodgkin; Remission Induction; Ribavirin; Rituximab | 2012 |
Economic burden associated with patients diagnosed with hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Comorbidity; Costs and Cost Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; Humans; Incidence; Insurance Claim Review; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Economic; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; United States; Young Adult | 2011 |
Zebrafish as a potential model organism for drug test against hepatitis C virus.
Topics: Alkaloids; Animals; Antiviral Agents; Blotting, Western; Disease Models, Animal; Drug Evaluation, Preclinical; Fish Diseases; Gene Amplification; Gene Expression Regulation, Viral; Genetic Vectors; Green Fluorescent Proteins; Hepacivirus; Hepatitis C; Hepatocytes; Humans; In Situ Hybridization; Larva; Microinjections; Microscopy, Fluorescence; Quinolizines; Replicon; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Untranslated Regions; Viral Nonstructural Proteins; Zebrafish | 2011 |
Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Therapy; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sequence Deletion; Treatment Outcome; Viral Load | 2012 |
A view to natural killer cells in hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Immunity, Innate; Interferon-alpha; Killer Cells, Natural; Liver; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
Topics: Antiviral Agents; Asian People; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; White People | 2011 |
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Pilot Projects; Premedication; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Coinfection; Drug Interactions; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Oligopeptides; Proline; Ribavirin; Serine Proteases; Serine Proteinase Inhibitors; Viral Proteins | 2011 |
Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Asian People; Female; Gene Frequency; Genotype; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome | 2011 |
IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2011 |
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carrier Proteins; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Intracellular Signaling Peptides and Proteins; Mutation, Missense; Polymerase Chain Reaction; Polymorphism, Genetic; Protease Inhibitors; Ribavirin; Viral Nonstructural Proteins | 2011 |
Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2011 |
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Medication Adherence; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Viral Load | 2011 |
Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients?
Topics: Adolescent; Adult; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Human Growth Hormone; Humans; Interferons; Liver Function Tests; Male; Middle Aged; Prothrombin Time; Ribavirin | 2012 |
Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
Topics: Anti-Bacterial Agents; Antiviral Agents; Daptomycin; Hepatitis C; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Rhabdomyolysis; Ribavirin | 2012 |
Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.
Topics: Aged; Antiviral Agents; Base Sequence; DNA, Complementary; Drug Therapy, Combination; Female; Genetic Heterogeneity; Genome, Viral; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Mutation Rate; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Retrospective chart review to assess the relationship between depression and sustained virological response from interferon treatment for hepatitis C virus.
Topics: Adult; Antiviral Agents; Depression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Medical Records; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin; Viral Hepatitis Vaccines; World Health Organization | 2011 |
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Plasma; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic.
Topics: Adult; Ambulatory Care Facilities; Antiviral Agents; Cohort Studies; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Program Evaluation; Recombinant Proteins; Referral and Consultation; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2011 |
Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
Topics: Adult; Aged; Alleles; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Heterozygote; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Serotyping | 2012 |
[Information for patients. Treatment of acute hepatitis C].
Topics: Antiviral Agents; Hepatitis C; Humans; Injections, Subcutaneous; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Ribavirin; Risk Factors; Young Adult | 2012 |
Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Prevalence; Ribavirin; Sex Factors; Thyroid Diseases; Thyroid Function Tests; Time Factors; Young Adult | 2011 |
Absenteeism and productivity among employees being treated for hepatitis C.
Topics: Absenteeism; Antiviral Agents; Cost of Illness; Efficiency; Employment; Hepatitis C; Humans; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; United States | 2011 |
Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.
Topics: Antiviral Agents; Blotting, Western; Cells, Cultured; Fluorescent Antibody Technique; GTP-Binding Proteins; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Immunoenzyme Techniques; Immunoprecipitation; Interferon-alpha; Myxovirus Resistance Proteins; Phosphorylation; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Viral Core Proteins; Virus Replication | 2011 |
Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.
Topics: Alleles; Biomarkers, Pharmacological; Drug Resistance, Multiple, Viral; Genetic Association Studies; Genotype; Haplotypes; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Membrane Transport Proteins; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin | 2011 |
Benefits of Reiki therapy for a severely neutropenic patient with associated influences on a true random number generator.
Topics: Anxiety; Consciousness; Hematocrit; Hepacivirus; Hepatitis C; Humans; Interferons; Leukocyte Count; Male; Middle Aged; Mind-Body Relations, Metaphysical; Neutropenia; Neutrophils; Ribavirin; Severity of Illness Index; Spirituality; Therapeutic Touch | 2011 |
The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Topics: Ambulatory Care Facilities; Antiviral Agents; Australia; Cross-Sectional Studies; Female; Health Care Surveys; Health Services Accessibility; Hepatitis C; Humans; Interferons; Interviews as Topic; Male; Methadone; Narcotics; Opiate Substitution Treatment; Politics; Prejudice; Ribavirin; Substance Abuse Treatment Centers; Substance Abuse, Intravenous | 2012 |
Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load; Young Adult | 2011 |
The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Topics: Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Topics: Adult; Algorithms; Antiviral Agents; Cohort Studies; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
The end of the beginning for hepatitis C treatment.
Topics: Antiviral Agents; Carbamates; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine; Viral Nonstructural Proteins | 2012 |
IL-28B polymorphism and response to anti-hepatitis C therapy.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Genetic; Ribavirin | 2011 |
Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Mutation; Phylogeny; Polymerase Chain Reaction; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2011 |
Acute hepatitis C in Spain: a retrospective study of 131 cases.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Cohort Studies; Cross Infection; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunoenzyme Techniques; Immunoglobulin G; Interferon-gamma; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Spain; Substance Abuse, Intravenous; Viral Load; Young Adult | 2012 |
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Topics: Adult; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Probability; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral | 2012 |
The influence of treatment with pegylated interferon-alfa and ribavirin on neutrophil function and death in patients with HIV/HCV coinfection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiviral Agents; Apoptosis; CD4 Lymphocyte Count; Coinfection; Female; Flow Cytometry; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Neutrophil Activation; Neutrophils; Reactive Oxygen Species; Ribavirin; Viral Load | 2012 |
Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
Topics: Antiviral Agents; Genotype; Haplotypes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Interferons; Interleukins; Polymorphism, Single Nucleotide; Ribavirin | 2012 |
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
Topics: Antiviral Agents; Apoptosis Regulatory Proteins; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Programmed Cell Death 1 Receptor; Ribavirin; Viral Load | 2012 |
Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression Profiling; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Interleukin-8; Male; Middle Aged; Ribavirin; T-Lymphocytes; Transcriptional Activation; Virus Replication | 2012 |
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; Insulin Glargine; Insulin, Long-Acting; Interferon-alpha; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, LDL; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
Topics: Adult; Antiviral Agents; Erythrocytes; Hemoglobins; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Plasma; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
Topics: Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Superinfection; Viral Load | 2012 |
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
Topics: Adult; Alleles; Anemia, Hemolytic; Antiviral Agents; Feasibility Studies; Female; Genotype; Hemoglobins; Hepatitis C; Humans; Inosine Triphosphatase; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin | 2012 |
Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients.
Topics: Acute Disease; Adult; Antiviral Agents; Disease Outbreaks; Female; Follow-Up Studies; Genotype; Hepatitis C; Hepatitis C Antibodies; HIV Seropositivity; Homosexuality, Male; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Retrospective Studies; Ribavirin; Risk Factors; Spain | 2012 |
Tongue hyperpigmentation during hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hyperpigmentation; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tongue; Tongue Diseases | 2012 |
Birth cohort screening may help find hepatitis C cases.
Topics: Aged; Antiviral Agents; Cost-Benefit Analysis; Health Care Costs; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Mass Screening; Middle Aged; Nutrition Surveys; Polyethylene Glycols; Population Growth; Prevalence; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States | 2012 |
Tuberculosis screening before anti-hepatitis C virus therapy in prisons.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Male; Mass Screening; Polyethylene Glycols; Prisoners; Radiography; Recombinant Proteins; Recurrence; Ribavirin; Tuberculosis, Pulmonary | 2012 |
Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Living Donors; Male; Middle Aged; Ribavirin; RNA, Viral | 2012 |
25-Hydroxyvitamin D3 suppresses hepatitis C virus production.
Topics: Antiviral Agents; Calcifediol; Cell Proliferation; Cell Survival; Cells, Cultured; Cholecalciferol; Dose-Response Relationship, Drug; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Sampling Studies; Sensitivity and Specificity | 2012 |
The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan.
Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; California; Cohort Studies; Confidence Intervals; Delivery of Health Care, Integrated; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Insurance, Health; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Private Sector; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Health Care Costs; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Homosexuality, Male; Humans; Immunoassay; Interferons; Life Expectancy; Liver Function Tests; Male; Mass Screening; Middle Aged; Protease Inhibitors; Ribavirin | 2012 |
Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erythrocytes; Feasibility Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phosphorylation; Quality Control; Recombinant Proteins; Ribavirin | 2012 |
Real-life costs of hepatitis C treatment.
Topics: Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Female; Health Care Costs; Hepatitis C; Humans; Interferon-alpha; Male; Netherlands; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2012 |
Hepatitis C infection in childhood.
Topics: Antiviral Agents; Biopsy; Child; Female; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Mass Screening; Polyethylene Glycols; Pregnancy; Recombinant Proteins; Ribavirin | 2012 |
Stabilization of hepatitis C associated collapsing focal segmental glomerulosclerosis with interferon alpha-2a and ribavirin.
Topics: Antiviral Agents; Biopsy; Drug Therapy, Combination; Glomerulosclerosis, Focal Segmental; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
Topics: Adult; Antiviral Agents; Australia; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Seropositivity; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Polymorphism, Single Nucleotide; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection.
Topics: Adult; Alaska; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Eligibility Determination; Female; Hepatitis C; Humans; Indians, North American; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin | 2012 |
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Interferons; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Ribavirin; Spain; Treatment Outcome; Viral Load | 2012 |
Physician do no harm.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2012 |
Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biopsy; Blotting, Western; CD8-Positive T-Lymphocytes; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; Endopeptidases; Female; Gene Expression Profiling; Gene Expression Regulation; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Immunohistochemistry; Interferon-alpha; Interferon-gamma; Liver; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Phosphorylation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; STAT1 Transcription Factor; Switzerland; Time Factors; Transcription, Genetic; Treatment Outcome; Ubiquitin Thiolesterase | 2012 |
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load | 2012 |
Week 4 viral response to peginterferon and ribavirin: how should it be used in combination with a baseline predictive factor?
Topics: Female; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Ribavirin | 2012 |
Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2012 |
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2012 |
Expression of IFNAR2 mRNA in peripheral blood mononuclear cells of patients with HCV infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; RNA, Messenger | 2012 |
Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.
Topics: Acute Disease; Adult; Aged; Biopsy; Female; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Liver; Liver Failure; Liver Transplantation; Male; Middle Aged; Recurrence; Renal Insufficiency; Retrospective Studies; Ribavirin; Steroids; Transaminases; Treatment Outcome | 2012 |
Understanding the switchbacks: the impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferons; Liver Transplantation; Mice; Ribavirin; Secondary Prevention | 2012 |
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Topics: Amino Acid Substitution; Antiviral Agents; Carcinoma, Hepatocellular; Cholesterol, HDL; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Neoplasms; Ribavirin; Risk Factors; Viral Core Proteins; Viral Load | 2013 |
Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Socioeconomic Factors; Treatment Outcome; Young Adult | 2013 |
The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C.
Topics: Acute Disease; Adult; Alanine Transaminase; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2012 |
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Topics: Aged; Antiviral Agents; Biomarkers; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2012 |
Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.
Topics: Antiviral Agents; Cell Cycle; Cell Survival; Drug Synergism; Gene Expression Regulation; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Replicon; Ribavirin; RNA, Viral; Tumor Suppressor Protein p53; Virus Replication | 2012 |
YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
Topics: Adipokines; Adult; Antiviral Agents; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lectins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Factors; Statistics, Nonparametric; Tacrolimus; Time Factors; Young Adult | 2013 |
Hepatitis C cure after 6 months of telaprevir-based therapy in an HIV-infected man.
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2013 |
SASLT practice guidelines: management of hepatitis C virus infection.
Topics: Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Evidence-Based Medicine; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Patient Care Team; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Risk Factors; Saudi Arabia | 2012 |
Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach.
Topics: Adult; Aged; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Interferons; Interleukins; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2013 |
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
Topics: Adult; Aged; Anticarcinogenic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Risk Factors | 2013 |
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load | 2012 |
The effect of unsuccessful treatment with peginterferon and ribavirin on the liver fibrosis course of HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2012 |
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Topics: Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2013 |
Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.
Topics: Antibody Specificity; Antiviral Agents; Autoantibodies; Cohort Studies; Hepatitis C; Humans; IMP Dehydrogenase; Interferon-alpha; Italy; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Seroepidemiologic Studies; Treatment Outcome; United States | 2013 |
Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Health Services Accessibility; Hepatitis A Vaccines; Hepatitis B Vaccines; Hepatitis C; Humans; Interferons; Male; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Ribavirin; Self-Help Groups; Social Marginalization; Substance-Related Disorders; Treatment Outcome; Viral Load | 2012 |
Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.
Topics: Amino Acid Substitution; Antiviral Agents; Base Sequence; DNA, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Mutation; Plasmids; Polyethylene Glycols; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Sequence Analysis, DNA; Viral Core Proteins | 2013 |
Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adult; Antiviral Agents; Drug Interactions; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Genetic Association Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Italy; Male; Membrane Transport Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin | 2012 |
Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence.
Topics: Aged; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Superinfection; Treatment Outcome; Viral Load | 2012 |
Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Area Under Curve; Drug Administration Schedule; Drug Dosage Calculations; Drug Therapy, Combination; Female; Fractals; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Precision Medicine; Recombinant Proteins; Regression Analysis; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Hepatitis C in 2012.
Topics: Antiviral Agents; Drug Therapy, Combination; Gastroenterology; Hepatitis C; Humans; Interferon-alpha; Oligopeptides; Proline; Ribavirin | 2012 |
Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.
Topics: Antiviral Agents; Drug Monitoring; Hepacivirus; Hepatitis C; Humans; Interferons; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferon-alpha; Kaplan-Meier Estimate; Polyethylene Glycols; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2013 |
Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Platelet Count; Polyethylene Glycols; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoietin | 2013 |
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
Topics: Adult; Antiviral Agents; Black or African American; Black People; Chemokine CXCL10; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2013 |
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2012 |
Trends in viral hepatitis cost-effectiveness studies.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Interferons; Quality-Adjusted Life Years; Ribavirin | 2012 |
Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.
Topics: Aged; Antiviral Agents; Drug Synergism; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA; Treatment Outcome | 2013 |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Mutation; Polyethylene Glycols; Promoter Regions, Genetic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Core Proteins | 2013 |
Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
Topics: Adult; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
[Outcome of treatment with peg-interferon and ribavirin in HIV-HCV co-infected patients: "real life" single center experience].
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guideline Adherence; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Medication Adherence; Patient Care Team; Polyethylene Glycols; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Topics: Adult; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Computational Biology; Female; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C; Humans; Immune Evasion; Male; Middle Aged; Mutagenesis, Site-Directed; Mutation; Neutralization Tests; Ribavirin; Structure-Activity Relationship; Treatment Failure; Viral Envelope Proteins; Virus Internalization | 2013 |
Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2013 |
Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis".
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon-alpha; Male; Oligopeptides; Polyethylene Glycols; Ribavirin | 2013 |
Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.
Topics: Acute Disease; Aged; Antiviral Agents; Blood Specimen Collection; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Needlestick Injuries; Occupational Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Students, Nursing; Time Factors; Treatment Outcome; Young Adult | 2013 |
Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cohort Studies; Female; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Proportional Hazards Models; Recombinant Proteins; Recurrence; Ribavirin; Taiwan | 2013 |
Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.
Topics: Adult; Aged; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Genes, Viral; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Phylogeny; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2002 |
Interferon and ribavirin for hepatitis C.
Topics: CD4 Lymphocyte Count; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Function Tests; Male; Ribavirin | 2000 |
Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
Topics: Anemia; Anti-HIV Agents; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin | 2001 |
Advisory panel: expand hepatitis therapy to HIV/AIDS patients.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; United States | 2002 |
Managing hepatitis C infection in HIV-positive patients.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Liver; Ribavirin; United States | 2000 |
Treatment of hepatitis C virus-associated thrombocytopenic purpura with a combination of interferon alfa-2b and ribavirin.
Topics: Adult; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Purpura, Thrombocytopenic; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Straight hair associated with interferon-alfa plus ribavirin in hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hair; Hair Diseases; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
[Treatment of hepatitis C: advances and consensus].
Topics: Aged; Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Consensus Development Conferences as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Paris; Research; Ribavirin; Risk Factors; Substance-Related Disorders | 2002 |
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Lung Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Ribavirin | 2002 |
[Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients].
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
I favor therapy for hepatitis C virus recurrence after transplantation.
Topics: Acute Disease; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral | 2002 |
Diffuse hypertrichosis in the course of hepatitis C treatment by IFN-alpha and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hair Removal; Hemophilia A; Hepatitis C; Humans; Hypertrichosis; Interferon-alpha; Male; Ribavirin | 2002 |
Hepatitis C. Understanding the issues.
Topics: Algorithms; Antiviral Agents; Biopsy; Decision Trees; Drug Monitoring; Hepatitis C; Humans; Infection Control; Interferon-alpha; Patient Selection; Polymerase Chain Reaction; Ribavirin; Risk Factors; United States | 2000 |
Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Diseases; Kidney Glomerulus; Liver; Male; Microscopy, Electron; Middle Aged; Nephrotic Syndrome; Recombinant Proteins; Ribavirin; Treatment Outcome | 2002 |
Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemolysis; Hepatitis C; Humans; Interferon-alpha; Kidney; Liver; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin | 2002 |
Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 2002 |
Management of hepatitis C in Rhode Island: opportunities for improvement within and beyond the department of corrections.
Topics: Antiviral Agents; Blood-Borne Pathogens; Case Management; Hepatitis C; Humans; Interferons; Prisons; Rhode Island; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2002 |
[Treatment of hepatitic C virus infection after the French 2002 Consensus Conference].
Topics: Adult; Antiviral Agents; Child; France; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Use of antiviral therapy in patients with hepatitis C.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Interactions; Hepatitis C; HIV Infections; Humans; Interferons; Retrospective Studies; Ribavirin | 2002 |
Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Urban Health; Urban Population | 2003 |
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.
Topics: Adult; Antiviral Agents; Female; Graft Rejection; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Male; Middle Aged; Ribavirin | 2003 |
[Hepatitis C].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Diagnosis, Differential; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Risk Factors | 2002 |
Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Glomerulonephritis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin | 2002 |
Effect of interferon alfa-2b and ribavirin treatment on hepatitis C-associated cryoglobulinemia and rheumatoid factor: comment on the article by Vassilopoulos and Calabrese.
Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Rheumatoid Factor; Ribavirin | 2003 |
[Despite improved healing chances with pegylated interferon, hepatitis C is frequently not optimally treated].
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Characteristics of and current treatment options for hepatitis B and hepatitis C.
Topics: Adult; Antiviral Agents; Drug Combinations; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Ribavirin | 2000 |
New combination treatment for hepatitis C is more beneficial than standard therapy, study says.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Evaluation Studies as Topic; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2002 |
Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Viremia | 2003 |
Renal manifestations of hepatitis C virus infection. Extrahepatic complications often are silent--and thus overlooked.
Topics: Antihypertensive Agents; Antiviral Agents; Cryoglobulinemia; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Erythropoietin; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2003 |
[Hepatitis C therapy is not pleasant. Patients must be prepared!].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Education as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2003 |
Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Seropositivity; Humans; Interferons; Liver Failure; Liver Function Tests; Ribavirin; Risk-Taking; Substance Abuse, Intravenous; Treatment Failure | 2003 |
Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2003 |
[Recurrence after customary hepatitis C therapy. Those patients are now treatable, too].
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viral Load | 2003 |
Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.
Topics: Age Factors; Antiviral Agents; Attitude of Health Personnel; Canada; Drug Combinations; Guideline Adherence; Health Care Surveys; Hepatitis C; Humans; Interferons; Practice Patterns, Physicians'; Ribavirin; Severity of Illness Index | 2003 |
[Treatment of acute hepatitis C with PEG-interferon and ribavirin].
Topics: Acute Disease; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin | 2003 |
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite.
Topics: Antiviral Agents; Bilirubin; Cholestasis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Viremia | 2003 |
Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit?
Topics: Adult; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2003 |
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Interferon-alpha; Ribavirin; Virus Replication | 2003 |
[Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients].
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Asthenia; Diarrhea; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Jaundice; Male; Middle Aged; Needlestick Injuries; Pain; Punctures; Recombinant Proteins; Retrospective Studies; Ribavirin; Serotyping; Sexual Behavior; Substance Abuse, Intravenous; Tattooing; Time Factors; Treatment Outcome | 2003 |
[Hepatitis? What is it?].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Biomarkers; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
[Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus?].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biopsy; Creatinine; Female; gamma-Glutamyltransferase; Hemoglobins; Hepatitis C; Humans; Kidney Transplantation; Liver; Liver Cirrhosis; Male; Middle Aged; Proteinuria; Ribavirin | 2003 |
[Hepatitis C. Chronic hepatitis. Outcome and treatment].
Topics: Adolescent; Antiviral Agents; Biopsy; Child; Drug Administration Schedule; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver; Prognosis; Ribavirin; Severity of Illness Index; Treatment Outcome | 2003 |
Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Remission Induction; Ribavirin | 2003 |
Current issues in hepatitis C, HIV co-infection discussed at lunch and learn.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Ribavirin; United States | 2002 |
Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence.
Topics: Anti-HIV Agents; Antiviral Agents; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Mental Disorders; Ribavirin; Substance-Related Disorders; Treatment Refusal; Viral Load | 2003 |
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.
Topics: Antiviral Agents; Black or African American; Black People; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Patient Compliance; Prospective Studies; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; White People | 2003 |
Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Female; Glucocorticoids; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prednisolone; Recombinant Proteins; Recurrence; Ribavirin | 2003 |
[Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
Topics: Antiviral Agents; Drug Therapy, Combination; Fees, Medical; Germany; Hepatitis C; Humans; Insurance Coverage; Interferon alpha-2; Interferon-alpha; National Health Programs; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.
Topics: Antigens, Viral; Antiviral Agents; Case-Control Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Male; Monitoring, Physiologic; Predictive Value of Tests; Probability; Ribavirin; Risk Assessment; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2003 |
Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Function Tests; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Management of hepatitis C.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Minnesota; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
[A small-sized hepatocellular carcinoma].
Topics: Antineoplastic Agents; Antiviral Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Patient Selection; Ribavirin; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2003 |
Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.
Topics: Antiviral Agents; Biopsy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Polyethylene Glycols; Radiography; Recombinant Proteins; Respiratory Distress Syndrome; Ribavirin | 2003 |
New warning for ddI.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Interactions; Drug Labeling; Hepatitis C; HIV Infections; Humans; Ribavirin | 2002 |
Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hemophilia A; Hepatitis C; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Interferons; Ribavirin | 2003 |
Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pancreatitis; Recombinant Proteins; Ribavirin; Risk Factors; Viral Load | 2003 |
Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.
Topics: Aged; Antiviral Agents; Chromatography, High Pressure Liquid; Creatinine; Female; Glomerulonephritis; Hepacivirus; Hepatitis C; Humans; Interferons; Kidney Diseases; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Ribavirin; RNA, Viral; Vasculitis | 2003 |
Hepatitis C infections. From diagnosis to treatment.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Saudi Arabia; Severity of Illness Index; Treatment Outcome | 2003 |
[Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
[Increasing chances. Effective HCV therapy lowers mortality of HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cause of Death; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Survival Rate | 2003 |
Some hepatitis C patients -- especially women -- don't really benefit from early therapy.
Topics: Cost-Benefit Analysis; Disease Progression; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Quality of Life; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; United States; Women | 2003 |
Peginterferon and ribavirin in a patient with acute hepatitis C.
Topics: Acute Disease; Adult; Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2003 |
Hepatitis C: the 'silent stalker'.
Topics: Antiviral Agents; Enzyme-Linked Immunosorbent Assay; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunoblotting; Interferon alpha-2; Interferon-alpha; Mutation; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Risk Factors; United States | 2003 |
Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Ribavirin; Treatment Outcome | 2003 |
Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rosacea | 2003 |
Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2003 |
Controversies in the management of hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous; Virus Replication | 2003 |
Treatment of patients with hepatitis C virus on the waiting list.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Waiting Lists | 2003 |
How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?
Topics: Antiviral Agents; Creatinine; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Patient Selection; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin | 2003 |
Successful treatment of hepatitis C in a patient with advanced AIDS and decompensated cirrhosis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Hepatitis C; Humans; Interferons; Male; Ribavirin; Treatment Outcome; Viral Load | 2003 |
Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa.
Topics: Aged; Antiviral Agents; Cell Line, Tumor; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Ribavirin; Splenic Neoplasms; Viral Load | 2003 |
[Cotton-wool spots appearing during the course of treatment with interferon and ribavirin].
Topics: Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Retinal Hemorrhage; Ribavirin | 2003 |
Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin; Uveomeningoencephalitic Syndrome | 2003 |
[Adverse effects of combining polyethylene glycol interferon with ribavilin on hepatitis C patients].
Topics: Antiviral Agents; Drug Therapy, Combination; Fatigue; Fever; Headache; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Pain; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2003 |
Hepatitis C: treatment challenges.
Topics: Antiviral Agents; Chronic Disease; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Education as Topic; Ribavirin; Treatment Outcome | 2003 |
Viral kinetics and hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; RNA, Viral | 2003 |
Infection with hepatitis C virus genotype 4 in the United States.
Topics: Adult; Antiviral Agents; Black or African American; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; United States; White People | 2004 |
Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-gamma; Ribavirin | 2003 |
A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres.
Topics: Academic Medical Centers; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Combinations; Female; Hepatitis C; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Private Sector; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Comparison of the VERSANT HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy.
Topics: Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Monitoring, Physiologic; Nucleic Acid Amplification Techniques; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome | 2003 |
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney; Kidney Function Tests; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Ribavirin | 2004 |
Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.
Topics: Adult; Aged; Anemia; Antiviral Agents; Creatinine; Dose-Response Relationship, Drug; Female; Hemoglobins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Function Tests; Male; Middle Aged; Plasma; Recombinant Proteins; Ribavirin | 2004 |
Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Male; Models, Theoretical; Ribavirin; RNA, Viral | 2003 |
The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Mutagenesis; Ribavirin; Viral Load; Viral Nonstructural Proteins | 2003 |
Folic acid supplementation does not prevent ribavirin-induced anemia.
Topics: Anemia, Hemolytic; Antiviral Agents; Female; Folic Acid; Haptoglobins; Hemoglobins; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin | 2003 |
Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Cells, Cultured; Drug Synergism; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; Virus Replication | 2004 |
Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Bilirubin; Creatine Kinase; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Muscular Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2004 |
Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral | 2004 |
Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Blotting, Northern; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Point Mutation; Recombinant Proteins; Replicon; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Alignment; Transfection; Virus Replication | 2004 |
Ribavirin-associated hemoglobinuria with treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Female; Hemoglobinuria; Hepacivirus; Hepatitis C; Humans; Middle Aged; Ribavirin | 2004 |
Response to "Hepatitis C virus, sickle cell disease treatment options"--a February letter to the editor.
Topics: Anemia, Sickle Cell; Antiviral Agents; Comorbidity; Hepatitis C; Humans; Interferons; Iron Chelating Agents; Ribavirin | 2004 |
High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Didanosine; Female; Hepatitis C; HIV Infections; Humans; Incidence; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Proportional Hazards Models; Ribavirin | 2004 |
Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Case-Control Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sequence Analysis, DNA | 2004 |
Adherence to combination therapy: influence on sustained virologic response and economic impact.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Role of epoetin alfa in maintaining ribavirin dose.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
Future trends in managing hepatitis C.
Topics: Antiviral Agents; Enzyme Inhibitors; Forecasting; Hepacivirus; Hepatitis C; Interferon alpha-2; Interferon-alpha; Oligonucleotides, Antisense; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Catalytic; Vaccines | 2004 |
Maximizing the benefits of antiviral therapy for HCV: the advantages of treating side effects.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Practice Guidelines as Topic; Ribavirin | 2004 |
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Mutation; Pilot Projects; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2004 |
[Is combined treatment with interferon alpha and ribavirin for 3 months enough in selected patients with a genotype 2 or 3 hepatitis C virus?].
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Ribavirin; Treatment Outcome | 2004 |
Nucleoside analogues and mitochondrial toxicity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Mitochondria; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine | 2004 |
Hepatitis C: speaking out about the silent epidemic.
Topics: Adaptation, Psychological; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon-alpha; Nurse's Role; Patient Education as Topic; Prevalence; Ribavirin; Risk Factors; United States | 2001 |
Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain rea
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2004 |
Treating HCV infection in HIV/HCV-coinfected patients.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Pegasys-Copegus combination treats both HIV and hepatitis C.
Topics: Antiviral Agents; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
[HIV/HCV coinfection: 40% of patients can successfully be treated].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Hepatitis C treatment eligibility in an urban population with and without HIV coinfection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Hepatitis C; HIV Infections; Humans; Illinois; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Patient Selection; Polyethylene Glycols; Poverty Areas; Recombinant Proteins; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Urban Health Services | 2004 |
Reversible decompensated liver disease as a possible complication of pegylated-interferon alfa 2b and ribavirin for recurrent hepatitis C.
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Treatment of acute hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Viral Load | 2003 |
Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Breath Tests; Carbon Monoxide; Cell Survival; Erythrocytes; Hemoglobins; Hepatitis C; Humans; Male; Middle Aged; Regression Analysis; Ribavirin | 2004 |
High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
Topics: Adolescent; Adult; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Prisoners; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; Risk Factors; RNA, Viral; Serotyping; Substance Abuse, Intravenous | 2004 |
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viremia | 2004 |
Bell's palsy: a rare complication of interferon therapy for hepatitis C.
Topics: Adult; Bell Palsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index | 2004 |
[Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C].
Topics: Adult; Anemia; Antiviral Agents; Blood Transfusion; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Kidney Failure, Chronic; Male; Polymerase Chain Reaction; Renal Dialysis; Ribavirin; RNA, Viral; Vesico-Ureteral Reflux; Viremia | 2004 |
Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Interferons; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplantation, Homologous | 2004 |
Outcomes of acute rejection after interferon therapy in liver transplant recipients.
Topics: Adult; Antiviral Agents; Female; Graft Rejection; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Effects of antiviral therapy on the cellular immune response in acute hepatitis C.
Topics: Acute Disease; Adult; Antiviral Agents; CD4-CD8 Ratio; Epitopes; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; T-Lymphocytes | 2004 |
Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C.
Topics: alpha-Glucosidases; Animals; Antiviral Agents; Bovine Virus Diarrhea-Mucosal Disease; Cattle; Cell Line; Cytopathogenic Effect, Viral; Diarrhea Viruses, Bovine Viral; Disease Models, Animal; Drug Synergism; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hepacivirus; Hepatitis C; Humans; Indolizines; Inhibitory Concentration 50; Interferon-alpha; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Envelope Proteins; Viral Plaque Assay | 2004 |
[HIV/HCV double infection: combination is a clear therapy option].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Hepatitis C and pregnancy.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferons; Pregnancy; Pregnancy Complications, Infectious; Ribavirin | 2004 |
Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell; Ribavirin; Treatment Outcome | 2004 |
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Prospective Studies; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
Topics: Animals; Antiviral Agents; Biological Assay; Cattle; Cell Line; Cytopathogenic Effect, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Vesicular stomatitis Indiana virus | 2004 |
Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; United States | 2004 |
Sarcoidosis presenting as tattoo changes in a patient undergoing treatment with interferon-alpha and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sarcoidosis; Tattooing | 2004 |
Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
Topics: Adult; Aged; Amino Acid Sequence; Antigens, Viral; Antiviral Agents; B-Lymphocytes; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunologic Memory; Interferon-alpha; Interferon-gamma; Interleukin-10; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Homology; T-Lymphocytes; Treatment Outcome; Viral Core Proteins; Viremia | 2004 |
Takayasu's arteritis and hepatitis C: a new association?
Topics: Adult; Antiviral Agents; Azathioprine; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Polymerase Chain Reaction; Prednisone; Ribavirin; RNA, Viral; Takayasu Arteritis | 2004 |
Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2004 |
Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Sequence Data; Ribavirin; Sequence Alignment; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Viral Nonstructural Proteins | 2004 |
[Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
Topics: Antigens, Viral; Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
Topics: Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Depression; Female; Follow-Up Studies; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2004 |
Is screening for interferon retinopathy in hepatitis C justified?
Topics: Adult; Aged; Antiviral Agents; Diabetic Retinopathy; Drug Therapy, Combination; Female; Fluorescein Angiography; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Remission, Spontaneous; Retinal Diseases; Retinal Hemorrhage; Ribavirin | 2004 |
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Viral Load | 2004 |
Interferon for hepatitis C patients with psychiatric disorders.
Topics: Antiviral Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Mental Disorders; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Substance Withdrawal Syndrome | 2004 |
[Sexual transmission of hepatitis C in homosexual men].
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Lymphogranuloma Venereum; Male; Middle Aged; Netherlands; Prevalence; Proctitis; Ribavirin; Risk Factors; Sexual Behavior; Sexually Transmitted Diseases, Viral | 2004 |
[Epidemiological, clinical and therapeutical aspects of HIV/HCV coinfection in a series of HIV seropositive Umbrian patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Italy; Liver; Male; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Substance-Related Disorders; Treatment Outcome | 2004 |
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Models, Biological; Ribavirin; RNA, Viral; Viral Load | 2004 |
PegIFN/ribavirin during acute HCV coinfection.
Topics: Acute Disease; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD1; Antigens, CD1d; Antiviral Agents; Cohort Studies; Cross-Sectional Studies; Dendritic Cells; Female; Flow Cytometry; Hepacivirus; Hepatitis C; Humans; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; T-Lymphocyte Subsets | 2005 |
Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C.
Topics: Aged; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferons; Leukoplakia; Lichen Planus; Lichen Planus, Oral; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Skin Diseases; Steroids; Time Factors; Transaminases | 2005 |
Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Hypersplenism; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Researchers identify better hepatitis C treatment for people with HIV.
Topics: Antiviral Agents; Drug Carriers; Hepatitis C; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
Topics: Administration, Buccal; Adolescent; Adult; Aged; Antiviral Agents; Cohort Studies; Depressive Disorder; Dose-Response Relationship, Drug; Drug Carriers; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Personality Inventory; Polyethylene Glycols; Prevalence; Prospective Studies; Psychiatric Status Rating Scales; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index | 2005 |
Complicated lichenoid drug eruption.
Topics: Antiviral Agents; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lichenoid Eruptions; Male; Middle Aged; Oral Ulcer; Propranolol; Recombinant Proteins; Ribavirin; Scrotum; Severity of Illness Index; Skin Ulcer | 2005 |
HIV and hepatitis C virus co-infection.
Topics: Antiviral Agents; Hepatitis C; HIV Infections; Humans; Ribavirin | 2005 |
Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.
Topics: Antiviral Agents; Cell Line; Drug Resistance, Viral; Genome, Viral; Hepacivirus; Hepatitis C; Mutation; Replicon; Ribavirin; RNA, Viral | 2005 |
Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
MxA and PKR expression in chronic hepatitis C.
Topics: Antiviral Agents; Biopsy; eIF-2 Kinase; Female; Gene Expression Regulation; Genotype; GTP-Binding Proteins; Hepatitis C; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Myxovirus Resistance Proteins; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin; Time Factors | 2004 |
The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection.
Topics: Antiviral Agents; Biopsy; Hepatitis C; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome | 2004 |
Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat.
Topics: Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Sampling Studies; Severity of Illness Index; Treatment Outcome; Viral Load | 2005 |
Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Remission Induction; Ribavirin; Tumor Virus Infections | 2005 |
Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Middle Aged; Receptors, Interleukin; Receptors, Interleukin-10; Ribavirin | 2005 |
PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Vasculitis | 2005 |
Delivering care to injection drug users coinfected with HIV and hepatitis C virus.
Topics: Adult; Antiviral Agents; Delivery of Health Care, Integrated; Eligibility Determination; Female; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Rhode Island; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2005 |
[Therapy of acute hepatitis C infection].
Topics: Acute Disease; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin | 2005 |
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Unsafe Sex | 2005 |
[Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2005 |
My personal experience in being HCV/HIV co-infected & how I cured hepatitis C.
Topics: Anecdotes as Topic; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2004 |
Transient corneal microcysts associated with interferon therapy.
Topics: Adult; Antiviral Agents; Corneal Diseases; Cysts; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Ribavirin | 2005 |
HIV and hepatitis co-infection: a consensus for treatment?
Topics: Antiviral Agents; Hepatitis B; Hepatitis B Vaccines; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2005 |
Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 2005 |
Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Hepatitis drug gets approval for coinfection treatment.
Topics: Antiviral Agents; Drug Approval; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 2005 |
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mitochondrial Diseases; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
The optimal treatment strategy for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Interferons; Models, Theoretical; Polyethylene Glycols; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2005 |
Treatment of hepatitis C in children.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Spleen; Treatment Outcome | 2005 |
Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Vasculitis | 2005 |
Successful treatment with peginterferon and ribavirin in a patient with acute hepatitis C evolving into chronicity.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Immunosuppressive Agents; Infections; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2005 |
Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients.
Topics: Antiviral Agents; Hepatitis C; Humans; Kidney Transplantation; Recurrence; Reproducibility of Results; Ribavirin | 2005 |
[Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Recombinant Proteins; Ribavirin | 2005 |
Regression of low-grade non-Hodgkin's lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection.
Topics: Antiviral Agents; Cryoglobulins; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, B-Cell; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
Topics: Adult; Alberta; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Postoperative Care; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention; Treatment Outcome | 2005 |
Hepatitis C: are there any options for non-responders?
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2005 |
Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Linear Models; Male; Ribavirin | 2005 |
Factor VIII inhibitor associated with peginterferon.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Therapy, Combination; Factor VIII; Glucocorticoids; Hepatitis C; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome | 2005 |
GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Heterotrimeric GTP-Binding Proteins; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Subunits; Recombinant Proteins; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Viral Load | 2005 |
Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test.
Topics: Alanine Transaminase; Antiviral Agents; Hepatitis C; Humans; Reference Values; Ribavirin | 2005 |
Second thoughts about secondary analyses.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Research Design; Retrospective Studies; Ribavirin | 2005 |
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Japan; Male; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Ribavirin; RNA, Viral; Serum Albumin; Viral Core Proteins; Viral Load; Viral Nonstructural Proteins | 2005 |
Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Evolution, Molecular; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukin-2; Male; Middle Aged; Ribavirin; Viral Load | 2005 |
Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
Topics: Adult; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Psychoses, Substance-Induced; Recombinant Proteins; Ribavirin | 2005 |
Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Mutation; Ribavirin; Sequence Analysis, Protein; Treatment Outcome; Viral Nonstructural Proteins | 2005 |
Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection.
Topics: Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Neoplasms; Lymphatic Metastasis; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Ribavirin; Salivary Gland Neoplasms | 2005 |
Dramatic response to granulocytapheresis in a Crohn's disease case complicated by hepatitis C virus.
Topics: Antiviral Agents; Crohn Disease; Cytapheresis; Drug Therapy, Combination; Granulocytes; Hepatitis C; Humans; Interferon-gamma; Male; Middle Aged; Monocytes; Ribavirin; Treatment Outcome | 2005 |
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Hyperglycemia; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Multivariate Analysis; Pancreatitis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2005 |
Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.
Topics: Antiviral Agents; Female; Hepatitis C; Humans; Interferon Type I; Liver; Liver Failure, Acute; Middle Aged; Recombinant Proteins; Ribavirin | 2005 |
[Cost comparison of two combination therapies with peginterferon alfa and ribavarin for the treatment of hepatitis C].
Topics: Algorithms; Antiviral Agents; Body Weight; Cost Savings; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Workshop report treating hepatitis C in HIV-infected patients: where are we now?
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; France; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain; United States | 2005 |
[The peripheral polyneuropathy in patients with chronic HCV infection treated peginterferon alfa with ribavirin].
Topics: Antiviral Agents; Autoantibodies; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Paresthesia; Polyneuropathies; Ribavirin; Treatment Outcome | 2005 |
[Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
Topics: Adult; Antiviral Agents; Case-Control Studies; Female; Ferritins; Hepatitis C; Humans; Iron; Male; Middle Aged; Ribavirin; Transferrin | 2005 |
Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2005 |
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy.
Topics: Acute Disease; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphocyte Activation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Up-Regulation; Viral Proteins | 2005 |
[Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].
Topics: Acute Disease; Aged; Antiviral Agents; Arteriosclerosis; Coronary Disease; Cross Infection; Disease Outbreaks; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Poland; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2005 |
[Ischemic neuroretinopathy associated with use of interferon].
Topics: Antiviral Agents; Drug Therapy, Combination; Fluorescein Angiography; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Optic Neuropathy, Ischemic; Polyethylene Glycols; Recombinant Proteins; Retinal Diseases; Ribavirin; Time Factors; Visual Acuity; Visual Field Tests | 2005 |
Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia.
Topics: Adult; Anemia; Antiviral Agents; Disulfides; Erythrocyte Membrane; Erythrocytes; Female; Glutathione Peroxidase; Hemolysis; Hepatitis C; Humans; In Vitro Techniques; Male; Membrane Proteins; Middle Aged; Oxidative Stress; Predictive Value of Tests; Ribavirin; Sulfhydryl Compounds; Thioredoxins | 2005 |
Delaying HCV treatment in HIV-positive patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load | 2005 |
Hepatitis C virus infection in adult Chinese hemophilia patients negative for the human immunodeficiency virus: treatment results with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; China; Female; Hemophilia A; Hepatitis C; HIV; HIV Seropositivity; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2005 |
Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience.
Topics: Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors; Treatment Outcome | 2005 |
A 49-year-old woman with hepatitis, confusion, and abnormal chest radiograph findings.
Topics: Antiviral Agents; Biopsy; Bronchi; Confusion; Female; Hepatitis C; Humans; Hypercalcemia; Interferon-alpha; Middle Aged; Radiography, Thoracic; Ribavirin; Sarcoidosis | 2005 |
Photolabeling probes of ribavirin and EICAR.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Hepacivirus; Hepatitis C; Humans; Imidazoles; Light; Models, Chemical; Models, Molecular; Molecular Biology; Nucleosides; Photoaffinity Labels; Photolysis; Ribavirin; Ribonucleosides; Severe Acute Respiratory Syndrome; Time Factors; Triazoles | 2005 |
Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients.
Topics: Demography; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Male; Prisoners; Ribavirin; Substance-Related Disorders; Treatment Outcome | 2005 |
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Viremia | 2006 |
Recurrence of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Immunosuppression Therapy; Interferons; Liver Transplantation; Prognosis; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment | 2005 |
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Mutation, Missense; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation.
Topics: Antiviral Agents; Feasibility Studies; Hepatitis C; Humans; Interferons; Liver Transplantation; Living Donors; Pilot Projects; Platelet Count; Recurrence; Ribavirin; Splenectomy | 2005 |
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Cadaver; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Living Donors; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Viral Core Proteins; Viral Load | 2005 |
Approach of primary care physicians to hepatitis C: an educational survey from a Southern Italian area.
Topics: Antiviral Agents; Attitude of Health Personnel; Clinical Competence; Education, Medical, Continuing; Guideline Adherence; Health Care Surveys; Hepatitis C; Humans; Interferons; Italy; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Ribavirin; Risk Factors; RNA, Viral | 2005 |
Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; DNA, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
[Co-infection with HIV-hepatitis C virus].
Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Hepatitis C; HIV Infections; Humans; Ribavirin | 2005 |
Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
[Treatment of viral hepatitis in children].
Topics: Child; Drug Therapy, Combination; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin | 2005 |
Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Blood Transfusion; Hepatitis C; Humans; Interferons; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin | 2005 |
Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Bilirubin; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Hepatitis C and didanosine: risk of lactic acidosis.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Contraindications; Didanosine; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin | 2005 |
Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2005 |
[Genotype 1 superresponder treat for only 24 weeks].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2005 |
[High dosage induction brings new hope].
Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
Topics: Antiviral Agents; Contraindications; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration; Viral Load | 2005 |
Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Recurrence; Red-Cell Aplasia, Pure; Ribavirin | 2006 |
The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia.
Topics: Antiviral Agents; Cholestasis; Embolization, Therapeutic; Female; Hepatitis C; Humans; Interferons; Liver Transplantation; Middle Aged; Ribavirin; Splenectomy; Splenic Artery; Thrombocytopenia | 2006 |
[Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
[Severe ocular bacterial infection associated with pegylated interferon and ribavirin treatment for hepatitis C].
Topics: Aged; Antiviral Agents; Eye Infections, Bacterial; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
Topics: Acute Disease; Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Recombinant Proteins; Retrospective Studies; Ribavirin; Sexual Behavior; Sexually Transmitted Diseases, Viral; Treatment Outcome | 2006 |
[Quality assurance in patient addiction treated with drug substitution].
Topics: Antiviral Agents; Buprenorphine; Comorbidity; Drug Information Services; Drug Interactions; Drug Therapy, Combination; Education, Medical, Continuing; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Methadone; Multimedia; Narcotic Antagonists; Opioid-Related Disorders; Polyethylene Glycols; Quality Assurance, Health Care; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms.
Topics: Acute Disease; Adult; Antiviral Agents; Case-Control Studies; CD11 Antigens; Cell Count; Dendritic Cells; Disease Progression; Drug Combinations; Female; Flow Cytometry; Hepatitis A; Hepatitis C; Humans; Interferons; Lipopolysaccharide Receptors; Male; Middle Aged; Myeloid Cells; Ribavirin | 2006 |
HCV infection in the setting of HIV: prevalence, disease, treatment.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin | 2006 |
Declining sustained virological response in hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2006 |
[Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic ant therapeutic difficulties].
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Hepatitis, Autoimmune; HIV Infections; Humans; Liver Function Tests; Ribavirin | 2006 |
Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2005 |
Effect of anti-viral therapy for occult hepatitis C virus infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Confidence Intervals; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; In Situ Hybridization; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Statistics, Nonparametric; Viral Load | 2006 |
[Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Topics: Adult; Aged; Antigens, CD; Antiviral Agents; Cytokines; DNA, Viral; Drug Therapy, Combination; Female; Flow Cytometry; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Interleukins; Killer Cells, Natural; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Monocytes; Perforin; Polyethylene Glycols; Pore Forming Cytotoxic Proteins; Recombinant Proteins; Ribavirin; RNA, Viral; Tetraspanin 28; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha | 2006 |
Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Cell Count; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Lymph node enlargement during combination therapy for chronic hepatitis C with pegylated interferon alpha and ribavirin: harmless reaction or harmful disease?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymph Nodes; Male; Medical Audit; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Switzerland | 2006 |
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Reproducibility of Results; Ribavirin; RNA, Viral; Switzerland | 2006 |
Rosacea fulminans related to pegylated interferon alpha-2b and ribavirin therapy.
Topics: Administration, Oral; Adult; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Female; Hepatitis C; Humans; Injections; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rosacea | 2006 |
[Prevalence of hepatitis C virus among HIV-infected patients in Area 2 of Madrid].
Topics: Adult; Alcohol Drinking; Antiviral Agents; CD4 Lymphocyte Count; Comorbidity; Cross-Sectional Studies; Drug Utilization; Female; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Outpatients; Prevalence; Ribavirin; Risk Factors; Seroepidemiologic Studies; Sexual Behavior; Spain; Substance Abuse, Intravenous; Surveys and Questionnaires; Urban Population; Viral Load | 2006 |
Natural history and therapy of 66 patients with mixed cryoglobulinemia.
Topics: Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antiviral Agents; Cryoglobulinemia; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Hepatitis C; Humans; Interferons; Kidney Diseases; Lymphoproliferative Disorders; Male; Middle Aged; Peripheral Nervous System Diseases; Purpura; Retrospective Studies; Rheumatic Diseases; Ribavirin; Severity of Illness Index | 2006 |
Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Italy; Liver Transplantation; Patient Dropouts; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Interferon-gamma; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure; Viral Load | 2006 |
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA; Treatment Outcome | 2006 |
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Topics: Age Distribution; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2006 |
Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation.
Topics: Adult; Cryoglobulinemia; Drug Therapy, Combination; Exanthema; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Male; Ribavirin; Treatment Outcome | 2006 |
Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV; HIV Seropositivity; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides | 2006 |
High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Topics: Aged; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Female; Graft Rejection; Hepatitis C; Hepatitis C Antibodies; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral | 2007 |
[Prophylaxis and treatment for recurrent hepatitis C virus after liver transplantation].
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recombinant Proteins; Ribavirin; Secondary Prevention; Tissue Donors | 2006 |
Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Hepatitis C; Humans; Immunoglobulin G; Interferon-alpha; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Ribavirin; Tumor Necrosis Factor-alpha | 2006 |
Management of hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Safety | 2006 |
Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Immunoglobulin G; Immunologic Deficiency Syndromes; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
[Selection for treatment of hepatitis C co-infected patients for ].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferons; Patient Selection; Polyethylene Glycols; Ribavirin | 2006 |
[Primer treatment of acute and chronic hepatitis C].
Topics: Acute Disease; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplantation, Homologous; Treatment Outcome | 2006 |
Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin | 2006 |
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Topics: Antiviral Agents; Drug Combinations; Female; France; Hepatitis C; Humans; Interferons; Male; Middle Aged; Patient Compliance; Retrospective Studies; Ribavirin; Treatment Outcome | 2006 |
Short-term treatment duration for HCV-2 and HCV-3 infected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number.
Topics: Antiviral Agents; Chemotherapy, Adjuvant; Erythropoietin; Hepacivirus; Hepatitis C; Humans; Interferons; Recombinant Proteins; Ribavirin | 2006 |
Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses.
Topics: Acute Disease; Antigens, Viral; Antiviral Agents; Hepatitis C; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Interferon-alpha; Lymphocyte Activation; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2006 |
Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.
Topics: Adult; Antiviral Agents; Crohn Disease; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Child; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis C; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Autoantibodies; Disease Progression; Drug Therapy, Combination; gamma-Glutamyltransferase; Golgi Apparatus; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Evidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapy.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Evolution, Molecular; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Phylogeny; Recombinant Proteins; Recombination, Genetic; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins | 2006 |
Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation.
Topics: Administration, Oral; Antiviral Agents; Disease Transmission, Infectious; Drug Therapy, Combination; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; RNA, Viral; Transplantation, Homologous | 2007 |
Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
Topics: Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Steroid-responsive demyelinating motor neuropathy with conduction block associated with hepatitis C infection and treatment with interferon alpha.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Demyelinating Diseases; Evoked Potentials, Somatosensory; Female; Hepatitis C; Humans; Interferon-alpha; Methylprednisolone; Middle Aged; Neural Conduction; Neuroprotective Agents; Polyradiculoneuropathy; Prednisone; Ribavirin | 2006 |
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
Topics: Antiviral Agents; Brazil; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kinetics; Liver Cirrhosis; Ribavirin; RNA, Viral; Viral Load | 2006 |
Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Weight Loss | 2007 |
A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Base Sequence; Drug Therapy, Combination; Electrophoresis; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Sequence Data; Polymerase Chain Reaction; Reproducibility of Results; Ribavirin; RNA, Viral; Sensitivity and Specificity; Serum Albumin; Viral Core Proteins; Viral Nonstructural Proteins | 2007 |
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Europe; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Enhancing hepatitis C treatment uptake and outcomes for injection drug users.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Naltrexone; Narcotic Antagonists; Patient Compliance; Ribavirin; Substance Abuse, Intravenous; Treatment Outcome | 2007 |
Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Viral Load | 2007 |
Focus on hepatitis. Increased RBV dose for better HCV treatment response.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis C; Humans; Interferons; Ribavirin | 2006 |
Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viremia | 2007 |
Future therapies for hepatitis C: where do we go from here?
Topics: Antiviral Agents; Biomedical Research; Drug Design; Hepatitis C; Humans; Oligopeptides; Pyrimidine Nucleosides; Recombinant Fusion Proteins; Ribavirin; Toll-Like Receptors | 2007 |
Liver transplant and hepatitis C in methadone maintenance therapy: a case report.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver; Liver Transplantation; Male; Methadone; Opioid-Related Disorders; Ribavirin; Secondary Prevention; Viral Load | 2007 |
[Assessment of the values of immune response mediators in patients with acute hepatitis C receiving combined antiviral therapy].
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biomarkers; Cytokines; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Immunoenzyme Techniques; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2006 |
Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
Topics: Antiviral Agents; Cryptosporidiosis; Enterocolitis; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation.
Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin | 2007 |
[Thrombotic thrombocytopenic purpura during treatment with interpheron].
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Purpura, Thrombotic Thrombocytopenic; Ribavirin; Time Factors | 2007 |
Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response.
Topics: Adaptation, Biological; Drug Synergism; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homeostasis; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Viral Load; Viral Proteins; Virus Replication | 2007 |
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Ribavirin; RNA, Viral | 2007 |
Focus on hepatitis. Baseline HCV VL, CD4 percentage predict HCV treatment response.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2006 |
[Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Focus on hepatitis. Weight-based RBV dosing = impressive treatment success rates.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin.
Topics: Adult; Antiviral Agents; Factor VIII; Hemorrhage; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Male; Mental Disorders; Middle Aged; Patient Compliance; Patient Selection; Retrospective Studies; Ribavirin; Veterans | 2007 |
Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Colitis, Ulcerative; Edema; Genotype; Hepatitis C; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Asia; Australia; Communicable Disease Control; Hepatitis C; Humans; Immunoenzyme Techniques; Interferon-alpha; Molecular Diagnostic Techniques; Practice Guidelines as Topic; Reagent Kits, Diagnostic; Ribavirin; Treatment Outcome | 2007 |
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Asia; Australia; Child; Communicable Disease Control; Genotype; Hemophilia A; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Immunoenzyme Techniques; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Molecular Diagnostic Techniques; Reagent Kits, Diagnostic; Ribavirin; RNA, Viral; Thalassemia; Treatment Outcome; Viral Load | 2007 |
Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2007 |
Interferon alfa-2b and ribavirin: new indication. In children: more risks than in adults.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; France; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Pregnancy; Recombinant Proteins; Ribavirin | 2007 |
Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
Topics: Anti-HIV Agents; Antiviral Agents; Bilirubin; Chi-Square Distribution; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2007 |
Ribavirin: is it a mutagen for hepatitis C virus?
Topics: Antiviral Agents; DNA, Viral; Hepacivirus; Hepatitis C; Humans; Mutagenesis; Ribavirin; RNA, Viral; Viral Load | 2007 |
Analysis of ribavirin mutagenicity in human hepatitis C virus infection.
Topics: Antiviral Agents; Base Sequence; DNA Primers; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Mutagenicity Tests; Polymerase Chain Reaction; Ribavirin; Virus Replication | 2007 |
Anemia and clinical outcomes in hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Ribavirin; Treatment Outcome | 2007 |
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Recent advances in hepatitis C virus research and understanding the biology of the virus.
Topics: Antiviral Agents; Biomedical Research; Disease Progression; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Topics: Algorithms; Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Erythropoietin; Genotype; Health Care Costs; Health Resources; Hepatitis C; Humans; Models, Theoretical; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Scleritis and peripheral ulcerative keratitis with hepatitis C virus-related cryoglobulinemia.
Topics: Antiviral Agents; Corneal Ulcer; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Eye Infections, Viral; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Scleritis | 2007 |
Predictors of response of US veterans to treatment for the hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Predictive Value of Tests; Racial Groups; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome; United States; Veterans | 2007 |
HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Gastroenterology; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Societies, Medical; Treatment Outcome | 2007 |
A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients.
Topics: Antiviral Agents; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; Interferon Regulatory Factor-7; Interferons; Oligonucleotide Array Sequence Analysis; Patient Selection; Ribavirin; RNA; Viral Proteins | 2007 |
Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
Topics: Antiviral Agents; Apoptosis; Genotype; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; RNA, Viral; Virus Replication | 2007 |
Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation.
Topics: Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Regression Analysis; Ribavirin | 2007 |
Triphasic decline of hepatitis C virus RNA during antiviral therapy.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Models, Biological; Ribavirin; RNA, Viral; Viral Load | 2007 |
[Acute hepatitis C infection: epidemiological and clinical aspects, and efficacy of interferon therapy].
Topics: Acute Disease; Adolescent; Adult; Aged; Antiviral Agents; Colonoscopy; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Ribavirin; Sexual Behavior; Substance Abuse, Intravenous | 2007 |
Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2007 |
Contribution of insertions and deletions to the variability of hepatitis C virus populations.
Topics: Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Gene Deletion; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutagenesis, Insertional; Ribavirin; Sequence Alignment; Spain; Species Specificity; Viral Envelope Proteins; Viral Nonstructural Proteins | 2007 |
Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Rituximab; Treatment Outcome | 2007 |
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2007 |
Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and ribavirin.
Topics: Adult; Antiviral Agents; Base Sequence; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.
Topics: Adult; Alleles; Antiviral Agents; Black or African American; Cytomegalovirus; Female; Genes, MHC Class II; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Th1 Cells; White People | 2007 |
Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Papillomavirus Infections; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Selective serotonin reuptake inhibitors in the context of hepatitis C infection: reexamining the risks of bleeding.
Topics: Adult; Antiviral Agents; Depressive Disorder; Drug Interactions; Female; Hemorrhage; Hepatitis C; Humans; Interferons; Male; Middle Aged; Retrospective Studies; Ribavirin; Selective Serotonin Reuptake Inhibitors | 2007 |
[Treatment with natural interferon (alfaferone) in clinical practice--our experience].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Treatment Outcome | 2007 |
Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis, Autoimmune; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Failure, Acute; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Viral Load; Virus Replication | 2007 |
Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Viral Core Proteins; Viral Load; Viremia | 2007 |
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.
Topics: Antiviral Agents; Biomarkers; Child; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Poisson Distribution; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2007 |
Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.
Topics: Antiviral Agents; Female; Hand; Hepatitis C; Humans; Interferon-alpha; Lichen Nitidus; Middle Aged; Ribavirin | 2007 |
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Topics: Adult; Aged; alpha-Fetoproteins; Amino Acid Substitution; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Japan; Kinetics; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Core Proteins | 2007 |
Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
Topics: Adult; Antiviral Agents; British Columbia; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Organizational; Patient Acceptance of Health Care; Patient Care Team; Patient Education as Topic; Peer Group; Polyethylene Glycols; Program Evaluation; Recombinant Proteins; Referral and Consultation; Ribavirin; Self-Help Groups; Substance Abuse, Intravenous; Time Factors; Treatment Outcome | 2007 |
Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral | 2007 |
[Ocular complications of hepatitis C treatment].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Optic Nerve Diseases; Retinal Diseases; Ribavirin | 2007 |
Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hearing Loss, Sudden; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
"True" weight-based dosing versus "flat" dosing of ribavirin: will the WIN-R please come forward?
Topics: Antiviral Agents; Black or African American; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; White People | 2007 |
Prevention of donor to recipient transmission of HCV in stem cell transplantation: some issues.
Topics: Antiviral Agents; Hematopoietic Stem Cell Transplantation; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
HCV research and anti-HCV drug discovery: toward the next generation.
Topics: Animals; Antiviral Agents; Cell Line; Drug Evaluation, Preclinical; Hepacivirus; Hepatitis C; Humans; Interferons; Mice; Pan troglodytes; Replicon; Ribavirin; Vaccines; Virus Replication | 2007 |
Highlights of the third international workshop on HIV and hepatitis coinfection.
Topics: Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C; Hepatitis, Viral, Human; HIV Infections; Humans; Interferons; Ribavirin | 2007 |
Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Granuloma; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Sarcoidosis | 2008 |
[The recurrence of hepatitis C virus after liver transplantation].
Topics: Adult; Antiviral Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reoperation; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2007 |
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin | 2007 |
Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Female; Hepatitis C; HIV; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Liver Diseases; Male; Necrosis; Ribavirin; RNA, Viral; Transaminases; Viral Load | 2007 |
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
Topics: Anemia; Antibodies; Antiviral Agents; Epoetin Alfa; Erythropoietin; Graft Rejection; Hematinics; Hepatitis C; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Prednisone; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin; Secondary Prevention; Tacrolimus | 2007 |
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Topics: Alanine Transaminase; Anemia; Computer Simulation; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Models, Theoretical; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Mutation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Viral Nonstructural Proteins | 2008 |
Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).
Topics: Adult; Aged; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Outcome; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Topics: Adult; Antiviral Agents; Filgrastim; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2007 |
Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reoperation; Ribavirin; RNA, Viral; Secondary Prevention; Time Factors | 2007 |
Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2007 |
Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Organ Preservation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2007 |
HCV genotype 5: epidemiology and spread of an uncommon genotype.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Phylogeny; Ribavirin; Treatment Outcome | 2008 |
Human uridine-cytidine kinase phosphorylation of ribavirin: a convenient method for activation of ribavirin for conjugation to proteins.
Topics: Anemia, Hemolytic; Asialoglycoproteins; Drug Delivery Systems; Hepacivirus; Hepatitis C; Humans; Liver; Nucleoside-Phosphate Kinase; Orosomucoid; Phosphorylation; Ribavirin | 2008 |
Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials, Phase III as Topic; Databases, Factual; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Comment on Neumann et al. 'Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients'.
Topics: Administration, Oral; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load; Virus Replication | 2008 |
Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Sequence Data; Mutation; Ribavirin; Sequence Analysis, DNA; Spain | 2008 |
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Survival Rate; Time Factors | 2008 |
Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Veterans | 2008 |
Treatment of acute hepatitis C in an HIV-positive man with pegylated interferon and ribavirin for 24 weeks.
Topics: Hepatitis C; HIV Infections; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
Shorter treatment for hepatitis C genotype 4 may be a possibility.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Viral Load | 2007 |
Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy.
Topics: Antiviral Agents; Asian People; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Multivariate Analysis; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; White People | 2008 |
Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Hemophilia A; Hemorrhage; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Israel; Liver; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.
Topics: Antiviral Agents; British Columbia; Cohort Studies; Community Health Services; Counseling; Delivery of Health Care, Integrated; Female; Geographic Information Systems; Health Services Accessibility; Hepatitis C; Humans; Interferons; Male; Middle Aged; Patient Education as Topic; Physician-Nurse Relations; Public Health Nursing; Ribavirin; Treatment Outcome; Workforce | 2008 |
Rationale and design of the virological response and ribavirin dosage (VIRID) study in hepatitis.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Netherlands; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |
Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2008 |
Genetic variability in hepatitis C virus and its role in antiviral treatment response.
Topics: Amino Acid Substitution; Antiviral Agents; Conserved Sequence; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Molecular Sequence Data; Mutation, Missense; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
Topics: Adult; Antiviral Agents; Female; Hemoglobins; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Plasma; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro.
Topics: Cells, Cultured; Dendritic Cells; Flow Cytometry; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Recombinant Proteins; Ribavirin; Viremia | 2008 |
High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Topics: Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepatitis C; Humans; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Immunophenotyping; Immunotherapy; Interferons; Interleukin-2; Killer Cells, Natural; Male; Middle Aged; Polyethylene Glycols; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome | 2008 |
Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation.
Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2007 |
Sarcoidosis presenting with granulomatous uveitis induced by pegylated interferon and ribavirin therapy for Hepatitis C.
Topics: Adult; Antiviral Agents; Female; Granuloma; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Uveitis | 2008 |
Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Argentina; Cluster Analysis; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Epidemiology; Molecular Sequence Data; Ribavirin; Sequence Analysis, DNA; Sequence Homology; Treatment Outcome; Viral Core Proteins; Viral Nonstructural Proteins | 2008 |
Oral lesions in HIV and HCV co-infected individuals in HAART era.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antiretroviral Therapy, Highly Active; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Coitus; Disease Susceptibility; Feeding Behavior; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Mouth Diseases; Mouthwashes; Ribavirin; Risk Factors; Smoking; Substance Abuse, Intravenous; Time Factors; Viral Load; Young Adult | 2008 |
Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Hepatitis C virus cirrhosis: prolonged sustained virological response in a patient after low-dose antiviral treatment.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
WIN-R revisited: Response to editorial.
Topics: Antiviral Agents; Black or African American; Body Weight; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation.
Topics: Antiviral Agents; Cohort Studies; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Tacrolimus | 2007 |
Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Ribavirin; Statistics as Topic; Treatment Outcome | 2008 |
[Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naïve patients with hepatitis C infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2008 |
Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2008 |
Publicly funded pegylated interferon-alpha treatment in British Columbia: disparities in treatment patterns for people with hepatitis C.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; British Columbia; Demography; Drug Utilization; Female; Health Services Accessibility; Hepatitis C; Humans; Interferons; Male; Middle Aged; Program Evaluation; Public Health Practice; Ribavirin; Sex Factors | 2008 |
Hepatitis C: current options for nonresponders to peginterferon and ribavirin.
Topics: Antiviral Agents; Decision Trees; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Failure | 2008 |
Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases.
Topics: Antiviral Agents; Biocompatible Materials; Cosmetic Techniques; Female; Granuloma; Hepatitis C; Humans; Hyaluronic Acid; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sarcoidosis; Sarcoidosis, Pulmonary; Silicones; Skin; Skin Diseases | 2008 |
Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Topics: Adult; Age Factors; Alanine Transaminase; Base Sequence; Cluster Analysis; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Mutation; Odds Ratio; Phylogeny; Prospective Studies; Protein Structure, Tertiary; Ribavirin; Sequence Analysis, DNA; Viral Envelope Proteins; Viral Nonstructural Proteins | 2008 |
[Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Hypertension; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Renal Insufficiency, Chronic; Ribavirin; Treatment Outcome | 2008 |
Persistence with hepatitis C therapy in the Department of Veterans Affairs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Patient Dropouts; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; United States; United States Department of Veterans Affairs | 2008 |
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.
Topics: Adult; Antiviral Agents; Conserved Sequence; Evolution, Molecular; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mutation; Open Reading Frames; Recurrence; Ribavirin; Treatment Failure; Viral Proteins | 2008 |
Ribavirin therapy for hepatitis C infection following liver transplantation.
Topics: Female; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Hepatitis C Antibodies; Humans; Liver; Liver Transplantation; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral; Transplantation, Homologous | 1995 |
Ribavirin for hepatitis C infection.
Topics: Hepatitis C; Humans; Interferons; Ribavirin | 1995 |
Changes in hepatitis C virus antigen in liver with antiviral therapy.
Topics: Adult; Aged; Alanine Transaminase; Antigens, Viral; Biopsy; Chronic Disease; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Virus Replication | 1993 |
Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Chronic Disease; Female; Hematocrit; Hepatitis C; Humans; Iron; Liver; Male; Middle Aged; Pilot Projects; Ribavirin; Time Factors | 1994 |
Hepatitis C virus infection in renal transplantation.
Topics: Azathioprine; Cyclosporine; Hepatitis C; Humans; Kidney Transplantation; Liver; Pancreas Transplantation; Polymerase Chain Reaction; Postoperative Complications; Ribavirin | 1995 |
[Half of the patients respond to interferon treatment. Combination therapy is an alternative in chronic hepatitis C].
Topics: Chronic Disease; Contraindications; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Prognosis; Ribavirin | 1995 |
[Hepatitis C in Scandinavia].
Topics: Carrier State; Hemophilia A; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Risk Factors; Scandinavian and Nordic Countries; Substance Abuse, Intravenous | 1995 |
Treatment of chronic hepatitis C.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Base Sequence; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Injections, Subcutaneous; Interferon-alpha; Liver; Male; Middle Aged; Molecular Sequence Data; Ribavirin; RNA, Viral; Treatment Outcome | 1994 |
Clinical features of chronic hepatitis C.
Topics: Chronic Disease; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Ribavirin; RNA, Viral | 1994 |
Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon.
Topics: Adult; Aged; Base Sequence; Chronic Disease; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Transaminases | 1993 |
Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C.
Topics: Administration, Oral; Alanine Transaminase; Base Sequence; Chronic Disease; DNA, Viral; Female; Hepacivirus; Hepatitis C; Humans; Male; Molecular Sequence Data; Polymerase Chain Reaction; Ribavirin; RNA, Viral | 1993 |
Introduction: combination antiviral therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Child; Chronic Disease; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Ribavirin | 1995 |
New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
Topics: Antiviral Agents; Aspartate Aminotransferases; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1995 |
[Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha].
Topics: Adult; Anemia; Antiviral Agents; Chronic Disease; Drug Evaluation; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Transaminases | 1996 |
Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow Transplantation; Child; Hepacivirus; Hepatic Veno-Occlusive Disease; Hepatitis C; Humans; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Safety; Time Factors; Transplantation, Homologous | 1996 |
Ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Lamivudine; Ribavirin; Zalcitabine | 1996 |
Mixed cryoglobulinemia and membranoproliferative glomerulonephritis associated with hepatitis C virus infection.
Topics: Antiviral Agents; Cryoglobulinemia; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Male; Middle Aged; Ribavirin | 1996 |
Chronic HCV infection: public health threat and emerging consensus. Vienna, Austria, October 27-28, 1995.
Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1996 |
Incidence and treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin | 1996 |
Interferon-associated thyroid dysfunction in anti-D-related chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferons; Retrospective Studies; Rho(D) Immune Globulin; Ribavirin; Thyroid Diseases | 1997 |
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral | 1997 |
Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 1997 |
[The effect of interferon in combination with ribavirin on the plus and minus strands of hepatitis C virus RNA in patients with hepatitis].
Topics: Adult; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Double-Stranded; RNA, Viral | 1996 |
Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis.
Topics: Amino Sugars; Animals; Antiviral Agents; Cells, Cultured; Drug Stability; Erythrocytes; Female; Hepatitis; Hepatitis C; Humans; Injections, Intramuscular; Liver; Mice; Mice, Inbred BALB C; Polylysine; Ribavirin; Tritium | 1997 |
Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Azathioprine; Chronic Disease; Contraindications; Drug Therapy, Combination; Female; Hemoglobins; Hemolysis; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Retrospective Studies; Ribavirin | 1997 |
The University of Toronto liver transplant program.
Topics: Adult; Alprostadil; Antiviral Agents; Child; Graft Survival; Hepatitis B; Hepatitis C; Hospitals, University; Humans; Immunization, Passive; Immunoglobulins; Immunosuppression Therapy; Lamivudine; Liver Neoplasms; Liver Transplantation; Ontario; Patient Selection; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Transplantation, Heterologous | 1996 |
[Severe local cutaneous necrosis during treatment with interferon-alpha and ribavirin for chronic viral hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Necrosis; Recombinant Proteins; Ribavirin; Skin | 1997 |
Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients.
Topics: Adolescent; Adult; Antiviral Agents; Blood Transfusion; Child; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Compliance; Ribavirin; Thalassemia | 1997 |
Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation.
Topics: Adult; Antiviral Agents; Cryoglobulinemia; Female; Follow-Up Studies; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin | 1996 |
Ribavirin therapy for cryoglobulinemia and thrombocytopenia associated with hepatitis C virus infection.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C; Humans; Middle Aged; Ribavirin; Thrombocytopenia | 1997 |
Hepatitis C. Infection, transmission, recognition, and treatment.
Topics: Combined Modality Therapy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Care Team; Primary Health Care; Recombinant Proteins; Ribavirin; Risk Factors | 1998 |
[Epidermolysis bullosa acquisita and hepatitis C].
Topics: Adult; Antiviral Agents; Epidermolysis Bullosa Acquisita; Female; Hepatitis C; Humans; Interferon-alpha; Ribavirin | 1998 |
Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.
Topics: Antiviral Agents; Drug Tolerance; Female; Glomerulonephritis; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nephrotic Syndrome; Recurrence; Ribavirin; Viremia | 1998 |
[Therapy of recurrent hepatitis C after liver transplantation].
Topics: Combined Modality Therapy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Pilot Projects; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 1998 |
Hepatitis C not incurable.
Topics: Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; United States; United States Food and Drug Administration | 1998 |
Hepatitis C and the 'cure'.
Topics: Antiviral Agents; Australia; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Function Tests; Ribavirin; Treatment Outcome | 1998 |
[Should we treat cirrhosis in hepatitis C carriers with antiviral agents?].
Topics: Antiviral Agents; Carrier State; Combined Modality Therapy; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Patient Selection; Ribavirin | 1999 |
The treatment of hepatitis C.
Topics: Antiviral Agents; Australia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Prevalence; Ribavirin | 1999 |
Combination therapy for hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 1999 |
Combination therapy for hepatitis C infection.
Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Treatment Outcome | 1999 |
[Infectious diseases in 1998].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Bacterial Vaccines; Blood Donors; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferons; Lamivudine; Middle Aged; Multicenter Studies as Topic; Pneumonia, Pneumococcal; Randomized Controlled Trials as Topic; Ribavirin; Streptococcus pneumoniae; Transfusion Reaction; Zidovudine | 1999 |
Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Ribavirin | 1999 |
The scientific challenge of hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Patents as Topic; Recombinant Proteins; Replicon; Ribavirin; Viral Hepatitis Vaccines; Virus Cultivation | 1999 |
Pediatric drug trials: women and children last?
Topics: Adult; Antiviral Agents; Child; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C; Humans; Interferon-alpha; Patient Selection; Ribavirin; United States; United States Food and Drug Administration | 1999 |
Treatment of hepatitis C infection. Review underplayed important public health issues.
Topics: Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferons; Ribavirin | 1999 |
Treatment of hepatitis C: a decision that needs careful consideration.
Topics: Antiviral Agents; Disease Progression; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Risk | 1999 |
Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
[Severe relapse of hepatitis C following liver transplantation. Successful treatment with a combination of interferon-alpha and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Treatment Outcome | 1999 |
Treatment of hepatitis C infection.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Risk Factors | 1999 |
Organ-transmitted HCV infection in kidney transplant recipients from an anti-HCV negative donor.
Topics: Adult; Antiviral Agents; Cadaver; Child; Fatal Outcome; Female; Hepatitis C; Humans; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Postoperative Complications; Ribavirin; Tissue Donors | 1999 |
Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders.
Topics: Adult; Antiviral Agents; Drug Combinations; Female; Hemorrhagic Disorders; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2000 |
[Hepatitis C more dangerous than AIDS. At last a breakthrough in therapy using the new combination treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Germany; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 1999 |
Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cross Infection; Disease Outbreaks; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Neoplasms; Remission Induction; Ribavirin | 2000 |
Hepatitis C virus infection with and without cryoglobulinemia as a case of Churg-Strauss syndrome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Churg-Strauss Syndrome; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Ribavirin | 2000 |
Retreatment of hepatitis C patients who do not respond to interferon: the search continues.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Treatment Failure | 2000 |
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.
Topics: Adult; Amino Acid Sequence; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Molecular Sequence Data; Mutation; Phylogeny; Ribavirin; Viral Envelope Proteins; Viral Nonstructural Proteins | 2000 |
Successful rescue of severe recurrent hepatitis C with interferon and ribavirin in a liver transplant patient.
Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 2000 |
Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Ribavirin; Treatment Outcome; Viremia | 2000 |
Combination of interferon-alpha and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2000 |
Needle-stick exposure in the health care setting: do not forget hepatitis C!
Topics: Acute Disease; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Health Personnel; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Needlestick Injuries; Netherlands; Primary Prevention; Ribavirin; Time Factors | 2000 |
How do we treat patients with hepatitis C virus associated-glomerulonephritis?
Topics: Adrenal Cortex Hormones; Cryotherapy; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Immunosuppression Therapy; Interferon Type I; Recombinant Proteins; Ribavirin | 2000 |
Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Alanine Transaminase; Antiviral Agents; Blood Coagulation Disorders; Child; Chronic Disease; Drug Therapy, Combination; Factor VII Deficiency; Female; Hemoglobins; Hemophilia A; Hemophilia B; Hepacivirus; Hepatitis C; HIV Antibodies; HIV Seronegativity; Humans; Interferons; Male; Middle Aged; Neutrophils; Platelet Count; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; von Willebrand Diseases | 2000 |
The science, economics, and effectiveness of combination therapy for hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepatitis C; Humans; Ribavirin; Treatment Outcome | 2000 |
[Treatment and prevention of hepatitis C].
Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin | 2000 |
Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Nucleosides; Ribavirin | 2000 |
Ribavirin: new preparation. An advance, but still no cure-all.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States | 2000 |
Hepatitis C: a hidden, growing problem.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Prognosis; Ribavirin; United States | 2000 |
Successful treatment of hepatitis C in sickle-cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Middle Aged; Recombinant Proteins; Ribavirin | 2000 |
Hypervariable region 1 of hepatitis C virus genome and response to interferon therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymorphism, Single-Stranded Conformational; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2000 |
Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Failure | 2000 |
Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Autoimmune Diseases; Cohort Studies; Female; Hepatitis C; Hormone Replacement Therapy; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Thyroiditis | 2000 |
Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Models, Theoretical; Ribavirin; Viral Load | 2001 |
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Mitochondrial Myopathies; Ribavirin | 2001 |
Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2001 |
Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
Topics: Amino Acid Sequence; Antiviral Agents; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Molecular Sequence Data; Ribavirin; Sequence Alignment; Viral Nonstructural Proteins; Viral Proteins; Viral Structural Proteins | 2001 |
Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral; Transaminases; Viral Load | 2001 |
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Fibrosis; Follow-Up Studies; Genotype; Hemophilia A; Hepatitis C; Humans; Interferon-alpha; Liver; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Ultrasonography; von Willebrand Diseases | 2001 |
Current management of hepatitis C in New Zealand.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; New Zealand; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2001 |
Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Hepatitis C and HIV: ribavirin plus interferon study recruiting.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Patient Selection; Ribavirin; United States | 1998 |
Combination therapy for hepatitis C.
Topics: Bone Marrow; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Ribavirin; Treatment Outcome | 1998 |
FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Combinations; Hepatitis C; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 1998 |
Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr.
Topics: Antiviral Agents; Biopsy; Body Weight; Dose-Response Relationship, Drug; Hepatitis C; HIV Infections; Interferon Type I; Liver; Liver Transplantation; Recombinant Proteins; Ribavirin | 1998 |
Hepatitis C: new treatment overview.
Topics: Antiviral Agents; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Internet; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Evolving strategies to attack hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 1998 |
Soaring prices, soaring sales.
Topics: Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Interferon alpha-2; Interferon-alpha; Oxazines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; United States | 1998 |
Product information.
Topics: Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Resistance, Microbial; Hepatitis C; HIV Infections; Humans; Ribavirin | 1999 |
Opportunistic infections update.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver; Ribavirin | 1998 |
Marketing scam spoils hep C treatment.
Topics: Antiviral Agents; Drug Packaging; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Marketing of Health Services; Ribavirin | 1998 |
Ribavirin for hepatitis C: 80% price reduction available July 9?
Topics: Anti-HIV Agents; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin | 1999 |
Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection.
Topics: Adult; Antigens, Viral; Antiviral Agents; CD4 Lymphocyte Count; Cell Division; Cohort Studies; DNA, Viral; Female; Genes, MHC Class II; Hepacivirus; Hepatitis C; Histocompatibility Testing; HLA-DQ Antigens; HLA-DQ beta-Chains; Humans; Interferon-alpha; Lymphocyte Activation; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral; T-Lymphocytes, Helper-Inducer | 2001 |
Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C.
Topics: Adult; Antiviral Agents; Cholestasis; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index | 2001 |
Mitochondrial toxic effects and ribavirin.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; Drug Interactions; Hepatitis C; HIV Seropositivity; HIV-1; Humans; Middle Aged; Mitochondria; Pancreatitis; Ribavirin | 2001 |
Treatment of hepatitis C infection in injection drug users.
Topics: Adult; Alanine Transaminase; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Opioid-Related Disorders; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sex Characteristics; Substance Abuse, Intravenous; Treatment Outcome | 2001 |
[Correction of immune thrombocytopenia associated with hepatitis C virus infection after combination therapy with interferon alpha and ribavirin].
Topics: Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Remission Induction; Ribavirin | 2001 |
Lack of seroconversion in a health care worker after polymerase chain reaction-documented acute hepatitis C resulting from a needlestick injury.
Topics: Adult; Antiviral Agents; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon-alpha; Male; Needlestick Injuries; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serologic Tests | 2001 |
Study results presented on interferon/ribavirin combination therapy.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States | 2001 |
Therapy for HCV nonresponders: Is two enough?
Topics: Antiviral Agents; Drug Resistance, Microbial; Hepatitis C; Humans; Interferons; MEDLINE; Ribavirin | 2001 |
Treatment of hepatitis C virus and HIV coinfection: the road less traveled.
Topics: Antiretroviral Therapy, Highly Active; Disease Management; Drug Therapy, Combination; Education, Continuing; Female; Hepatitis C; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Recombinant Proteins; Ribavirin | 2001 |
Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Drug Contamination; Hepatitis C; Humans; Immunoglobulins, Intravenous; Immunologic Deficiency Syndromes; Interferon-alpha; Middle Aged; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2001 |
Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis.
Topics: Adult; Aged; Cryoglobulinemia; Diagnosis, Differential; Drug Therapy, Combination; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon-alpha; Male; Nephrotic Syndrome; Ribavirin; Treatment Outcome | 2001 |
[PEG-interferon alfa 2a against hepatitis C. Better as the standard therapy].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Recombinant Proteins; Ribavirin; Time Factors | 2001 |
Assessing the cost-effectiveness of pharmacogenomics.
Topics: Anticholesteremic Agents; Anticoagulants; Antimetabolites, Antineoplastic; Cardiovascular Diseases; Carrier Proteins; Child; Cholesterol Ester Transfer Proteins; Cost-Benefit Analysis; Drug Therapy; Genotype; Glycoproteins; Hepatitis C; Humans; Interferons; Mercaptopurine; Methyltransferases; Pharmacogenetics; Pharmacology, Clinical; Phenotype; Pravastatin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribavirin; Warfarin | 2000 |
Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study.
Topics: Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Combination reduces HCV load.
Topics: Clinical Trials as Topic; Drug Combinations; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; United States | 2001 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; United States; United States Food and Drug Administration | 2001 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Contraindications; Hemoglobinopathies; Hepatitis C; Humans; Interferons; Ribavirin | 2001 |
Hepatitis C: who should you treat and how?
Topics: Amantadine; Antiviral Agents; Decision Making; Decision Trees; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
HIV/HCV co-infection has treatment implications.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Practice Guidelines as Topic; Ribavirin | 2000 |
Inhibition of warfarin activity by ribavirin.
Topics: Anticoagulants; Antiviral Agents; Drug Interactions; Heart Valves; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prothrombin Time; Recombinant Proteins; Ribavirin; Warfarin | 2002 |
Prevalence of hepatitis C genotypes in Indian patients and their clinical significance.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Chi-Square Distribution; Child; Data Interpretation, Statistical; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; India; Interferons; Male; Middle Aged; Prevalence; Ribavirin; Sex Factors | 2001 |
Management issues in patients coinfected with hepatitis C virus and HIV.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Hepacivirus; Hepatitis A Vaccines; Hepatitis B Vaccines; Hepatitis C; HIV Infections; Humans; Interferons; Male; Ribavirin; RNA, Viral; Vaccination | 2002 |
Interferon-induced depression treated with citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Middle Aged; Ribavirin; Treatment Outcome | 2002 |
Immunological and virological effects of ribavirin in hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Cytokines; Female; Hepatitis C; Humans; Liver; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Messenger; RNA, Viral | 2002 |
A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds.
Topics: Anti-HIV Agents; Antiviral Agents; Emigration and Immigration; Family Practice; Health Care Surveys; Hepatitis C; Humans; Interferons; Lamivudine; Ribavirin; Risk Factors; Victoria | 2002 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |
Diagnosis and management of the HCV/HIV-coinfected patient.
Topics: Anti-HIV Agents; Biopsy; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin | 2002 |
HIV and hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Hepatitis A Vaccines; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Ribavirin | 2002 |
[Hepatitis C and HIV coinfection. Current aspects of therapy].
Topics: Anti-HIV Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Survival Rate | 2002 |
HIV & hepatitis C: treatment.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2002 |
Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis.
Topics: Adult; Age Factors; Amino Acids; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Markov Chains; Middle Aged; Mutation; Pharmacogenetics; Quality of Life; Ribavirin; RNA, Viral; Treatment Outcome | 2002 |
Treating hepatitis C in methadone maintenance patients: an interim analysis.
Topics: Adult; Aged; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Male; Methadone; Middle Aged; Ribavirin; Substance Abuse, Intravenous | 2002 |
Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients.
Topics: Adult; Antiviral Agents; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2001 |
A pilot study of ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Drug Administration Schedule; Female; Hepatitis C; Hepatitis, Chronic; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; RNA, Viral | 1992 |
Ribavirin: a possible alternative for the treatment of chronic non-A, non-B hepatitis.
Topics: Aged; Drug Administration Schedule; Female; Hepatitis C; Humans; Ribavirin; Transaminases | 1990 |